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Abstract
In this thesis, I give a metascientific account of causality in medicine. I begin with two historical cases
of causal discovery. These are the discovery of the causation of Burkitt’s lymphoma by the Epstein-Barr
virus, and of the various viral causes suggested for cervical cancer. These historical cases then support
a philosophical discussion of causality in medicine. This begins with an introduction to the Russo-
Williamson thesis (RWT), and discussion of a range of counter-arguments against it. Despite these,
I argue that the RWT is historically workable, given a small number of modifications. I then expand
Russo and Williamson’s account. I first develop their suggestion that causal relationships in medicine
require some kind of evidence of mechanism. I begin with a number of accounts of mechanisms and
produce a range of consensus features of them. I then develop this consensus position by reference to
the two historical case studies with an eye to their operational competence. In particular, I suggest that
it is mechanistic models and their representations which we are concerned with in medicine, rather than
the mechanism as it exists in the world.
I then employ these mechanistic models to give an account of the sorts of evidence used in for-
mulating and evaluating causal claims. Again, I use the two human viral oncogenesis cases to give this
account. I characterise and distinguish evidence of mechanism from evidence of difference-making, and
relate this to mechanistic models. I then suggest the relationship between types of evidence presents us
with a means of tackling the reference-class problem.
This sets the scene for the final chapter. Here, I suggest the manner in which these two different
classes of evidence become integrated is also reflected in the way that developing research programmes
change as their associated causal claims develop.
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Chapter 1
Introduction
In this thesis, I wish to explore the concept of causality in medicine. Rather than giving an account that
focuses on theoretical aspects of this issue, I wish to concentrate on the operational features of causes
in medical practice. How can we practically differentiate causal from non-causal processes? What is
the relationship between evidence and causality? How can we best exploit causal knowledge to guide
medical practice?
Why focus on these issues? First, causal knowledge brings advantages to medical practice that non-
causal knowledge does not. These advantages are apparent in core medical practices, such as diagnosis
and treatment, in medical research, such as disease and treatment discovery, and in the wider medical
milieu, such as medicolegal and policy applications. Knowledge of causes supports these various prac-
tices because of the range of special properties that only causes possess. Causal relationships tend to
be stable, or at least robust, over a range of background conditions. Even if they are not, it tends to be
the case that we can predict which background conditions they are likely to remain stable over in a way
that we cannot reliably do for non-causal relationships. This means that causal knowledge of, say, the
aetiology of a disease makes for sounder judgements in a range of situations over non-causal knowledge.
Causes are also exploitable: that is, they allow us to plan and perform interventions in a rational manner.
In other words, good medical practice requires the notion of causality.
However, despite the great advantages of thinking causally, it has proven very difficult to construct
practical schemes for determining cause that are suitable for general use in medicine. Physicians and
medical researchers have made a great many attempts to devise such schemes, as I review in section 1.2.
These can be, like the Henle-Koch postulates (HKP),1 locally very successful. But it is uncontroversial
to say that no one of these schemes provides a general way of detecting a causal relationship that has
universal (or even broad) applicability. These practical difficulties are matched by similarly daunting
theoretical ones. Philosophers too have produced a great number of theories of causality. Yet here too
there is no dominant view or consensus. Nor is there a theory, or type of theory, that seems to satisfy even
a modest desideratum of theoretical causal knowledge. So it is not the case that the practical problems
that medical researchers face in thinking about causes arise from a lack of philosophical knowledge.
1I have provided a list of acronyms used in this thesis above. As with items in the bibliography, each is followed by the page
number(s) upon which it appears.
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However, because of the advantages of providing practically workable schemes of cause, the provi-
sion of causal tools suitable for clinical use seems, to me, a more pressing problem than the theoretical
one. This means that I will give an account of causality that concentrates on how we should work with,
and think about causes, rather than one that attempts to understand causality itself. In other words, in
what follows I will take causality as a primitive concept that we might employ in order to do things in
practice. These things include being able to discriminate causal from non-causal processes in a reliable
way, to provide tools to understand and evaluate causal claims in practice and to take account of the
relationship between evidence and cause. Importantly, I want to do this in a way that is generalisable,
and does not depend upon, say, interpreting causes using any particular medical technology.2 In short,
I am interested in theories of causality that show how a particular causal phenomenon is situated within
the causal structure of the world (Craver, 2007, 21), rather than one that attempts to define just what
causality is.
Because this thesis is motivated by practical concerns, I will take an approach that might be broadly
characterised as metascientific. Instead of beginning with a metaphysical stance regarding causality, and
attempting to translate this position such that it is compatible with scientific practice, I will begin with the
study of scientific practice itself. This study will be an historical one. In chapters 2 and 3 I will introduce
two detailed historical examples in which complex causal claims were formulated and tested. Both of
these cases are early examples of tumours caused by viral infections (viral oncogenesis). As such, they
not only deal with the construction and evaluation of novel, specific, causal claims linking a particular
virus with a particular clinical disease, but also demonstrate the much broader shift in causal thinking
that, in part, arose from the discovery of these sorts of causes in medicine. Here, I will demonstrate the
ways in which different types of evidence were generated and synthesised to support these new kinds of
causal claim.
These case-studies will then form the foundations for the more philosophical parts of the thesis.
I will begin this by exploring Russo and Williamson’s recent work on causality in medicine. I argue
that their distinction between causality and the types of evidence that support causal claims is correct.
I then attempt to expand upon their distinction between mechanistic and probabilistic evidence. This
programme of expanding upon their thesis, by means of recent historical episodes in medicine, forms
the latter parts of the thesis.
For now, though, I need to introduce three key topics that will form the background to what follows.
Therefore, in section 1.1, I will give some very short historical details about the discovery of viral
oncogenesis in non-human animals. In section 1.2 I will then give a broad overview of the ways that
medical researchers have attempted to understand causality. Finally, in section 1.3, I will give a short
introduction to an account of causal discovery that, I think, is compatible with what follows.
2See footnote 8 on p.18 for an example of how schemes of causality that depend on particular technologies can be practically
problematic.
1.1. Non-human viral oncogenesis 15
1.1 Non-human viral oncogenesis
Cancer was historically held to be a transmissible disease. Yet with the introduction of the germ theory of
disease in the late nineteenth century, an infectious origin for it became implausible (Epstein, 2001a, 413-
4). However, in the middle decades of the twentieth century, the study of a number of tumours in animals
gradually led to a re-evaluation of this concept. In time, several instances of viral oncogenesis - tumours
caused by viruses - were discovered in non-human animals. These conditions were very important
to researchers studying later cases of human viral oncogenesis for two reasons. First, they acted as
exemplars of how viruses might generally act to cause cancer. Thus, the pattern of viral causation of
cancers, and its discovery in these cases, was important as a methodological guide in the cases of human
viral oncogenesis discussed in chapters 2 and 3. Second, several of these conditions played a more
direct evidential role in causal discovery. For example, the knowledge that several different herpesvirus
infections were capable of causing cancers in animals played a vital, but problematic, role in supporting
the claim that infection with herpes simplex virus (HSV) caused cervical cancer. In this section, I will
give a brief, non-technical, outline of these early examples of non-human viral oncogenesis.3
One general aspect of these cases is worth highlighting in advance. While a number of conditions,
later determined to be virally caused, were clinically described in the early decades of the twentieth
century, the actual viruses responsible were not discovered until much later. In fact, most of the viruses
involved in the following examples were not described until after about 1950. This lag appears to be
due to the technology required to give convincing descriptions of viruses. For example, the electron
microscope, which played a vital role in discovering and describing oncoviruses, did not enter general
use until the early 1950s.4 What suspicions there were before this date were supported with a range of
techniques that presented much less convincing evidence for the nature and characteristics of oncoviruses
than the striking images produced by electron microscopy. For instance, a common technique was the
transmission of tumours by cell-free filtrates (CFF).5 This delay presents the historian with difficulties in
precisely dating the beginnings of theories of viral oncogenesis. With that proviso in mind, I will review
the important examples of non-human viral oncogenesis that informed the early work on human viral
oncogenesis.
Marek disease. This is a T-cell lymphoma that affects chickens (Biggs, 2001). The disease was first
clinically described by Marek in 1907 (Marek, 1907), and was recognised to be a malignant condition
by Pappenheimer et al. in 1929 (Pappenheimer et al., 1929a). It was discovered that the disease could
be transmitted by the inoculation of tissue from affected individuals into unaffected ones (Pappenheimer
3There are a number of good technical reviews of this material. See, for example, zur Hausen, 1980; zur Hausen, 2006, chapter
1 and Javier and Butel, 2008.
4Although Ernst Ruska and Max Knoll had developed an experimental electron microscope in 1931, it was not until 1939 that
a transmission electron microscope (the ‘Siemens Super’) was commercially available. Even by the beginning of 1945 only about
35 laboratories in the world were equipped with one (Ruska, 1986), and it was not until 1940 that reviews of viral detection were
published (Kruger et al., 2000, 1714). This technology did not become widely disseminated outside Germany until the end of the
Second World War, and it took some time before electron microscopy was a routine part of virological practice (Bang, 1952).
5This involved attempting to transmit the tumour by inoculations of tumour material that had been passed through a filter that
was sufficiently fine to exclude any whole cells.
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et al., 1929b). The causal virus (now known to be gallid herpesvirus 2) was discovered in 1967 (Churchill
and Biggs, 1967) and described in 1969 (Witter et al., 1969). Interestingly, Epstein, who would later
play such an important role in discovering Epstein-Barr Virus (EBV), was involved in early work on the
description of this herpesvirus (Epstein et al., 1968).
Rous sarcoma. This disease, which causes sarcomas in chickens, was described and discovered to
be transmissible by Rous in 1911 (Rous, 1911a; Rous, 1911b). A possible oncogenic mechanism, im-
plicating an RNA virus in the development of this condition, was demonstrated in 1968 (Temin, 1968).
This agent was later discovered to be a retrovirus by the discovery of virally-encoded reverse transcrip-
tase activity. This was independently discovered by both Temin and David Baltimore in 1970 (Baltimore,
1970; Temin and Mizutani, 1970), leading to them jointly winning the Nobel Prize in Medicine in 1975
(Anonymous, 1975).
The causal virus is now known to be a member of the avian sarcoma-leukosis virus group. In
addition to the Rous sarcoma virus, this group includes a further chicken virus which played a minor
role in the early story of non-human viral oncogenesis. This is the avian leukosis virus, which was the
agent responsible for one of the first known transmissible tumours (Ellermann and Bang, 1909). The
complexities of this story are well reviewed in Pitot, 1983.
Shope papillomavirus. This papillomatous disease, affecting rabbits, was clinically described and
shown to be transmissible by CFF in the early 1930s (Shope, 1932; Shope and Hurst, 1933). It was later
demonstrated to be a maligant disease (Rous and Beard, 1934). The causal agent is now known to be
a papillomavirus, cottontail rabbit papillomavirus (CRPV) (Ito and Evans, 1961). I discuss this disease
in more detail in section 3.6.1.3, along with another papillomavirus infection of historical importance,
bovine papillomavirus (BPV).
Murine mammary tumour virus (MMTV). Mammary tumours in mice were discovered to be
transmissible via milk (Bittner, 1936) and this transmission was suggested to be due to the action of a
virus (Andervont and Bryan, 1944). Virus-like particles (VLP) were subsequently discovered in mouse
milk using electron microscopy (Passey et al., 1950) and were noted to be similar to those seen in
mammary tumour tissue biopsies. This agent is now known to be a milk-transmitted retrovirus called
MMTV, and was, for a time, suggested as a possible cause of human disease (Gross et al., 1952). Perhaps
because of this, murine models of breast cancers have played a vital role in understanding human breast
cancers (Callahan and Smith, 2008, which prefaces an entire journal issue dedicated to this issue).
Lucke´ renal adenocarcinoma. This is a kidney tumour that affects the northern Leopard frog
(Rana pipiens). It was described, noted to be transmissible by grafting and suspected to be of viral
origin by Baldwin Lucke´ (Lucke´, 1934; Lucke´, 1938a; Lucke´, 1938b). The suspicion of its viral origin
was largely based on the presence of intranuclear inclusion bodies in tumour cells (see, e.g. Lucke´,
1938a, 457). It was also noted that tumour cells could be maintained in culture, both in vitro (Lucke´,
1939) and in vivo (Schlumberger and Lucke´, 1949). Lucke´ continued to argue persuasively, on rather
circumstantial evidence, that the tumour was caused by a virus (Lucke´, 1952). However, it was not
until the demonstration of herpesvirus-like particles in tumour cells (Fawcett, 1956) that any stronger
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evidence became available. However, it appeared that a variety of different viral agents were present in
these tumours (Gravell, 1971), and it took a number of years until the causal role of ranid herpesvirus 1
(RaHV-1) in the development of the tumour was clear (Naegele and Granoff, 1977).
Murine leukaemia and lymphoma. VLPs were demonstrated in certain types of mouse leukaemia
during the 1950s and 1960s (Gross, 1952; Rauscher, 1962). A range of possible viral agents were
suspected (comprehensively reviewed in Moloney, 1962). Similarly, a large number of viral agents were
also detected in various murine lymphomas. Of interest here was the apparent role played by reovirus 3,
and its relationship to Burkitt’s lymphoma (Papadimitriou, 1966; Stanley et al., 1966; Stanley and Keast,
1967). I go on to discuss this issue in section 2.4.2.4.
Simian vacuolating virus 40 (SV40). Preparations of renal cells from Rhesus and cynomolgus
monkeys yielded a polyomavirus (Sweet and Hilleman, 1960). This had no cytopathic effects (CPE)
in its host species, but was found to induce lysis in cells derived from other primates. It was found to
induce tumours when inoculated into hamsters (Eddy, 1962). Because rhesus monkey cells were used in
the production of the Sabin polio vaccine, many millions of people were inadvertently exposed to SV40
during the second half of the twentieth century. This is worrying, as SV40 is thought to play a causal
role in several human tumours (Martini et al., 2007).
Adenovirus. Adenoviruses usually cause fairly mild eye, respiratory tract and gut infections in
humans. However, they were discovered to have oncogenic properties when transfected into non-human
animals. Adenovirus type 12 was intially found to cause tumours in hamsters (Trentin et al., 1962).
Similar properties were also described for adenovirus types 18 (Huebner et al., 1962), 7 (Girardi et al.,
1964) and 31 (Pereira et al., 1965).
Herpes ateles and Herpes samirii These two primate herpesviruses were discovered to cause
lymphomas when transfected into non-natural hosts (Mele´ndez et al., 1968; Mele´ndez et al., 1969a;
Mele´ndez et al., 1969b; Mele´ndez et al., 1972). This discovery was important in the Burkitt’s lymphoma
(BL) research programme (zur Hausen, 1975, 44-6).
1.2 Medical schemes of causality
There is a substantial medical literature on causality, parallel to that of the philosophy of science.6 This
literature has had an enormous conceptual impact on the manner in which causal relationships have been
understood in medical practice. In turn, the changing nature of medical practice has acted to change
these medical schemes of causality. A study of causality in medicine that seriously engages with the
historical aspects of medical practice must therefore take account of this literature.
Generally, the types of things that these medical theories of causality suggest as characteristic of
causal relationships are broadly similar to those found in philosophy. For instance, the requirement for
a particular causal factor to be found in most, or all, cases of the disease is common to many of these
schemes. We might interpret this as the medical corollary of Humean constant conjunction.7
6Good medical reviews of this material include Evans, 1976; Lilienfeld and Lilienfeld, 1977; Lilienfeld, 1980; Evans, 1993;
Weed, 1995; MacMahon and Trichopoulos, 1996 and Vandenbroucke, 2008.
7Despite this similarity, though, there is significant resistance to being ‘philosophical’, rather than practical, about causality.
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I have already suggested that medical theories of causality tend to change with changes in med-
ical practice. Historically, this change is apparent in the types of causal relationships that these med-
ical theories attempt to deal with. This produces three broad classes of medical schemes of causality.
Chronologically speaking, the first were those schemes formulated to deal with the demands of infec-
tious disease causation. These sorts of scheme dominated the medical literature on causality between
about 1880 and 1960. They were initially developed to account for the causation of bacterial diseases
(the HKP),8 but were later developed to account for viral diseases (Rivers, 1937; Huebner, 1957). They
are consistent with the aetiological standpoint, with a clinical disease defined in terms of its causal entity
(Carter, 2003). Importantly, and because of this aetiological standpoint, these theories of causality are
distinctively monocausal. That is, they attempt to demonstrate that a particular agent is the necessary
and sufficient cause of a clinical disease.
However, this monocausal stance meant that these theories of causality were poorly suited to the
kinds of causal relationships that were discovered in chronic non-infectious diseases (CNID). So new
types of causal scheme were formulated to account for these sorts of (more complex) causal relationships,
and their use was to become dominant during the 1960s and 1970s. There are two major distinctions that
can be drawn between these theories, and the previous infectious disease schemes. First, these schemes
are distinctively multifactorial, allowing for the consideration of a great number of causal factors as
This can lead to pronouncements with a notable degree of internal tension. For instance, in a discussion of Evans’ (Evans, 1978)
work on causality we might find the following: ‘He offers a practical field guide, eschewing philosophy, in step-by-step procedures
for arriving at causation in studies of disease. These procedures essentially realize in practice the triad, in sequence, of Hume’s
requirements for causality, which can be freely translated as association, time order, and causal direction.’ (Susser, 1995, 1125)
8Koch’s postulates cast a long shadow over causality in medicine. They were first developed to demonstrate the causal re-
lationship between infection with Mycobacterium tuberculosis and the development of TB (Carter, 2003. See also reviews by
Aronowitz, 2004 and Gillies, 2007). It is well worth taking account of Evans’ persuasive arguments for recognising the role of
Henle (see Henle, 1938, which is Rosen’s translation of Henle’s 1840) in forming Koch’s opinions about infectious disease cau-
sation. I have attempted to do this by adopting Evan’s terminology - Henle-Koch postulates, rather than the conventional Koch’s
postulates - to reflect Henle’s influence (Evans, 1976). For more background to the formulation of the HKP, see also Carter’s
volume of translations of Koch’s publications (Carter, 1987) and reviews of same (McGraw, 1989).
The HKP are still used extensively in clinical practice (Grimes, 2006). However, as they depend upon particular technologies
to demonstrate cause, the changes in technology that have occurred since their first formulation place the contemporary user in a
difficult position. For instance, many have attempted to modify the postulates to take account of non-bacterial illnesses. As an
example, Walker et al., 2006, have recently produced a set of ‘Koch’s postulates’ for slow viral diseases and prion disease. I think
that this is problematic, as it seems unwise to simply replace Koch’s requirement that a causal organism can be grown in ‘pure
culture’ by a requirement that we can, say, express a particular protein in an in vitro expression system, without considering the
implications for the other parts of the postulates. This concern about incommensurability has not restricted the growth of these
modern reformulations. For example, Hackney and Linn, 1979 (HKP for lab research and policy in environmental toxicology);
Falkow, 1988 (HKP for molecular microbiology); Hall and Lemoine, 1991 and Wright and Wynford-Thomas, 1991 (HKP for
molecular pathology); Brown and Goldstein, 1992 (HKP for cholesterol); Abboud, 1993 and Johnson et al., 1993 (HKP for renal
cytokine disease); Fredericks and Relman, 1996 (HKP for molecular microbiology); Fouchier et al., 2003 (HKP for SARS);
Walker et al., 2006 (HKP and prion diseases); Inglis, 2007 (an idiosyncratic reformulation of the HKP); Joles, 2008 (HKP for
chronic renal disease). There is also a substantial critical literature on the HKP: Stewart, 1968; Evans, 1977 (failure to meet HKP
does not necessarily exclude an organism as a cause of disease); Jacomo et al., 2002 (Bartonella spp. as exception to HKP);
Mazzarello, 2004. There is also a small literature on the HKP as of interest to philosophers of science: Tulodziecki, 2007 being a
particularly good example.
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being significant in bringing about a single disease. Second, and because of the greater heterogeneity of
these CNIDs, their accompanying schemes of cause are not typically couched in strictly methodological
terms (as the HKP are). Instead, schemes such as Dorn, 1953; Hammond, 1955; Yerushalmy and Palmer,
1959; Sartwell, 1960; Surgeon General, 1964; Hill, 1965; Wynder, 1966 Yerushalmy, 1966 and Cassel,
1976 tend to suggest general evidential features that pointed to the operation of a cause, rather than a
non-causal correlation. Many of these arose from the struggles to demonstrate a causal role for smoking
in carcinoma of the lung.
Thirdly, schemes that attempted to find a ‘grand unified theory of cause’ arose in the 1970s. The
authors of these schemes attempted to unify the types of causes that were demonstrated to operate in
both infectious diseases and in CNIDs. They make no apparent distinction between cause in these
two classes of disease. These schemes fall into two distinct sub-groups. The first are rather general
schemes of cause that were intended for fairly casual use in clinical practice. These include Evans,
1976; Evans, 1978; Doll and Peto, 1981; Elwood, 1988; Susser and Rothman, 1988; Kassirer, 1989;
Susser, 1991 and MacMahon and Trichopoulos, 1996. These schemes allow the user to apply similar
sorts of causal thinking to all kinds of disease. This includes both those which cannot be happily fitted
into the acute-chronic categories or, even more cuttingly, those which have moved from one group to
the other during the broad historial period that these schemes cover, such as the two examples of viral
oncogenesis considered below. This integrated way of thinking about different types of causes also had
advantages for understanding causation in infectious diseases, as developments in the understanding
of their pathogenesis at about this time began to reveal the important role played by host factors in the
aetiology of most infectious diseases. These host factors often presented difficulties for existing schemes
of infectious disease causation.
However, these unified theories did not work very well when it came to understanding very com-
plicated causal situations. At the same time, a second group of more sophisticated schemes were also
developed that were capable of accounting for highly complex causal relationships. These epidemio-
logical theories of causality stand apart from these more simple, suitable for clinical practice schemes
reviewed above. These might be referred to as ‘modern epidemiology’ causal systems, and there are
really five main players. These are the Sufficient-Component Cause Model (Rothman, 1974; Roth-
man, 1976a; Rothman, 1976b; Koopman, 1981; Khoury et al., 1989) which is similar to Mackie’s INUS
conditions (Mackie, 1974); various medical adaptations of counterfactual theories of causality (Rubin,
1974; Hamilton, 1979; Miettinen, 1982; Greenland and Poole, 1988; Rubin, 1990; Robins and Green-
land, 1992; Dawid, 2002); analysis of variance (ANOVA); structural equation modelling (Spirtes
et al., 1993; Pearl, 1995; Pearl, 2000; Robins, 2001) and Bayesian Networks (Cornfield, 1976; Pearl,
1993; Crupi et al., 2007). There are also a few instances of attempted syntheses between different species
of these causal modelling methods (see, e.g. Greenland and Brumback, 2002).
While there are distinctive differences in the means by which all these different types of theory
seek causes, there is one important common factor. All are pluralistic in the types of evidence they
take into consideration. Most broadly, they consider evidence arising from observation (of populations,
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individuals) and also evidence arising from intervention. For a metascientific account this is excellent
evidence in support of a pluralistic account of evidence for causality.
1.3 A note on causal discovery
My historical cases involve the discovery of distinctively causal relations. In what follows, I will use
a simple account of causal discovery in order to clarify the manner in which the relationship between
causality and evidence changes as such causal claims are constructed.
I suggest that the organisation of medical research programmes change as their central causal claims
develop. This change can be seen in the kinds of institutions doing work, the types of research strategies
employed, in the kinds of methodologies employed by these researchers, in the nature of the evidence
produced by them, and in the ways in which this evidence is employed to strengthen, to alter or to discard
these causal claims
Strategies employed early in the history of disease discovery - for example, in attempting to demon-
strate that a clinical scenario is real - rather than spurious - or novel - rather than an unusual version
of some known disease - will be dissimilar from that causal research found in more mature research
programmes. Characteristically, this more mature research would be concerned with attempting to un-
derstand the detailed properties of causal entities, and to understand the manner in which they produce
particular pathological features of the disease state. This concern with detail is sociologically apparent in
the extreme specialisation typical of mature medical research programmes. Researchers may spend en-
tire careers working on one aspect of one cause of one disease without arousing particular surprise. Their
understanding of causality, and the types of evidence they think about, will be very different from that
of the early researcher in the field, attempting to discover if the (diverse) clinical features of a particular
individual represent some kind of new disease. Similarly, their causal methodology may well be quite
different from the specialist researcher working on a different area of research into the same disease.
This shifting nature of the kinds of questions and answers encountered in these long - and diverse
- research programmes thus presents us with an historical problem: we cannot understand causality or
evidence for that causality monolithically. Instead, in order to deal with causation in medicine properly,
we will need to treat it relative to the degree of development of the research program into the condition.
In order to do this, I have employed a simple account of causal discovery to make these distinctions
between different phases of research. This account characterises different phases of research on the
grounds of the type of causal claims sought as the basis for forming an appropriate distinctions between
historical periods.
It is based upon Kuhn’s model of discovery (Kuhn, 1962). While this was developed around his-
torical examples from the physical sciences (Priestley’s discovery of oxygen (or dephlogisticated air),
Herschel’s discovery of Uranus and Roentgen’s discovery of x-rays), it seems to be highly compatible
with causal discovery in medicine. Briefly, Kuhn argues that discoveries are processes that are extended
across time, persons and places. This extension grants discoveries a describable internal history:
. . . discoveries have a proper internal history as well as prehistory and a posthistory.
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Furthermore, within the rather vaguely delimited interval of internal history, there is no
single moment or day which the historian, however complete his data, can identify as the
point at which the discovery was made. Often, when several individuals are involved, it is
even impossible unequivocally to identify any one of them as the discoverer
(Kuhn, 1962, 763)
Now this extension of the history of discovery appears right for these medical cases of causal dis-
covery too. For example, the discovery of the manner in which infection with EBV causes BL took
roughly 20 years to firmly establish, and involved a great many researchers. This suggests that these
causal discoveries in medicine have a rich internal history. Kuhn suggests that this internal history of
discovery can be divided into three, characterisable, stages. First comes the production and recognition
of an anomaly. Discoveries, he claims, begin with the awareness that a particular observation or exper-
imental finding is, in some way, remarkable. As he suggests, the production of such anomalies suggest
that all is not as it should be, and such anomalies are therefore indicative of a tension between an existing
theory and an observation. Anomalies are ‘nature’s failure to conform entirely to expectation.’ (Kuhn,
1962, 762).
However, it is not the case that these anomalies are necessarily easy to recognise. In fact, Kuhn
suggests that for an anomaly to be meaningfully recognised as such, two prerequisites must be in place.
The first of these is that the finder of the anomaly must recognise the anomaly as something striking that
requires further investigation:9
The first. . . is the individual skill, wit, or genius to recognize that something has gone
wrong in ways that may prove consequential. Not any and every scientist would have noted
that no unrecorded star should be so large, that the screen ought not have glowed, that nitrous
air should not have supported life.
(Kuhn, 1962, 763)
The second of these prerequisites is that there must be appropriate theories and technologies avail-
able, such that the anomaly can be both produced and recognised as anomalous:
Whatever the level of genius available to observe them, anomalies do not emerge from
the normal course of scientific research until both instruments and concepts have developed
sufficiently to make their emergence likely and to make the anomaly which results recog-
nizable as a violation of expectation.
(Kuhn, 1962, 763)
This production and recognition of an anomaly is merely the start of the internal history of a dis-
covery. Kuhn’s second stage is the formulation of this anomaly and making it lawlike. This can be
characterised as:
9A good example of this is Burkitt’s very early description of BL, which I discuss in sections 2.2.3.
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. . . a more or less extended period during which the individual and often many mem-
bers of his group struggle to make the anomaly lawlike. Invariably that period demands
additional observation or experimentation as well as repeated cogitation. While it contin-
ues scientists repeatedly revise their expectations, usually their instrumental standards, and
sometimes their most fundamental theories as well.
(Kuhn, 1962, 763)
Finally, he suggests that the process of discovery is not complete until the implications of the new
discovery are investigated. Rather than suggesting that discovery is typically just about finding new facts
that can be added, in an aggregative fashion, to the store of total knowledge. Kuhn argues that important
new discoveries fundamentally change scientific practice, making them assume much greater importance
than they would have as simple facts:
Very often these transformations in the established techniques of scientific practice prove
even more important than the incremental knowledge provided by the discovery itself.
(Kuhn, 1962, 763)
In what follows, I employ a slightly modified version of Kuhn’s model of discovery that is based
upon cases of causal discovery in the history of medicine. Unlike Kuhn, this is an account that is therefore
intended to deal with the discovery of the detailed operation of causes, rather than one that begins with
the discovery of existence claims about entities (as with Kuhn’s examples).
First, I think that something happens to causal anomalies before they become really suitable for
the kinds of collaborative investigations of Kuhn’s second stage. In other words, I want to tell a fuller
story about the internal history of anomaly recognition than Kuhn. Not only do researchers discover an
anomaly, but their initial investigations seek to determine the kinds of ways that it may come about. I thus
break Kuhn’s first stage, of anomaly production and recognition, into two distinct stages. I suggest that
researchers first suspect that a novel type of cause is responsible for some kind of anomaly. However,
they then perform early investigations to detect over what kinds of things this cause operates. I term this
kind of research domain finding. Perhaps this division between types of research activity is related to
Kuhn’s two prerequisites of discovery, with the individual ‘wit’ of a researcher underwriting the process
of suspicion, while the business of domain finding is the causal corollary to the ‘violation of expectation’
from Kuhn’s account.
We might define causal domains as the result of a first-pass classification of possible, likely causes.
I suggest that a newly discovered anomaly must be placed in a broad causal category. To illustrate, does
an anomaly result from the actions of some kind of infectious cause? Or is it produced by a neoplastic
cause? A congenital abnormality? Broadly, deciding the particular domain of a cause is a problem of
classifying possible causes for a particular phenomenon.
Two related example drawn from medical practice serve to illustrate both that this kind of behaviour
occurs, and plays a significant role in learning about causes. The first, rather well described, is that of
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seeking a differential diagnosis for a particular condition (see, for example, Bouchier et al. (1996) as just
one example of entire textbooks devoted to this topic).
The second, while being a key feature of medical practice, is rather less well described.10 This is
classification by an aide-me´moire known colloquially as the ‘surgical sieve’. This kind of classificatory
behaviour consists of generating a list of possible causes by reference to a learned set of possible types
of cause. So we might use a surgical sieve ‘consisting of normal, developmental, trauma, infection,
neoplasia, inflammation, vascular, metabolic’ (Toms et al., 2006, 668) to provide us with the possible
types of disease process as classificatory categories. We can then use these broad pathological categories
to generate the likely possible diagnoses operating in a particular instance - that is, to form a differential
diagnosis. For instance, Stell (1977, 265) classifies the causes of epistaxis (bleeding from the nose
as follows). First, epistaxis may result from either congenital abnormality or acquired insult. These
acquired causes can either be infections (acute or chronic), tumours, trauma, disorders of coagulation,
or idiopathic (i.e. no cause known). These classifiers, provided by the surgical sieve, are general, non-
specific, and predicated more on plausibility than anything else, then act as containers for much more
specific diagnoses evoked when producing a differential diagnosis. Stell (1977, 265), for example, gives
the following specific suggestions as examples of chronic infections likely to cause epistaxis: infection
with syphilis, infection with tuberculosis, infection with Klebsiella ozaenae (ozaena) and so on. In
contrast then, these possible causes are local, deal with specific possible causes, and requires thinking
about the specific manner in which a particular effect comes about.
The causal domain is therefore a manifestation of the kind of simple classificatory behaviour repre-
sented by the surgical sieve.11 Why is it important? First, it plays a vital sociological role. For instance,
which investigators should investigate a newly discovered x? Second, there is a closely related method-
ological point: which research practices should be used to investigate x, and why? The researchers and
research practices involved in investigating an anomaly that is suspected to arise from the actions of an
infectious agent will be quite different from those used to investigate something with a presumptively
neoplastic cause.
I also differ slightly from Kuhn’s position when it comes to the later stages of discovery. The
first of these is the process of mechanism construction. This phase is where researchers develop an
understanding of the specific causal processes that account for the observed anomaly. Finally, researchers
assess this newly developed putative causal mechanism by applying it in disease populations. Perhaps
the full realisation of this stage also consists of some of Kuhn’s third stage of discovery. This application
to disease populations therefore both tests the new causal mechanism, and aims to discover where and
when it occurs. Perhaps this slightly different distinction results from the role of laws of nature in
medicine. Metascientifically, it is not the case that the discovery of a causal relationship in medicine is
10However, it really is very well known in medical practice, and familiar enough to form the basis of a humorous piece in a
festive edition of a major medical journal without explanation (Turmezei, 2009). Briefly, this is a surgical sieve represented in the
form of Beck’s renowned mapping system for the London Underground network.
11I avoid the term: it sounds more like equipment than anything else. In any case, there is very often nothing surgical about the
kinds of relationships I want to use it to characterise.
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described as the discovery of a causal (or indeed, any other) sort of law.
So causal discovery in medicine is characterisable into four stages, and I will use them chronolog-
ically in the case histories. A further characteristic of each of these stages is their evidential pluralism.
At no particular point is any single type of evidence or investigation necessary or sufficient to define
the discovery or characterisation of a causal process in medicine.12 As a related issue, these stages of
causal discovery seem to operate somewhat recursively. First, a novel causal mechanism is suspected to
be responsible for a particular state, E. Next, the likely domain of possible causes, C, are sought. After
this, a mechanism linking C and E is constructed. At this stage, the overall C-E causal mechanism is
broken down into a series of smaller causal processes, C-C1-C2. . . Cn-E. Each of these smaller links is
then investigated in the same way. Their existence is first suspected, and their domain sought, before
they, in turn are related to the operation of a mechanism.13
The cases of viral oncogenesis presented below have formed the evidence base for this account of
causal discovery. It is also illustrated by the other histories of causal discovery mentioned in section 4.5.
However, owing to the particular contingent difficulties of establishing the existence and nature of causal
relationships in these cases, I am reluctant to defend this as a general account of causal discovery in
medicine. In particular, I suspect that in the many cases where discovering causes was much less tricky
than it was in these instances, the characteristic differences between these stages will not be apparent in
the historical sources available. After all, if suspicion, domain-finding and mechanism construction all
occur as part of the research conducted for a single paper, this characterisation will not be apparent. In
what follows, I will therefore use it simply to clarify these histories of viral oncogenesis.
12c.f. also Bechtel and Abrahamsen, 2005, 426
13An historical example of this recursion is provided in section 2.4.
Chapter 2
Epstein-Barr Virus and Burkitt’s Lymphoma
2.1 Introduction
2.1.1 Chapter outline
Burkitt’s lymphoma (BL) is a tumour that is caused by infection with Epstein-Barr virus (EBV). In this
chapter, I outline the manner in which this causal relationship was discovered. I will begin with a brief
note on the contemporary understanding of BL and EBV. I will then move back to the earliest parts of
the story in section 2.2 to discuss the discovery of BL as a clinical syndrome. Section 2.3 will then
detail the initial investigations of the pathology and basic epidemiology of this tumour syndrome in the
field. During this period, researchers used a variety of evidence and techniques to attempt to discover
what sort of causal mechanism1 could account for the unusual features of this tumour syndrome. The
important conclusion arising from these investigations was the suspicion that the disease was a malignant
one, possibly caused by a virus. The next step was the construction of a causal mechanism, linking the
development of the tumour with a viral infection. I will therefore shift my focus to the laboratory in
section 2.4, with a review of the investigations that led to the discovery of EBV, and the construction of
a mechanistic model of its involvement in the pathogenesis of BL. Finally, in section 2.5, I will show
how this mechanistic model was employed to investigate populations at risk of BL in the field.
This story of the linked discoveries of BL, EBV and the BL-EBV causal mechanism, is notable in
a number of respects. It was the first example of viral oncogenesis discovered in humans. As schemes
for demonstrating causality had historically treated tumours and infectious diseases rather differently
(see section 1.2), this case required researchers to think about causality in novel ways. For an infec-
tious agent to cause cancer, the nature of causal claims available to medical researchers had to undergo
fundamental adjustment. Not only did these causal claims have to be unusually transparent and robust,
but researchers also had to appraise the usually tacit assumptions underlying the development of causal
claims in medicine. Instead of remaining in the background, they were drawn out, critically examined
and in some cases reformulated as part of the process of discovery. For the time being, I suggest that
the most important of these relates to evidential pluralism. Not only did researchers look for constitutive
1In this and the next chapter, I will use the term mechanism in a philosophically agnostic fashion. By a mechanism, I mean to
refer simply to some sort of underlying series of linked causal processes. I will return to mechanisms in chapter 5 to give a more
sophisticated reading
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or supportive mechanistic evidence2, but they also reasoned by analogy with the mechanisms of other
disease processes. Multiple types of evidence are often assumed to be characteristic of truly causal pro-
cesses in medicine. But it is only in this sort of highly contentious causal situation where this assumption
is examined. In many ways, a pluralistic approach to evidence is the defining characteristic of this his-
torical case. This evidential pluralism operates across the four stages of causal discovery discussed in
section 1.3 (suspicion, domain-finding, mechanism construction and application). More interesting, it
operates across them in a recursive manner. So not only do we find these steps during the process of
causal discovery linking the clinical syndrome of BL to infection with EBV, but we also see similar
multi-step processes occurring at interim points. As an example, in section 2.4, I show just such an
example of nested causal discovery in EBV research. I will go on in later chapters to discuss this process
of causal discovery in terms of the Russo-Williamson thesis (Russo and Williamson, 2007).
All this means that the inner workings of causal discovery are unusually prominent in the BL-EBV
literature. In particular, both the clinical discovery of the lymphoma syndrome and the early laboratory
work leading to the detection of EBV are unusually explicit in their examination of the assumptions that
usually remain tacit in medical research. These are therefore the sections of the story that I will focus
on. A fuller picture of events as they came about can be found in a number of historical reviews, such as
Epstein, 2001a; Epstein, 2005; zur Hausen, 2006 and Stebbing and Bower, 2009. BL is exceptional for
other reasons too, as it played a paradigmatic role in cancer biology during the late twentieth century.
Likewise, much of our understanding of the detailed functions of both RNA and DNA viruses, including
our knowledge of viral latency, has derived from work on EBV. More broadly, our understanding of
the functioning of gene promoters and of cell-cycle regulation arose in large part from the early work
on B-cell immortalization by EBV. Thus, the BL-EBV story has held greater importance to medical
researchers than perhaps it deserves as a purely clinical problem (Galloway, 1989, 464).
2.1.2 Burkitt’s Lymphoma
So what is BL? It is an extranodal B-cell lymphoma of mature form (Harris et al., 1999, 3837; 3844ff).
Lymphoma describes a solid blood-cell tumour, particularly of lymphocytes or lymphocyte precursors.3
B-cell refers to B-lymphocytes, and mature form suggests that the tumour cells resemble normal B-
lymphocytes, which are the immune cells responsible for mounting antibody attacks against foreign
agents. Finally, extranodal suggests that the disease tends to form solid tumours outside lymph node
structures.
Clinically, the tumour usually presents as a large mass in the bones of the jaw, often involving more
2As with the use of the term mechanism, I do not mean this to carry any baggage for the time being. I will develop the term
mechanistic evidence in chapter 6
3Leukaemia, in contrast, refers to blood-cell tumours which exist in a distributed form in the blood and bone marrow, rather
than constituting a solid tumour. There are a range of intermediate forms between lymphomas and leukaemias (Magrath, 2002,
2377). For instance, some patients with lymphomas may begin to develop a leukaemic stage with cancer cells circulating in the
blood. This happens in some cases of BL, meaning that strictly speaking researchers now construe it existing as a spectrum of
disease, with BL as one extreme, Large B-Cell Lymphoma (LBCL) at the other and with an intermediate category of Burkitt-
Like Lymphoma (BLL) between the two. (Harris et al., 1999, 3845; Magrath, 2002, 2379; 2391). But the terms leukaemia and
lymphoma are descriptive enough to sustain the following discussion.
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than one quadrant4 with further tumours in the abdomen (Ziegler, 1981, 738; Magrath, 2002, 2390). It
is highly malignant, possibly the most rapidly growing tumour of humans (Iversen et al., 1974; Ziegler,
1981, 738). It has a characteristic age incidence, with almost all cases occurring between 2 and 16 years,
peaking at 7 years. There is a male:female ratio of about 2:1 (Ziegler, 1981, 738). Globally, it constitutes
about 5% of all childhood malignancy (Magrath, 2002, 2378).
Histologically, the cells are relatively monomorphic (i.e. all the tumour cells appear similar), with 2-
5 nucleoli and an ‘open’ nuclear chromatin pattern (Magrath, 2002, 2378). The tumour is said to display
a ‘starry sky’ pattern, owing to the presence of tingible body macrophages, although this appearance is
not specific for BL (Magrath, 2002, 2379). The cells have a germinal centre phenotype (CD38-positive)
and 90% express IgM surface immunoglobulin with κ or λ light chains. The cells also express typical
B-cell antigens.5
There are three forms of the disease.6 Most cases occur in tropical Africa, and are known as
endemic BL. Outside this area exists a sporadic form of the disease. Sporadic BL affects slightly older
children, who more often develop abdominal tumours (Ziegler, 1981, 738). The two forms also have
different cytogenetics, with a degree of variability in the types of chromosomal translocations found
in them. However, the tumour cells, response to treatment and patient prognosis are similar (Ziegler,
1977; Ziegler, 1981, 738). There is also an AIDS- or immunosuppression-associated form of the disease
(Hecht and Aster, 2000, 3708). While aware of this distinction between types, I will speak exclusively
of the endemic form in this chapter.
2.1.3 Epstein-Barr Virus
EBV is a B-lymphotropic γ-herpesvirus. It infects B-cells, and is capable of immortalizing them (Kieff
and Rickinson, 2001, 2511-5). The virus is highly prevalent in adult human populations worldwide, with
up to 90% of adults displaying evidence of infection (Henle et al., 1969). Detailed seroepidemiological
studies have, however, revealed that the age of first infection differs greatly between populations. EBV
infects children in the developing world much earlier than in developed countries (Evans and Niederman,
1989). This difference in age at primary infection has been explained in terms of differential mechanisms
of transmission between populations. As EBV is transmitted via buccal fluid (Gerber et al., 1972), any
activities that share saliva can cause the transmission of the virus. For example, pre-chewing of food by
adults as a weaning practice in developing countries is often held as a cause of childhood infections with
EBV.7
Clinically, primary infection is usually asymptomatic, although a minority of adolescents and
adults develop infectious mononucleosis (IM). This is a non-malignant syndrome of fever, cervical lym-
4Right and left hand sides of the maxilla (upper jaw) and mandible (lower jaw)
5CD10, CD19, CD20, CD22, CD 77 and CD79a positive (Magrath, 2002, 2378)
6An excellent comparison between the forms is Thorley-Lawson and Allday, 2008, 914: box 1
7However, the precise mechanism by which EBV reaches the saliva remains controversial (Allday and Crawford, 1988; Niedo-
bitek and Young, 1994; Rickinson and Kieff, 2001). Some suggest that the virus, in addition to infecting B-lymphocytes, is
also active in epithelial cells of the oral mucosa, which are then shed in saliva (Sixbey et al., 1984). Others argue that the virus
reaches the saliva through a lytic form of infection occurring in mucosal lymphocytes (Weiss and Movahed, 1989; Tao et al., 1995;
Karajannis et al., 1997).
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phadenopathy and sore throat, followed by a lengthy period of fatigue and malaise. Research suggests
that infection with the virus relatively late in life predisposes to developing IM, and this suggestion is
born out by the very low incidence of IM in the developing world, where the average age at primary
EBV infection is very much lower than in the West. While IM will play a role in this chapter (see section
2.4.3), a much greater one will be played by diseases associated with EBV re-activation. The virus can
remain dormant in B-cells (Kieff and Rickinson, 2001, 2515), often for very many years. Rarely, long
after initial infection, the virus become active again in the B-cell population or in other cells, resulting
in a range of malignant human diseases.8 These include BL, nasopharyngeal carcinoma (de Schryver
et al., 1969; zur Hausen et al., 1970), gastric cancers (Herath and Chetty, 2008), Hodgkin’s lymphoma
(Pallesen et al., 1993), childhood leimyosarcomas (Lee et al., 1995; McClain et al., 1995), T-cell and NK-
cell lymphoma (Pallesen et al., 1993) and the premalignant condition oral hairy leukoplakia (Komatsu
et al., 2005). There are also a number of EBV-associated tumours found specifically in HIV/AIDS pa-
tients (MacMahon et al., 1991) or in individuals with other forms of immunosuppression (Hopwood and
Crawford, 2000). EBV has also been tentatively suggested to be a possible cause of some chronic non-
malignant diseases, including multiple sclerosis (Pender, 2009) and chronic fatigue syndrome (Glaser
et al., 2005).
The world-wide distribution of EBV and the wide range of clinical manifestations of EBV-
associated disease presented major difficulties for researchers attempting to show that the virus caused
BL, as I will discuss in section 4.4.1.
2.2 Suspicion: BL as a tumour syndrome
2.2.1 The clinical discovery of BL
Burkitt’s first description of the lymphoma syndrome made the following points.9 First, while malignant
tumours of the jaw were thought to be rare in children, they appeared to be unusually common in parts
of Uganda. In fact, in the region of the Mulago hospital on the outskirts of Kampala, they were by far
the commonest malignant disease of childhood (Burkitt, 1958, 218; 223). Based on 38 cases occurring
during the period 1951-8, he described an apparently novel jaw tumour syndrome (Burkitt, 1958, 218).
This tumour was multifocal, with histologically similar material found both in the bones of the jaw and
at other anatomical sites, including within the abdomen (Burkitt, 1958, 219; 221-3). He then gave a
histological description of the tumour,10 before speculating about its origins and nature:
. . . the clinical picture of this sarcoma is easily recognized, [but] its site of origin and
nature remain obscure. . . It may well be that we have in Uganda a syndrome of diverse
characteristics. . . which has attracted attention owing to its very striking clinical features.
8For a review see Deyrup, 2008
9A note on terminology. The term Burkitt’s lymphoma dates from the 1962 UICC conference on reticuloendothelial tumours
in Africa (Glemser, 1971, 124). Despite this anachronism I will use the term from the outset for the sake of clarity.
10‘[the tumour is]. . . highly malignant. . . with a large open vesicular nucleus, usually showing two prominent nucleoli. The
cytoplasm is scanty and mildly eosinophilic. These cells occur singly or in clusters, often in rounded, otherwise clear spaces
surrounded by masses of small, dark, round cells with dark compact hyperchromatic nuclei and scanty cytoplasm and strongly
resembling lymphocytes; in some cases the tumour resembles a lymphosarcoma.’ (Burkitt, 1958, 220).
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Still less is it intended to speculate as to why this sarcoma should occur so frequently here.
So far no common factor has been recognized which might have a bearing on the aetiology.
(Burkitt, 1958, 221-3).
So Burkitt here described the clinical features of an unusual, possibly novel, tumour syndrome, with
high incidence in Uganda. His description, at this stage, did not concern the details of any underlying
pathological mechanism. However, as the tumour appeared to strike at many different parts of the body
simultaneously, including multiple sites within the jaw and within the abdomen, this clinical description
itself implied some kind of aetiological novelty - most primary tumours11 do not behave like this.
For these phenomenological features of the tumour syndrome to be accounted for by a malignant
process, a novel mechanism of simultaneous, multifocal oncogenesis occurring in both jaws and ab-
domen of each of these subjects would be required. The alternative would be equally challenging: if
the primary tumour began in either the jaws or abdomen, and metastasised to the other sites, a novel
mechanism of simultaneous, specific and multifocal metastasis would be needed.12 For the time being,
Burkitt suggested neither. Instead, he stressed the novelty of the clinical picture qua clinical picture.
At this juncture it seems worthwhile to give a brief biographical sketch of Burkitt, together with
some historical background to this first description of BL. I will return to the lymphoma syndrome
presently.
2.2.2 Denis Burkitt
Denis Burkitt (1911-1993) was born in County Fermanagh, Northern Ireland. After initially training as
an engineer, he read medicine at Trinity College Dublin, graduating in 1935. After completing positions
as a house surgeon, he successfully sat the examinations for the Fellowship of the Royal College of
Surgeons of Edinburgh in 1938, before sailing as a ship’s surgeon to China. While on this voyage, he
made a decision to continue his surgical career in the developing world (Epstein and Eastwood, 1995,
91). During the Second World War, he applied to join the Royal Army Medical Corps and, at his second
attempt (Glemser, 1971, 36) was posted to Uganda in 1943. Following demobilisation in 1946, he
applied to the then Colonial Office in order to continue his work in Uganda, and was briefly posted to
Lira, in the Lango district before being transferred to the Mulago hospital on the outskirts of Kampala in
1948 (Epstein and Eastwood, 1995, 92), where he was to remain until he retired from surgery in 1964.
A period of working for the Medical Research Council then followed, initially in Uganda, and then in
London from 1966-76 (Heaton, 1993, 951).
Studying Burkitt’s bibliography (available ff. Epstein and Eastwood, 1995) the range of his early
work - including publications on vascular surgery, urology, orthopaedics and general surgery - is remark-
able. This is perhaps not so surprising given his likely range of clinical duties at the Mulago hospital.
Located on the outskirts of the Ugandan capital, and now a flourishing university hospital, at the time
11Primary tumours refer to those found at the original site of the tumour. Secondary tumours, on the other hand, are those that
have spread - metastasised - from a primary tumour at a remote body site
12Most tumours metastasis by either spread in the blood, in the lymphatic system, or by direct contact - for example within the
abdomen. None of these mechanisms appears a good fit with the clinical details of this tumour
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of Burkitt’s appointment, it ‘consisted of thatched, single-storey huts housing the wards together with
rudimentary ancillary facilities’ (Epstein and Eastwood, 1995, 92). It was at this institution that he was
to describe his eponymous tumour. How did a general surgeon - without specialist experience of either
paediatrics or oncology - come to describe this disease?
2.2.3 Background to the clinical discovery of BL
Convention dictates that Burkitt first encountered the disease in 1957. Burkitt was called by his colleague
Hugh Trowell (1904-1989) to see a 5 year old boy named ‘Africa’ in Ward One of the Mulago Hospital
(Glemser, 1971, 49). The boy’s symptoms were strikingly unusual, but did not cause Burkitt to suspect
a significant anomaly in need of investigation:
His face was massively swollen, with bizarre lesions involving both sides of his upper
and lower jaws. I had never seen anything like it. The teeth were loose and the features
grossly distorted. If a single jaw quadrant had been involved, I might have considered it to
be an infective process such as osteomyelitis, but not with all four quadrants affected. This
unusual distribution also seemed to rule out any form of neoplasia. Results of the biopsy
had suggested some form of granuloma. I was totally baffled, but photographed the child
and considered this to be another of the curiosities one had to become accustomed to seeing
from time to time in Africa.
(Burkitt, 1983, 1777).
However, it appears that this wasn’t the first time that Burkitt had been made aware of unusual
tumours of the jaw in children in Uganda. For one, these tumours had been noted by other medical offers
at Mulago since at least 1948 (Glemser, 1971, 49). Further, a record of a clinical meeting in Mulago
entitled ‘Tumours of the Jaw’ on the 29th October, 1955 exists, at which Burkitt was present (Singh,
1955). In this note, the higher incidence of jaw tumours at Mulago than in either Europe or America
was noted (Singh, 1955, 70). Furthermore, the histology of at least ten of these tumours were suggestive
of the Burkitt type.13 Burkitt is mentioned in the discussion of these ‘small round-cell sarcomas’. This
suggests that Burkitt was already somewhat acquainted with these unusual jaw tumours before meeting
his ‘first’ case.
Some evidence also suggests that Trowell had previously encountered the tumour:
Once, in 1935, when he [Trowell] was on safari to the islands of Lake Victoria, in-
specting the population for evidence of sleeping sickness, he came across a little boy with
“lumps” on the jaws. ‘I can’t remember much about it except that I thought it was a peculiar
complaint, and I told the boy, I can’t treat you here, you must come back to Mulago with
me. I didn’t know what the disease was, because it wasn’t one lump, which might be called
13They are recorded as ‘lymphosarcomas. . . mainly in the younger patients. . . [which] were small round-celled growths without
rosettes’ (Singh, 1955, 70). As I will discuss, there was no clear referent for Burkitt-type tumours before Burkitt’s description. The
terms lymphosarcoma and reticulum-cell sarcoma are often considered to encapsulate the majority of tumours that would now be
described as Burkitt’s lymphoma or Burkitt-like lymphoma.
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an ordinary cancer, but several lumps. Vaguely, at the back of my mind, was the knowledge
that the children out here had these lumps: one encountered them from time to time, one
would ask surgeons to see them but nobody could throw much light on the trouble.’
(Glemser, 1971, 60).
E.H. Williams, who would later publish extensively on the epidemiology of BL (see e.g. Burkitt
et al., 1963; de-The´ et al., 1978) also recounted seeing several cases of the syndrome over the years
(Glemser, 1971, 102). Others did too. For instance, Sir Albert Cook’s 1901 records from Mengo hospital
in Uganda mention similar jaw tumours (Hutt, 1981, 762). There are further reports noting the high
frequency of jaw tumours in Uganda, dating from at least 1897 (Davies et al., 1964, 339 and appendix
1).
So it is clear that this phenomena was fairly wide-spread, and that many individuals were in some
way aware of it before Burkitt. However, it was Burkitt who meaningfully recognised the strangeness of
these jaw tumours.14 His curiosity was pricked when he saw a child with similar symptoms to Africa a
few weeks later while visiting the district hospital in Jinja, on the northern shores of Victoria Nyanza,
fifty miles from Kampala (Glemser, 1971, 50):
A few weeks later, I was doing a ward-round in another hospital which I visited reg-
ularly. . . my attention was attracted by a child with a swollen and distorted face. . . to my
surprise, recognized precisely the same features as I had observed in the Mulago Hospital
ward a few weeks previously. My interest was rivetted immediately. A curiosity can occur
once, but two cases indicated more than a curiosity.
(Burkitt, 1983, 1777-8)
2.2.4 Two cases become a syndrome
Burkitt began to believe that these two patients were not isolated oddities (Burkitt, 1983, 1778). I sug-
gest that it was at this point that Burkitt began to suspect the possibility of a distinct causal mechanism
underlying this tumour syndrome. More than just jaw tumours, other features of these cases, such as ab-
dominal tumours, were suggestive of fundamental, generalizable similarities. This association between
jaw and abdominal tumours had been previously noted at Mulago. Burkitt’s examination of the hospital
records, spurred by these two cases, led to a growing recognition of this as a significant unifying feature
of the syndrome. He recounted how he began formulating his description of a clinical syndrome based
on these cases:
I went retrospectively through the records of all children suffering from malignant tu-
mors, and the majority were found to be in certain particular sites, including the jaws, or-
bit and eye, kidneys, adrenals, and ovaries and, occasionally, in the liver, testicles, thyroid
gland, and long bones. . . A characteristic feature was the usual absence of peripheral lymph-
node involvement. Two points became abundantly clear: first, these various tumors tended
14The nature of this anomaly recognition (c.f. Kuhn, 1962) is something that I address in sections 1.3 and 6.3.1
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to be associated with one another in individual patients; and second, since the jaws were not
always involved, tumors there could not be the primary lesion. The recognized associations
between what were previously assumed to be totally different diseases prompted the conclu-
sion that whatever the nature of these tumors, they must be part of the same disease process,
a conclusion that was strengthened by the similar age distribution regardless of where the
tumor was cited.
(Burkitt, 1983, 1778)
There was also histopathological consistency, not only between both tumours in each patient, but
between the tumours of different patients:
C. T. O’Conor and J. N. P. Davies went retrospectively through histologic slides of can-
cers in children, and came to the conclusion that all of these tumors were not only histo-
logically identical, but also were some form of lymphoma.15 Consequently, they altered
previously made diagnoses and what had emerged as a clinical syndrome became a patho-
logic entity.
(Burkitt, 1983, 1778)
So by the time these first two cases were reported, the clinical features, histological consistency and
the suspicion of a clinical cohort with a characteristic age incidence were already present. These initial
findings were presented at a staff meeting at the Mulago hospital in 1957 (Glemser, 1971, 68-9), before a
more formal presentation at the annual meeting of the East African Association of Surgeons in Kampala,
during January 1958 (Glemser, 1971, 106). The 1958 paper developed from these two presentations.
Remarkably, however, it was not widely read, despite its apparent importance as a novel description of
an apparently common condition. Burkitt is most clear upon the reasons for this failure:
. . . I wrote my first paper describing this tumor and, as a surgeon, considered it an op-
portunity to get an article into the British Journal of Surgery. In retrospect, it was the wrong
journal in which to report work of this nature, and it received minimal attention.
(Burkitt, 1983, 1779)
Happily, this indifference was short-lived, and subsequent publications were much more successful.
These later findings, though, represented a significant shift in the direction of BL research. The first BL
publications largely attempted to make the case for the possible existence of a distinct causal mechanism
underlying the observed clinical features of BL. Later papers, however, in the main assume the existence
of some sort of causal mechanism, and focus on demonstrating and exploring its features. Notable are
the attempts made to demonstrate the novelty of this mechanism, and the attempts made to determine
the causal domain within which this new mechanism operated.
15Discussed in O’Conor and Davies, 1960
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2.3 Domain finding: BL as a geographical disease
This phase of research therefore comprised two related branches of investigation. First, researchers
demonstrated that the suspected mechanism was a novel one. This involved giving a detailed, unified
clinical description of the disease, with the intention of ensuring that this syndrome was not, for instance,
an unusual manifestation of another, known disease. One characteristic part of this process was the
distinction drawn between the lymphoma syndrome and leukaemia, as I discuss in section 2.3.2. Second,
researchers attempted to determine the nature of the domain of the suspected causal mechanism. This
began with the demonstration of the malignant nature of the syndrome. Then, the character of research
altered towards attempting to discover the domain of the likely causes of this malignancy. In large part
this focused on the possible infectious nature of the tumour, as suggested by its unusual epidemiology.
At the end of this phase, though, there was no detailed causal mechanism capable of explaining the
occurrence of BL. Instead, what was understood was the likely nature of this, as yet undiscovered,
mechanism.
2.3.1 Building a clinical picture
The second, third and fourth papers published on the lymphoma syndrome detailed the clinical and
epidemiologic features of the tumor (Burkitt and O’Conor, 1961), and its pathological and histopatho-
logical features (O’Conor and Davies, 1960; O’Conor, 1961). Unlike their predecessor, they were to
arouse global interest in the tumour (Burkitt, 1983, 1779).
Burkitt and O’Conor, 1961 described a review of the lymphoma syndrome based on 106 cases aged
from birth to 14 years living in the Mengo district of Uganda. The clinical features were similar to
those previously documented. The authors found that the disease had a peak incidence at ages 3-8 years
(Burkitt and O’Conor, 1961, 262), and recorded that abdominal tumors seemed to be present in all cases
with jaw tumours. Furthermore, the authors claimed that the syndrome had a generalized distribution in
an East-West belt across Equatorial Africa, with localized areas within this belt having a much higher
BL incidence than others. When combined with the observation that tribal and racial factors did not alter
the disease incidence, the authors therefore concluded that the syndrome was likely to be caused by the
influence of environmental factors.
O’Conor and Davies, 1960 confirmed that the jaw and abdominal tumours seen in the lymphoma
syndrome were histologically indistinguishable, poorly differentiated lymphosarcomatous lymphomas
(O’Conor and Davies, 1960, 531-4). O’Conor, 1961 reinforced the other descriptions of clinical features
and offered a histological characterisation of the tumour, reporting that 95% (101 of the 106 cases)
were of similar histological appearance,16 and went on to suggest that this histological homogeneity was
evidence for these clinical cases being instances of a unified clinicopathological entity:
As has already been inferred from the histological description, there is a closer morpho-
logical and apparent cytogenetic relationship between the tumors of this entire series than
one would expect to encounter in such a large group of lymphomas, so that they seem to
form a histological entity as well as a clinical syndrome. If the purpose of classification is
16In fact, 83% were ‘poorly differentiated lymphocytic’, 10% stem-cell type and 2% mixed-cell type (O’Conor, 1961, 277).
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primarily to indicate a probable course or prognosis, there would hardly be justification for
division within these 106 cases. . .
(O’Conor, 1961, 277)
Before long, the multicentric nature of the tumour, and its strong preference for unusual anatomical
sites17 became, rather than a diagnostic puzzle, a characteristic feature of the syndrome (Burkitt, 1962a,
232-3; Burkitt, 1962d, 217; Burkitt, 1962f, 71). This provided further evidence for the unified and
distinctive nature of the disease. This process of unification was exceptionally clinically important:
It may be wondered how this tumour syndrome has passed unnoticed until the last few
years. Individual trees had called for comment, but the wood had apparently not been seen.
Rapidly growing tumours had been observed in the jaws of children, but had not been rec-
ognized as a specific entity and part of a multicentric tumour syndrome. Also the frequent
occurrence of ovarian lymphosarcoma had been reported from the Cameroons (Capponi,
1953). It was the recognition that many unusual and hitherto unconnected tumours were, in
fact, but different manifestations of one tumour syndrome that initiated investigation of the
problem as a whole.
(Burkitt, 1962f, 75-6)
The features of the disease were refined by three early reviews of the clinical aspects of the lym-
phoma syndrome (Burkitt, 1962a; Burkitt, 1962d; Burkitt, 1962f), each of which spelled out the malig-
nant nature of the disease. Burkitt’s other three papers of 1962 (Burkitt, 1962b; Burkitt, 1962c; Burkitt,
1962e), though, focus on finding the domain of the likely causes of this malignancy, largely by investi-
gating the geographical features of the disease epidemiology. What were these geographical features?
First, that BL is a common and distinctive syndrome of children in Africa, as opposed to a disease
of children of African descent. While Burkitt’s initial cases did not include any Caucasian children, and
only one each of Asian descent and of mixed race, this was to be expected given the relative proportions
of different races in the catchment of the Mulago hospital. Burkitt was most careful to stress that the
syndrome was not specific to any one racial, tribal or social group and was, instead, a disease of all
children living in Africa, with an apparent bias towards black Africans purely because of their majority
status within the population.18
Second, that this disease was not new, being instead locally and anecdotally reported long before
the recognition that it was a distinct clinical entity (Burkitt, 1962a, 232; Burkitt, 1962d, 211; Burkitt,
1962f, 71). When the clinical prominence of the lymphoma syndrome is considered, it is surprising that
Burkitt was the first to describe it as a common clinical entity. Some justification for this may be found
in the early publications on the subject:
17Not only does BL tend to attack parts of the body usually spared by malignant disease, but it also spares other sites which are
usually considered highly susceptible, such as the axial skeleton, lymph nodes and the lungs.
18Later came reports of BL in European children living in Africa (Clift et al., 1963, 244; Glemser, 1971)
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We know too that it has been occurring for many years past although its unitary nature
was not recognised. . . The exact nature of this tumour has yet to be defined and a number
of names could and have been applied to it: lymphosarcoma, reticulum cell sarcoma, stem
cell lymphoma. It is here referred to as “lymphoma”. It is evidently a highly anaplastic
malignancy developing in primitive mesenchymal cells of the reticuloendothelial system.
(Burkitt and Davies, 1961, 368)
So the failure to recognise this tumour syndrome reduced its apparent incidence. This is hardly
surprising. But there were more interesting manifestations of this classificatory confusion. For instance,
several malignant diseases, with apparently high incidence in Africa at this time, turned out to be part
of the lymphoma syndrome. These included round-cell sarcoma of both the kidney and liver, retinoblas-
toma, neuroblastoma and lymphosarcoma of the ovary (Higginson and Oettle´, 1960; Brew and Jackson,
1961).19 Some cases of BL were also reported as non-malignant disease (Murray and Brandt, 1951;
Bowesman, 1960).
One important aspect of this diagnostic confusion was apparent in the investigations of the relation-
ship between BL and childhood leukaemia.
2.3.2 BL and leukaemia
Perhaps surprisingly, there was a detailed registry of cancer cases kept in the Ugandan capital at this
time.20 Of special note is the high incidence of lymphomas recorded in the area. O’Conor and Davies,
1960, reviewing the data on childhood malignancies from the Kampala cancer registry, noted the high
incidence - approaching 50% of all childhood cancer - of lymphoma, and the very low rates of leukaemia.
This was despite the relatively effective surveillance in place for leukaemia, an accidental feature of
examination of blood-films for malaria, which would also detect the abnormal cells seen in leukaemia.
19It is a puzzle that, despite the distinctiveness of the syndrome, its recognition was so tricky: ‘Experienced clinicians, radiolo-
gists and pathologists are of opinion that, accepting the criteria appropriate to their specialty, they can recognise this clinical entity;
and it is perhaps strange that before Burkitt’s observations the condition had escaped identification.’ (Pulvertaft, 1964, 238). If
the tumours were mistakenly classified as a variety of different conditions then the apparent incidence of each would have been
artificially reduced. This diagnostic confusion is evident in many publications from this period. For example a review of head and
neck tumours from Kenya in 1961 (Clifford, 1961), the author referred to forty cases of the lymphoma syndrome as instances of
Hutchison’s syndrome (Clifford, 1961, 710). While this term is no longer widely used, it refers to a syndrome of a primary adrenal
tumour with metastases to the bones of the skull, generally caused by a neuroblastoma. It was first described by Hutchinson in
1907. Referring to Hutchison, 1907, the clinical differences between this and the Burkitt tumour are striking. Histologically, while
the cells of the tumour are similar to those of Burkitt’s lymphoma, both being small, round and basophilic, the overall microscopic
appearance is quite different owing to the fibrillar matrix within which the cells of Hutchison’s syndrome are typically embedded.
Clifford recognised this difficulty: ‘Histologically, the tumour appears as a lymphoma or round cell sarcoma rather than a neurob-
lastoma, though clinically there is nothing to suggest such a diagnosis. It is recognized that the term “round cell tumour” is inexact
and unsatisfactory, but to label this tumour a lymphoma or a neuroblastoma, would be incorrect at present.’ (Clifford, 1961, 716)).
This was despite the very close fit in clinical appearance between the syndrome he described, and that which Burkitt described in
his 1958. It is most unlikely that Clifford’s cases were true neuroblastomas.
20For background on the Kampala Cancer Survey at the time see Davies et al., 1958. This gives very useful general information
on the nature of the survey. It also gives overall rates of different types of cancers in the area of Mulago, with comparison rates
from Denmark.
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This high lymphoma:leukaemia ratio was the converse of that which one would expect to see in a Western
population (O’Conor and Davies, 1960, 528-9). Further confirmation of the high historical incidence of
lymphoma in the Mulago hospital pathology records arose as a side-effect of research into malignant
diseases of the heart (Lothe and Somers, 1960).21 They concluded, on the basis of their research and a
review of the contemporary literature that: ‘. . . in the Uganda series malignant lymphoma is nearly four
times as common as it is in British and American series.’ (Lothe and Somers, 1960, 160).
This tallied with the observations of Burkitt and O’Conor (Burkitt and O’Conor, 1961, 259-60) that
leukemias were present at a much lower incidence, and the lymphomas at a much higher incidence, than
would be expected in a European population. They went on to add: ‘We have not as yet seen leukemia
in association with this lymphoma syndrome, even in the terminal phases of the disease.’ (Burkitt and
O’Conor, 1961, 268). This was further supported by an analysis of leukocytes from 32 cases of the
lymphoma syndrome seen at Mulago, which demonstrated no evidence to suggest that the lymphoma
syndrome was in any way leukaemic (Stansfield, 1961). Likewise, O’Conor and Davies (1960, 533)
suggested that they had seen only one patient who had developed any leukaemic features in their series of
57 cases. So was the lymphoma syndrome in some way an unusual manifestation of acute lymphoblastic
leukaemia? Could the two diseases share a similar aetiology, with each disease developing on the basis
of prevalent local environmental factors?
Study of the lymphomas of African children has led to the observation that these may
well be simply a different expression of childhood lymphoma which in North America usu-
ally manifests itself as acute leukaemia.
(Dalldorf, 1962, 1028)
Similarly, O’Conor and Davies (1960) mention the relationship of lymphoma and leukaemia in
Africa:
Since malignant lymphoma in this study has replaced lymphatic leukaemia as the most
common neoplasm of childhood, it is suggested that this may represent a true variation in
the site of malignant proliferation and, more important, an alteration in the natural history
and course of the diseases of the lymphopoietic system.
(O’Conor and Davies, 1960, 529)
Part of this environmental thinking was due to the sharp local variations seen in leukaemia and
lymphoma incidences. Surveys from Africa, but outside the lymphoma belt (see section 2.3.4), such as
Higginson and Oettle´ (1960, 651-3), showed similar rates of leukaemia and lymphoma to those of Europe
and North America. This inversion of the expected ratio of leukaemia and lymphoma cases within the
belt led to the suspicion that some kind of geographically distributed environmental factor was causally
responsible. When this suspicion was combined with the other unusual features of the tumour, the theory
21Interestingly, this work was carried out at the urging of Professor J.N.P. Davies, who features heavily in the story of the
discovery of BL. (Lothe and Somers, 1960, 166).
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that BL might have an infectious cause became a serious possible explanation for the aetiology of the
tumour.
2.3.3 BL as an infectious disease?
It is worth at this point reviewing the evidence that supported the hypothesis that BL was an infectious
disease, or one at least caused by the influence of an external environmental factor. First, the homo-
geneous nature of the lymphoma syndrome supported a distinct identity for the syndrome. Second, its
characteristic age incidence and geographical distribution, in the absence of some identified racial or
tribal (specifically behavioural) cause (Burkitt and Wright, 1963, 130-1). Third, the apparently recip-
rocal relationship between leukaemia and the lymphoma syndrome. Finally, it was suggested that the
tumour histologically resembled certain animal tumours caused by viruses.22 Only an infectious cause
really seemed to plausibly account for these features, as the environmental factors generally considered
to be plausible contributors to oncogenesis appeared not to correlate with the tumour. These factors in-
cluded diet, aflatoxin exposure (see section 4.5.2.3) and background radiation levels (reviewed in Burkitt
and Wright, 1963, 131ff).
This infectious hypothesis gained some further support from a previous research programme. Au-
thors had previously noted unusual jaw swellings in this part of the world which were apparently due
to the actions of an infectious agent (e.g. Bowesman, 1960, ascribed similar lesions in Ghanese chil-
dren to histoplasmosis; while Murray and Brandt, 1951 outlined the possibility of a relationship between
histoplasmosis and malignant lymphoma). However, as no fungi were seen in any of the material, this
research had become outdated. But a viral infection could provide a very convincing explanation of the
phenomena:
Although there is no doubt that the disease as reported in this paper is a neoplastic one,
and we have found no identifiable fungi in any of the material studied, the possibility of
a priming action of the reticuloendothelium by some parasite with subsequent malignant
change must be seriously considered.
(O’Conor, 1961, 282)
Put together, this evidence suggested that the syndrome might be due to an arthropod-vectored virus
(Burkitt, 1962a, 234; Burkitt, 1962d, 217-9; Burkitt, 1962f, 77). This suspicion led to the re-examination
of an old direction of research: a more detailed investigation of the geography of the disease.
2.3.4 Geographical epidemiology and the tumour safari
The suspicion that BL occurred in a particular geographical pattern - soon known as the lymphoma belt
- was an important reason for researchers to suspect an infectious aetiology for it. However, substantial
refinement was required before this could be anything other than speculation. This research proceeded in
two ways. First, the boundaries of the lymphoma belt were sought by attempting to discover cases of BL
occurring outside the endemic area. The diagnostic confusion that existed before the clinical description
22See the brief review of animal viral oncogenesis in section 1.1.
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Figure 2.1: Cases of the lymphoma syndrome reported from the 1961 postal survey. Each blue dot
represents a medical centre reporting one or more cases. The red dot is Mulago hospital. Data derived
from Burkitt, 1962a.
of BL suggested that diagnosis could be easily be missed altogether, or fitted in to many other diagnostic
categories. Thus they sought to demonstrate the scarcity of the disease outside the lymphoma belt. For
instance, O’Conor (1961) stressed the relatively precise localisation of BL by reviewing the literature
for cases, and finding just four plausible reports occurring outside the lymphoma belt,23 although Burkitt
later managed to increase this to fourteen.24 All give descriptions of similar cases occurring well outside
the endemic area. However, this scarcity suggested that the disease was very much less common outside
tropical Africa than within it.
The second part of their research was to map out the precise spread of the lymphoma belt itself.
Burkitt initially conducted a postal survey of African hospitals, asking for sightings of the distinctive
clinical features of the lymphoma (Burkitt and Wright, 1963, 103-4). This was sufficiently successful to
allow him to map the location of these case reports of lymphoma syndrome, as demonstrated in figure
2.1.
Thus, Burkitt (Burkitt, 1961) concluded that the lymphoma syndrome was seen to occur in a belt
across the continent, spanning the equator with a tail running down the east coast and sparing the northern
and southern extremities (Burkitt, 1961, 511-2).25 He also noted that the islands of Zanzibar and Pemba,
lying off the coast of Tanganyika (now incorporated into Tanzania) were spared entirely (Burkitt, 1961,
23These are Maxwell, 1954, Nigam, 1954, Egan and Dodd, 1957 and Orso´s, 1958.
24These publications, listed in Burkitt and Wright, 1963, 69-70, are three cases in Dargeon, 1961, and one each in Brown and
O’Keefe, 1928, Craver and Copeland, 1934, Christiansen, 1938, Salman and Darlington, 1944, Burford et al., 1944, Hellwig, 1947,
Maxwell, 1954, Nigam, 1954, Egan and Dodd, 1957, Orso´s, 1958 and Phan-Ngoc-Duong and Dao-Duc-Hoanh, 1961.
25It appeared that Burkitt had a ‘. . . lifelong passion for plotting things on maps’ (Heaton, 1993, 951). His later work, on dietary
fibre and its link to diseases of the developed world, also came, in part, from work on geographic pathology. This love for maps
has been attributed to the influence of his father, a surveyor. His earlier work also demonstrates geographical skill, for example
demonstrating geographical variations in the incidence of testicular hydrocoeles (Burkitt, 1951).
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Figure 2.2: Map showing reported cases of BL (blue dots) with climatic area indicated in yellow.
512). Furthermore, there appeared to be areas within the tumour belt in which the tumour did not occur
or, at least, occurred with greatly reduced frequency. This distribution led to enquiries into the unifying
factors common to these areas:
I showed my maps of tumour distribution to Dr. Haddow, of the Virus Research Institute
at Entebbe, and he tried by a reverse process to see whether he could produce a map similar
to mine. He found that if he took a map of Africa and eliminated all areas where the mean
temperature fell below 60 degrees F. at any time of year, areas over 5,000 feet in altitude,
and areas where the mean rainfall of the year fell below 30 inches, he could produce a
map which is almost identical with the map of tumour distribution. This suggests that the
type of vegetation (being dependent on rainfall) and the temperature are two major factors
determining the distribution of this tumour.
(Burkitt, 1961, 512-3)
This map of climactic factors, overlaid with Burkitt’s survey cases, is given as figure 2.2. As varia-
tions in the local climate seemed to influence the incidence of the tumour so strongly, agents dependant
on particular climatic conditions became implicated in the development of BL. For instance, certain
arthropods were known to have distributions that appeared compatible with the lymphoma belt. Two
arthropods of known medical importance seemed likely candidates (Burkitt and Wright, 1963). The first
was tsetse (Glossina spp.), which are the insect vectors of African trypanosomiasis (Burkitt and Wright,
1963, 131-2). Distribution maps of the tsetse fly seem to fit the climate and case maps rather well, as
indicated in figure 2.3.
A similar correlation was seen with Anopheles mosquitoes, the vector of malaria. The geographical
distribution of malaria, and hence the insect, was again similar to the case distribution(see figure 2.4).
A further piece of supportive evidence was also available implicating the mosquito. An epidemic of
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Figure 2.3: Map showing reported cases of BL (blue dots) with areas of high rates of tsetse indicated in
red. Tsetse data derived from Buxton, 1955
O’Nyong-Nyong fever had occurred in Uganda at the time that Burkitt and colleagues were working.
This infection appeared to be geographically limited by environmental features in a similar way to the
lymphoma syndrome, and was later shown to be transmitted by Anopheles mosquito. Thus climatic
factors had been shown, in this case, to limit the extent of a clinical disease.
Put together, the thought that the tumour syndrome was caused by some sort of arthropod-vectored
agent, such as a virus, seemed highly plausible.26 In further support of the vectored-virus theory, Burkitt
and Davies argued from analogy:
From what has been found out so far about this tumour one cannot but be impressed
with the resemblance this has to some of the virus induced tumours of mammals and cannot
avoid wondering if this might not be a virus induced tumour of African children and rarely
of African adults. It would appear that there is a prima facie case for investigating this
possibility.
(Burkitt and Davies, 1961, 369)
This led to the tumour safari in late 1961 (Burkitt, 1962e; Burkitt and Wright, 1963, 113ff), where
Burkitt, T. Williams and C. Nelson visited 56 medical centres across eight countries on the south-eastern
tail of the lymphoma belt (as per figure 2.5).
It was therefore decided to make an attempt to visit every medical unit along the pre-
sumed “positive” side of the tumour belt edge, and then every unit on the “negative” side.
(Burkitt and Wright, 1963, 113)
26The implication of a vectored virus in the aetiology of the tumour syndrome was not initially Burkitt’s: ‘. . . it was Professor
Davies who first suggested to me that this tumour might be virus-induced and the credit for that insight goes entirely to him.’
(Burkitt, 1961, 512).
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Figure 2.4: Map showing reported cases of BL (blue dots) with areas of holoendemic malaria indicated
in green. Malaria data derived from MARA, 2010.
Figure 2.5: Route of the tumour safari. Reproduced from Burkitt, 1962e, 381
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With geographical precision in mind, and given the sparse distribution of health-care in this region, the
researchers attempted to improve the accuracy of the survey by recording the place of origin of the
sufferer, rather than the location of the medical centre at which they were seen.
2.4 Making mechanisms: EBV
By the end of 1962 researchers strongly suspected that the tumour syndrome was caused by a virus.
This weight of suspicion led to further changes in the type of investigation they conducted. Rather than
investigating the possibility that the tumour could be caused by a virus, researchers instead attempted to
discover which particular virus was causing the tumour, and the underlying mechanism of this causation.
This phase of inquiry is therefore characterised by the construction of a specific causal mechanism for
BL. Much of this section will therefore be concerned with the way that EBV was discovered from BL
samples, and the way in which a causal link was made linking the two. The structure of this discovery
will be familiar; again, researchers passed through the steps of suspicion, domain-finding, mechanism
construction and application. But these stages attempt to answer a slightly different research question
from those previously. Instead of addressing the question of what causes BL, the question under inves-
tigation was “what causes our cultured BL cells to behave as they do”. This section therefore aims to
demonstrate the nested nature of causal discovery in medicine, by showing that similar processes occur
in component parts of causal discovery as happen in the broader case.
2.4.1 Suspicion and domain finding
As we have seen, the epidemiological features of BL, in particular its odd geographical distribution,
suggested that it was caused by an infectious agent. When this suspicion was combined with contem-
porary discoveries of the role of viruses in causing malignancies in animals, BL became a prime target
for virological investigation. The next step was to discover, if possible, which virus or sort of virus was
specifically implicated. How did this come about?
2.4.1.1 The meeting at the Bland-Sutton, 1961
During his time at Mulago, Burkitt maintained informal connections with the Academic Surgery Unit at
the Middlesex hospital (Epstein, 2005, 2). When he visited England in early 1961, he gave the first lec-
tures about the lymphoma syndrome outside Africa. One of these lectures was at the Academic Surgery
Unit of the Middlesex hospital on the 22nd March 1961. Entitled ‘The Commonest Children’s Cancer in
Tropical Africa. A Hitherto Unrecognized Syndrome’ (Epstein, 2005, 2-3), it was a short review of the
clinical and epidemiological features of the tumour. Anthony Epstein, a physician with research interests
in tumour virology,27 was, by chance, in the audience. He immediately became captivated, in particular
by the apparent epidemiological dependency of the tumour syndrome on climatic factors. This led him to
suspect that the tumour was caused by an arthropod-vectored oncovirus. This led to Epstein’s immediate
decision to investigate the tumour for viruses. He therefore arranged for BL material to be sent from
Kampala to London by air, and began work.
27He began his research career working on the Rous sarcoma virus (Epstein, 1956; Epstein, 1958a; Epstein, 1958b), before
moving on to work on HSV at the Middlesex hospital in London (Epstein, 1962a; Epstein, 1962b; Epstein et al., 1964c).
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2.4.1.2 No virus found!
Epstein’s initial investigations on the tumour material were thorough, but unpromising. Some 2 years
of research passed by without the detection of a virus in the tumour cells (Epstein, 2005, 4). This was
despite the use of the best available techniques, including cell cultures, infection of fertilized hens’ eggs
and inoculation of material into newborn mice. While no virus could be found, there were tantalising
suggestions of viral activity in Burkitt’s lymphoma cells when inspected using electron microscopy. In
eleven tissue samples taken from two patients, Epstein reported significant evidence of viral infection,28
but no viruses:
The findings reported here are important therefore, since they suggest that it is unlikely
that the characteristic nuclear features of the cells are connected with the presence of an
hypothetical infecting virus. Certainly in the present material. . . there was no morphological
evidence whatsoever of particles with virus-like characteristics, and this conclusion is of
particular relevance for Burkitt’s syndrome with its circumstantial pointers to a possible
virus cause.
(Epstein and Herdson, 1963, 57-8)
2.4.2 Making mechanisms
2.4.2.1 Cell Lines
Epstein remained convinced a virus was to be found. Luckily, in late 1963, he managed to obtain a
substantial research grant of $45000,29 which allowed the recruitment of Bert Achong and Yvonne Barr
in the winter of 1963. With extra hands available, the decision was made to attempt to grow BL cells
in vitro. This would presumably allow the developing cells to avoid immune system attack, permitting
viral replication and hence detection. Attempting to culture the cells was an audacious move. At the
time, it was considered either very difficult or perhaps impossible to grow human lymphoid cells in free
suspension. Certainly, no human lymphoid cell had been maintained long-term in this manner. It had
occasionally been done with other types of tumour cell. For example, researchers had established the
HeLa cell line from a cervical tumour in 1951 (see footnote 19, p.71). Some types of animal lymphoid
cell lines had also been successfully established. For instance, Fischer, in the late 1950s, had successfully
cultured malignant mouse lymphoblasts (Fischer, 1957; Fischer, 1958). Significantly, while no virus was
detectable in these cells in vivo, when they were cultivated in vitro, VLP became detectable by electron
microscopy (Epstein et al., 1964d). In this case, it was thought that isolating the cells from the host
immune system might permit the growth of otherwise latent viruses, and thus reveal their presence
microscopically to investigators (Epstein, 2005, 4). This analogous research was an important evidential
28The nuclear changes that Epstein refers to were known to occur as a consequence of many types of viral infection. For instance,
Leplus et al., 1961, in a review of 36 cases of Hodgkin’s lymphoma, lymphosarcoma and reticulosarcoma, noted three types of
characteristic nuclear changes, and suggested their similarities to those changes seen in infections with adenovirus, varicella zoster
virus, ectromelia virus, encephalomyocarditis (a porcine picornavirus), molluscum contagiosum virus, Rous sarcoma virus and
murine polyomavirus (Leplus et al., 1961, 2790).
29This was from the U.S. Public Health Service, grant number C6407 (Epstein and Barr, 1964).
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prompt for the coming work. But the actual establishment of a culture line of Burkitt lymphoma cells
arose by accident.
A delayed flight led to a breakthrough. The 3rd Dec 1963 BOAC Kampala flight, bringing a fresh
sample of Burkitt’s lymphoma tissue to London,30, was diverted to Manchester due to bad weather. When
the delayed sample was received, the usually clear transport medium had become turbid. Suspecting
bacterial contamination, and hence possible spoilage of the sample, the cloudy fluid was examined under
the microscope. No bacteria were apparent. Instead, the cloudiness was due to tumour cells, shaken free
from the cut edges of the biopsy sample, and apparently surviving free in suspension.31 These free cells
continued to thrive, and became known as the EB1 cell line. By the time this finding was published, the
cells had survived in free culture for eight weeks (Epstein and Barr, 1964, 253). This ability of BL cells
to grow freely in culture was truly remarkable, as only a few human tumours possessed this property. In
fact, culturability was more normally associated with animal tumours. As Epstein commented:
Morphologically, the cells appear to be altered primitive lymphoblasts, and their unusual
mode of growth without attachment to glass closely resembles that of cultured malignant
mouse-cells of this type.
(Epstein and Barr, 1964, 253)
2.4.2.2 Detection of virus in cultured cells
On the 24th of February 1964, samples of the EB1 line were examined using thin section electron
microscopy. The findings were exciting - with ‘. . . unequivocal virus particles in a cultured BL cell in
the very first grid square to be searched’ (Epstein, 2005, 6). These VLPs, seen in a small proportion
of EB1 cells at 75 and 82 days culture, resembled HSV, but with two important differences. First, they
were significantly - about 20% - smaller, with a diameter of about 110-115nm. Second, unlike infections
with HSV, they did not cause cultures to become damaged and lytic. Yet they appeared to be actively
infecting the cells, rather than being a contaminant. As the first report of viral detection in the tumour
cells (Epstein et al., 1964a) reported:
. . . the presence of immature and mature forms certainly indicates active virus replica-
tion. The appearances recorded are not consistent with mere virus uptake. . . with regard to
the more important question of the relationship of the virus to the Burkitt lymphoblasts in
which is has been found, it seems that a “passenger” role can be assumed since the agent
has persisted in vitro in the dividing cells for many weeks. Any more significant connection
remains to be established.
30This sample was taken from a maxillary lymphoma of a nine year old girl (Epstein et al., 1965a, 69).
31It may well have been the case that the transport medium from other specimens, too, would have contained these suspended
cells. What was distinctive in this instance was simply the delay in transit, which permitted more cells to become detached from
the tissue mass than usual. The particularly large number of cells in suspension led to the cloudy appearance of the transport
medium, which raised the spectre of possible bacterial contamination. In order to exclude this - which would have made the tissue
sample useless - Epstein examined the transport medium microscopically. This prompting to look at the transport medium under
the microscope was therefore the reason that this property of BL cells was recognised at this time.
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(Epstein et al., 1964a, 703)
The identification of virus by morphology alone was remarkable, and controversial (Epstein, 2005,
6).32 The EB1 line continued to survive, and was also reported as containing detectable virus at 287
days (Epstein et al., 1964b, 1233). In summary, a virus had been detected in BL cells, which appeared to
be responsible for their malignant transformation. As I will discuss in section 2.4.2.4, EBV was not the
only virus to be isolated from BL cells. However, it was the only one that was regularly associated with
BL tumour cells. In fact, it was detected in each of the BL cell lines that were rapidly established from
diverse types of BL tissue.
2.4.2.3 More cell lines, more tumours?
At the same time as the workers in London were discovering the unusual properties of BL cells, Nigerian
researchers were engaged in identical work.33 Pulvertaft, 1964 reports the establishment of a second cell
line at the University College Hospital, Ibaden, Western Nigeria: ‘At the time of writing one strain has
been maintained in subculture for ten weeks, and a second for five weeks, without change of charac-
teristics.’ (Pulvertaft, 1964, 239). These cells, which later became known as the Raji line, had similar
cytological features and characteristics to the EB1 line, and contained similar viruses on electron mi-
croscopy, as described in Epstein’s report (Epstein et al., 1966).
Following the reports of the establishment of the first two cell lines - EB1 in London, and Raji in
Ibaden - and the reports of an unknown virus in them, subsequent cell lines were established. A further
two were made by the Epstein lab - EB2 (Epstein et al., 1964b) and EB3 (Epstein et al., 1965a), while a
fifth cell line - SL - was reported in Stewart et al., 1965. See table 2.1 for an overview of these early cell
lines.
The first notice of the EB2 line was Epstein et al., 1964b. This detailed the detection of VLPs in
a second cell line, originating in tissue taken from an ovarian tumour from a 7 year old with abdominal
and left-sided facial tumours. Again, 1-2% of cells contained a morphologically similar virus to the
maxillary-origin EB1 line. The cells themselves had virtually identical characteristics to the EB1 line.
The authors thus concluded that culturability was a general property of BL cells. As with EB1, they did
not (yet) ascribe a causal role to the virus in immortalization, but:
. . . the failure of extensive attempts to isolate and identify this agent clearly indicates that
it is not merely some banal “passenger” virus such as herpes simplex which it somewhat
resembles morphologically.
(Epstein et al., 1964b, 1234).
Furthermore, this virus appeared to share similarities with other known viral pathogens beyond its
gross appearance:
32This was, incidentally, the first case in which a virus was discovered solely by electron microscopy (Epstein, 2005, 7). It is
worth noting Epstein’s familiarity with using the gross structure of viruses for classificatory purposes (Epstein, 1962a).
33In fact, the two teams reported their findings simultaneously in the February 1st 1964 issue of the Lancet
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Line name Date Patient details Tumour location Geographical origin Publication
EB1 Dec 1963 9 yrs, female Maxillary Uganda Epstein and Barr, 1964
Raji Late 1963 Various Various Nigeria Pulvertaft, 1964
EB2 Sep 1964 7 yrs, female Ovarian Uganda Epstein et al., 1964b
EB3 Late 1964 3 yrs, male Temporal Uganda Epstein et al., 1965a
SL Dec 1964 7 yrs, male Mandibular Nigeria Stewart et al., 1965
Table 2.1: Summary of early BL cell lines, showing original designations, characteristics of originating
material, and first report.
. . . the virus found. . . is in many respects similar to that in the Lucke´ frog neoplasm34,
and in addition recent fluorescent antibody studies have shown that these virus-carrying
lymphoblasts have very close antigenic affinities with a murine neoplastic virus and a virus
associated with human leukaemia.
(Epstein et al., 1964b, 1234)
This fluorescence work is worth briefly reporting. Fink et al. (1964) demonstrated that antigen from
the as-yet unidentified virus, when tested against cells from other malignant diseases, showed reactivity
against both blood cells and bone marrow from patients with leukaemia. Further, antigen prepared from
Rauscher murine leukaemia35 reacted against BL cells in culture. This led to the suspicion that EBV
caused other tumours in humans.
The ‘extensive attempts’ (Epstein et al., 1964b, 1234) made to isolate the virus by Epstein, Achong
and Barr is no hyperbole. As they later recounted in the paper detailing EB3, they attempted the following
using EB1 and EB2 material:
. . . various kinds of virus preparation from both strains of lymphoblasts were inoculated
on a large scale into groups of developing chick embryos, litters of newborn hamsters, litters
of newborn C57 brown mice, litters of newborn Swiss mice, and into tissue culture systems:
nine different test culture systems have been tried for every virus preparation and have each
been carried through eight blind passages. All these biological tests have been uniformly
negative, as have tests for mycoplasma, and the virus would therefore seem to be a new
unusual unidentified agent of unknown nature.
(Epstein et al., 1965a, 70-1)
This publication then goes on to describes the new EB3 line. EB3 originated from a tissue sample
taken from a 3 year old boy with temporal and maxillary tumours (Burkitt case J258, Epstein et al.,
1965a, 74). After about two months, a morphologically, kinetically and ultrastructurally identical strain
to EB1 developed, although the rate of detection of VLPs was slightly higher, with virus found in roughly
3-4% of the cells.
34See section 1.1
35See section 1.1
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The SL line originated from a tissue sample from a 7 year old Nigerian boy (D.A.), who had been
treated for BL at the National Institute for Health in Bethesda, Maryland. They noted that the virus seen
was similar to Epstein’s, suspected that it was probably a type of herpesvirus, but excluded the possibility
of it being HSV, on the grounds that it displayed no cytolytic effect (Stewart et al., 1965, 320). They also
noted that it appeared to cause a distinctive cytogenetic alteration in the cultured cells (Stewart et al.,
1965, 321; Jacobs et al., 1963).
What did this work on cell lines do? First, it demonstrated that BL was unusual in the respect that
cells of the tumour could survive long-term in free culture. This property appeared to be a general one
of the tumour. We see this in the observation that various tissue samples taken from different anatomical
and geographical sites were similarly capable of cultivation in vitro. This also provided evidence that
the clinical syndrome really was a unified one, probably arising from a common cause. Second, it
demonstrated similar VLPs in each of these tumour lines. This in turn suggested that the viruses seen
in the cell lines were not mere contaminants (say, oral flora with a propensity to live in tumour cells).
Third, it suggested that the virus was, in some way, aetiologically responsible for the transformation that
made it possible to culture BL cells. This was, in part, dependant on the analogical research conducted
on non-human animal tumour cells. Fourth, it sparked the investigations of the possible role of this
unknown virus in other diseases. All this fruitful investigation occurred in the absence of a clear, distinct
description of the virus. This was soon to follow.
2.4.2.4 Describing the virus
Epstein et al., 1965b has been cited as the first real description of EBV (Miller, 1974). First, they review
and discuss other possible causes of BL. It is worth digressing slightly here in order to mention these
other agents:
Reovirus 3. An agent closely related to reovirus 3 (CAN 230) was first detected by serial cell
cultures in a single Ugandan BL sample (Bell et al., 1964). Further, a small serological survey revealed
antibodies to this virus in almost all individuals with BL tested. This was extended to ten related reovirus
strains in further work (Bell et al., 1966). As with EBV, the original BL tissue was taken from a variety of
anatomical and geographical sites. Sero-prevalence surveys, for antibodies against three reovirus strains,
were undertaken in areas of Africa with differing BL incidence. This also included testing the sera of
fourteen children with the disease. This work showed generally low incidence of antibodies against
reovirus 3, except in the BL group (Levy et al., 1968). A possible synergy was also suspected between
reovirus 3 and HSV. Reoviruses were also known to cause murine lymphomas (Stanley et al., 1966;
Joske et al., 1966). These murine lymphomas also shared cell-surface markers with BL (Stanley and
Keast, 1967). A very similar virus was also known to cause plant tumours (Streissle and Maramorosch,
1963). Reovirus was a plausible cause for a number of other reasons, not least because it was also known
to be carried by several species of mosquito (Parker et al., 1965).
Arbovirus. It was suggested very early in research into BL that an arbovirus36 could be respon-
sible. For example, Haddow and McCallum (1962, 36) noted that the epidemiological character of the
36Arboviruses are viruses that are transmitted by arthropods
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tumour suggested that this agent was at least a plausible one ‘. . . up to the time of writing, nothing has
been found to preclude the possibility that Burkitt’s syndrome could be caused by an arthropod-borne
virus.’ A summary of the evidence was reviewed by Haddow (1964). He suggested, amongst other
factors, that BL must be an uncommon outcome of a common infection. This, in combination with the
geographical evidence, suggested a mosquito-borne viral infection. In concert with the characteristic
age-incidence of the tumour syndrome, this evidence led him to suggest an analogy with yellow fever, a
common, mosquito-borne arbovirus. So arbovirus was initially suggested to cause BL on the grounds of
plausibility and analogy. While the view that arboviruses alone were the cause of BL fell out of favour,
the suspicion that they are somehow causally implicated in BL pathogenesis has recently been some-
what resurgent. In very brief summary, arboviruses have been shown to be potentially oncogenic, occur
in an epidemic fashion and apparently temporally precede BL case clusters (van den Bosch, 2004, 742).
More, the likely age at first arbovirus infection is a good match for BL (van den Bosch, 2004, 741). It is
therefore suspected that arboviruses can act as potential co-factors for BL oncogenesis (van den Bosch,
2004, 742).
Echo 11. This virus was detected in two cases of BL, as well as in three other types of tumour
(Munube and Bell, 1967). However, no further research program seems to have come about based on
this finding.
HSV. Woodall and Haddow (1962, 30) reported the isolation of a herpes virus of unknown type
from BL biopsy material. Regrettably, this paper is often cited as a report of - specifically - HSV
isolation. Other reports (e.g. Simons and Ross, 1965; Woodall et al., 1965) are similarly equivocal.
Epstein posited contamination from the nasal cavity, for instance, as a possible source for these unknown
herpesviruses (Epstein et al., 1965b).
Other agents. These included Mycoplasma (Dalldorf et al., 1966), and multiple other filterable
agents (Dalldorf and Bergamini, 1964; Dalldorf et al., 1966; Munube and Bell, 1967)
The evidence supporting the role of EBV in BL, though, was different from that supporting these
other agents. EBV was not merely found in tissue samples (although one group did manage to directly
detect it, and a range of other candidate viruses, in BL biopsy material (Griffin et al., 1966)). Instead,
it could grow in tissue culture systems (Epstein et al., 1965b, 766). The many instances in which this
virus was detected prompted a morphological description. Two forms of VLP were seen. The first was
a 75nm diameter, hexagonal, enveloped particle, with a single membrane and an empty or a ring-shaped
inner body. This was found in large quantities in both the nucleus and cytoplasm of affected cells. The
authors suggest that it represented an immature form of the virus. Secondly, and more rarely found, were
larger 110-5nm diameter particles, which were bienveloped and contained a dense nucleoid of diameter
45-50nm. These were invariably cytoplasmic (Epstein et al., 1965b, 763). In addition, there was also
some evidence for the budding of particles as part of maturation, in a similar fashion to HSV (Epstein
et al., 1965b, 764-5). These were found exclusively in dead or abnormal cells, and in strict association
with cellular structural changes. Epstein et al. (1965b) claimed that the virus was both novel and distinct
from HSV. Yet they appeared wary of making aetiological causal claims for this new virus:
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The fact that this unknown virus has now been observed in each of three lines of cultured
Burkitt tumour lymphoblasts examined by electron microscopy is perhaps no more than a
coincidence; this type of cell could be picking up as a passenger a particular unknown non-
pathogenic agent harboured by patients with BL. Alternatively, the cultured cells may have
grown in vitro just because they are persistently infected with this agent, which might be
responsible for their growth potential.
(Epstein et al., 1965b, 766)
2.4.3 Application: The Henles, transformation, seroepidemiology and infectious
mononucleosis
The virus found in the various cell lines remained apparently inert (Epstein, 2005, 7). While it was mor-
phologically similar to other herpesviruses, various attempts at propagation or transmission in vivo were
unsuccessful. This failure led Epstein, who had previously collaborated with Gertrude and Werner Henle
in Philadephia, to invite them to investigate the virus. Their initial in vivo research suffered similar dif-
ficulties to Epstein’s (Henle and Henle, 1966b, 1248). However, their in vitro investigations were much
more successful. They first demonstrated both the immunological (Henle and Henle, 1966a; Henle and
Henle, 1966b) and biochemical (zur Hausen et al., 1970) uniqueness of the virus and named it (Henle
et al., 1968). Immunofluorescence testing revealed that viral antigens were immunologically reactive
against the serum of patients with BL, and against BL cells. As might be expected, the extent of im-
munofluorescence correlated with virus particles as seen using electron microscopy (Henle and Henle,
1966b, 1252). Mystifyingly, though, despite the relatively specific immunological response obtained,37 it
was also immunologically reactive against the sera of non-BL individuals, including leukaemia patients
(Henle and Henle, 1966b, 1249), individuals with nasopharyngeal carcinomas (Henle et al., 1970) and,
most confusingly of all, against many normal North American control individuals (Henle and Henle,
1966b, 1250-1).38 This suggested that infection with EBV was far more common in non-African pop-
ulations than previously expected. It also suggested that, far from being specific to BL, EBV infection
might cause a range of other diseases, or might cause no clinical disease at all.
However, support for an aetiological role for the virus in the development of cancer came from suc-
cessful cellular transformation experiments. When BL cells containing virus were killed by irradiation,
and inoculated into normal human white blood cells, these cells became transformed into an immortal-
ized cell line (Henle et al., 1967). However, this did not happen with BL cells that were microscopically
free of the virus. This experiment, in many ways complementary to the original establishment of cell
lines from BL tissue, was also a methodologically significant step, as it allowed researchers to cultivate
EBV outside BL cell-based culture systems. It also suggested a possible mechanism for BL develop-
ment, which gained further support by the recognition of chromosomal abnormalities in the cultured
cells (Henle et al., 1967, 1065), similar to those found in BL (Miles and O’Neill, 1967).
37There was no staining against most other suspected candidate agents, including reoviruses, with the partial exception of HSV,
which had equivocal results.
38About 30% of children and 90% of adult controls reacted.
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The high proportion of apparently healthy individuals displaying evidence of EBV exposure re-
quired explanation, however, if the aetiological role of EBV in BL was to be confirmed. Various work
suggested that the virus had a global distribution, with a similar age-at-infection profile to other child-
hood disease. However, no likely clinical manifestations of childhood infection with EBV was known,
and it required a fortunate coincidence for one to be identified. While conducting a series of surveys for
EBV antibodies using sera from a variety of paediatric illnesses of unknown, but presumptively viral,
aetiology, one researcher by chance developed IM.39 It was discovered that, following this infection, her
leukocytes became capable of growing in cell culture, a property they had not possessed when tested
before the development of the disease. While she initially did not display antibodies to EBV, from the
outset her cultured cells expressed EBV antigens, and contained the chromosomal abnormalities charac-
teristic of BL (Henle et al., 1968, 95-6). When further sera from IM patients were examined, they were
all found to be strongly positive for anti-EBV antibodies. This led to the conclusion that IM was causally
related to EBV:
Patients with infectious mononucleosis regularly develop antibodies to the herpes-type
virus (EBV) found in cultures derived from Burkitt’s tumors or other cells of the hematopoi-
etic system. . . The epidemiology of IM and the seroepidemiology of EBV share many fea-
tures. Thus, it appears that EBV, or a close relative of it, is the cause of IM. This conclusion
does not preclude the possibility that EBV might also be involved, either directly or indi-
rectly, in the etiology of Burkitt’s lymphoma.
(Henle et al., 1968, 101)
This probable aetiologic relationship could therefore explain the serological evidence of past EBV
infection in otherwise healthy individuals. However, the causal mechanism linking BL and EBV was
still rather incomplete. For one, it seemed that intact EBV particles could not be detected in biopsied
(rather than cultured) BL cells. However, EBV genetic material could be found when these cells were
examined using DNA-DNA hybridisation. When EBV genomes were purified and used to probe BL
cells, annealing took place, indicating the presence of EBV genetic material within the host cell genome
(zur Hausen and Schulte-Holthausen, 1970; zur Hausen et al., 1970). This genome integration suggested
a causal, rather than passenger, role for EBV.
In summary, many kinds of laboratory and epidemiological evidence supported the existence of a
causal role for EBV in BL. First, the common clinical, pathological and histopathological features of BL
suggested a unified cause for the disease. These features also indicated that the disease was a malignant
process. However, epidemiological findings suggested the possibility that it was an infectious disease.
Next, the unusual ability of BL cells to grow in continuous culture, and the subsequent recovery of a virus
from many of them, implicated a virus as the cause. This offered researchers the possibility of reconciling
the apparently contradictory epidemiological and pathological features of the disease. This virus, when
used to infect other lymphoid cells, caused cellular transformation, pointing to the likely role of the virus
39She was Elaine Hutkin, and received the thanks of the Henles in an acknowledgement to: ‘. . . patient E. H., who provided the
main clue’ (Henle et al., 1968, 101)
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in causing malignant transformation in vivo. Other confusing epidemiological features - in particular the
high prevalence of anti-EBV antibodies compared to the very low incidence of BL - were accommodated
by the immunological and serological findings implicating EBV in diseases other than BL. Finally, EBV
was shown to become incorporated into the host-cell genome, and to cause chromosomal abnormalities.
This suggested the possible nature of the detailed causal mechanism linking infection with EBV and the
development of malignancy in vivo.
2.5 Application: prospective epidemiology
The last part of the early history of EBV and BL involves a return to epidemiological research. As the
summary above suggests, the causal mechanism for the role of EBV in BL was still incomplete by the
early 1970s. There was, therefore, much resistance to these causal arguments at this time.40 Various
pieces of epidemiological evidence were acquired that indicated that populations at high risk of BL
tended to have higher levels of anti-EBV antibodies, and tended to acquire them younger than individuals
in populations at low risk (see, e.g., Henle et al., 1969). In fact, it was not until the completion of a large
prospective seroepidemiological study in the lymphoma belt that it became generally accepted. This
study (de-The´ et al., 1978) began in 1971 and followed 42 000 children from birth to 8 years old in the
West Nile District of Uganda. Serum samples were taken at enrolment. This group was then observed.
In total, 14 of the 42 000 participants developed BL at some point during the trial. These individuals had
higher levels of anti-EBV antibodies than controls at baseline (de-The´ et al., 1978, 759), suggesting that
EBV infection preceded the development of BL by some time.
This specific increase in antibodies preceding the development of BL, when combined with the other
evidential features of the disease and of the virus discussed above, was generally seen as a conclusive
demonstration of causation of BL by EBV. To conclude our survey of evidence:
The virus can be isolated from tumour cells, virus-associated membrane antigen can be
detected on the surface of tumour cells (Klein et al., 1966) and viral DNA is present in
tumour derived cell lines (zur Hansen et al., 1970). All children with BL in endemic areas
have antibodies to viral antigen and the geometric mean antibody titres are higher in patients
than in controls (Henle et al., 1969). Moreover, prospective studies on 45,000 children in
the West Nile region of Uganda showed that the 14 children who developed the tumour had
acquired antibody to the virus from seven to 54 months before the lesion was detectable and
that the VCA (viral capsid antigen) titre in these children exceeded the titres found in nearly
all the controls (de The´ et al., 1978).
40As Epstein noted of this change in attitudes towards a causal role for EBV in malignancy: ‘This change in perception has come
about slowly and painfully; once EBV was accepted as a virus it was only with the later advent of the unequivocally oncogenic
herpesviruses of Marek’s disease. . . and New World non-human primates. . . that its possible function as a human tumour virus
received its first tentative consideration. Even after the accumulation of abundant data on the biology and powerful lymphocyte
transforming ability of EBV . . . , and the persuasive evidence from the massive World Health Organization (WHO) prospective
7-year study of 42 000 Ugandan children, the reluctance to believe there could be a carcinogenic virus of man persisted.’ (Epstein,
2001b, 111)





This story of causal discovery should be seen as complementary to that of BL and EBV. Why then
include both? First, while both tumours are caused by viruses, they are generally dissimilar. Cervical
cancer, unlike BL, is a fairly typical tumour: it occurs relatively commonly, has a worldwide distribution
and (generally) increases in incidence with age. Before about 1940, cervical cancer was believed to share
a similar degenerative-chronic aetiology with most other malignant diseases.
This is the first difference between the cases. The second is concerned with differences in the
manner of discovery of the causal mechanisms for each tumour. With BL, as we have seen, a large
part of the story of causal discovery was the process of clinical discovery in the first instance. Thus, I
focused on telling the parts of the causal story dealing with the suspicion of mechanism, and the process
of domain finding. Here, these two phases will play a minor role. Instead, I will concentrate on the
linked processes of mechanism construction and application. I will attempt to underline the differences
between two different attempts at drawing a causal mechanism that occurred in the history of cervical
cancer.
So this story begins with an understanding of cervical cancer as a chronic, degenerative disease.
However, research on disease populations between about 1940 and 1960 suggested that this was not,
in fact, the case. Cervical cancer actually had extremely unusual risk factors for a malignant disease.
A great deal of sound epidemiologic data appeared to suggest that cancer of the cervix behaved like a
sexually transmitted disease, and a complex web of socio-economic factors, particularly those indicating
social class, marital and sexual habits and features of male sexual partners, appeared to modify the risk
of developing the disease. Thus the story of the identification of these risk factors will form the first part
of this chapter.
As a result of the recognition of these risk factors, and of the recently identified role played by
viruses in the causation of several tumours, including BL, a virus was thus seen as a highly likely cause
of the disease. Again, largely by analogy with these other viral causes of cancer, infection with HSV was
suggested as the specific cause of cervical cancer. A great deal of mechanistic and statistical evidence
was generated in support of this hypothesis, and between about 1970 and 1985 HSV was commonly
accepted as the cause of cervical cancer. The story of the causal identification of HSV will thus form the
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Figure 3.1: HPV phylogenetic tree (Lowy and Howley, 2001, 2232). Here, the distance from the root
position is determined by the degree of sequence variation of a short section of the L1 open reading
frame.
second part of this chapter.
This causal story has a twist. While we still believe that cervical cancer is caused by a virus, we
now think that this specific virus is human papillomavirus (HPV), rather than HSV. In fact the causal
association is so strong that HPV has been proposed as a necessary cause of cervical cancer (Bosch et al.,
2002, 244). This change in causal thinking will form the final part of this chapter.1
HPV is a virus of the genus Papillomavirus, family Papovaviridae. It has five super-groups, cat-
egorised by sequence homology as super-groups A-E (McCance, 2004, 661), as shown in figure 3.1.
Super-group A infects humans, and includes the types of the virus responsible for cervical cancer and
genital warts. Viruses of supergroup B cause the rare skin disease epidermodysplasia verruciformis (EV).
This disease played an important role in early cervical cancer research, as discussed in section 3.6.1.2.
1I will here give enough detail of the current state of knowledge of cervical cancer to sustain the historical discussion. For
further information about cervical cancer epidemiology see Parkin et al., 1984; Parkin et al., 1993 and IARC Working Group on
the Evaluation of Cancer Preventive Strategies, 2005. For the current position on screening for the disease, see Andrae et al.,
2008; Savage, 2008. For a review of the role of papillomaviruses in cervical cancer causation, see zur Hausen and de Villiers,
1994; Bosch et al., 2002, 250. McCance, 2004 is an detailed review of HPV virology, while zur Hausen, 1989b; Howley, 1991;
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1995; McCance, 1998; IARC Working Group on
the Evaluation of Carcinogenic Risks to Humans, 2006 and Paavonen, 2007 are excellent reviews of the current mechanism of
causation of cervical cancer by HPV.
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Supergroup E causes cutaneous warts (benign skin papilloma), which were also vital to this causal story,
as I discuss in section 3.6.1.1. Groups C and D do not infect humans, but are responsible for a variety
of animal diseases, some examples of which I will mention in section 3.6.1.3. Each type of the virus
is biologically distinct. For instance, they are relatively specific in terms of the species they affect, the
anatomical sites which they prefer and the types of disease they cause. They are also, largely, immuno-
logically distinct. Acquired immunity to one type does not, in general, provide immunity to others. This
complex organisation of types becomes extremely important later in the story, as discussed in section
3.6.2.
The viral genome is double-stranded DNA virus of 7900 base pairs in a supercoiled circular con-
figuration. The viral capsid is 52-5nm in diameter, consisting of an icosohedral arrangement of 72
capsomeres. Other than structural proteins, the virus encodes a number of ‘early’ or E proteins, three of
which, E5, E6 and E7, appear causally important in oncogenesis. Together, expression of these proteins
causes disruption of the normal cell cycle, possibly via interactions with tumour protein 53 (p53) and the
retinoblastoma gene product (pRb). I give a brief review of the mechanism by which HPV is thought to
act in section 3.6.3.
3.1.1 Cervical cancer as a chronic, non-infectious disease
Unlike the previous chapter, I will be extremely schematic when describing the suspicion that cervical
cancer was a unified clinical entity, as the process of syndrome recognition is less interesting in this case.
In large part, I suggest this is due to the substantial clinical cohort of patients which would have been
apparent to clinicians and researchers, something quite unlike the situation with BL. Just for example,
data from the USA at the beginning of the period of interest shows about 20,000 new cervical cancer
diagnoses, leading to about 8,500 deaths, per year. These figures reflect a total population of about
120,000 women with invasive disease and a further 250,000 with carcinoma in situ (all Stamler et al.,
1967, 802).
Cervical cancer was initially considered to be a type of uterine cancer, but became a clinically
distinct entity in the late nineteenth and early twentieth century (Mengert et al., 1949). Thus in the
following sections, while cervical and other uterine cancers are usually clearly distinguished, there may
be occasional instances of classificatory confusion. For instance, publications from the middle decades
of the twentieth century based upon historical data collected much earlier, particularly that dealing with
retrospective surveys of epidemiological data, may be unreliable. For example, Kennaway, 1948, a
review of aetiological factors responsible for cervical cancer, features some data where cervical and
uterine body cancers are distinguished, and other data where the two are conflated together into cancer
of the uterus. However, because of this early classificatory division, I suggest that this minor point did
not present a significant issue in this causal story.
What is of interest is the nature of the causal processes suggested. Although the disease was well-
known, it was generally thought before about 1960 that it was caused in a similar way to most malignant
disease. For instance:
Long-continued irritation and chronic inflammation are probably the conditions which
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pave the way for the development of the new growth.
(Deaver and Reimann, 1931, 383)
Similarly, cervical trauma during childbirth was identified as a common cause of cellular irritation
(Anonymous, 1919), implicating childbirth as a cause of cervical cancer. The suggestion that childbirth
increased the risk of developing cervical cancer would persist. However, the future direction of cervical
cancer epidemiology would not concentrate on investigating the nature of cellular irritation. Instead, it
would focus on the act of childbirth itself, and its related activities, as possible causes of the disease.
3.2 Suspicion: Cervical cancer as a venereal disease
By the 1960s it was becoming apparent that, instead of behaving like most tumours, the risk factors
for cervical cancer resembled those of a sexually transmitted disease. One important driver of this re-
alisation was the introduction of cervical screening programmes in many parts of the developed world.
For instance, one of the major reviews of the epidemiology and aetiology of cervical cancer at this time
(Aitken-Swan and Baird, 1966a; Aitken-Swan and Baird, 1966b) derived from the screening programme
in Aberdeenshire introduced in 1960. As a blunt summary of this aetiological work, the authors com-
ment:
The cancer patient is characterised by more marital misadventures, divorce and separa-
tion, more pre-marital coitus and deliveries and more sexual partners.
(Aitken-Swan and Baird, 1966a, 656)
I will therefore briefly outline these risk factors, and the evidence supporting them, below.2
3.2.1 Sex
This arose from two linked observations. First, that a preventive factor seemed to operate in groups of
women who did not engage in sexual intercourse. In fact, those who practice life-long abstinence are
essentially at no risk of the disease. The very low incidence of cervical cancer in nuns has been known
since at least the middle of the nineteenth century. For instance, Rigoni-Stern working in 1842 (available
in English translation as Stavola, 1987) described a long historical series of cases in Verona (1760-1839)
in which much higher rates of cervical cancer occurred in married women than in nuns. This finding was
later repeated (Gagnon, 1950; Towne, 1955 and Fraumeni et al., 1969). Further work demonstrated the
low incidence of the disease in monogamous populations (Gardner and Lyon, 1977; Sumithran, 1977).
Second, women with multiple sexual partners had an increased risk of developing the disease com-
pared to controls (Wynder et al., 1954; Stocks, 1955; Jones et al., 1958; Stern and Dixon, 1961; Terris
et al., 1967). Two groups were important; first, commercial sex workers, second, divorced and remarried
women (Martin, 1967, 804). Both had higher rates of the disease than expected.
2Much of the material on cervical risk factors from this period is repeated between publications. An exceptionally useful
general summary is Boyd and Doll, 1964 - which presents a case-controlled study of these risk factors in Britain. Their findings
are, in general, the same as the following analysis.
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As a consequence of these observations of related risk- and protective- factors, by the mid-1960s, it
was thought that some covariate of sex, or of sex with multiple partners, was causally responsible:
. . . mere frequency of intercourse is unlikely to account for the differences found. Inter-
course must be further analysed for special features which conduce to cancer.
(Elliott, 1964, 232)
As we will discuss, the nature of other cervical cancer risk factors support this view. However,
no causal mechanism or candidate causal entity was immediately suggested as a consequence of the
discovery of the link with sex.
3.2.2 Marriage
Marriage increases the risk of cervical cancer. By 1950 any direct causal effect of marriage itself was
generally seen as implausible.3 Instead, married women tended to have higher rates of the other identified
risk factors than unmarried ones, including having more sexual partners and more children. This was
particularly the case in women who remarried after divorce. While their increase in cervical cancer risk
could therefore be explicable in terms of marriage being covariate with other risk factors, the picture was
slightly confused by the apparently reciprocal relationship identified between cervical and other uterine
cancers. Married women had higher rates of cervical cancers than unmarried ones, but lower incidence
of cancers of the uterine body (Aitken-Swan and Baird, 1966b, 628-9).
3.2.3 Parity
High parity (number of births) increased cervical cancer risk (Aitken-Swan and Baird, 1966b, 633ff).
It was unclear how this related to other cervical cancer risk factors as parity seemed to bear a highly
variable relationship to youth at marriage, faith and so on.
3.2.4 Faith
Disease incidence appeared to be modified by membership of certain faith groups. For instance, in a
series of epidemiological surveys across Europe, North America and Palestine, members of the Jewish
faith had attack rates roughly half that expected in European Christian women. Similar reductions in
risk were seen in Moslem women compared to Hindu women in studies on the Indian subcontinent
(Kennaway, 1948, 177-193). This is despite the high parity and generally low socio-economic status of
both of these groups (Kennaway, 1948, 202-3).
Four main explanations for this reduction in risk were offered. First, perhaps the genetic origin of
these groups reduced their predisposition towards developing the disease (Kennaway, 1948, 183; 204).
Alternatively, perhaps this risk reduction was due to the observance of religious rituals around sexual
intercourse. For instance, the Talmudic proscription of sexual intercourse (Niddah) in the first half of
the menstrual cycle, from the onset of menstruation to approximately two days before the expected
date of ovulation (Kennaway, 1948, 197-9; 208), and similar ritual ablutions required by Moslem law
3‘No one would consider the mere ceremony of marriage to have a bearing on the causation of the disease’ (Lombard and
Potter, 1950, 1330)
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(Kennaway, 1948, 200), might have been causally responsible for the reduction in risk. Thirdly, perhaps
the tendency of these groups to be highly monogamous and to practice endogamous marriage reduced
the chance of contracting a venereal agent (Martin, 1967, 813). Finally, perhaps this reduction in risk
was due to the ritual circumcision practised by both these groups, as I discuss in 3.2.10.
3.2.5 Youth
Relative youth at marriage, first pregnancy or first sexual intercourse increased the risk of eventually
developing cervical cancer (Kennaway, 1948, 203-4; Stamler et al., 1967, 804; Meisels et al., 1977,
3078). Research into this risk factor was complicated both by its relation with other risk factors, and
by interdependence between the youth risk factors. Women who had their first sexual experience when
unusually young tended to both marry and have children unusually young (Aitken-Swan and Baird,
1966b, 633ff). But they also tended to have more sexual partners, to have more children, to suffer other
sexually transmitted diseases and to belong to lower socio-economic classes.
3.2.6 Syphilis
The link between cervical cancer and syphilis had been known for some time. Several authors noted that
syphilis appeared to modify the natural history of cervical cancer - women with both syphilis and cervical
cancer tended to develop malignancy younger, more severely and with a worse prognosis (Harding, 1942;
Morris and Meigs, 1950; Røjel, 1953; Wynder et al., 1954; Elliott, 1964, 233).
In all these cases the precise nature of the association is unclear: authors variously question the
specificity of the Wassermann test for syphilis (Harding, 1942)4, suggest a directly causal role for syphilis
in the development of cervical cancer or suggest that syphilis may simply be an exposure marker to
another agent with a causal role in cervical cancer. Familiarly, this research was complicated by the
equivocal relationship of syphilis to other known risk factors.
3.2.7 Class
Women from lower socioeconomic classes had higher rates of the disease than wealthier women (Ken-
naway, 1948, 193-7; Elliott, 1964, 232; Aitken-Swan and Baird, 1966b, 631; Stamler et al., 1967, 802).
As with the other strands of this investigation, the research was heavily confounded by the unknown
relationship that class bore to other identified risk factors. For instance, women of lower class tended
to have sex and marry younger, have more sexual partners, more children, more venereal disease and
tended to belong to particular faith groups. Other factors were also suggested as part of the class phe-
nomena. The disease seemed to occur at higher rates in cities than in the countryside (Aitken-Swan and
Baird, 1966b, 627). There was also much variability within social groupings depending on the woman’s
partner’s occupation (Aitken-Swan and Baird, 1966b, 639).
3.2.8 Race
Based on a study in the USA, African-American women were found to have significantly higher rates
of invasive and in situ disease than their white counterparts (Stamler et al., 1967, 801-2). They also
appeared to have a significantly worse prognosis once the disease was established. While incidence rates
4i.e. that cervical cancer in some way caused a false positive when testing for syphilis
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were 50-100% higher, the mortality rates for African-American women were more than double those
expected for white women (Stamler et al., 1967, 796-9).
3.2.9 Age
Increasing age appeared to be, in general, a risk factor for the development of the disease (Stamler et al.,
1967, 799). This finding was, however, complicated by the apparent bimodal incidence of cancer of the
cervix, with incidence peaks at about 40 and about 60 years. Two explanatory strategies were offered.
First, these two peaks actually represented aetiologically distinct conditions with similar pathologies
(Kennaway, 1948; Elliott, 1964). Alternatively, this bimodality may have reflected a degree of variability
in the disease course (Kashgarian and Dunn, 1970). While interesting, I will ignore this complication.
3.2.10 Male factors
As work continued on these risk factors and their relationships, the role of male factors in the devel-
opment of cervical cancer became increasingly important. This ‘male factor’ - that women were at
increased risk of developing the disease if their husband was either promiscuous or had been previously
married to a women who developed cervical cancer - was unpicked in a variety of ways.
For example, the wives of circumcised men tended to have lower incidence of cervical cancer
(Kennaway, 1948, 204-5). This reduction did not seem to depend upon the reason for which circumcision
was performed, as wives of men circumcised for either ritual and medicinal reasons appeared at similar
risk. Thus circumcision, and its relationship to faith, was an important preventive factor. One important
supportive finding was the preventive role of barrier contraception (Kennaway, 1947; Kennaway, 1948;
Wynder et al., 1954; Wynder, 1955; Khanolkar, 1958; Elliott, 1964; Aitken-Swan and Baird, 1965).
It was suggested that this risk reduction was predicated upon the reduction of smegma that cir-
cumcision produced. Smegma, a deposit of secretions from the penis, was mechanistically investigated
as a potential cause of cervical cancer in experimental animal systems (Plaut and Kohn-Speyer, 1947;
Pratt-Thomas et al., 1955).
Considered too were notions of the partners degree of ‘cleanliness’ (‘. . . cleanliness of the male
partner seems to be the most important single factor’ (Kennaway, 1948, 234)). While it is difficult to
interpret exactly what is meant by this, it seems that this represents bodily cleanliness, perhaps related to
occupation. So this might be a possible explanation for the diversity of risk within social class dependent
on husband’s occupation.
3.2.11 Others
A number of factors were identified that appeared protective against cervical cancer. These included di-
etary factors - especially high dietary intake of β-carotene (Vecchia et al., 1984) and vitamin A (Romney
et al., 1981) - and previous history of diathermoelectro-coagulation of the cervix (DKG) (Vonka et al.,
1984b, 56). On the other hand, use of the oral contraceptive pill (Stern et al., 1970) and cigarette smoking
(Tokuhata, 1967; Winkelstein et al., 1984) both increased the risk of developing the disease.
In summary, a number of complex risk- and protective- factors were identified for cervical can-
cer. In general, these factors suggested that cervical cancer shared some aetiological similarities with
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sexually transmitted diseases. However, the precise nature of the relationship between risk factors was
extremely unclear, with no consensus about their status as either cause or covariate of cause. Multiple
explanatory hypotheses were offered to accommodate these risk factors. This debate continued, even
when mechanisms for cervical cancer had been suggested (Rotkin, 1967; Terris et al., 1967; Thomas,
1973; Kessler, 1976; Kessler, 1977).
3.3 Domain finding: HSV and cervical cancer
One explanation of the pattern of risk factors seen in cervical cancer was that the disease was caused by
a transmissible agent, possibly a virus. While this hypothesis is mentioned in general terms in many of
the publications identifying risk factors, the first case in which a specific agent is mentioned dates from
1966. This publication (Naib et al., 1966) suggested that cervical cancer might be caused by infection
with HSV. In a study of about 40 000 cell samples from cervical screening tests in Atlanta, the authors
demonstrated a strong correlation between HSV CPE and signs of malignant or pre-malignant changes
of the cervical epithelium (Naib et al., 1966, 1026). They offered three plausible explanations for this
phenomena. First, this apparent link might be nothing more than a coincidence. Second, HSV might
have some predilection for malignant cells, and thus the correlation could be explainable in terms of
an increased risk of contracting HSV in women with cervical cancer. Finally, HSV infections might be
causally implicated in oncogenesis:
. . . it can. . . be hypothesized that either a pre-existing cervical atypia invites a secondary
viral infection or genital herpetic infection had some oncogenic potentiality
(Naib et al., 1966, 1031)
This observation was, as the authors admitted, not completely novel. The characteristic CPE of
herpesviruses had been previously detected in cervical screening samples. What was novel, however,
was the possible causal role suggested for HSV. This idea quickly gained credence; subsequent authors
noted that women with cervical cancer seemed to have a higher risk of being infected with HSV.
Causation of cervical cancer by HSV appeared to offer a highly plausible explanation of the known
risk factors (Alexander, 1973; Kessler, 1976). First, the virus was known to be transmitted venereally.
This offered a possible explanation of the apparent role of sex as an aetiologically significant factor in
the development of the tumour. Second, the correlation between cervical dysplasia and HSV infection
seemed to involve one particular type of the virus, HSV2, which is responsible for most cases of genital
herpes infection (Cleator and Klapper, 2004a, 35). Thus an explanation could be formulated for the
causal role in terms of host-cell tropism. Third, the virus could be isolated from smegma (Rawls et al.,
1968a), and infections with HSV2 occurred at lower rates in circumcised males than uncircumcised ones
(Parker and Banatvala, 1967, 212; 216). This could therefore offer a possible explanation of the appar-
ently protective role offered by circumcision of sexual partners. This could in turn offer an explanation
for the low rates of cervical cancer seen in members of faith groups who practiced ritual circumcision,
especially if other ritual and cultural sexual practices also reduced the chance of contracting the virus
(Alexander, 1973).
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Explicable too was the role of youth at first sex, marriage or first pregnancy. If the virus were first
transmitted to the women during adolescence, and the uterine cervix had a hypothetical greater sensitivity
to any oncogenic effects of the virus at this age, it would be plausible that these risk factors could be
explained by the actions of the virus (Rotkin, 1973).
If a multi-step model of oncogenesis, with HSV infection as a necessary component was hypothe-
sised, then various other risk factors could be also explained. For example, the role of social class, diet
and smoking could all be compatible with a causal mechanism driven by HSV infection.
This plausible role for HSV2 was reinforced by a number of apparently specific indicators of a
causal mechanism. First, HSV2 and cervical cancer appeared to be serologically associated. Antibodies
against HSV2 were present in prostitutes more than twice as often as in control populations (Rawls et al.,
1969) and four times as often in women with cervical cancer than controls (Rawls et al., 1968b). Second,
HSV was known to be capable of causing chromosomal abnormalities in vitro in both animal (Hampar
and Ellison, 1963) and human cells (Stich et al., 1964). These abnormalities were similar to those known
to be associated with many sorts of cancer. Third, it also became apparent that fragments of HSV DNA
could be directly detected in cervical cancer cells (Frenkel et al., 1972), suggesting some specific role
in pathogenesis. Finally, other herpes viruses were also implicated in other malignant diseases. In
particular, when all this suggestive evidence was interpreted in the light of the recently discovered causal
link between EBV and BL (see section 2.4ff), HSV became a highly plausible cause of cervical cancer.
However, plausibility alone would not digest these risk-factors, and much effort was therefore focused
on attempting to formulate a causal mechanistic link between HSV and cervical cancer, a selection of
which I will detail in the next section.
3.4 Making mechanisms I: HSV (1966-1983)
By the early 1970s, HSV was generally accepted as the cause of cervical cancer. A survey of publica-
tions from the field at this time, for example those taken from the proceedings of the 1972 American
Cancer Society conference ‘Herpesvirus and cervical cancer’, demonstrate the existence of a thriving
research program surrounding the HSV mechanism. Discussion of the nature of evidence for and against
it, considerations of other possible causal agents, discussions of the similarities and differences between
the case of cervical cancer and of other virally-caused tumours and discussions of the best way to con-
tinue investigations are all present. Two broad classes of hypothesis relating to herpes were in play.
First, HSV and cervical cancer might both correlate with sex (Rawls et al., 1973, 1481). However, the
finding that other sexually transmitted diseases did not correlate in such a way with cervical cancer led
toward a second conclusion, which was that HSV and cervical cancer might be aetiologically associated
(Rawls et al., 1973, 1482). This lack of correlation further undermined the position of other possible ae-
tiologic agents considered. These had included Trichomonas, Chlamydia, and cytomegalovirus (CMV),
while other agents that appeared to correlate with cervical cancer (for instance gonorrhoea, syphilis, and
Mycoplasma spp.) had previously been ruled out as mere markers of sexual activity (Alexander, 1973).
However: ‘Whatever the evidence for the association of these agents with cervical cancer, none appears
to be so likely a candidate for its cause as herpesvirus type 2.’ (Alexander, 1973, 1485).
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BL as a useful model system for cervical cancer was extensively considered, in combination with
other animal models of disease, especially Marek’s disease and Herpes saimiri.5 These diseases offered
researchers naturally occurring experimental models to understand sections of the HSV mechanism.
However, unlike the very close parallels between the clinical manifestations of EBV infections and
Herpes saimiri (Deinhardt, 1973), there was no such obvious role-model that closely modelled the whole
disease process for cervical cancer and HSV. As one author commented:
I do not think that they are models beyond what they show, namely, that some her-
pesviruses, quite different from HSV, can induce neoplasia under certain conditions. These
conditions are very different, however, from the way in which a postulated oncogenic effect
of HSV would take place.
(Klein, 1973, 1558)
Given this lack of a suitable ‘natural’ disease model, researchers attempted to produce experimen-
tal disease models. However, most attempts at doing this appeared problematic. Early experimental
attempts to induce tumours in animals by inoculation with various HSV types failed (Rapp and Falk,
1964). Later animal inoculation experiments too were equivocal, although some of them displayed a
slight apparent effect of HSV2 inoculation on tumour development (e.g. Nahmias et al., 1970), although
this work was complicated by the very high subject mortality caused by the lytic effects of HSV.
Similar experiments using in vitro cell cultures behaved very differently. For instance, Duff and
Rapp, 1971 showed that cells in vitro were transformed by incubation with UV-inactivated HSV2. These
transformed cells, known as the 333-8-9 line, continued to display HSV antigens (Duff and Rapp, 1971,
472), and were capable of inducing malignant tumour formation when inoculated into animal subjects
(Duff and Rapp, 1971, 471). Similar findings occurred with HSV1 (Duff and Rapp, 1973). These
findings were rapidly repeated by other groups using a variety of animal cell lines for both HSV1 and
HSV2 (Kutinova´ et al., 1973; MacNab, 1974; Boyd and Orme, 1975; Duff and Rapp, 1975; Kimura
et al., 1975). Fragments of HSV nucleic acids were also detectable in these cell lines (Collard et al.,
1973; Frenkel et al., 1976) although it became apparent that this was an unstable property of the cells, as
HSV DNA became rapidly undetectable when cell culture was prolonged (Minson et al., 1976).
The success of cell transformation in vitro led to a resurgence of attempts to directly induce cervi-
cal tumours in experimental animals by HSV exposure (Mun˜oz, 1973; Sever, 1973, 1510; Palmer et al.,
1976; Fish et al., 1982). A further study also demonstrated the induction of cervical carcinoma, rather
than atypia, using UV-inactivated HSV (Wentz et al., 1975). I will not talk about these (generally unsuc-
cessful) attempts in detail, but I might speculate that the effects of publication bias makes it likely that
there were even more unsuccessful attempts to induce cervical tumours using HSV than the literature
reveals.
HSV2 nucleic acids were also recovered, in a single case, from cervical cancer tissue samples
(Frenkel et al., 1972). However, this finding was not replicable, and it remained the case that HSV
5A herpesvirus affecting primates whose clinical manifestations include T-cell lymphomas. See section 1.1.
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genetic material could generally only be detected from cells grown in in vitro cell cultures (Aurelian
et al., 1971; Melnick et al., 1974). In order to strengthen this highly incomplete mechanism, the following
suggestions were made for an ideal programme of ongoing research:
1. To improve HSV tests such that easy differentiation of HSV1 and 2 would be possible in practice6
2. To conduct prospective epidemiological studies, including recording data regarding subjects’ hor-
monal status, details of their sexual partners and serial viral antibody titres.
3. To better understand the nature of the HSV life-cycle in the cell, including details of proteomics,
genomics and mechanism of cellular transformation. This should include parallel work on similar
conditions in an attempt to develop an animal model, including Herpes saimiri, Herpes ateles,
Marek’s disease, Lucke´ renal adenocarcinoma and EBV.
4. To better understand the disease immunology, including both a serological survey and an investi-
gation of the possibility of immunotherapy.
(Deinhardt, 1973)
Much of this research on cells in vitro was inspired, in part, by the demonstration of EBV in cultured
cells of BL (Duff and Rapp, 1971, 469; 476). One important suggestion for resolving these difficulties of
causal inference was to carry out an intervention. If it could be shown that immunisation against HSV2
could reduce cervical cancer incidence, this would count as very strong evidence for the aetiological role
of HSV in the pathogenesis of the disease:7
Dr. Nahmias suggested that the proof concerning an etiological involvement of HSV-2
in cervical carcinoma may be obtained only by showing that immunization against HSV-2
has a preventive effect.
(Klein, 1973, 1561)
However, developing such an intervention never in fact came about.
3.5 Application I: HSV
3.5.1 Confirming the mechanism
Of primary importance in causation, given this absence of a specific causal mechanism, were statisti-
cal studies of HSV2 seroepidemiology in cervical cancer. Nearly all retrospective studies showed that
patients with cervical cancer had higher anti-HSV antibody titres than control subjects, and that, for
individuals with evidence of HSV infection, those with cervical cancer underwent infection earlier in
6Workable serological tests were eventually developed that were capable of discriminating HSV1 and 2 (Sucha´nkova´ et al.,
1984)
7Similarly strong evidence for causation arising from vaccination happened as part of the research programme linking hepatitis
B virus (HBV) infection with the development of hepatocellular carcinoma (HCC). See section 4.5.2 for further details. Other
authors have suggested interventions as proof of causation in cases such as these (Vonka, 2000; Bosch et al., 2002, 246). See also
section 5.8
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life (reviewed in Rawls et al., 1973). These antibodies appeared before the development of cervical
dysplasia,8 and their level reduced with its presumptive cure (Catalano and Johnson, 1971).
This work was supported by the specific correlations noted between cervical dysplasia and the pres-
ence of HSV CPE noted in individual histological examinations of cervical cancer samples, although
not in cytological examination of cells from Papanicolaou smears (Naib et al., 1973). As no prospec-
tive studies were available at this point,9 this work therefore relied on retrospective studies, a class of
investigation subject to characteristic systematic errors.10 However, this did not seem to be especially
problematic in the case of cervical cancer research: matched breast cancer patients had similar recall of
sexual behaviours (Melnick, conference discussion, cited Klein, 1973, 1561-2). Given this assumption
of high quality, these retrospective studies indicated that detection of anti-HSV antibodies approximately
correlated with cervical tumour burden (Thiry et al., 1974). This paralleled similar work in BL (Henle
et al., 1973), but was complicated by experimental difficulties in serologically distinguishing HSV1 and
HSV2 infections (Wildy, 1973; Plummer, 1973). This was especially pressing: infections with HSV1
were felt to be likely modifiers (by immune system modulation) of the clinical course of infections with
HSV2 (Klein, 1973, 1561). For example, Adam et al. (1973) showed no significant difference in HSV
antibodies between controls and cervical cancer or dysplasia groups until HSV1 and HSV2 were dis-
tinguished. Once this was done, the patient groups had higher levels of HSV2 antibodies than matched
controls. Many similar studies were carried out (reviewed by Melnick and Adam, 1978, 52-3).
Other features for optimising retrospective case-control studies - in particular urging researchers
towards matching on a small number of features - were discussed (Schneiderman and Levin, 1973). I
will discuss this at more length in section 6.6.
While no trial of immunisation against HSV was conducted, other interventions seemed to provide
support for the aetiological role of HSV. First amongst these was the finding that the use of barrier
contraception reduced the incidence of cervical cancer. Although no interventional trial of this method
appears to have been conducted, evidence from observational trials (e.g. Boyd and Doll, 1964, 430-1;
Rotkin, 1973) suggested that cervical cancer patients had a lower rate of use of barrier contraception
than matched control patients with other gynaecological disorders. This observation thus functioned as
a natural experiment of barrier contraception.
3.5.2 Problems with HSV; alternate models
While both epidemiological evidence and suggestive mechanistic evidence was strong for HSV and cer-
vical cancer, it did not appear possible to detect the HSV genome in cervical cancer cells. It seemed gen-
erally impossible to detect either HSV1 or HSV2 nucleic acids in cervical cancer biopsies (zur Hausen
et al., 1974b), quite unlike the ease with which EBV nucleic acids could be detected in EBV-related
tumours. This specific case may have been caused by the relatively low sensitivity of HSV tests at this
8Cervical dysplasia, more correctly known as cervical intraepithelial neoplasia, is the growth of abnormal cells on the cervix.
It is a pre-malignant condition for cervical cancer.
9Later prospective seroepidemiological studies, such as Vonka et al., 1987, would reveal no such effect, as I discuss in section
3.5.2
10Retrospective studies are frequently criticised for their susceptibility to recall bias, in particular
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time (Pagano, 1975, 219-22). But even when assay sensitivity was improved, HSV was still undetectable
in either cervical dysplasia or cervical cancer (Cassai et al., 1981). When combined with the other prob-
lems facing the HSV mechanism, some authors began to seriously consider the role of papillomaviruses
in cervical cancer (zur Hausen, 1975, 40-3).
Other models of oncogenesis were therefore suggested. First, could HSV be responsible for just
one step of oncogenesis? zur Hausen (1982) suggested that cervical oncogenesis could be a multi-step
process. Infection with one virus, in this case HSV, could initiate tumourigenesis. This tumour could
then be maintained by infection with a second virus, in this case HPV. This ‘hit and run’ hypothesis could
explain the serological role of HSV, while too explaining the failures of detection of the virus in tumour
cells. This initiation of oncogenesis by HSV without leaving nucleic acid traces was experimentally
plausible (Skinner, 1976; Schlehofer and zur Hausen, 1982), could be related to a partially confirmed
genetic mechanism (Galloway and McDougall, 1983) and was shown to occur in cervical epithelial cells
(DiPaolo et al., 1990).
More damning evidence would come from the failures of prospective studies. While a large
prospective study of more that 10 000 women in Prague agreed with earlier retrospective risk factor
epidemiology (Vonka et al., 1984b), no differences in HSV2 status appeared to exist between carefully
matched control subjects and cancer cases (Vonka et al., 1984a; Krcma´r et al., 1986).11 Thus prospec-
tive studies did not seem to support a causal role for HSV in the development of the cancer. Similar
results for HSV2 were generated in other studies, although one of them did detect a correlation between
HPV CPE and the development of cervical dysplasia (Adam et al., 1985), while the second suggested a
possible explanation for the higher levels of anti-HSV2 antibodies seen in women with cervical cancer
(Lehtinen et al., 1992).12
Despite the suggestive evidence gathered, HSV remained a plausible, rather than a proven, cause of
cervical tumours. There was a strong association between anti-HSV antibodies and the disease. These
were increased in women with cervical cancer, cervical intraepithelial neoplasia and cervical dysplasia,
when compared to matched controls. Comparisons of breast and cervical cancer patients suggested that
this serological association was not just a function of recall bias. Finally, the expression of non-virion
proteins in cervical cancer samples, and the apparent recovery of sections of HSV DNA from cervical
cancer tissue, appeared to suggest a causal rather than a passenger role for HSV in the genesis of the
disease. While this mechanism was highly incomplete, it was still generally accepted. I suspect that
a major reason for this acceptability was its high degree of apparent plausibility, illustrated in its easy
accommodation of the known risk factors.
11Each individual who developed cervical cancer was matched with up to four healthy controls on the basis of five factors.
These were age, age at first sexual intercourse, number of sexual partners, smoking and history of cervical diathermy. I will return
to this process of selecting factors in section 6.6. The Prague study was really the most important single piece of evidence against
the theory that HSV caused cervical cancer. Interestingly, this apparently Popperian falsification of the theory was conducted at a
time and place where the works of Popper were forbidden (Vonka, personal communication).
12They suggest that cervical cancer causes an increase in the quantities of HSV2 antigen presented to the immune system
compared to the degree of presentation in women without cervical cancer. For a given severity of HSV2 infection, this leads to an
apparent increase in antibody titres in cervical cancer patients.
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3.6 Making mechanisms II: HPV (1983–)
3.6.1 Historical background
Despite the plausible aetiological role of HSV2, various other mechanisms also appeared to offer alter-
nate accounts of cervical cancer causation. Foremost among these was HPV. It initially seemed a much
less plausible cause of the disease than HSV. While herpes viruses were implicated in a wide variety
of malignant disease states, less such supportive evidence existed for HPV. There was some, however,
which I will briefly review below (also reviewed by zur Hausen, 1996a; zur Hausen, 1996b). In brief, the
factors supporting a causal role for papillomaviruses in the development of cervical cancer were these.
Papillomaviruses were known to cause tumours in humans. As their name suggests, by far the most
common type of papillomavirus-induced tumour was the benign skin papilloma (wart). Some malig-
nant conditions were also thought to be related to HPV infection, for instance EV, as I will discuss in
section 3.6.1.2. Papillomaviruses were also responsible for a range of benign and malignant diseases of
non-human animals. I will discuss two examples in section 3.6.1.3, BPV and CRPV.
3.6.1.1 Warts
Warts (benign skin papilloma) are common, benign skin tumours. They exist in a variety of forms,
including the common skin wart (simple papilloma), verruca (plantar warts), genital and laryngeal. They
have long been suspected to have a transmissible aetiology. For example, warts have been transmitted
between a variety of anatomical sites by a plethora of means, both experimentally and accidentally
(reviewed by Rowson and Mahy, 1967). Cases were reported where warts were transmitted through the
inoculation of ultra-filtered material, suggesting that their aetiologic agent was sub-cellular in size (Wile
and Kingery, 1919; Kingery, 1921). The apparently common nature of transmissibility, a suspected
correlation between the occurrence of different types in individual cases, and histological similarities
between types of wart (Findlay, 1930, 254) suggested a common cause for common, plantar, laryngeal
(Ullman, 1923) and genital (Wilson, 1937) warts. This unitary theory of wart causation (Oriel, 1971, 2)
began in the 1920s and was not seriously challenged until the 1970s.
As warts were transmissible by CFF, a virus seemed a highly likely cause. Research into this
suggestion followed a similar course to the other examples of viral oncogenesis discussed above. For
instance, the use of preventative intervention was suggested as a useful way of determining causation
(Biberstein, 1944). However, the viral hypothesis really took off with the wide-spread availability of
the electron microscope,13 which revealed considerable evidence for the presence of viruses in wart
cells. For instance, crystalline aggregates of VLPs were demonstrable (Strauss and Shaw, 1949). These
particles had a characteristic morphology (Melnick et al., 1952), which appeared consistent between
samples (Bunting, 1953; Reagan et al., 1954), although there was some minor disagreement about their
diameter (Siegel, 1960). Inclusions bodies, suggesting active viral replication, were also found in wart
material (Lyell and Miles, 1951), some types of which seemed to be correlated with the microscopic
presence of aggregates of viral particles when examined microscopically (Almeida et al., 1962). Similar
co-location results were produced by the use of immunofluorescence techniques, using antigens derived
13see section 1.1
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from these virus particles (Walter et al., 1965).
All this implicated these virus particles in the causation of warts. However, it proved very difficult
to grow these viruses in culture systems. While Bivins, 1953 reported presumptive success at growing an
agent derived from common warts in fertilized hens eggs, this finding was not replicable by other authors
(Felsher, 1947; Fischer, 1953; Siegel and Novy, 1955). This led to suggestions that the successfully
cultivated virus in the Bivin’s case was a contaminant, possibly canary pox virus (Siegel, 1956).
Only in human cell cultures did it seem possible to cultivate the virus.14 Successes were reported
using material derived from both genital (Morgan and Balduzzi, 1964) and common warts, with the
production of large quantities of viral particles (Oroszlan and Rich, 1964). Cultures of wart viruses
in human cell cultures appeared to lead to morphological and behavioural changes in the culture cells
(Noyes, 1965). HPV was therefore thought to be non-culturable in vitro (Butel, 1972).
This highly specific viral tropism represented a substantial difficulty for researchers working on the
wart virus. As research continued, it became apparent that unitary theory of wart causation was flawed.
Despite the apparent similarities between wart viruses in terms of clinical features, transmissibility, viral
morphology and culturability, warts at different anatomical sites had subtle, but important, differences.
Taking the case of genital warts, the natural history seemed distinct from common cutaneous warts (Oriel,
1971). Other findings such as the correlation between multiple types of warts in particular patients, also
appeared spurious (Oriel, 1971). While papillomavirus-like particles were sometimes visible in genital
warts under electron microscopy, in common with other types of warts, (Dunn and Ogilvie, 1968; Oriel
and Almeida, 1970), they generally appeared at a lower frequency. In conclusion, and importantly for
our story, it also appeared that wart viruses with different host tropisms were immunologically distinct
(Almeida et al., 1969).
3.6.1.2 Epidermodysplasia Verruciformis
EV is a rare, familial skin disease, which was first described by Lewandowsky and Lutz, 1922. It is
characterised by lifelong eruptions of large, transmissible skin lesions resembling planar warts. These
lesions, unlike true warts, have a high risk of malignant transformation, with about 25% of cases even-
tually developing some skin malignancy (Jablonska et al., 1972). Papillomavirus particles are detectable
within the lesions in a similar way to other warts (Delescluse et al., 1972), although they become unde-
tectable if malignant transformation occurs (Ruiter and van Mullem, 1970).
This condition was important for papillomavirus research in two ways. First, it implicated papillo-
maviruses in a malignant disease of humans. Second, once type variability of the papillomaviruses was
discovered in warts, EV became an important second source for discovering new papillomavirus types
with differing pathological proclivities (for instance, Orth et al., 1978b).
14One success was apparently obtained in animal cell culture: Mendelson and Kligman, 1961 reported the isolation of the wart
virus using cultures of MK (monkey kidney) cells. This virus, when inoculated into human volunteers, led to the development of
warts at the inoculation sites. Interestingly, the authors note that this research fulfilled Koch’s postulates for the agent. This seems
unlikely owing to the requirement for growth in pure culture.
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3.6.1.3 Animal tumours and papillomaviruses
Two types of papillomavirus found in non-human animals were particularly important to this story.
BPV, a member of papillomavirus superfamily C, was known to cause cutaneous papillomas in
cattle in a similar fashion to HPV in humans. However, this agent caused malignant bladder tumours
when injected into cow bladder mucosa (Olson et al., 1959), and was capable of causing similar cellular
transformation in vitro (Black et al., 1963). This suggested that individual papillomaviruses types might
have a ‘natural’ pathological effect at one anatomical site (so they might cause warts if they infected the
skin) but might also have an alternate effect if introduced into a different site (so they might cause cancer
if they were to infect the cervix). Like HPV, while it was cultivatable in tissue culture using cells of its
tropic host, it was extremely difficult to induce the virus to affect cells of any other species (Boiron et al.,
1964).
The second, CRPV,15 a member of papillomavirus supergroup E, was the first animal papillo-
mavirus identified. Its clinical manifestations are large, cutaneous fibrous tumours, similar to large warts,
that occur in wild cottontail rabbits (Sylvilagus floridanus). It was shown to be transmissible by cellular
inoculation (Shope, 1932) and by inoculation with cell-free filtrates (Shope and Hurst, 1933) to both
other cottontail rabbits and to common domestic rabbits (Oryctolagus spp.). Malignant change in these
papillomas was later observed (Rous and Beard, 1934; Syverton and Berry, 1935), although this may
have been a feature of the disease only when induced in Oryctolagus spp. (Rous and Beard, 1935). The
tumours also appeared to induce serum immunity to the agent (Rous and Beard, 1935, 541-2). Malignant
transformation appeared to be synergistically potentiated by the addition of chemical carcinogens (Rous
and Kidd, 1938; Rous and Friedewald, 1944). Viruses were detected in these papilloma (Moore et al.,
1959), and demonstrated to be papillomavirus by electron microscopy (Stone et al., 1959).
CRPV has been extremely important in other ways to recent papillomavirus research as a model-
system of papillomavirus action. While the details are beyond this piece, an excellent technical review
is Breitburd et al., 1997.
3.6.2 HPV types
So working with papillomaviruses presented significant challenges to researchers. By the early 1970s,
papillomaviruses had become a troubling puzzle. Much evidence supported the idea that various clini-
cal diseases - warts, EV, bovine papillomas and cottontail rabbit fibromas - were apparently related to
infection with papillomaviruses. Electron microscopy of material derived from different types of warts
(human skin, human genital and various kinds of warts in animals) revealed strong morphological sim-
ilarities between the various virus particles (Oriel and Almeida, 1970). This morphological similarity
seemed to fit in with the similarities of the clinical course of the disease seen during experimental or
accidental wart transmission experiments (as discussed in section 3.6.1.1). Together, these two features
suggested that papillomaviruses could cause both benign and malignant diseases, and were transmissible.
Yet this support was more equivocal than first appearances would suggest. For one, the different
known papillomaviruses, despite having similar gross morphologies and genome lengths (Crawford and
15also known as the Shope papillomavirus
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Crawford, 1963), were antigenically distinct (Bouvier et al., 1966) and their genomes showed a good
deal of variance when analysed in terms of base composition (Crawford and Crawford, 1963, 262). Both
immuno-electron microscopy and RNA-hybridisation experiments revealed a significant degree of dif-
ference between the papillomaviruses associated with different diseases, with material derived from one
type of disease appearing not to share immunological nor genetic characteristics with material derived
from other types (Almeida et al., 1969; zur Hausen et al., 1974a; Delap et al., 1976).16 There were
important epidemiological questions too. Different papillomavirus diseases in humans (warts, genital
warts or laryngeal warts) characteristically occurred at different ages and in different populations. This
finding too seemed to count against a strongly unified cause for these diseases. For instance, the results
of transplantation experiments on skin and genital warts (where warts were removed from one individual
and implanted on another, or where a wart was moved between anatomical sites on one subject) were, at
best, highly equivocal (see Oriel and Almeida, 1970, 37 for a review of these findings), suggesting that
even if papillomaviruses were implicated in the causation of these diseases, other unknown causal factors
were also important. Even more puzzling was the failure of the development of molecular methods to
detect these viruses. For instance, it did not appear possible to detect HPV DNA in warts, despite all the
other supporting evidence for their causal role (zur Hausen et al., 1974a).
Were HPV a group of related viruses? Could this explain the different clinical and experimental
properties of the (visually identical) viruses? Part of the puzzle was resolved when researchers exam-
ined in detail the genomes of papillomaviruses from different types of wart material. It rapidly became
apparent that a number of diverse HPV types were present. This difference applied too even between
different samples from warts of similar type-for instance Gissmann and zur Hausen, 1976, who reported
two apparently different papillomavirus types by restriction endonuclease digestion from plantar wart
material. This was not an isolated finding. Favre et al., 1975, during work to map the genome of HPV,
discovered a degree of genetic variation between types.
What was the significance of this finding for cervical cancer research? It led to the first serious
suggestion that, despite the lack of detection of the virus in cervical cancer cells, HPV could still be the
cause of cervical cancer (zur Hausen, 1976). zur Hausen commented:
The condyloma agent has been entirely neglected thus far in all epidemiological and
serological studies relating . . . to cervical . . . carcinomas. This is particularly unusual in view
of the localization of genital warts, their mode of venereal transmission, the number of re-
ports on malignant transition, and the presence of an agent belonging to a well-characterized
group of oncogenic DNA viruses.
(zur Hausen, 1976, 794)
In fact, zur Hausen was later to suggest that three features of HPV were particularly important in
the decision to conduct a detailed investigation of their role in cervical cancer (zur Hausen, 1983, 317-
8). These were, first, the failure of HSV detection in cervical cancer (as discussed in section 3.5.2), the
16For a contemporary review of the details of techniques used to detect HPV in a variety of settings see Koutsky et al., 1988.
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venereal transmission of HPV (as suggested by the sexual transmission of genital warts) and the ability,
in rare cases, of genital warts to undergo malignant transformation (Friedberg and Serlin, 1963).17
But this would all depend upon demonstrating distinct types of HPV. Gissmann et al. (1977) de-
scribed the detection of four types of HPV (HPV 1, 2, 3 and 4)18 in skin wart material. While HPV
1-3 appeared closely related to each other when examined by a variety of techniques (by restriction en-
donuclease digestion and electrophoresis, by RNA hybridisation and by immunological methods), HPV
4 seemed to be an altogether distinct virus. These differences seemed to correlate with histopathological
differences too. Wart samples with low numbers of virus particles tending to be infected with HPV 4
when examined microscopically. Yet the virus particles themselves were indistinguishable from each
other (Gissmann et al., 1977, 577). More interestingly, of the 50 samples of skin warts examined, 12
did not show evidence of infection with any of the four types. Neither were they detected in genital or
laryngeal wart samples (Gissmann et al., 1977, 579). Were there more types to be found?
A further two types of HPV were provisionally described by Orth et al., 1977. One, HPV 1, which
shared features with HPV 1-3 identified by Gissmann et al., 1977 was detected in a plantar wart. The sec-
ond was a novel type from a common skin wart, which became known as HPV 2. Again, they had iden-
tical microscopic morphologies and similar-size genomes, produced different fragments on restriction-
endonuclease digestion and lacked homology on RNA-DNA hybridisation. While HPV 2 did not behave
similarly to any of Gissman’s 4 types, Orth’s HPV 1 was similar to Gissman’s HPV 1-3. Hybridisation
experiments with the new HPV 2 material against pooled HPV isolates revealed hybridisation, leading
to the conclusion that HPV 2 was a cause of warts in general.
At much the same time, isolates from EV were seen to be immunologically distinct from wart types
found in plantar and skin warts (Pass et al., 1977). Two new types were described (Orth et al., 1978b),
designated JD HPV and JK HPV. Again, these types had similar electron microscopy and genome char-
acteristics, but were distinct from each other and from HPV 1 and HPV 2 by hybridisation and immunol-
ogy. Again, the different types were associated with clinical differences: JD was discovered in a flat,
wart-like EV lesion, while JK was found in red, plaque-like lesions, which had a tendency towards ma-
lignant transformation (Orth et al., 1978b, 1541). This suspicion was reinforced by a later clinical study
showing just that (Orth et al., 1979).
As might be expected, HPV types from genital warts had similar morphological and genomic prop-
erties to those from other sources, but showed little sequence homology with any other HPV types (Orth
et al., 1978a). However, genital warts presented an especially challenging research target, owing to the
relative paucity of viral particles present in them. It was not until Gissmann and zur Hausen, 1980 that
extraction of a genital isolate was achieved, made possible by a sample containing exceptionally high
levels of virus. The main development here was the extraction of DNA from a novel type, designated
17zur Hausen was, for many years, almost the sole supporter of the theory that papillomaviruses played a causal role in cervical
cancer. This prolonged involvement in a research programme that was unsuccessful for so long has been lately recognised by the
Nobel committee (zur Hausen, 2008).
18The naming of HPV types became extremely confusing. In the following passage I will use the terminology used in the
original publications. However, the known types were reclassified in July 1978 (Coggin and zur Hausen, 1979) into HPV 1-5 by a
combination of sequence homology and serology. See table 3.1.
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HPV-6, isolated from genital warts. Again, it seemed to share no homology with HPV 1-5. However, all
samples of genital wart material tested against the virus derived from a single sample seemed to show
homology. It was thus suggested that genital warts, contra the other types of papillomas, might display a
high degree of causal homogeneity. The paper also ends with a return to considering malignant disease:
Characterization of these agents should provide the basis for a further analysis of their
possible involvement in human malignant disease.
(Gissmann and zur Hausen, 1980, 608)
Type isolation proceeded rapidly, with HPV-7 isolated from cutaneous warts from meat workers
(Orth et al., 1981; Ostrow et al., 1981). This virus was distinct from BPV. Further isolates were made
from patients with EV (Pfister et al., 1981), and with laryngeal papilloma (Gissmann et al., 1982a).
HPV-6 material was cloned, and used as a DNA probe (de Villiers et al., 1981; de Villiers et al.,
1981) in order to look for papillomavirus material in other samples (zur Hausen, 1983) In summary, 6
malignant genital warts (Buschke-Lo¨wstein tumours) contained HPV-6 or -11 DNA (Gissmann et al.,
1982b). Importantly for our story, five of 27 cervical cancer biopsies examined contained HPV-11
(Gissmann et al., 1983). Similar findings were made by other groups (Green et al., 1982; Okagaki
et al., 1983). While this evidence was suggestive of a role for HPV in cervical cancer, it was not until
the discovery and cloning of HPV-16 (Du¨rst et al., 1983) that HPV could be detected in most cervical
cancer tissue samples. The story of the discovery is interesting. First, a number of cervical cancer tissue
samples were screened using HPV-11 DNA under nonstringent conditions. One of these (WV 2916)
contained a papillomavirus sequence which hybridised with HPV-11. However, under conditions of high
stringency this sample failed to hybridise with known HPV types. When it was analysed by restriction
endonuclease digestion, it revealed an unusual cleavage pattern, suggesting that this was a novel type.
Thus a new papillomavirus was detected in cervical cancer tissue. When this new sequence was used
to probe 18 German cervical cancer samples, it hybridized with high stringency with 11 of them. In
comparison, when screened against genital wart material, it was present in only two of 33 samples used.
There also seemed to be a degree of geographical variation, with the sequence being detectable in only
eight of 23 Kenyan and Brazilian cervical cancer samples screened. Thus this isolation seemed to be a
very likely cause of cervical cancer, in European women at least.
One of these negative Kenyan samples was shortly shown to contain a second novel type, HPV-18,
by similar means to that in HPV-16 (Boshart et al., 1984). As might be expected, fewer German (2/13)
or Brazilian (9/36) samples were positive. Related DNA was also found in a number of existing human
cervical cancer cell lines, including HeLa, KB and C4-1.19 Taken together, HPV-16 and -18 were present
in most tested cervical cancer samples. But what was the pathogenic mechanism?
19The detection of HPV-18 in HeLa cells is, perhaps, unsurprising. These cells, named for the patient from whom they were
harvested (Henrietta Lacks), were derived from a cervical tumour in 1951 (Skloot, 2010). They are the most commonly encoun-
tered human cell in research practice. The induction of this tumour by HPV-18, and its continuing presence in these cells, has since
been confirmed (Macville et al., 1999).
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3.6.3 HPV-mediated oncogenesis
While I won’t attempt a detailed review of the mechanism by which HPV causes cervical cancer, it is
worth discussing a few of the major developments here.20 First, it was found that cloned HPV DNA
alone was capable of transforming cells in vitro. While this was first demonstrated with HPV types not
thought to be implicated in cervical cancer (Watts et al., 1984), it was later shown to be possible with
HPV-16 (Yasumoto et al., 1986). This ability of HPV-16 to immortalize animal cells in vitro was found
to extend to human cells of various types (Du¨rst et al., 1987; Pirisi et al., 1987), including cells of the
cervical epithelium (Chen et al., 1993). This process of transformation involved incorporation of the
HPV genome into the host genome and its amplification (Schwarz et al., 1985), possibly explaining the
high levels of HPV DNA detectable in human cervical cancer cell lines. HPV integration was found to
be the case in most human cervical cancer cell lines (Yee et al., 1985).
RNA analysis revealed the expression of a number of non-structural viral proteins in these immor-
talized cells.21 These ‘early’ viral proteins appeared causally important in cellular transformation (Kaur
and McDougall, 1988). In particular, the E6 and E7 proteins appeared to be responsible for modify-
ing cell cycle regulation (von Knebel Doeberitz et al., 1988) through a number of specific mechanisms.
Acting together, HPV-18 E6 and E7 proteins were found to be necessary and sufficient for cell transfor-
mation, in vitro, at least (Mu¨nger et al., 1989).
E6 is necessarily responsible for the maintenance of tumours (von Knebel Doeberitz et al., 1994).
However, acting alone, it also appeared capable of inducing immortalization in some cell-types (Band
et al., 1991). It causes cell-cycle deregulation by p53 degradation (Scheffner et al., 1990). E7, though,
acts through interactions with pRb (Dyson et al., 1989), leading to cell-cycle deregulation via disruption
of the actions of transcription factor E2F (Chellappan et al., 1992). Thus, E7 acts as the initiator of cell
immortalization (Halbert et al., 1991).
This process of HPV integration, early protein expression and disruption of cell-cycle regulation
was suggested as also being capable of inducing malignant transformation, rather than immortalization.
For instance, in vitro studies of keratinocytes immortalized by HPV showed that they might occasionally
became malignant upon prolonged passage (Hurlin et al., 1991; Pecoraro et al., 1991). However, it is
generally the case that HPV is seen as an agent capable of producing cell immortalization, rather than
malignant transformation in vitro, and most researchers use another transforming agent (such as activated
H-ras) to produce maligant cells experimentally (Vonka, personal communication).
20I can recommend the following reviews of the subject: zur Hausen, 1986; zur Hausen, 1991; zur Hausen, 1996a; zur Hausen,
1996b; zur Hausen, 2000; McCance, 2004.
21See also Moody and Laimins, 2010 for a review of the current state of knowledge on the manner in which these early proteins
act to transform cells.
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3.7 Application II: HPV
3.7.1 Testing the mechanism
By this point, almost all the evidence implicating HPV in the development of cervical cancer had arisen
from laboratory studies (zur Hausen, 1989a, 1680; zur Hausen, 1989b).22 However, in the early 1990s,
work was conducted that attempted to reconcile the causal mechanism identified in the laboratory with
the known risk factors for cervical cancer. The first step was to show general applicability. This occurred
in two ways. First, von Knebel Doeberitz et al., 1992 noted that the promotion of the expression of E6
and E7 in vivo led to increased tumour growth, while their inhibition led to regression. So HPV appeared
to act in a similar way in either experimental systems or in whole organisms.
Second, population studies were conducted to study the relationship between HPV, previously iden-
tified cervical cancer risk factors and cervical cancer itself. Bosch et al., 1992, a case-control study
between Spain and Colombia suggested, first, that HPV infection (as assessed by polymerase chain re-
action (PCR)23 in exfoliated cervical epithelial cells) was a strong risk factor for cervical cancer. Further
analysis of the same population sample suggested that the link between HPV-16, -18, -31, -33 and -35
was likely to be causal, on the grounds primarily of the strength of the association.24 Second, this study
suggested that some risk factors, in particular promiscuity, could be explained largely in terms of risk of
HPV exposure. However, some risk factors, while plausibly accounted for in terms of modifying HPV
exposure risk, could not be accounted for in terms of HPV in this study.
Similar findings occurred in other epidemiological surveys, showing a strong association between
HPV and cervical cancer across populations. More than 90% of cervical cancers were HPV positive
(Bosch et al., 1995), and adjustment for other risk factors suggested that in a very high proportion of
cases it was infection with HPV that was causal (Schiffman et al., 1993). As previously suspected,25
while the precise prevalence of HPV types varied geographically (Bosch et al., 1995), in most cases
HPV-16 and -18 appeared to be the most important in terms of cervical cancer causation.
22‘Interestingly and in remarkable contrast to other viruses linked to human cancer. . . most of the evidence originated from
laboratory studies revealing transforming activity of these viruses, a specific mode of integration and of genetic activity in cancer
cells, and the role of viral genes in the maintenance of the proliferative phenotype in cells of HPV-positive cervical carcinoma
lines. To a much lesser degree, epidemiologic approaches contributed to our present state of knowledge, whereas seroepidemiology
virtually contributed not at all’ (zur Hausen, 1989a, 1680).
23PCR entered general research contexts in the early 1990s, offering in this case a relatively inexpensive and highly sensitive
means of detecting HPV types far superior to other techniques (Bauer et al., 1991).
24‘When the results. . . were combined to better define clearly negative and clearly positive specimens an extremely strong
association emerged, OR = 146.6 (35.5-606.4). Odds ratios of this strength are extremely rare in cancer epidemiology. The
strength of this association points towards a causal association and there is at present no experimental evidence suggesting that
this association could be explained either by enhanced susceptibility of cancer cells to HPV infection or by enhanced HPV-DNA
detectability in cancer cells.’ (Mun˜oz et al., 1992, 747). In fact, as a recent study suggests, this may well be a substantial
underestimate of the OR associated with high-risk HPV types. For types -16 and -18 respectively, the odds ratios are 2770 (95%
CI 1050-7320) and 950 (95% CI 330-2740), while the OR for the other oncogenic types are in general much lower (between about
20 and 400) in the same population (Powell et al., 2010).
25e.g. Du¨rst et al., 1983; Boshart et al., 1984
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3.7.2 Sharp observations, sharp interventions
While I do not want to discuss the epidemiology of cervical cancer at any more length, I do think that it
is worth discussing a couple of recent research themes that arose from it, which were significant in their
own right as causal evidence. The first was using HPV status as a means of assessing cervical cancer
risk, the second is the use of vaccination against HPV as a preventative and (potentially) therapeutic tool
against cervical cancer (Vonka and Hamsı´kova´, 2007).
Testing for HPV either as a replacement or as an adjunct for conventional cervical cytology has
been suggested (Mayrand et al., 2006) and attempted in trial contexts, where it has been found to be
more sensitive that cervical cytology alone (Mayrand et al., 2007). This appears to be the case using
a variety of HPV testing protocols (Gravitt et al., 2008). However, this great sensitivity may well be
problematic. For example, while pre-cancerous lesions likely to progress to malignancy will be detected
by HPV testing, so will precancerous lesions likely to spontaneously regress (Ronco et al., 2008). The
heterogeneity between HPV types is also a problem for sequence-based tests. Each system is designed
to test for a certain range of HPV types. So depending upon the exact test used, different types may or
may not be detected (Klug et al., 2008), complicating epidemiology and practice.
Successful vaccination programmes have been suggested as useful evidence for causation, as I
discuss in sections 4.5.2 and 5.8. The majority of effort in this case is concerned with preventative,
rather than therapeutic vaccination.26 Two HPV vaccines have recently entered clinical use. Gardasil R©
(Merck & Co.), which is a quadrivalent vaccine active against HPV-16, -18, -6 (genital warts) and -
11 (laryngeal warts) (Villa, 2007) and Cervarix R© (GSK), a bivalent vaccine against HPV-16 and -18.
Both are based upon recombinant virus-like particles of the various L1 major capsid proteins. While
safe and apparently effective in terms of preventing HPV infection, they are relatively expensive, with
a basic NHS cost of approximately £250 per course (Joint Formulary Committee, 2009). Vaccination
programmes against HPV have therefore begun in much of the developed world (Senior, 2008), but costs
have restricted the implemention of these programmes in the developing world (Anonymous, 2008).
Current vaccination research focuses on producing vaccines with activity against greater numbers of
HPV types. In particular, attempts are being made to produce recombinant, chimeric, VLPs that include
fragments of the L2 capsid protein, which provides a higher degree of immune system cross-reactivity
(Kondo et al., 2008).
26Although there are currently attempts being made to use vaccines in a therapeutic way - for instance, Hung et al., 2008 and




In their 2007 paper, Russo and Williamson promote a thesis on the nature of causality in medicine.
Causes, they suggest, are monistic. That is, there is only one sort of causality in medicine. This causal
monism, though, depends upon evidential pluralism. More specifically, they claim that both mechanistic
and probabilistic evidence are typically required to support causal claims in medicine. Thus, they claim
that causes in medicine are metaphysically monistic, but evidentially pluralistic. This is the essence of
their claim, and it will form the basis of this chapter. I intend to show that, with certain modifications,
the Russo-Williamson thesis (RWT) can become operationally useful in examining causal claims from
the history of medicine. This programme of creating an historically motivated version of the RWT will
form the basis for the subsequent parts of this thesis.1 Thus, the job of this chapter is to outline Russo
and Williamson’s arguments accurately, to examine them critically, and then to suggest a number of
objections and counterexamples. By means of introducing the remainder of this thesis, I will conclude
this chapter with a sketch of how these objections might be overcome. This chapter is, therefore, largely
a review of the RWT and a series of problem statements. It will assume the following structure. First, in
section 4.2, I will outline the claims that Russo and Williamson make. At the outset, I suggest that most
of their claims are correct. But even here, I will suggest that certain aspects of their account are likely to
be problematic when we try to understand and evaluate real, medical, complex causes. I will also outline
a number of philosophical objections to the RWT in section 4.3.
Next, what light can the examination of detailed historical cases shed on the RWT? In section 4.4,
I outline the reasons why I regard their thesis as a practical, historical proposition. This section will be
based upon the development of a causal claim linking EBV infection with BL from chapter 2.
I conclude this chapter by introducing three prima facie historical counterexamples to the RWT. The
first of these deals with the history of discovery of the causation of McArdle disease. This appears to be
a case of robust causal inference made in the absence of probabilistic evidence. The second of these, the
discovery of the role played by chronic HBV infection in the aetiology of primary liver cancer, appears
to be a case where mechanistic evidence was lacking, and probabilistic evidence alone seemed sufficient
1Russo and Williamson employ some brief historical examples too: on smoking and lung cancer, the Semmelweis case, cholera,
Helicobacter pylori and stomach ulcers. The historical side of their thesis will be developed further in what follows.
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to support a sound causal claim. The third case, based upon the discussion of HSV and cervical cancer
in sections 3.3-3.5, relates the development of a faulty causal claim which was supported by apparently
high-quality probabilistic and mechanistic evidence.
How can we save the RWT in the light of these difficulties? The cases and counterexamples in this
chapter will form the basis for the necessary developments. First, I will outline my position on mech-
anisms in chapter 5. I will then use features of the historical cases to develop an account of evidence
for causality in chapter 6. This account is intended to show that Russo and Williamson’s mechanis-
tic/probabilistic distinction is historically and conceptually tenable. Here, I will suggest that we can
make Russo and Williamson’s differentiation between types of evidence for causality. Finally, in chapter
7, I will give an account of the nature of integration of evidence in the examples. Briefly, I suggest that
mechanisms provide a means by which we can address the reference-class problem when examining our
probabilistic evidence. We take the (likely) significant causal landmarks identified during the process of
mechanism construction, and partition our probabilistic evidence using them. Thus, probabilities tell us
about the pertinence of a causal mechanism to a given population, while mechanisms tell us about the
manner in which an effect can come about in that same population.
With these developments in place, the RWT can accommodate both our examples and our coun-
terexamples. But I also suggest that my account of the manner in which evidence is integrated is not
only a feature of successful causal claims, but that it also represents an important epistemic tool that can
provide us with the means to assess new or controversial claims of causation in medicine. But that is
for much later in the thesis. For now, I will simply introduce the RWT, outline a range of philosophical
objections to it, briefly illustrate some of its features by reference to the EBV example and set out the
three historical counterexamples.
4.2 The Russo-Williamson Thesis
Russo and Williamson begin by making the claim that medicine requires the notion of causality. Medical
researchers, they argue, look for causes. This opposes recent claims that such causal talk is ‘redundant
and misleading’ (Lipton and Odegaard, 2005, 6), and is perfectly replaceable by non-causal terminology.
Thus the employment of weakened causal terminology, such as ‘risk factor’ or ‘determinant’, in the
medical literature does not reflect an underlying reduction in the importance of causation in medical
practice (Russo and Williamson, 2007, 157-8). I think this claim is generally correct. Certainly, the EBV
and HPV cases seem to support an historical case for the centrality of causality to medical research. So
Russo and Williamson’s first claim is that:
It is quite uncontroversial that the health sciences look for causes, namely for causes of
disease and for effective treatments.
(Russo and Williamson, 2007, 157)
We might, for the sake of clarity, pre´cis the first part of this quotation as:
RW1. Medicine requires the notion of cause
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This quotation also contains a second claim, and one which is supported by the roles played by
causes in the two historical cases. This is that medicine seeks causes that fall into two broad classes.
These are aetiological causes and therapeutic causes (Russo and Williamson, 2007, 157). Aetiological
causes are those that are concerned with the cause of diseases, while therapeutic causes deal with the
manner in which a disease may be prevented or cured. This simple distinction is of profound importance.
In general, it is simply not the case that therapeutic interventions always consist of preventing aetiological
causes. For example, therapy for BL does not involve preventing infection with EBV. Instead, it involves
the use of chemotherapeutic drugs which act by preferentially killing tumour cells. While a fuller account
of the distinction and relationship between aetiological and therapeutic causes will have to wait for
section 5.8, this claim seems historically well supported. Although the bulk of the EBV and HPV
cases deal with the process of discovering aetiological causes, there are distinct hints of subsequent
work directed at finding therapeutic causes apparent in both cases. So Russo and Williamson’s second,
historically supported claim is:
RW2. Two sorts of causal relationship - aetiological or therapeutic - are
important in medicine.
However, Russo and Williamson then go on to formulate a slightly different type of distinction, one
which differentiates the reasons that researchers hunt causes, rather than (as with RW2) distinguishing
between types of cause. Medicine, they argue, seeks causes for both cognitive and action-oriented goals:
On the one hand, the health sciences pursue a cognitive goal, detecting causal factors
and identifying mechanisms of disease. . . on the other hand, they pursue an action-oriented
goal, informing policies and guiding early diagnosis or treatment on the basis of causal
knowledge. . .
(Russo and Williamson, 2007, 157)
The cognitive goals for which causes are sought are largely encapsulated by considering the role
of causes in forming good explanations. Action-oriented goals, on the other hand, are largely used to
ground clinical medical practice - for example, in guiding policy, diagnosis and intervention. Now this
distinction divides along a different axis from the aetiological/therapeutic distinction of RW2. It is not
the case that there is a simple correspondence between cognitive reasons for seeking causes and finding
aetiological causes or between seeking for action-oriented reasons and finding therapeutic causes. It
is easy to imagine a cognitive goal for which a therapeutic type of cause is sought (for instance, by
seeking to explain the success of a therapeutic agent). Likewise, we might imagine many action-oriented
reasons for attempting to discover the aetiological relationships at work in a particular disease. Russo and
Williamson ground this intentional distinction in a differentiation between the sorts of epistemic practices
to which causal relationships can be put. Specifically, they suggest that the first of these functions reveals
a potentially explanatory aspect to causal relationships, while the second goal reveals an inferential
component.
RW3. Causes are sought for either cognitive or action-oriented reasons
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As with RW2, this distinction appears logically very important. However, unlike RW2, I have
doubts about the historical support that can be provided for it. Particularly, distinctions of this sort
appear lacking in the viral oncogenesis cases. If we interpret RW3 in a strong sense, where the different
reasons for seeking causes reflects an issue of distinct agency, the following dilemma results from this
lack of historical support. Either Russo and Williamson are wrong about this distinction; or we must
suggest that the historical literature does not accurately reflect the way that causes are sought.
The first horn appears logically problematic. Good causes do appear to provide a rational licence
for both these distinct sorts of practice. It therefore appears incorrect to suggest that this distinction is
utterly baseless. On the other hand, accepting the second horn appears equally difficult for any analysis
of causality that is grounded in (historical) medical practice. So some sort of alternative strategy seems
appropriate here. My suggestion is this: that the cognitive/action-oriented distinction really just repre-
sents the uses to which causal relationships are put, rather than being any sort of issue of distinct agency.
Under this analysis, we can still make Russo and Williamson’s distinction. However, as it now becomes
a question of the employment of causal relationships, rather than one dealing with their construction, we
cannot seek historical support for it from the historical literature dealing with particular cases of causal
inference. Instead, if we want to support this distinction we need to look for evidence in contexts where
causes are used, rather than made. Doing this in detail seems beyond the scope of this thesis, so instead,
I will claim here that I think this distinction should be interpreted as a claim about the use of causes,
rather than one about their construction or evaluation.
Perhaps these different senses of, and reasons for seeking, causes have been a possible source of the
conceptual difficulties previously experienced in interpreting causality in medicine. In fact, as Russo and
Williamson identify, several recent reviews of medical causation have identified a range of meanings or
senses of causation, without reaching either consensus or a conceptually satisfactory position (Russo and
Williamson, 2007, 158).2 Given both their claim about the general importance of causality in medicine
(RW1) and the likely importance of it to a number of more specific aspects of medical practice (suggested
by RW2-3), this failure of previous accounts seems profoundly problematic. Russo and Williamson too
find this troubling:
RW4. Current accounts of causality in medicine are unsatisfactory
It is from this position that Russo and Williamson begin the constructive aspect of their account.
First, perhaps some of this confusion about causality results from the many senses of ‘cause’ encountered
in medicine. In addition to their distinction about the sorts of causes (RW2) and the uses to which these
causes are put (RW3), Russo and Williamson suggest a further clarification about causes versus causal
evidence. In this respect, they suggest that we should take care not to conflate the nature of causal
relations themselves with their supporting or constitutive evidence:
2‘. . . recent review articles try to extrapolate a concept of cause as it is used in scientific practice . . . They isolate several, none
of which seems to be fully satisfactory or attract a firm consensus. Parascandola and Weed (2001) isolate five different meanings
of “cause”: production, necessary cause, sufficient-component cause, probabilistic causation, and counterfactual. None of these
can alone account for all the possible ways in which causes operate.’ (Russo and Williamson, 2007, 158). See also my brief review
of medical schemes of causality in section 1.2
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We shall argue that although causal relations are inferred from mixed evidence, includ-
ing knowledge of mechanisms and of probabilistic relations, one ought not to confuse the
causal relation itself with the types of evidence used to support putative causal relationships.
(Russo and Williamson, 2007, 158)
Thus, they make the claim that causality and the evidence for causality should be distinguished:
RW5. The nature of causality is distinct from the evidence used to construct causal claims
Now this claim seems, initially, trivialy true. Of course a causal process is distinct from the evidence
used to infer the existence or nature of that causal process. However, in the light of later claims (in
particular RW11), this claim begins to make more sense. It is, essentially, directed against the claims of
causal pluralists. Russo and Williamson first argue that, there exist both mechanistic and probabilistic
types of evidence:
RW6. ‘Evidence is constituted by two complementary elements: probabilities and mechanisms.’3
(Russo and Williamson, 2007, 159)
However, the double-edged notion of causal evidence (RW6) does not - because of RW5 - imply
that these different notions of evidence support the existence of two distinct notions of causality.4
So we require both probabilistic and mechanistic evidence to make causal claims (Russo and
Williamson, 2007, 159; 161), but both these types of evidence support a single type of causal claim.5
Why are both required? What functions do these types of evidence perform? First, probabilistic evidence
tells us about the effects of causes via their dependencies.6 After all, if we want to develop an under-
standing of disease aetiology or therapeutic strategies then our causes must make some sort of difference
3Note that while Russo and Williamson give various examples of mechanisms, they do not define a mechanism, nor do they
relate their conception of a mechanism to any particular philosophical concept of mechanism. I will attempt to expand their
account in this direction in chapters 5 and 6. They also revise their position on the role of probabilities in Russo and Williamson,
2010, by suggesting that evidence of difference-making, rather than of probabilities, is what is required to accompany evidence of
mechanism. I expand upon this in sections 4.5.1 and 6.5ff.
4As Russo and Williamson argue: ‘Suppose that the pluralist advocates two notions of cause, a mechanistic, cause1, and a
probabilistic, cause2. Take any particular causal claim, e.g., “smoking causes cancer”, that the pluralist cashes out in terms of
one or other of these notions but not both. . . the evidence for this claim is multi-faceted, consisting of observed dependencies and
mechanistic/theoretical considerations. But the pluralist’s analysis of this claim will be single-faceted, say “smoking is a cause1
of cancer”. But then the pluralist opens herself up to the epistemological problems of monism. If this particular use of “cause” is
mechanistic, cause1, then how can it be that, even when the mechanism is established and uncontroversial, further probabilistic
evidence is cited in support of the causal claim? However, if the use is probabilistic, cause2, why are mechanisms invoked as
evidence, even when there is ample probabilistic evidence? The pluralist can’t explain the variety of evidence for the claim: if
pluralism is right, it should be possible that the evidence just be mechanistic, or just be probabilistic.’ (Russo and Williamson,
2007, 167).
5Russo and Williamson have recently suggested that, in fact, it is only ‘typically’ the case that both kinds of evidence are
required (Russo and Williamson, 2010, 15)
6‘The probabilistic aspect is crucial because, in the health sciences, causal claims are used for prediction, diagnosis, and
intervention; for these modes of inference to be possible, a cause needs to make a difference to its effects, i.e., there needs to be
some appropriate probabilistic dependence.’ (Russo and Williamson, 2007, 159)
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in terms of their effects. We determine the presence and magnitude of this difference from probabilistic
evidence. Probabilistic correlations are also heuristically important guides to the likely presence of some
sort of causal relationship. In other words, correlations themselves are good - but not infallible - evidence
for causation.7
RW7. Probabilistic evidence is required because causes need to make a difference to their effects.
Correlations also suggest the possibility of a causal relationship.
The suggestion that correlations are important indicators of the existence of causal relationships
is an interesting one. For instance, if we know that a particular disease increases in frequency with
a particular behaviour, and reduces when that behaviour is excluded, then we have some limited causal
knowledge about the relationship between the disease and the behaviour. Depending on, say, the personal
impact of refraining from that behaviour, we may recommend abstention from it in order to prevent the
disease without worrying too much about how it causes the disease.
This sort of strategy is often described as ‘risk factor’ epidemiology, and it can be very effective.
For instance, consider the example of lung cancer and watching television. Say that an individual who
watches a great deal of television is more likely to smoke cigarettes than an otherwise matched control.
We would then, if we were to carry out an observational study, see higher rates of lung cancer in a
group of television watchers than non-television watchers. We might therefore conduct a second, inter-
ventional, study in which television watchers were asked to decrease their level of viewing. This might
well decrease the number of cigarettes they smoked, leading to a decrease in lung cancer incidence. By
probabilistic evidence alone we might therefore suggest that individuals should refrain from watching
television in an attempt to reduce their chance of developing lung cancer.
However, while these studies imply some kind of causal link between television and cancer upon
which we can intervene, it might well be a more effective strategy to intervene directly upon cigarette
smoking itself, which in this case is a more direct cause of lung cancer than television watching. In
general, if we are to develop detailed causal knowledge that sustains effective, precise intervention, then
we need some further evidence that tells us about such confounding variables.8
This correlation between television and lung cancer is also non-explanatory, in that it tells us nothing
about the manner in which consuming television is supposed to cause cancer. In the light of RW2-3, we
need some other form of evidence to make our causal claims reliable. Russo and Williamson suggest
that this other form of evidence is that of mechanisms:
RW8. Mechanisms are required because they explain causal dependencies
7‘Although, as is well known, correlation does not prove causation, strong correlations can be good evidence for the presence
of a causal relation.’ (Russo and Williamson, 2007, 162).
8In this case, smoking is a confounding variable for the observed correlation between television consumption and the devel-
opment of lung cancer. In general terms, confounders are ‘. . . factors (exposures, interventions, treatments, etc.) that explain or
produce all or part of the difference between the measure of association and the measure of effect that would be obtained with a
counterfactual ideal.’ (Rothman et al., 2008, 58).
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Evidence of mechanism tells us about causal dependence.9 This seeks to explain the internal work-
ings of our evidence of difference making, in a way that rationally permits us to generalise and explain
our findings. For example, similar types of dependencies are likely to have similar causal mechanisms.10
There are further methodological advantages to considering these two types of evidence. Mechanisms
also do the important work of negatively constraining the permitted types of causal processes that we
might consider explanatory for our probabilistic dependency. In the example above, we would begin
to distrust the correlation seen between television and cancer, given the lack of a plausible mechanism
linking television exposure and lung cancer:
RW9. Mechanisms are useful because they allow us to generalise a causal relation and to impose
negative constraints on probabilistic causes. No plausible mechanism suggests no cause.11
So Russo and Williamson claim that causation in medicine depends on these two types of evidence.
Probabilities play the role of showing the existence and strength of a particular cause on an effect, while
mechanisms demonstrate the manner in which these probabilistic correlations function. With this basic
framework in place, Russo and Williamson turn to the sort of causality that this evidential pluralism
supports. First, they argue against conventional, monistic accounts of causality,12 on the grounds that all
of them fail to accommodate the sorts of evidential pluralism that they, and medical practice, demand.
RW10. Traditional causal monism cannot accommodate this evidential pluralism.
Broadly, mechanistic accounts of causality cannot explain the reliance on difference-making evi-
dence that appears to be so important in defending causal claims in medicine. That is, the role played
by finding and evaluating correlations that plays such an historically important role cannot be accounted
for by mechanistic monists. Similarly, difference-making accounts cannot account for the use of mech-
anistic evidence in practice. Thus, Russo and Williamson argue, any monistic interpretation of causality
in medicine that depends upon any one of these accounts appears false. They also argue that any simple
admixture of both mechanistic and difference-making accounts is false too. It is simply not the case,
argue Russo and Williamson, that a number of different types of causality are a feature of the medical
literature:
9‘. . . the mechanistic aspect is required because mechanisms explain the dependencies, and in the health sciences causal rela-
tionships are also meant to be explanatory.’ (Russo and Williamson, 2007, 159)
10Take, for example, the research programme that developed around HSV as a cause of cervical cancer. While this was eventually
demonstrated to be mistaken, it was in part driven by the heuristic that many other herpesviruses appeared to play a causal role in
the development of tumours
11‘. . . mechanisms allow us to generalise a causal relation: while an appropriate dependence in the sample data can warrant a
causal claim “C causes E in the sample population”, a plausible mechanism or theoretical connection is required to warrant the
more general claim “C causes E”. Conversely, mechanisms also impose negative constraints: if there is no plausible mechanism
from C to E, then any correlation is likely to be spurious.’ (Russo and Williamson, 2007, 159)
12Russo and Williamson include both mechanistic and difference-making accounts of causality here. They mention, for the
class of monistic mechanistic theories, the conserved quantities (CQ) theory of causality (Salmon, 1998; Dowe, 2000). Monistic
difference-making theories are represented by a range of probabilistic theories (e.g. Suppes, 1970), counterfactual theories (e.g.
Lewis, 2000) and agency theories (e.g. Price, 1991).
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. . . only a single notion of cause is used in the health sciences. More specifically, health
scientists use two types of evidence for a single causal claim, ‘C causes E’, not for two
different types of causal claim, C-causes1-E and C-causes2-E. Because only one notion of
cause is used in the health sciences, pluralism is false.
(Russo and Williamson, 2007, 165)
This gives us Russo and Williamson’s 11th claim, arguing against any form of ontological or con-
ceptual causal pluralism:
RW11. Medicine is not pluralistic about causality
This refutation of causal pluralism gains support from two sources. Firstly, the homogeneity of
causal language in the medical literature seems to support causal monism (Russo and Williamson, 2007,
166).13 Second, they suggest that pluralistic accounts will inherit the difficulties of monistic accounts
in accomodating alternative forms of evidence (Russo and Williamson, 2007, 166-7). Thus Russo and
Williamson appear stuck. They need a monistic interpretation of causality that can accommodate a
plurality of evidence. Their solution is to turn to an epistemic theory of causality:
RW12. ‘. . . an epistemic account of causality is required to capture the full complexity of causal
evidence’ (Russo and Williamson, 2007, 169)
Russo and Williamson suggest that an epistemic theory of causality, in which causal relationships
are identified as ‘. . . the causal beliefs of an omniscient rational agent’ (Russo and Williamson, 2007,
168),14 is the correct interpretation of causality in this situation. This epistemic theory means causality
should be understood as arising from causal epistemology:
The epistemic theory understands causal relationships in terms of rational beliefs as
follows. First, it gives primacy to an account of how an agent’s evidence determines which
causal beliefs she should adopt. Second it analyses the causal relation to be the set of causal
beliefs that an agent with total evidence should adopt. Thus causality itself is determined by
causal epistemology. . . How, then, does evidence constrain rational causal beliefs? Roughly
speaking, an agent’s causal belief state should satisfy the following conditions: (i) her causal
beliefs should account for all known dependencies that are not already accounted for by
known non-causal relationships; (ii) her causal beliefs should be compatible with her other
13Referring to a sample passage from the recent medical literature, Russo and Williamson say: ‘Here causal language is used
(“the same concentration in the target tissue may cause the same level of effect in rats and humans”); the scientists are clearly
looking for mechanisms . . . and for difference-making, too . . . Likewise, when Kuhl (2006, 680) says “About 10% of breast cancers
are ‘hereditary’, i.e., caused by a pathogenic mutation in one of the ‘breast and ovarian cancer susceptibility genes’ (BRCA)” the
word “caused” is associated both with a genetic mechanism and with making a difference to 10% of breast cancer patients.’ (Russo
and Williamson, 2007, 166)
14This quotation continues: ‘This gives a view of causality that is analogous to the objective Bayesian view of probability,
according to which probabilistic beliefs are determined by an agent’s evidence, and probabilities themselves are just the beliefs
that an omniscient agent should adopt.’ (Russo and Williamson, 2007, 168)
4.2. The Russo-Williamson Thesis 84
knowledge (including knowledge of mechanisms); and (iii) she should not have any causal
beliefs that are not warranted by her evidence.
(Russo and Williamson, 2007, 167-8)
This (monistic) theory of causality can also account for the evidential pluralism that Russo and
Williamson claim:
The epistemic theory of causality can account for this multi-faceted epistemology, since
it deems the relationship between the various types of evidence and the ensuing causal
claims to be constitutive of causality itself.
(Russo and Williamson, 2007, 168)
Like Russo and Williamson, I will concentrate on the epistemic aspects of this relationship between
causality and evidence. However, unlike Russo and Williamson, I will not give an account of a general
epistemic theory of causality. In other words, I will neglect the implications of RW12, and will instead
concentrate on the kinds of epistemic devices that allow us to conceptualise the relationship between
evidence and causality. Thus the key feature of my account is the same as Russo and Williamson’s. This
is the distinction between causality and evidence (RW5). While, they suggest, there is only one sort of
cause in medicine, this single, monistic causation is not supported by just one sort of evidence. As they
note, accounts of causation based upon a single type of evidence fail. Therefore, the decision to accept
or reject a monistic causal claim requires the consideration of a plurality of evidence.
However, here there is a difficulty that must be addressed: current medical practice does not seem
to be pluralistic about evidence. While Russo and Williamson argue in support of evidential pluralism
by highlighting an apparent pluralism in the kinds of evidence used to support causal claims (see foot-
note 13, page 83), this claim is compromised by the widespread use and acceptance of Evidence-Based
Medicine (EBM).
EBM is defined as ‘the conscientious, explicit, and judicious use of current best evidence in making
decisions about the care of individual patients’(Sackett et al., 1996). In this context, ‘current best evi-
dence’ has a specific meaning. According to proponents of EBM, it is possible to rank evidence about
the efficacy of interventions in terms of its reliability. This is achieved by using so-called hierarchies of
evidence. These systems of ranking provide healthcare workers with ‘a measure of the trust that can be
placed in the recommendations’ (Evans, 2003, 79) produced by clinical studies. In fact, for the EBM
practitioner, the best kind of evidence is usually that provided by either a randomised control trial (RCT)
or - even better - a meta-analysis of RCTs (Guyatt et al., 2008):
Because the randomised trial, and especially the systematic review of several ran-
domised trials, is so much more likely to inform us and so much less likely to mislead
us, it has become the “gold standard” for judging whether a treatment does more good than
harm.
(Sackett et al., 1996)
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While it is true that there are a great many different evidence hierarchies without exact consensus
about precisely how such evidence should be ranked, in general RCTs and meta-analyses are regarded as
the most reliable form of evidence. This position therefore lends strong support to a claim that medicine
is monistic, rather than pluralistic, about evidence. How can this difficulty for the RWT be overcome?
First, EBM is generally not presented as an explicitly causal methodology. So a lack of evidential
pluralism here does not necessarily present difficulties for the proponent of the RWT. Taking this tack
as a way of defending the RWT would be disingenuous, though: while EBM does not purport to be a
causal methodology, as it looks to investigate the relationship between an intervention (a cause) and an
outcome (effect) it is really concerned with causation (Bluhm, 2005). So this line of argument is no
adequate defence against this criticism.
However, closer consideration of the hierarchies of evidence employed in EBM practice suggests
a more adequate response. In fact, I argue that the EBM hierarchy of evidence is not an hierarchy of
evidence at all. I (and others - Bluhm (2005), for example) claim that the hierarchy of evidence is
really a hierarchy of experimental methodologies, rather than of evidence itself. Studies are ranked by
means of reference to the way they were carried out, rather than the types of thing they provide evidence
about. The only evidence worth having, argues the EBM-proponent, is that which arises from an RCT,
or meta-analysis. It is therefore monism about methodologies that is promoted by the EBM movement,
not monism about evidence.
As these two distinctions between types of evidence are likely to cross-cut each other in complex
ways, this suggests that the evidential pluralism required by Russo and Williamson might be some-
what compatible with the methodological monism proposed as a part of EBM. In fact, as Russo and
Williamson require pluralism about the kinds of things we have evidence of, rather than the kinds of
methodologies employed to produce this evidence,15 I will argue that the type of methodological monism
required by EBM conceals a profound pluralism about evidence itself.
Take, for example, a particular RCT. It is not the case that this trial will be simply concerned with
one kind of evidence, either mechanistic or probabilistic. While investigators will report the results of
this trial in terms of statistical data about the relationship of cause and effect, and this technique might
perhaps lead us to the conclusion that RCTs are therefore concerned only with probabilistic evidence,
a closer investigation of these results convincingly demonstrates the central role of mechanisms in pro-
ducing and evaluating this evidence.
How does mechanism participate in the construction of an RCT? First, the kinds of correlations
that RCTs aim to detect are generally not simple. Instead, trials are usually designed to find out what
happens, in terms of change in outcomes and intermediate markers of outcomes, what happens when an
intervention is performed. For example, (O’Shaughnessy et al., 2011) - an entirely random example from
a recent medical journal - looked to demonstrate the differing effects of using iniparib (‘a small molecule
with PARP-inhibitory activity’ (O’Shaughnessy et al., 2011, 205)) as an adjunct chemotherapeutic agent
for treating breast cancer. In this paper, patients were selected for inclusion on a range of mechanistic
15I develop a similar distinction in section 6.4, along lines first developed by McKay Illari (McKay Illari, 2010). I will leave the
details of this distinction for that section.
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features of breast cancer (so they could only participate in the trial if they had ‘triple-negative’ breast
cancer),16 as well as a number of general mechanistic features of fitness (adequate renal and hepatic
function, for example). These factors were selected because - mechanistically - it is the case that presence
of these particular things changes outcome. Thus recruitment to this trial was dependent on mechanistic
reasoning. Similarly, the complex set of outcome measures collected (clinical benefit, rate of overall
response, progression-free survival and median overall survival) are themselves causally complicated. If
we deny the role of causal mechanisms in informing the design of such a clinical trial, we cannot account
for the particular choice to observe or control these factors. Indeed, the choice of intervention in this case
was itself dependent on a mechanistic understanding of the actions of iniparib. As no other trials of this
agent had previously been performed, what other kind of knowledge could guide the decision to see if
this molecule - and not some other - might improve cancer survival? As the authors suggest, it is because
this agent was known to interfere with Poly-ADP ribose polymerase (PARP) - a protein that controls cell
death - that made it a suitable candidate for such a study.
Similarly, interpreting these results requires some mechanistic knowledge about breast cancer and
breast cancer interventions. It is not simply the case that this agent will lead to likely improvements
in survival for all individuals with breast cancer. Instead, it is only a certain subgroup - those with
triple-negative breast cancer - that this study provides evidence of benefit for.
In short, RCTs are monistic about methodologies, but not about evidence itself. To suggest that
EBM methodology does not require any consideration of mechanism is to miss the point entirely. With-
out evidence of mechanisms, the construction and evaluation of an RCT would be impossible.
Finally, Russo and Williamson’s account is really concerned with the acceptance, rather than the
construction, of causal claims.17 However, given the account of causal discovery given in 1.3, I will
develop the RWT such that it can give an account of some parts of discovery. I will exclude from this
treatment only the very earliest stage of discovery - that of suspicion. As I will discuss in section 6.3.1,
the treatment of evidence at this early stage is distinctly unlike that found at other points. So I want to
specifically exclude just the very earliest parts of discovery from the RWT.
Now, though, I will turn to some philosophical objections to Russo and Williamson’s arguments.
4.3 Philosophical counterarguments to the RWT
There are two main types of philosophical objection to the RWT. First, some authors argue that Russo
and Williamson are mistaken to require mechanisms, or mechanistic evidence, as a necessary component
of causal claims. Here, I will review two such objections by Broadbent (2010) and Howick (2010).18
Second, Weber (2009) has criticised RW10, the claim that evidential pluralism cannot be accounted for
16i.e. that the tumour cells expressed neither oestrogen receptors, progesterone receptors nor human epidermal growth factor 2
receptors
17‘. . . two different types of evidence - probabilistic and mechanistic - are at stake when deciding whether or not to accept a
causal claim.’ (Russo and Williamson, 2007, 163)
18Gillies, while broadly supporting the RWT, has suggested that a plausible mechanism may well be sufficient warrant to support
RWT-type causal claims (Gillies, 2010). I think this is an unnecessarily weak version of the thesis, and one that may well lead to
real operational difficulties - as the HSV case suggests. I will go on to discuss plausible mechanisms in section 6.4.1.
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by traditional monistic theories of causality.
Broadbent’s criticism of the RWT depends upon the interpretation of it as either a descriptive or a
normative account (Broadbent, 2010).19 First, if the RWT is interpreted as a descriptive theory, then (as
it stands), it does not support any claims about causation or causal inference:
. . . a purely descriptive reading of Russo and Williamson’s claim renders it largely ir-
relevant from a methodological point of view, and does not justify or explain why they
themselves treat it a motivation to seek a theory of causation, apt for the health sciences.
(Broadbent, 2010)
Thus the descriptive RWT is irrelevant. However, Broadbent’s suggestion about a normative reading
is even more damning. He argues that, if the RWT is interpreted normatively, then the requirement for
mechanistic evidence is faulty (i.e. against RW6 and RW8). He provides both a methodological and an
historical argument to support this claim. His methodological argument is as follows:
Modern epidemiologists set very high store in some methods, such as the randomized
control trial, which involve no requirement to identify underlying mechanisms.
(Broadbent, 2010)
While historically, Broadbent refutes the normative interpretation of the RWT by reference to the
Semmelweis case:
. . . the lesson Russo and Williamson draw from the Semmelweis episode is that Semmel-
weis’s theories ought not to have been accepted until knowledge of underlying mechanisms
was obtained. (This explains why they offer a theory of causation intended to justify this
stance. . . then they are committed to the startling view that, had germ theory not come along
and the underlying mechanism remained a mystery, we today would be rational to dismiss
Semmelweis’s work, no matter how much evidence we had gathered in the meantime about
the efficacy of disinfecting hands.)
(Broadbent, 2010)
He also suggests the two arguments, methodological and historical, seem to complement one an-
other:
In particular, the evidence for the efficacy of his [Semmelweis’s] proposed intervention
- disinfecting (not merely washing) hands - is extremely strong. And replication would have
made it stronger, without necessarily advancing knowledge of underlying mechanisms.
(Broadbent, 2010)
19‘I am unsure whether it is meant as a descriptive account of causal inference (then and now), or as a normative account of the
standards which ought to be used when deciding whether to infer causation.’ (Broadbent, 2010). I support a normative reading of
the RWT, as I discuss in section 7.3.
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I think this criticism is based on a mis-reading of what mechanistic evidence is. First, his method-
ological argument seems to badly neglect the role of mechanistic evidence in informing the methodolo-
gies of epidemiological investigation. As I will discuss in sections 4.5.2 and 6.5, the design of detailed
epidemiological studies critically depends upon mechanistic evidence. Otherwise, the manner in which
particular factors are selected for study in clinical studies seems nothing short of miraculous. It seems
highly implausible that drugs, vaccines, immunological tests and so on arise in the absence of any mech-
anistic understanding whatsoever.
Now Broadbent’s historical argument seems similarly flawed. He offers the following counterfac-
tual: ‘had germ theory not come along and the underlying mechanism remained a mystery, we today
would be rational to dismiss Semmelweis’s work, no matter how much evidence we had gathered in the
meantime about the efficacy of disinfecting hands.’
I disagree with this counterfactual statement for two reasons. First, assuming that the germ theory
had not arisen, it would be rational to argue that we did not understand the manner in which disinfecting
hands caused a reduction in the incidence of puerperal fever, not that this intervention should not be
performed. Failing to establish a causal claim does not imply that a particular research programme
should be ignored or rejected.
Second, the conditions necessary to instantiate this counterfactual appear highly implausible. For
the germ theory to not be developed, yet for medical practice to proceed in such a way as to produce
much evidence showing the benefits of disinfecting hands, appears to me very unlikely. This is because
the very concept of disinfection itself is unintelligible without some theoretical understanding of what
is happening in terms of germs. Without the germ theory,20 the only possible means of discriminating
between these two behaviours would be a contingent, methodological one, such as a classification in
terms of the cleansing agent employed. I suggest that this would render the Semmelweisian methodology
exquisitely fragile, and thus unlikely to survive (i.e. produce similar benefits in survival) any translation
to different practical contexts. In this case, unless Semmelweis’s methodology was followed exactly,
similar improvements would not accrue. I thus reject the assertion that a programme of disinfection,
capable of producing similar improvements in clinical outcomes, could have come about in the absence
of some kind of germ theory of disease.
Howick objects to the RWT on similar grounds to Broadbent. His general argument is in support
of an increased role for mechanistic evidence in EBM practice.21 However, this support for mech-
anisms is strongly tempered by the limitations of mechanisms as causal evidence when compared to
evidence arising from comparative clinical effectiveness studies, such as RCTs. While Howick thinks
that mechanisms may be useful supporting evidence for causation, they should not be used to conduct
causal inference in isolation, neither should they be relied upon to overturn alternative, superior, forms
of evidence, nor are they a necessary part of causal inference.
First, he argues against the exclusive use of mechanisms in formulating causal claims. Howick first
20Or some other mechanism capable of explaining, in general terms, the difference between washing and disinfecting hands.
21‘. . . a central thesis of this paper is that high quality mechanistic reasoning should be allowed a more prominent place in
Evidence-Based Medicine’ (Howick, 2010).
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defines just what it means to reason in this way:
Mechanistic reasoning: involves an inference from mechanisms to claims that an in-
tervention produces a patient-relevant outcome. Such reasoning will involve an inferential
chain linking the intervention (such as antiarrhythmic drugs) with a clinical outcome (such
as mortality).
(Howick, 2010)
He then goes on to outline just how this kind of causal reasoning is likely to lead to faulty causal
conclusions:22
. . . mechanisms, by themselves, do not count as evidence. Accounts of how the heart,
brain, and liver work will not tell us what will happen to these mechanisms under interven-
tion. To count as evidence for claims that interventions have their putative patient relevant
effects, we must infer from (supposed) knowledge of the relevant mechanisms to claims that
treatments have patient relevant effects. In order for this inference to be acceptable, we must
know what happens to each of the relevant mechanisms under intervention.
(Howick, 2010)
Second, he then argues against treating mechanistic evidence as a superior form of evidence to that
generated from comparative effectiveness studies, such as RCTs. In situations where evidence arising
from comparative clinical effectiveness studies and mechanistic evidence are contradictory, Howick ar-
gues against the general overturning of evidence of comparative clinical effectiveness by mechanistic
evidence:
. . . there are reasons to be cautious about using mechanistic reasoning to rule out or re-
duce our confidence in results from comparative clinical studies, and moreover the principle
of total evidence does not imply that we require mechanistic reasoning to rule out implausi-
ble hypotheses.
(Howick, 2010)
Finally, he argues that it is not the case that mechanistic evidence is necessary to support causal
claims. As this contradicts RW8 - and therefore compromises the RWT - it is this argument that I will
focus the remainder of this section on.23 Howick provides three arguments in support of this claim - two
directed against the historical component of the RWT, and one against the theoretical.
Howick presents two arguments against the historical component of the RWT, which suggest that it
is unwise to require mechanistic evidence in the presence of high-quality comparative clinical research
22I agree that you cannot understand disease aetiology or therapeutic interventions by describing physiology. I therefore develop
a very similar position in further chapters.
23Howick’s two other arguments seem similar to those made by Russo and Williamson. As per RW10, Russo and Williamson
too seem to concur that mechanisms alone are an inadequate means of assessing causality. Nor do they suggest that one form of
evidence should generally overturn another.
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for the following reasons. First, that requiring mechanistic evidence may delay the clinical introduction
of effective techniques (Semmelweis, Helicobacter pylori), and second, because a wide range of aeti-
ological and therapeutic causal hypotheses have been accepted and successful without any mechanistic
content.24 Because of these two types of empirical argument, Howick suggests that the mechanistic
component of the RWT is redundant.
His theoretical argument is as follows: Russo and Williamson claim that mechanisms avoid con-
founding, and thus rule out spurious relationships. But, according to Howick, this is not true. In fact,
he suggests that comparative clinical effectiveness studies are better at ruling out spurious relationships
than mechanistic reasoning. He provides an impressive list of historical cases where clinical research
has overturned incorrect mechanistic reasoning. But this claim appears to support the RWT: Russo and
Williamson absolutely do not claim that causality is established through mechanistic reasoning alone.
Instead, both probabilistic and mechanistic evidence are required. Giving examples where evidence of
one form overturns evidence of another is not an effective argument against their thesis. Howick then
suggests that looking for both evidence of mechanism and evidence of clinical effectiveness might lead
to better causal claims:
One might alter the claim that mechanistic reasoning is required to rule out spurious re-
lationships and argue instead that hypotheses that are supported by both comparative clinical
studies and mechanistic reasoning are less likely to be spurious than hypotheses supported
by one type of evidence alone. Such a claim might rest on the plausible premise that since
each type of evidence suffers from different potential pitfalls, a hypothesis that is supported
by both types of evidence is less likely to have been confounded. This weaker claim is al-
together acceptable and indeed underwritten by the principle of total evidence. However, in
its altered form it can no longer be interpreted as Russo and Williamson’s thesis.
(Howick, 2010)
In summary, while Russo and Williamson insist on both mechanistic and probabilistic evidence,25
Howick suggests that mechanistic evidence is just a useful adjunct to understanding causality, rather
than an essential component. In fact, as his historical cases suggest, requiring mechanistic evidence may
sometimes not only be redundant, but may actually cause harm.
A suggestion for this difference of opinion might be as follows: Howick disagrees with Russo and
Williamson because they understand mechanistic evidence differently. Howick takes a narrower view
of what mechanistic evidence is than do Russo and Williamson. As per his definition of mechanistic
reasoning above, Howick suggests that mechanistic evidence is concerned with inferring the relationship
that obtains between an intervention and its clinical effects. Russo and Williamson, on the other hand,
24These include Pott’s discovery of the causal relationship between exposure to soot and cancer of the scrotum in chimney
sweeps, Jenner’s discovery of vaccines against smallpox, Snow’s epidemiological investigations of cholera, Finlay’s discovery that
yellow fever could be prevented by killing mosquitoes, the discoveries of aspirin, anaesthesia and steroids and the (more recent)
discovery that electrical deep brain stimulation improves the symptoms of various movement dystonias.
25Although it seems that Russo and Williamson may now agree with Howick on this point, as they have subsequently modified
their argument such that claim ‘typically’ both kinds of evidence are required (Russo and Williamson, 2010, 15).
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seem to take a much broader view of what constitutes appropriate mechanistic evidence (see footnote
13, page 83.). Under the RWT, mechanistic evidence is only part of such an inference, rather than
wholly constituting it. In fact, Russo and Williamson require that additional, probabilistic evidence -
such as might result from performing an RCT - will also be required to make such an inference. I
support a similarly broad reading of what constitutes mechanistic evidence. Mechanistic evidence is
employed extensively in the design of clinical trials, their interpretation and the implementation of their
results. For example, when we attempt to discriminate high- from low-quality comparative effectiveness
research, we rely on employing a great deal of mechanistic evidence to tell us about the appropriate use
of ‘employed placebo controls, double blinding, allocation concealment and also checked for baseline
differences between comparison groups, and hence avoided known plausible confounders’ (Howick,
2010). Designing a study such that these virtues are sought requires mechanistic knowledge about the
particular case. Otherwise, the choice of an appropriate placebo, of blinding procedures, of baseline
comparisons and the avoidance of confounders would appear miraculous.
Weber criticises the RWT by attempting to demonstrate that Russo and Williamson’s claim that
evidential pluralism cannot be accommodated by traditional causal monism (RW10) is incorrect. He
suggests that Giere’s theory of probabilistic causality can, in fact, accommodate both mechanistic and
probabilistic evidence when it comes to establishing causal claims in scientific practice:
I have presented Giere’s theory of probabilistic causation, and argued that it can account
for the use of mechanistic evidence in various contexts in which scientists use such evidence.
This undermines the thesis of Russo and Williamson that probabilistic theories of causality
cannot account for the use of mechanistic evidence.
(Weber, 2009, 293)
Giere’s basic idea is this. Say we wish to establish a causal claim linking a dichotomous causal
variable, C, with an effect, E, in a population U. We should do this by comparing the probability of E
arising in two hypothetical populations, X and K, where all members of X do C, and all members of K
do ¬C. C will then be a positive causal factor for E in U iff PX (E) > PK(E), a negative causal factor
for E in U iff PX (E) < PK(E), and causally irrelevant iff PX (E) = PK(E).
Weber defends this claim through examination of two different situations in causal evaluation. First,
he discusses the case where we wish to establish causal claims in the absence of probabilistic evidence
(Weber, 2009, 285-6). As, in this case, our Gierean claims would depend upon thought experiments,
Weber claims that: ‘. . . to make a Gierean causal claim about a population, it is perfectly rational to
gather mechanistic evidence, since that evidence can help. . . to establish the claim’ (Weber, 2009, 286).
This, as Weber admits, seems to be perfectly compatible with the RWT.
His next situation is where both mechanistic and probabilistic evidence are present, and we wish
to establish a causal claim. Weber claims that the Gierean theory can also account for the use of mech-
anistic evidence within a probabilistic framework (Weber, 2009, 287ff). His argument is as follows.
Ideally, when we wish to establish a Gierean causal claim, we would perform randomised trials on our
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population of interest. However, there are various operational and ethical strictures on actually follow-
ing this methodology in practice. So there will be many occasions where an ideal, randomised trial is
impossible. In situations like these, we must rely on observational studies on our population of interest,
or on randomised trials on a different population. Weber argues that Giere’s theory can account for the
use of mechanisms that intervene between the actual results of these trials, and the human population
of interest, in both these situations. That is, mechanisms can account for confounding variables (in the
observational trial case) and also deal with questions of external validity (in the case of trials on other
populations). As he suggests:
. . . for a scientist who wants to make Gierean causal claims about populations, it is per-
fectly rational to look for mechanistic evidence: it will be useful for processing the results
of prospective and retrospective studies.
(Weber, 2009, 288)
and:
a scientist who wants to make a Gierean causal claim, needs a warrant to link the animal
data to the hypothetical human populations. Mechanistic evidence can provide this link. So
it is rational for such a scientist to look for mechanistic evidence.
(Weber, 2009, 289)
Now these arguments certainly do seem to be a good representation of scientific practice. But these
claims also seem compatible with the RWT. Weber does not make the case that the Gierean probabilistic
causality fully accounts for this mechanistic evidence. Rather, this seems to be an argument in support
of employing Giere’s theory to understand probabilistic evidence as part of the RWT. For, while it may
be rational for a Gierean to employ mechanistic evidence to support their evaluation of probabilities,
this process is not part of establishing an exclusively Gierean causal claim. Quite the opposite: a high-
quality Gierean causal claim (one that, say, employs a randomised trial on the actual population of
interest) cannot account for the use of mechanistic evidence at all.26
So I do not think this objection seriously damages the RWT. While Weber makes a convincing case
that it may well be rational to employ both mechanistic and Gierean methodologies in establishing a good
causal claim, he does not adequately make the case that the Gierean theory itself can account for the use
of mechanistic evidence. As Weber suggests that it is only Giere’s account that has this advantage, and
no other theory of probabilistic causality, this does not seem a general objection to the RWT.
4.4 The RWT as an empirical proposition
While Russo and Williamson make their claims in a theoretical manner, their one-cause, plurality-of-
evidence view gains general support from the medical literature on causation (c.f. section 1.2). For
26Williamson has argued similarly against Weber’s claim. He also suggests that most of Weber’s examples that feature mecha-
nistic evidence in support of Gierean causal claim are rather weak, in terms of their probabilistic evidence. Williamson, paper to
the Second UCL-Kent workshop on causality, 27th January 2010.
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instance, both the HKP (see, for instance, Carter, 2003) and the Hill criteria (Hill, 1965) require a range of
evidence, yet do not distinguish between types of causation based upon these differing evidential inputs.
They gain further empirical support for their thesis from the position of mechanisms and probabilities.
In fact, Russo and Williamson argue, these types of evidence are so important, and so widely used, as to
be a commonplace in the medical literature.
At the outset, I think that the empirical validity of the RWT can be demonstrated in both cases of
viral oncogenesis detailed above. However, I will for the time being only discuss the EBV case, while ig-
noring the history of cervical cancer. The reason for this partial reading of the history is straightforward.
As I have already mentioned, the cervical cancer case is complicated by the HSV episode. Thus, as it
stands, this case seems to present a counterexample to Russo and Williamson. I think this impression is
misleading. But in order to demonstrate exactly why this is so, I need first to do some minor elucidation
of the RWT, which will follow, along with an analysis of the HSV case, in section 4.5. For now (and for
the sake of clarity) I will focus on the EBV case.
An important stage in the discovery of the causal relationship between EBV and BL was the pro-
cess of mechanism construction. This process clearly demonstrates the fundamental evidential pluralism
required to make good mechanisms. In it, we see the exploitation of a wide variety of experimental and
observational strategies. Briefly, and for the sake more of illustration than completeness, we see mecha-
nistic features arising from clinical observations on cases of the tumour syndrome, from histopatholog-
ical investigations of these same cases, from interventions upon tumour cells (notably the establishment
of cultured lines of BL cells) and from a number of specific virological techniques (including observa-
tions of viral CPE, attempts to perform viral cultures on material derived from BL tumours, and the use
of numerous immunological technologies). Importantly, though, significant advances in mechanism con-
struction were also made by investigators concentrating on diseases other than BL. Two unusual themes
are apparent. First is the exploitation of other, possibly aetiologically related or clinically similar dis-
eases as sources of evidence for the EBV-BL causal claim. These areas of inquiry yielded both negative
constraints on the shape of the EBV-BL causal mechanism (by, say, differentiating the pathogenic mech-
anism of leukaemia from that of BL) as well as suggesting possible areas where the EBV-BL mechanism
might be expanded (as, for instance, occurred in the work arising from the geographical correlation noted
between BL and various arthropod-borne diseases). Second, this case demonstrates a vital role for the
related concepts of analogy and plausibility in biomedical research. I will address the general aspects of
these phenomena in later chapters. For now then, I will make a few remarks on the specifics of the EBV
case.
4.4.1 The EBV mechanism
There were three problems that persistently complicated causal claims implicating EBV infection in
the development of BL, and it was not until they were overcome (or at least became disregarded) that
causal claims about EBV causing BL became generally accepted. The first of these was the range of
viruses problem. In addition to EBV, many other infectious agents, generally regarded as plausible
causes of cancer, were found in BL tissue. These included arboviruses, Echo 11, HSV and a range of
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other agents.27 Why should EBV be regarded as the cause of the tumour, and not these others?
The ubiquity problem. EBV was soon found to have a ubiquitous, worldwide distribution. Almost
all adults were found to have serological evidence of prior infection. Yet BL appeared to have a remark-
ably clearly demarcated distribution. How could a virus everyone had cause clinically apparent disease
in such a specific population?
The malaria problem. Geographical evidence highlighted the similarity between the distribution
of certain arthropod-borne diseases and that of BL. Plausibly, this might happen in three ways. One, the
causal agent of BL might be vectored by an arthropod. Two, an arthropod-borne agent such as malaria
or African trypanosomiasis might be a cofactor in the development of the disease. Finally, the insect
distribution might merely geographically correlate with some other causally significant environmental
or climate-dependant factor. While EBV was shown not to be arthropod-borne (thus ruling out insect-
transitted EBV as a solution to this problem), no clear evidence was forthcoming that enabled researchers
to select between outcomes two and three.
Together, these three problems represented a substantial threat to the soundness of the developing
EBV-BL mechanism. Their resolution, however, did not come about by the result of any specific mech-
anistic inquiry directed at them. Instead, the satisfactory resolution of these problems arose by primarily
statistical means; through interpretation of the results of the 1978 prospective study (de-The´ et al., 1978).
First, the range of viruses problem. While researchers did not perform serology for all the pos-
sible candidate agents previously recovered from BL tissue, they did perform matched-control testing
for a range of EBV antigens, for CMV, HSV and measles virus (de-The´ et al., 1978, 758-60). These
results indicated that the abnormal immunological response to EBV in those later to develop BL was
EBV-specific. Importantly for the range of viruses problem, the specificity of this response strongly
counted against an aetiologically significant role for other viral agents in the development of BL. It
further suggested interesting features of the primary EBV infection that were in need of mechanistic
decomposition.
This specificity of response neutered the ubiquity problem. Not only was the demonstrated im-
mune response found to be solely one of EBV, but it was specific to just one viral antigen. Individuals
who later developed BL showed an increase in just one anti-EBV antibody (EBV viral capsid antigen
(VCA)), and not, in general, increases in any of the other antibodies. This suggested that the primary
EBV infection in those later to develop the tumour was not simply a prolonged, or especially severe form
of normal EBV infection. Instead, the causally responsible primary infection was of an unusual type.
This, when combined with the rather different serological profile of IM, suggested avenues of further
mechanistic inquiry. Of particular importance was the way in which the infection, and thus the tumour,
developed over time. It seemed that the abnormal serological response seen was likely to indicate the
effects of some sort of co-factor, modulating the immune response to primary EBV infection.
Finally, the growing understanding of the temporal sequence of events in BL pathogenesis pro-
vided the means to understand the malaria problem. First, BL patients did not have higher levels of
27see section 2.4.2.4
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malaria parasites at recruitment than controls (de-The´ et al., 1978, 60). However, the specific nature
of the increase in VCA antibodies seen in BL indicated that BL was not the manifestation of some un-
known underlying immune dysfunction. Instead, this abnormal serological response to BL suggested
that malaria was acting as the final triggering event for BL in individuals with evidence of abnormal
primary EBV infection (de-The´ et al., 1978, 761). Malaria therefore becomes a target for further mech-
anistic investigation, as suggested by attempts to prevent BL by rigorous attempts at paediatric malaria
prevention.
What role did mechanism play in this eperimentum crucis? As we have seen, the construction and
interpretation of sophisticated population-level studies critically depends on knowledge of mechanisms.
This case is no exception; without the EBV-BL mechanism, this experiment could neither have been
designed, nor understood, in the way that it was. As a consequence, a study not based on this kind of
knowledge could not have convincingly demonstrated that EBV really was causally implicated in the
development of BL. This is because, importantly, it was not the case that there was any kind of simple
correlation between EBV infection and BL. Instead, EBV behaved in a completely different way in those
later to develop BL compared to those who did not, in that the specific serological markers of infection
differed qualitatively and quantitatively between the two groups. While it seems perfectly plausible that
we could discover a simple correlation between these two things without needing any knowledge of
mechanism, it does not seem plausible that we could have detected the subtle relationship that actually
obtains in this case. For without knowledge of how EBV mechanistically behaved in individuals likely
to develop BL and in the unlikely majority, these differences would have been neither detected nor
understood. It was this detailed knowledge, linking both mechanistic and probabilistic evidence, that
provided the solutions to the three problems affecting the BL-EBV mechanism, and lead to the general
acceptance of EBV as the first known human oncovirus.
4.5 Historical counterexamples to the RWT
4.5.1 Causation Without Statistics - McArdle Disease
McArdle disease is a rare28 autosomally recessive condition of abnormal muscle glycogen metabolism.
Individuals with the condition suffer excessive tiredness and severe cramps on exertion. Skeletal muscle,
in common with other metabolically active tissue, must be provided with a constant supply of energy.
One of these sources of energy is glucose, which circulates in the blood. At rest, the supply of glucose
from the blood is more than sufficient to fulfil the energy requirements of the muscle. However, during
exercise the total energy demand of the muscle exceeds the maximum possible rate of uptake of glucose
from the blood. Hence, the muscle must obtain glucose from another source. This source is glycogen, a
large, branched polymer of glucose. Stores within normal muscle are enzymatically cleaved into glucose
during times of intense metabolic demand. The muscle can then replenish its glycogen stores from
28Also known as myophosphorylase deficiency (OMIM 232600). It is very rare. While no precise prevalence figures are
available, a recent study in Canada identified a rate of 1.4/100 000 births for all glycogen storage disorders, with McArdle disease
as just one of them (Applegarth et al., 2000, e3). 55 individuals with McArdle disease are currently known in the UK (Hilton-Jones,
2001, 122), suggesting a rate of about 1/1 000 000 births. This is supported by Chen’s estimate of 1/800 000 (Chen, 2001, 1530).
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circulating glucose when at rest.
Figure 4.1: Simplified mechanism of glucose-glycogen interconversion. Note that the details of both the
conversion of glucose to energy, and the conversion of glucose to glycogen have been omitted for the
sake of clarity. G-1-P: glucose-1-phosphate, G-6-P: glucose-6-phosphate, PGM: phosphoglycomutase
and UDPG: uridine diphosphate glucose.
A simplified pathway for the synthesis and breakdown of glycogen is shown on page 96. As can
be seen, the anabolic and catabolic pathways are asymmetric. Two different enzymes exist, one to add
glucose molecules to glycogen,29 and one to remove them. McArdle disease is caused by a functional
lack of myophosphorylase,30 the enzyme which removes glucose units from the glycogen molecule.
Thus, patients with the disorder can form normal glycogen, but cannot convert it back to glucose.31 Thus
we may begin to explain the brief clinical scenario above. Skeletal muscles function normally until called
29Glycogen synthase
30IntEnz Nomenclature EC 2.4.1.1. The official systematic name is 1,4-a-D-glucan:phosphate a-D-glucosyltransferase
31Note that the defect is confined to skeletal muscle, as the phosphorylase enzymes occurring in other tissues are coded for by
different genes. The gene encoding myophosphorylase is found on the long arm of chromosome 11 (11q13) whereas the gene for
the liver form is found on chromosome 14 (14q21-q22) and the brain form is found on chromosome 20 (20p11). A large number
of mutations of myophosphorylase are known, currently at least 14 (Chen, 2001, 1538).
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to strenuous activity. When this occurs, they rapidly run out of energy, leading to fatigue and pain. With
the exception of these limitations to physical exercise (and their obvious limitations upon the patients
activities of daily living), McArdle disease appears to be relatively benign and affected individuals have
a normal life-expectancy. No specific treatment is needed (Quinlivan et al., 2009, 1).
How does this condition present difficulties for the RWT? It was described on the basis of a single
patient, and ‘formulated’ as a diagnosis on the basis of a very small number of patients. In fact, causal
claims made about the disease were generally accepted after the investigation of three individuals. A
brief summary of these cases will be helpful in thinking about the nature of evidence in this case.
4.5.1.1 The Discovery of McArdle Disease
McArdle, 1951, details the extensive investigation of a 30 year old man, George W. He had suffered life-
long fatigue, muscle stiffness and pain on exertion. Despite his grossly normal physical examination,
several subtle biochemical abnormalities were apparent. First, the level of lactate (a breakdown prod-
uct of glucose) found in the blood was significantly less than expected during exercise, indicating that
the patient was utilising less glucose than a normal control subject. Secondly, the patient experienced
electrically silent muscle cramps32 during exercise, indicating that his muscles were failing to contract
normally.
On the basis of these results, McArdle concluded that the patient was suffering an apparently novel
defect of muscle metabolism and that this defect appeared to involve a problem in the production of
energy from glycogen. He therefore suggested that a defect in the glucolytic pathway was responsible.
He went on to suggest that a lack of glyceraldehyde phosphate dehydrogenase (GPD) was specifically
responsible, perhaps due to the action of a poison.
McArdle’s publication provides a fundamentally sound clinical description of the disease. However,
his causal thinking was mistaken. It is not altogether clear why this enzyme was chosen as the causative
entity, as impairment of GPD results in the inability to break down glucose, rather than glycogen. Al-
though some of the enzymes involved in glycogen synthesis and breakdown had been discovered and
their properties investigated (see, for example, Cori and Green, 1943, and Green et al., 1943 for work on
the properties of myophosphorylase), it is regrettably impossible to say which work in this area McArdle
was familiar with. Perhaps this was the reason for his rather tentative language when presenting his
findings.
The next important step in the development of a causal claim was the elucidation of the correct
enzyme defect. This came about by investigation of the second known case of McArdle disease, patient
D.G. He was investigated by the Mommaerts group, working in Los Angeles in the late 1950s. Two
papers were published relating the features of his disease. The first was primarily biochemical (Mom-
maerts et al., 1959), reported an analysis of a biopsy of D.G.’s skeletal muscle. The second was largely
clinical, and outlined D.G’s symptoms and test results (Pearson et al., 1961). While the clinical pic-
32Normally, contracting muscle fibres produce an electrical signal, which can be measured. Electromyography was performed on
the cramped muscles of this patient, and no electrical activity could be detected, indicating that the muscles were not contracting.
Given the shortening of the muscles seen during these cramps, it appeared that the muscle fibres were ‘stuck’ in a contracted
position due to lack of energy.
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ture was extremely similar to that of George W., Mommaerts et al. disagreed with McArdle about the
likely causal mechanism at work. They suggested that the characteristic symptoms were due to a lack of
myophosphorylase (Mommaerts et al., 1959, 792).
This conclusion is based on the following evidence. First, in skeletal muscle samples, very little
phosphorylase activity was detected (Mommaerts et al., 1959, 793-5). Second, as normal function was
restored if myophoshorylase was added, it was concluded that this lack of activity was due to an absence
of myophosphorylase, rather than any sort of regulatory problem (Mommaerts et al., 1959, 794). Third,
the defect could similarly be bypassed if downstream products of glycogen metabolism were added
(Mommaerts et al., 1959, 792-3), indicating that the metabolic problem was specific to the glycogenol-
ysis pathway. Finally, it was noted that muscle glycogen stores were very much higher than normal
(Mommaerts et al., 1959, 792), suggesting that the pathology resulted from a primary problem with
glycogen catabolism, rather than one resulting from abnormal glycogen synthesis. So, in summary, the
paper suggests an isolated lack of myophosphorylase was the likely causal agent for what was rapidly
becoming known as McArdle disease.
The third known case of McArdle disease, patient A.D., was reported by the Schmid group, work-
ing primarily in Boston. Their work progressed in parallel with the Mommaerts group, and led to the
publication of three papers in 1959 and one in 1961. Of these, two are counterparts to those published
by the Mommaerts group, detailing the clinical (Schmid and Mahler, 1959) and biochemical (Schmid
et al., 1959) features of patient, A.D., a 54 year old male. The third, Larner and Villar-Palasi, 1959,
is a summary of measured enzyme activity from the same muscle tissue. The final paper (Schmid and
Hammaker, 1961) is a short report of an hereditary study carried out on the patient’s family.
Between the four papers, the group made a number of interesting observations. Chief amongst them
was the discovery of post-exertional myoglobinuria, showing that muscle cells were becoming damaged
by lack of energy during exercise. They also suggest a reason for the slight heterogeneity in symptoms
between this patient and the other two studied by McArdle and Mommaerts. Due to the greater age of
‘their’ patient, they suggested a picture of slowly progressive muscle weakness
In addition to developing the clinical features of McArdle disease, the group published some obser-
vations about the biochemical lesion. They argued that the defect was due to an absence of the enzyme,
rather than due to the presence of an inhibitory substance. This point stems from the observation that
a 50:50 mixture of normal and diseased muscle tissue has approximately half normal phosphorylase
activity (Schmid and Mahler, 1959, 2049, table V). They confirmed that liver exhibited normal glu-
cose production from glycogen, indicating that the action of the liver form of phosphorylase was normal
(Schmid and Mahler, 1959, 2054). Finally, they added further weight to the suspicion that the breakdown
and synthesis of glycogen must be mediated by different enzymes.
4.5.1.2 Back to the RWT: Difference-making, not probabilities
The McArdle case therefore seems to present a problem for the RWT, in that probabilistic evidence did
not seem to play a significant role in the construction of a number of (correct) causal claims, thus con-
tradicting RW6. This, in turn, threatens both RW7 and RW12, while also making RW10-11 irrelevant.
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This leaves us with four possible options. First, we can reject the causal claims made in this case. Sec-
ond, we can reject the RWT. Third, we can treat this case as a simple exception to the RWT. Fourth, we
can modify the RWT to accommodate this case.
Given that it seems inappropriately bold to reject myophosphorylase deficiency as the cause of
McArdle disease on the basis of the RWT, I do not think the first option is the right one. Given Russo and
Williamson’s recent restatement of their thesis, such that mechanisms and probabilities are ‘typically’
required (Russo and Williamson, 2010, 15), it likewise seems too strong to reject the RWT entirely. So
we have two options. We could take McArdle disease as an atypical case, and one that is an exception to
the RWT. This is by no means out of the question. But I think a more conceptually satisfactory alternative
is to make a slight modification to the RWT to save this, and similar cases. This is to modify RW6
and RW7 by substituting ‘evidence of difference-making’ for ‘probabilities’. Probabilistic evidence
will, I think, be the most common form of evidence of difference-making anyway. So in most cases
this modification will not affect the operation of the RWT. I develop the philosophical aspects of this
modification at greater length in section 6.6. For now, I will outline the historical case for making such
a modification.
I will begin by clarifying the problem. Why was probabilistic evidence absent from causal claims
in McArdle disease? Put another way, what is the difference maker here? I suggest this question is
best approached by considering an unusual feature of the McArdle mechanism, which instantiates clin-
ically apparent McArdle disease in a relatively deterministic fashion. Given the absence of functional
myophosphorylase, the other causal factors required to produce the clinical features of the disease - ex-
ertion, primarily - are utterly ubiquitous. Thus this single causal factor is approximately sufficient to
produce the disease. Therefore, in this case, our effect (clinically apparent McArdle disease) can only
arise because of the cause (absence of functional myophosphorylase). So we have clear evidence of
difference-making, without any statistical investigations. This strong sufficiency of a single causal factor
has parallels with the change in classificatory practices associated with the introduction of the germ the-
ory of disease (Carter, 2003). In particular, the reclassification of clinical syndromes by their aetiologic
organism, known as the aetiological standpoint, strongly resembles this move. In this way, organisms
causally associated with disease became at least necessary causes of them. In the case of McArdle dis-
ease, though, the reclassification has even greater impact. Myophosphorylase deficiency becomes the
sufficient, necessary and universal causal of the clinical disease.
The analagous reclassification in this case means that, by definition, we do not find myophospho-
rylase deficiency in the normal population. Perhaps a comparision of myophosphorylase activity in the
normal versus the McArdle population could have been conducted. This would have provided proba-
bilistic evidence in support of the causal claim. But the historical case makes no mention of such an
analysis. Comparisons in the publications mentioned instead generally proceeded on a matched-control
basis (see e.g. McArdle, 1951, 19-26). So instead of doing observational trials, researchers assumed that
myophosphorylase deficiency was the salient difference-maker in the McArdle population. This seems
a good assumption. The difference-making effect myophosphorylase deficiency exerts is strong. More-
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over, the behaviour that is required for the disease to become clinically apparent (exertion) is common to
the point of ubiquity. More interestingly, I suspect that as a function of this definitional sleight-of-hand,
even if we were accidentally to find myophosphorylase deficiency in an asymptomatic individual, we
would (probably) say they had asymptomatic McArdle disease.
There are pragmatic factors that mean that this lack of probabilistic evidence will probably per-
sist. First, the disease is very scarce. This leads to difficulties with conducting prevalence surveys on
unselected populations. Given the prevalence data on page 95, we expect to find about one case per
million from an unselected population survey. There is a further difficulty with carrying out screening-
type tests for the disease. Because of the wide range of mutations that can produce a functional absence
of myophosphorylase, diagnosis of the disease really requires a muscle biopsy - a distinctly unpleasant
procedure.33 This means that, rather than conducting a survey of myophosphorylase activity in a range
of subjects, the abnormality in clinically apparent cases is compared to an implicit norm, largely based
on animal models and on occasional studies on normal volunteers. So there is no place for a survey of
myophosphorylase levels.
We might also consider the role of statistical investigations within the clinical aspects of the disease.
For instance, a survey of functional impairments, age of onset, and so on might be carried out. This could
provide probabilistic evidence helpful in making other, related causal claims about McArdle disease. For
example, we might be able to claim that “McArdle disease causes sufferers to be unable to run for 75%
of buses”. Once again, the extreme rarity of the disease means that these investigations will be unlikely
to be carried out in a statistical manner. Instead, they usually take the form of a series of case reports, or
even enumerations of all known patients. So probabilities are unlikely to play a role here either. Neither
are there likely to be probabilistically-dependent causal claims about the causes of myophosphorylase
deficiency. These mutations are, at present, non-modifiable - by the time of presentation at least. Once
the mutation is inherited (or once a primary mutation occurs during early in utero development) the
disease is inevitable.
This seems slightly contrived. But it has important ramifications for causal inference in medicine
in general, especially when it comes to relying on case-controlled studies, or on case reports for rational
causal inference. I therefore think the RWT needs to be modified in the following way. Instead of
requiring probabilistic evidence, we will instead need to employ a slightly wider category of evidence of
difference-making, of which probabilities will be the most commonly found sub-type.
4.5.2 Causation Without Mechanism - Hepatitis B and Liver Cancer
4.5.2.1 Introduction
Hepatitis B (HBV), an orthohepadnavirus, is a chronic viral liver infection that is causally implicated in
the development of HCC.34 While hepatitis has been known as a clinical syndrome since the prehistory of
medicine, its aetiology remained unknown until the second half of the twentieth century. In this section, I
33This is changing slightly, as there are now PCR-based tests to identify some of the mutations. But given the scarcity of this
condition, and the range of causal mutations, it seems unlikely that a simple but comprehensive test will be forthcoming.
34I would like to thank Vladimir Vonka for introducing me to this fascinating case
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will very briefly give the history of the discovery of the causal relationship found linking HBV infection
with HCC. I will suggest that, at first sight, it seems to offer an important counterexample to the RWT,
as the discovery of the connection seemed to take place without a good mechanistic understanding of the
manner in which the virus could cause the tumour. Does this case therefore present an example of causal
discovery arising from probabilistic evidence alone?
I suggest that it does not. I will defend this claim in the following way. First, I will give a fuller
outline of the story of this causal discovery. Here, I will show that while probabilistic evidence was
an essential and important part of making this causal claim, it was by no means the only essential or
important evidence that was actually used. I will show how mechanism, far from being absent, was
an essential component of the experimental results that are conventionally construed as providing just
probabilistic support. In the light of this example, I wish to make two claims about causation in medicine.
The first is in support of the RWT. Examples like this demonstrate that knowledge of a causal mechanism
is an essential, rather than desirable, part of understanding most causes in medicine. My second claim
aims to develop the RWT by demonstrating the manner in which heterogeneous evidence can become
integrated into monistic causal claims.
4.5.2.2 The discovery of HBV
While various forms of hepatitis have been known for many years, the modern conception of viral hep-
atitis dates from the 1930s. The most significant step arose when it was noted that a small proportion of
patients (somewhere between 2 and 3%) receiving vaccination against yellow fever developed hepatitis
(Findlay and MacCallum, 1937, 305). This clinical correlation was unusual. For instance, the delay of
between two and six months between vaccination and hepatitis was rather longer than the known in-
cubation period of infectious hepatitis. This raised the suspicion that some novel infectious agent was
at work in these individuals. As the vaccine used in these cases was derived from human serum, and
similar outbreaks were subsequently noted as a result of other instances of transfusion with human sera
(zur Hausen, 2006, reviewed 244), the argument that this was a novel disease being spread between
individuals by means of contaminated blood derivatives was highly plausible.
By 1947, this clinical syndrome was sufficiently well recognised to allow an aetiological classifica-
tion of infectious hepatitis into hepatitis A and B (Anonymous, 1947, report on speech by FO MacCallum
to the International Congress of Physicians, 1947), reflecting the recognition of underlying aetiological
distinctions between the two clinical syndromes. But it was not until 1963 that the agent responsible for
hepatitis B was discovered. This came about as follows.
In the early 1960’s Blumberg discovered a serum antibody in the blood of a haemophiliac which
reacted against an antigen found in the blood of an Australian aborigine. He named this antigen the
Australia antigen (Blumberg et al., 1965, 541). Early research into this protein lead to several anecdo-
tal reports of the infectious power of blood containing this antigen (e.g. Okochi and Murakami, 1968).
Thus, a research programme developed attempting to determine the causal significance, if any, of this
agent in the development of human disease. Relatively quickly, the agent was noted to be the likely cause
of hepatitis B, on both statistical and mechanistic grounds (Blumberg et al., 1968). Statistically, a strong
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correlation was noted between individuals suffering either acute viral hepatitis or Down syndrome35 and
the presence of the Australia antigen. Mechanistically, in addition to conventional laboratory findings,
three anecdotes were exceptionally important. First, a member of laboratory staff working with the Aus-
tralia antigen became Australia antigen-positive and hepatitic (Blumberg et al., 1968, 1569), suggesting
that the antigen was in itself infectious. Second, another member of laboratory staff, employed immuniz-
ing rabbits with the antigen, developed antibodies directed against it (Blumberg et al., 1968, 1569-70).
Thirdly, a single case was reported in which an individual, who was donating annual blood samples to
the project, received a blood-transfusion which was presumably hepatitis B positive. Thus, a single case
became available in which the sequential chronology of infection, seroconversion and the development
of clinical disease was apparent (Blumberg et al., 1968, 1570).
However, it was not until 1970 that the origin of the Australia antigen became clear. In fact, it
required the electron microscopic demonstration of VLPs in serum from hepatitis patients displaying the
Australia antigen (Dane et al., 1970). It was at about this time, as a result of this demonstration and the
previous work implicating the Australia antigen in viral hepatitis that the causal link between a virus and
hepatitis became generally accepted.
4.5.2.3 HBV and HCC
Infectious hepatitis had been anecdotally implicated in the development of HCC since at least the 1950s
(Payet et al., 1956). Early suspicions of a causal link were investigated epidemiologically, with multiple
studies being conducted during the 1970s and 1980s. In general, three strategies were practised. First,
cases of HCC were sought in geographical regions with known high prevalence of chronic infectious
hepatitis. For example, a study in Uganda suggested a strong correlation (relative risk = 13) between
hepatitis and HCC (Vogel et al., 1970). Second, populations of individuals with existing HCC were
serologically investigated for patterns of antibodies or antigens indicating chronic HBV infection. For
example, both Hadziyannis et al., 1970 and Sherlock et al., 1970 studied a group of Mediterranean
patients who had developed HCC following hepatic cirrhosis. Many of these individuals had high serum
levels of hepatitis B surface antigen. Finally, studies comparing populations with differing HBV and
HCC rates were conducted. As an example, Okochi and Murakami, 1968 compared a sample in Japan
(which had about a 1% prevalence of the Australia antigen in the general population) to the United
States, where rates of Australia antigen were only about 0.1%. However, the precise nature of any causal
relationship between HCC and HBV infection remained unclear. In fact, at least five distinct causal
pathways appeared highly plausible (see diagram 4.2).
First, some authors suggested that HBV infection caused, in a direct fashion, the development of
HCC (figure 4.2A). Others (e.g. Kumar and Taylor, 1973) suggested that the development of HCC
predisposed individuals to develop chronic forms of HBV (figure 4.2B). Was it perhaps the case that
something about having HCC caused the development of persistent antigenaemia? That is, could the
35Down syndrome was a marker of institutionalisation. As those living in institutions were considered at greater risk of de-
veloping infectious diseases than the population as a whole, individuals with Down syndrome had a high chance of contracting
blood-borne infections such as viral hepatitis
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Figure 4.2: Plausible causal pathways linking HBV, HCC and aflatoxin. Arrows indicate causal relation-
ships, dotted lines correlations. Cell mediated immunity (CMI) is the type of immune-system activity
that typically acts against viral infections.
finding that individuals with HCC had high levels of antigens associated with HBV because the tumour
was somehow promoting the expression of these viral proteins? Alternatively, as suggested by Dudley
et al., 1972, perhaps some pre-existing condition of modified CMI could cause both the development
of HCC (perhaps by the action of some unknown oncovirus) and also prevent the normal, effective re-
sponse to HBV infection, with the result that markers of HBV chronicity were seen in these patients
(figure 4.2C). A fourth causal hypothesis suggested was that there was no link at all between HBV and
HCC. For instance, a correlation was noted between regions of high HBV prevalence and high dietary
consumption of aflatoxin - a poison known to cause liver tumours (e.g. Peers and Linsell, 1973). Was
aflatoxin really causing the excess incidence of HCC seen in these populations (figure 4.2D)? Finally,
perhaps exposure to aflatoxin might both cause the development of HCC and also alter the normal im-
munological responses to HBV infection (figure 4.2E). Thus, consumption of aflatoxin might cause both
the development of HCC, and also cause the characteristic serological profile of chronic hepatitis B
infection (Coady, 1975).
This controversy was settled by early in the 1980s in favour of the first of the competing hypotheses.
It appears that HBV infection does cause HCC.36 How did this come about? The first really convincing
epidemiological evidence for the direct causal role of HBV on HCC was a large population study of
22707 Taiwanese civil servants. Taiwan has a high incidence of HBV infection. This study showed a
greatly increased risk of developing HCC given chronic HBV infection. In fact, for those infected with
HBV, the annual incidence rate of HCC was 1158 per 100 000, while for those free of infection the rate
was 5 cases per 100 000. This gives a relative risk of developing HCC given HBV of 233:1 (Beasley
36Aflatoxin also causes HCC, and appears to act synergystically with HBV. Thus individuals with both chronic HBV and high
dietary consumption of aflatoxin are at very high risk of developing HCC. However, neither is a necessary factor.
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et al., 1981). This is a devastatingly strong effect. Most relative risks encountered in epidemiology are
at least an order of magnitude less that this. For comparison, the ten-year relative risk of lung cancer
in those smoking more than 20 cigarettes per day compared to non-smokers is about 11 (Higenbottam
et al., 1982). In itself, this is generally considered an impressively strong effect.
This observational claim is the first piece of vital probabilistic evidence linking the tumour with the
infection. The second came about from intervention. An effective subunit vaccine for HBV, derived from
human plasma, was developed in the mid-1970s (Buynak et al., 1976). It was shown to be effective in
preventing HBV infection (Francis et al., 1982), and was therefore licenced for clinical use in 1981 (zur
Hausen, 2006, 260). This vaccine was later supplanted by a recombinant subunit vaccine (McAleer et al.,
1984). Together, these agents appears to have been effective in reducing the incidence of HCC (Zanetti
et al., 2008). Thus a specific intervention acting against HBV appears to be effective in preventing its
oncogenic effects. Together, these two pieces of evidence seem to offer so much support to the claim
that HBV causes HCC that consideration of mechanism seems redundant. This case therefore acts as a
counterexample to the RWT. That is, unless I can somehow demonstrate that mechanistic evidence plays
a vital role in its formulation. In the following section, I will attempt to do just that.
4.5.2.4 HBV and HCC: Finding the mechanism
My first claim is that Beasley’s epidemiological finding is compatible, more or less equally plausibly,
with any of the five possible models for HCC causation given above. Neither data indicating aflatoxin
exposure, nor markers of abnormal CMI, were obtained from trial subjects. Importantly, the apparent
temporal relation between HBV and HCC detected is also compatible with any of the five models -
assuming, that is, that some unknown time elapses between the inititiation event of any of the processes
discussed and the development of detectable biomarkers. I think this is a highly plausible claim.
This observational result weakly depends upon a particular mechanistic model, implicating HBV
infection in the aetiology of HCC.37 However, the next major population finding in this area depended
much more strongly on an understanding of the mechanism. This was the development of an effective
HBV vaccine likely to prove effective against HCC. Two types of research were important in this. First,
the development of a mechanism for HBV-mediated oncogenesis involved the discovery that the HBV
genome was detectable within HCC cells (Summers et al., 1978b). This was followed by the discov-
ery that, in some cells at least, the HBV genome was integrated with that of the host cell, leading to
the expression of virally-encoded RNAs (Chakraborty et al., 1980). This opened the door to suggest-
ing a plausible mechanism of viral oncogenesis by HBV integration and subsequent transformation of
hepatocytes occurring in those with chronic hepatitis B. Most importantly, this mechanistic sequence
temporally preceeded the development of macroscopic tumour formation (Shafritz et al., 1981). This
process of mechanism construction was, in part, analogous to that encountered in the other cases of viral
oncogenesis here described. One important difference, however, was the conspicuous role played by
research on one animal model of oncogenesis. This was the woodchuck hepatitis virus, an orthohepad-
navirus closely related to HBV (Summers et al., 1978a). The analogy between HBV and woodchuck
37For instance, in deciding to seek particular specific indicators of HBV infection in the study population
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hepatitis virus was evidentially significant because this agent provided a useful animal model that could
be used to understand the likely pathogenesis of HCC in a system free from the practical, ethical and
legal constraints applying to experimentation on humans.38
In summary, before attempts at vaccination, three types of evidence mutually lent support to the
causal claim that HBV was the cause of HCC. These are the clear epidemiological correlation between
the virus and the tumour, dating from about 1970, the molecular mechanism implicating HBV in oncoge-
nesis, which developed from about 1975, and investigation of the analogous case of woodchuck hepatitis
virus, dating from about 1978. As one contemporary author reviewed:
Epidemiology, molecular biology, and comparative pathology have all contributed to
this inquiry. Epidemiological investigation has supplied evidence that HBV infection is
associated with PHC.39 Molecular biological studies have thrown light on the mechanism
by which it may occur, while a surprising exercise in the comparative pathology of small
rodents has served to reinforce the case by showing that man is not alone in this matter.
(Anonymous, 1981, 1394)
So these forms of mechanistic evidence appear important in the causal story of HCC and HBV.
For now I am content to say that the suggestion that this case preceded in the absence of mechanistic
evidence is to simply mistake the chronology. Causally, the role played by HBV in the genesis of HCC
appears to have been well accepted before the introduction of the HBV vaccine into clinical practice.
More importantly, it seems highly implausible that the vaccine could have been developed without a high
degree of mechanistic understanding of HBV itself. This example highlights some of the developments
required of my account of mechanistic evidence, which will follow in chapter 6.
4.5.3 Probabilities and Mechanism Without Causation - Cervical Cancer and
HSV
The HSV episode seems to provoke a problem with a normative interpretation of the RWT. Here, high
quality evidence of both mechanisms and probabilities supported a causal claim that turned out to be
faulty. In this section, I therefore outline a possible means of discovering just what, exactly, was wrong
with the evidence that supported the theory that HSV caused cervical cancer. In particular, it seems
that the different types of evidence in this case were not integrated together. I regard this property of
integration of evidence as essential if the RWT is to be understood normatively. As such, it will form a
key part of chapter 7.
Let us recap the evidence in favour of HSV as the cause of cervical cancer from chapter 3 in a man-
ner compatible with the RWT. First, evidence of difference-making. Six pieces of difference-making
evidence did the majority of the work in supporting the HSV causal claim.40 HSV1: venereal transmis-
sion of both diseases. Probabilistic, observational data, such as co-variance in different patient groups,
supported the claim that both HSV and cervical cancer were transmitted venereally. Sexual intercouse,
38I discuss the important evidential role played by analogies in greater depth in section 6.4.1.
39PHC stands for primary hepatocellular carcinoma, which is synonymous with HCC
40I will elaborate on what, exactly, characterises this evidence as evidence of difference-making in section 6.5ff.
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therefore, appeared to makes a difference to the development of both HSV and cervical cancer. This was
supported by HSV2: the serological correlation observed to exist between HSV and cervical cancer,
which arose from similar, seroepidemiological data. One important additional difference-maker also
arose here - HSV3: HSV seroconversion anteceded oncogenesis. Next, HSV4: increased rate of
HSV infections in uncircumcised men suggested that something about circumcision prevented HSV
infection. The combination of HSV1 and HSV4 partners with the next two difference-making claims to
further suggest that it was specifically a feature of unprotected sex that made a difference to cervical can-
cer incidence. HSV5: low incidence of cervical cancer in partners of circumcised men and HSV6:
barrier contraceptives reduced cervical cancer incidence.
Next, evidence of mechanism. Most of the difference-making evidence linking HSV, cervical can-
cer and sexual activity arose from similar types of investigation. These were generally large, retrospec-
tive, observational studies comparing disease rates in different populations. But the mechanistic evidence
employed was methodologically and epistemically much more diverse. What exactly consitutes mecha-
nistic evidence is something that I will explore at more length later. For now, though, it is worth noting
that this evidence of a mechanism seems to fall into three groups.
First, there was a group of evidence supporting the malignant potentiality of HSV. HSV7: HSV
is mutagenic in vitro. As might be expected, it could therefore lead to the malignant transformation of
cells in culture. Thus, HSV8: HSV transforms some cell lines in vitro. So HSV causes chromosome
damage, and thus can cause some sorts of cells to become malignant. These two pieces of mechanistic
evidence were at the heart of the claim that HSV caused cervical cancer. Very importantly, they also
depended on a vital piece of analagous evidence, HSV9: the known, analagous role of herpesviruses
in other tumours.
Together, this group suggests that HSV could cause cancer. Did they mean that HSV could cause
cervical cancer? This is addressed by two pieces of evidence specifically implicating HSV in cervical
cancer. First, HSV10: the detection of HSV in cervical cancer cells. The specific detection of HSV in
cervical cancer cells happened only once. Thus, this finding was disputed and controversial. However,
it gained some support from the plausible counterclaim that existing tests for HSV were insufficiently
sensitive to find the small quantities of nucleic acids likely to be found in mature cancer cells.41 Further
support was gained from HSV11: the visual similarities between dysplastic cervical cells and cells
demonstrating HSV cytopathic effects seen in histological samples of the tumour (see 3.5.1). This
issue was further complicated by the suggestion that cervical cancer could result from a model of HSV
infection that did not leave residual traces of HSV in the tumour cells. This possible causal model
formed an important piece of mechanistic evidence in favour of HSV, thus HSV12: the ‘hit and run’
hypothesis. Certainly, general failures of HSV detection did not seem to mechanistically exclude a
causal role for HSV in cervical oncogensis.
Finally, certain events came to light that suggested the nature of the aetiological mechanism operat-
ing in study populations. These findings served to link the plausible mechanism constituted by HSV7-12
41That is, the failure of HSV detection was underdetermined
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to facets of the difference-making evidence HSV1-6. The first of these, which served to explain the link
between HSV and circumcision, was HSV13: the isolation of HSV from smegma. Finally, the differ-
ential susceptibility seen at various ages was explained by HSV14: a plausible change in sensitivity of
the cervix to oncoviruses in youth.
However, the evidential story here is more complicated than it would initially appear to be. Take
the first piece of difference-making evidence (HSV1). Not only does this suggest that sexual intercourse
makes a difference to the incidence of both HSV and cervical cancer, but it also tells us some likely facts
about the mechanism involved. That is, some aspect of sexual intercourse seems to play a role in both
causal stories. So this claim also provides grounds for a claim about causal dependencies: HSV and
cervical cancer happen or come about, in a similar way. This mechanistic claim is elaborated by other
pieces of mechanistic and difference-making evidence, which further elaborate the sorts of events that are
likely to be the common cause of this phenomena. So, for example, the reduction seen in both conditions
with the use of barrier contraception tells us that it is something about unprotected sex, rather than sex
simpliciter, that is causally significant. The evidence for circumcision of male sexual partners too seems
to support this mechanistic claim. Therefore there are a group of, if you like, second-order, emergent
pieces of causal evidence that arise when existing pieces of causal evidence are placed in context with
one another. This web-of-evidence, I suggest, plays a vital role in my account of the nature by which




In this chapter, I aim to give an account of mechanisms that is compatible with the RWT. While mech-
anistic theories of causality are generally intended to be theories of causality in their own right, I here
intend to do something rather different. In fact, what follows is compatible with the idea that mechanisms
are simply an epistemic device that allows us to conceptualise and organise complex causal relationships.
Following this line of investigation, I will give an account of mechanisms as a necessary, but insufficient,
part of conceptualising causality in the health sciences.1 To do this, I will begin by giving a short re-
view of the current literature on mechanisms. Here, I suggest that there are a number of consensus
features that arise from these disparate accounts which appear highly suited to interpreting Russo and
Williamson’s sense of mechanism. I will then turn to thinking about mechanisms in medicine in a more
specific sense, and I will identify a number of demands that working in this area places on accounts of
mechanisms. These demands will lead me to modify the consensus position in a number of ways. In
particular, I will criticise the view that mechanisms can be fully characterised in terms of either causal
laws or counterfactuals grounded in interventions, and I will suggest an alternative way of proceeding.
Using this modified account of mechanisms, I will then defend the use of mechanisms as tools for
understanding causality in a non-reductionistic sense. Specifically, I suggest that mechanistic theories
of causality, unlike regularity theories, counterfactual theories, agency theories and process theories, are
capable of giving a useful analysis of causal processes that does not seek to reduce causal processes to
non-causal ones.2 Following this, I will then develop my account of mechanisms with an eye to making
1There might be an infinite regress here. Say we are trying to construct a mechanism between C and E, C1 - C2. . . Cn - E.
However, once this is done, then the causal mechanism C1 - C2 will, in turn, be in need of a causal mechanism too. And so on. I
attempt to avoid this objection in section 5.4.3 by suggesting that, in a given context, a mechanistic model will have a fairly clearly
defined level of organisation at which it bottoms-out. At this function-specific fundamental level, we will no longer be interested
in the causal interactions of any more fundamental processes. Thus, while there may be a regress, it will not be an infinite one.
2I will term theories that seek to make this reduction reductivist theories of causality. For regularity theories, I include Humean
regularity theories (Hume, 1975 (1748, Section VII)), Mackie’s INUS conditions (Mackie, 1974, 60ff), as well as a number of
probabilistic theories (such as Granger, 1969 and Eells, 1991). In general, these theories seem unsuited to the job of analysing
causes where confounding variables or common-cause situations obtain. For counterfactual theories, I am primarily thinking of
Lewis’s account (Lewis, 1979; Lewis, 1986; Lewis, 2000; Psillos, 2002, 93ff). This theory suffers greatly from the difficulties that
conventional accounts of world-similarity ranking face (Lewis, 1979, 47-8) when dealing with causality in medicine. For agency
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it more fully compatible with the RWT. I will first suggest, and disambiguate, the role of mechanisms
in giving operationally adequate interlevel explanations in section 5.4.3 I will then suggest, as a con-
sequence of this interlevel behaviour that mechanisms need to be carefully specified in terms of their
function if they are to play a useful role in forming RWT-type causal claims. I will do this in section 5.5.
That is, we need to carefully consider exactly what a particular mechanism is for when we attempt to
construct it. I will then suggest, in section 5.6, that most medical mechanisms, if correctly functionally
specified, will display a characteristic branched structure, and that an important part of thinking about
causes in medicine is to decide just which causal ‘track’ is taken in a particular instantiation. This will
form the basis for the final part of this chapter, which is to describe just how this kind of functionally
specified, branched mechanism can accommodate causation by prevention or by omission, both of which
are generally difficult using other theories of causality.
This account of mechanisms then requires an account of mechanistic evidence. This will follow in
the first half of chapter 6. I will then turn to thinking about difference-making in the second half of that
chapter. I will return to mechanisms, and their relationship to difference-making, in chapter 7, where I
will give an account of the expanded RWT.
5.2 Mechanistic theories of causality
We might begin with Williamson’s recent definition of mechanistic theories of causality in general:
A mechanistic theory of causality holds that. . . two events are causally connected if and
only if they are connected by an underlying physical mechanism of the appropriate sort.
(Williamson, 2010, 2-3)
I suggest this applies to the original formulations of all the theories of causality that follow. As I
previously mentioned, though, I think that mechanisms do not tell us the whole story about causality in
medicine. I suggest, in line with the RWT, that describing causal relationships in terms of mechanism
and the relevant evidence used to construct them is a necessary, but insufficient component of assessing
causation. For the time being, then, I will take the conceptual components of these accounts of causality
as my focus, and I will say very little in specific terms about how they fare as theories of causality in
their own right. In any case, I think there are two simple objections to treating all causes as simply mech-
anisms. The first is the difficulty of dealing with causation by omission or by absences, while the second
relates to the difficulty of accounting for the types of evidence that are actually employed in scientific
practice to form and assess causal claims. I think that these problems are closely related, and I suggest
just an account that combines mechanistic with other forms of evidence can be formulated - and used to
address the problems of negative sorts of causation - later. With that proviso in mind, I will give here
theories, I’m concerned with Menzies’s and Price’s (Menzies and Price, 1993, 187) theory, which seems unable to account for
situations where natural experiments seem to provide us with useful causal knowledge. I deal with process theories of causality in
section 5.4.1.
3To distinguish it from reductivism, I shall call theories that define causality in terms of microphysical interactions reductionistic
theories of causality
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a short introduction to five recent mechanistic theories of causality, which have distinct similarities. A
little terminological disambiguation is in order at this stage. First, I intend to refer only to that recent
group of mechanistic theories that are referred to as the New Mechanistic Philosophy (NMP). I do not
intend to address mechanisms in the reductive, Cartesian, historical, sense (see e.g. des Chene, 2005).
Second, when addressing these recent theories, I will restrict my discussion to those arising from the
complex-system tradition. I will neglect, for the time being, a second, reductionist, group of mechanistic
theories of causality. These are the process theories, reviews of which can be found in Psillos, 2002
and Williamson, 2010, 4ff. Later, in section 5.4, I explain why I regard these theories - Salmon’s mark-
transmission (MT) theory (Salmon, 1984) and Salmon and Dowe’s CQ theories (Salmon, 1998; Dowe,
2000) - as unsuitable for the analysis of causality in medicine, and likewise suggest that the sort of epis-
temic tools that these theories licence are inappropriate for the task of representing causal relationships
in medicine. With those distinctions under our belts, I will outline some NMP-type, complex-system
theories of causality.
5.2.1 Machamer, Darden, Craver
The first of these accounts is that of Machamer, Darden, Craver (MDC). Their account is explicitly based
upon studies in the biological sciences, most notably neuroscience, and has been extensively developed
over many publications on the subject (see, for example, Machamer et al., 2000; Craver, 2001; Craver,
2002; Darden, 2002; Machamer, 2004; Craver and Darden, 2005; Darden, 2005; Darden, 2006 and
Craver, 2007). However, their account of mechanisms begins with an highly succinct definition:
Mechanisms are entities and activities organized such that they are productive of regular
changes from start or set-up to finish or termination conditions.
(Machamer et al., 2000, 3)
Let us analyse these claims in detail. First, MDC claim that mechanisms are - ontologically - con-
stituted by both entities and activities. Entities are the things, the physical matter, which participate in
the causal process via their properties. Examples might include viruses, cells, proteins, nucleic acids,
organs and so on. Activities, on the other hand, are the ‘producers of change’ (Machamer et al., 2000,
3). Entities thus act on other entities via their activities. So a protein might bind a ligand. Or a virus
might infect a cell. These causal verbs are the activities, and their actions between a series of entities is
responsible for producing the function of the mechanism. Description of both entities and activities are
therefore required to give an ontically adequate account of a mechanism. Thus they reject accounts of
causality that attempt to reduce causality to an exclusive ontological property of either substances or pro-
cesses (Machamer et al., 2000, 4-5). Craver later proposed that this dualistic conception of entities and
activities brings epistemic and methodological advantages when compared to an account that prioritises
either alone:
Calling them “activities” rather than “capacities”. . . emphasizes the way that mecha-
nisms work as opposed to the way that a set of parts has the capacity to work or is disposed
to work. This shift of gestalt is recommended and defended. . .
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(Craver, 2001, 58, footnote 2)
Thus MDC’s account rejects both process and substantivalist ontologies, instead placing entities and
activities on an separate-but-equal ontological footing. I agree that these non-ontological advantages are
important, and I employ them as part of my own account of mechanism. However, MDC do not offer
a stronger defence of this dualism than similar abductive arguments from epistemology. For instance,
they suggest that the apparent independence of activities and entities as subjects of enquiry suggests this
ontic dualism. In defence of this stance, Machamer later wrote:
From the fact that activities have measures that may be applied to them, and from the
fact that they may be identified independently of any particular entities that are acting, we
might infer that they have some independent status as referents. This is presumably what we
need in order to attribute ontological status. Nevertheless, such general characterizations do
not begin to come close to a definition.
(Machamer, 2004, 29)
Now this ontological argument, I think, has convincing epistemic consequences. It is the case that
we quite often identify causal activities without identifying entities to which those activities relate. For
example, Lucke´ (see section 1.1) was able to very clearly describe the clinical features which resulted
from the activities of an unknown virus, without really understanding how these activities related in detail
to any particular infectious agent. Likewise, we may find and describe an entity without necessarily
knowing its activities. For instance, we might discover a viral genome without knowing how, or even if,
it acts to produce disease. I develop this epistemic and methodological argument for dualism further in
section 5.3.
The next feature of MDC’s account deals with the manner in which activities and entities are ar-
ranged. MDC claim that mechanisms are organised in some way. As they suggest, mechanisms are not
simply aggregates of things. Instead, the activities and entities constituting a mechanism are distinctively
organised in some way. Mechanisms themselves are characterised by the ’spatial and temporal organi-
zation of the[ir] component parts’ (Craver, 2007, 135–6).4 By way of effecting this differentiation of
mechanisms from aggregates, MDC identify a special kind of organisational property that is characteris-
tic of mechanisms: active organisation. Active organisation is a description of the manner in which the
components of a mechanism interact together. As Craver puts it, active organisation is characterised by
the arrangement of ‘activities of and interactions among the entities in the working mechanism’ (Craver,
2007, 136).
This property arises from the particular spatial and temporal patterns of organisation in the mecha-
nism in question (Craver, 2001, 60ff). That is, the active organisation of a mechanism comes about from
the particular organisation of its components in terms of, say, their size, orientation, shape, duration,
manner of contact and so on (Craver, 2007, 137–8).
4 Craver, 2007 does a great deal to disambiguate this distinction between mechanisms and aggregates along lines originally
suggested by Wimsatt (1997).
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For mechanisms, the term organisation thus refers to two different, interrelated, properties. The
first is the particular pattern of organisation that the components of a specific mechanism displays. The
second - active organisation - arises from this particular pattern and is the source from which claims
about causal function can be made for that mechanism. In order to give an adequate description of a
mechanism, we therefore need to consider two kinds of organisation. We first need to give a description
of how the components of that mechanism are organised in terms of shape, spatial arrangement, temporal
sequence, manner of interactions and so on (Craver, 2007, 136–7). For example, the manner in which a
drug interacts with a receptor may be a question of the morphologies of both the interacting entities, or
the organisation of particular enzyme complexes, or of the spatial arrangement of parts of the interacting
entities. However, in addition to describing how the components of a mechanism are organised, we also
need to give a description of how these organisational properties give rise, together, to the property of
active organisation.
Thus, for MDC, active organisation is a property that is distinctively mechanistic. While other
kinds of organisation, such as spatial arrangement of parts, can happily be a characteristic feature of
non-mechanistic aggregates, mechanisms alone have the property of active organisation. Without active
organisation, we would no longer have a mechanism. As a consequence, performing interventions that
interfere with active organisation - by rearranging, substituting, disaggregating or reaggregating parts -
typically breaks, or otherwise alters, the function of a mechanism. In contrast, the parts of an aggregate
can be rearranged without such functional disruption.
Active organisation, as a general property of mechanisms, gives rise to the feature of regularity.
MDC suggest that regularity deals with ‘. . . the typical way the mechanism runs from beginning to end’
(Machamer et al., 2000, 3). That is, a degree of regularity between a cause and an effect arises in a given
mechanism because of the existence of active organisation in that mechanism. When a mechanism is
suitably organised there therefore exists a productive continuity, between each of the particular links of
the mechanism, linking cause and effect. In order to provide an adequate description of a mechanism, we
need to demonstrate the existence of this productive continuity as an unbroken chain of causal relations
linking cause and effect:
Complete descriptions of mechanisms exhibit productive continuity without gaps from
the set up to termination conditions.
(Machamer et al., 2000, 3)
If this organisation is disrupted then the connection will be lost. Thus it is something about the
sequence of causes at play in a mechanism that require us to make the distinction between aggregates
and mechanisms. In other words, mechanisms can only exhibit their behaviour when organised. If this
organisation is lacking then the instantiation of a cause in the mechanism will (generally) give rise to
different, or no, effects.
Therefore the overall relationship between a cause and an effect that a mechanism describes and
the linked sequence of causal relationships that constitute it means that this account of causality is non-
reductivist. In fact, MDC adopt a distinctly agnostic attitude regarding any more reductivist account of
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causality. Theirs is an account of causality that neither seeks to reduce causal to non-causal concepts (as
further outlined in Craver, 2007, 64), nor to seek the secret connexion that Hume could not find.5 This
is not always the case with NMP-type theories of mechanism, as I will address later. What this theory
does purport to do, though, is to allow the analysis of complex causes in convenient terms. For example,
it might permit an investigator to understand the manner in which a cause operates such that they can
give an explanation. Or perhaps this process of conceptualising causes might be performed for reasons
of exploiting the kinds of special features that we expect of causal relationships.6
As a related issue, MDC’s understanding of causes does not simply rely on relating the operations of
causes to causes operating at the most fundamental level. Their account is therefore non-reductionistic.
Instead of thinking about causes as encountered in scientific practice as being explainable only in terms
of their relation to, say, micro-physical causal interactions, MDC instead value higher-level phenomena
as genuinely explanatory. In other words, for MDC, mechanisms are interlevel (this position is most
strongly developed in Craver, 2005).
However, moving to using this theory of causality brings some difficulties that relate to what, ex-
actly, we mean by a mechanism. There is a vital clarification that needs to be made here between mech-
anisms, models of mechanisms and representations of these models. I take the definition given above
to speak to claims about the mechanism as it exists in the world. That is, I think these claims about
entities, activities, organisation and so on are about the ontology of mechanisms themselves. However,
when it comes to thinking about understanding and exploiting causes we move to discussing features
of our mental models of mechanisms. That is, claims about the performance of MDC’s account in an
operational sense will involve thinking about features of these causal models, rather than the causes as
they exist in the world. I think that models of mechanisms have important differences from ontological
mechanisms. I will address some of these below, and I will also return to this issue when I come to
discuss Glennan’s account of mechanisms in section 5.2.2.
But for now, I can identify aspects of the model/mechanism distinction in MDC’s work. For exam-
ple, they suggest that our interpretation of a mechanism (i.e. as a mechanistic model) is contextualised:
Functions are the roles played by entities and activities in a mechanism. To see an
activity as a function is to see it as a component in some mechanism, that is, to see it in a
context that is taken to be important, vital, or otherwise significant.
(Machamer et al., 2000, 6)
I take this sort of argument to imply that if we wish to suggest a mechanism as a potential expla-
nation of a phenomena then our descriptions of that mechanism must take account of the context within
which it operates. In particular, we will have to specify just which one of the many possible behaviours
of that mechanism we are seeking to employ in our explanation. For example, the heart both pumps
5‘It appears that, in single instances of the operation of bodies, we never can, by our utmost scrutiny, discover any thing but
one event following another, without being able to comprehend any force or power by which the cause operates, or any connexion
between it and its supposed effect.’ (Hume, 1975 (1748, 12.58)
6c.f. Russo and Williamson’s claims about cognitive and action-oriented goals, which are reviewed in section 4.2.
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blood and produces heart sounds. If we are trying to give a mechanistic explanation for circulation, we
will seek to describe the pumping behaviour, rather than the sound-producing behaviour, of the heart
as part of our mechanistic explanation. MDC describe this kind of consideration as functional spec-
ification. I return to why there is a need for this sort of practice in section 5.2.6. However, the how
is worth describing here. In practice, this functional specification is performed by describing, in some
detail, the set-up and termination conditions for the mechanistic model. There are a number of provisos
that MDC have made about these which need not concern us too much at this stage (e.g. that these
conditions will be relative to both a set of idealised background conditions and to the initial states of the
entities and activities. Likewise a number of implicit ceteris paribus conditions may well be crucial to
seeing how the mechanism will actually go (Craver, 2001, 11ff)). However, the general principle is quite
straightforward.
Both set-up and termination conditions are defined at explanatorily privileged endpoints (Craver,
2001, 11-2). For instance, if we wish to explain why an individual developed a disease, we might select
a set of set-up conditions that represent a normal, physiological state, while our termination conditions
would represent some kind of description of the disease of interest. On the other hand, if we were
to seek a causal explanation of the success of a treatment for this same disease, our set-up conditions
would be descriptors of the disease, and our termination conditions descriptors of the cured or palliated
state that (hopefully) obtains following treatment. Thus set-up and termination conditions depend upon
the functional specification of the mechanism in question. Thus the causal structure represented by a
mechanism is highly context-dependent. We can only specify these conditions once we give an account
of what the mechanism in question stands for. They are therefore a feature of mechanistic models, rather
than mechanisms:
To give a description of a mechanism for a phenomena is to explain that phenomenon,
i.e. to explain how it was produced.
(Machamer et al., 2000, 3)
This context-dependent aspect of mechanistic models means that mechanistic models of a particular
mechanism are liable to change with circumstances. This means models of mechanism are dynamic; they
can change over time.
. . . one should not think of mechanisms as exclusively mechanical (push-pull) systems.
What counts as a mechanism in science has developed over time and presumably will con-
tinue to do so.
(Machamer et al., 2000, 2)
This, as I interpret it, supports MDC’s claim that their mechanistic metaphysics arise from scientific
practice:
In many fields of science what is taken to be a satisfactory explanation requires providing
a description of a mechanism. So it is not surprising that much of the practice of science can
be understood in terms of the discovery and description of mechanisms.
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(Machamer et al., 2000, 1-2)
5.2.2 Glennan I
Glennan has produced two differing positions regarding mechanisms. His first, which might be de-
scribed as a mechanical theory (Glennan, 1996) relies on interpreting mechanisms in terms of causal
laws, whereas the second, mechanistic theory (Glennan, 2002) explicates causal interactions between
parts of a mechanism in terms of Woodward’s account of ‘invariant, change relating generalizations’
(Woodward, 2000). I will therefore introduce his earlier formulation here, and I will interleve an account
of Woodward’s position on mechanisms before I discuss the second.
Glennan begins by arguing, contra Hume, that there is more to causality than regular succession.
He suggests that a mechanical theory of causality instead explains the necessity that seems to distinguish
laws from accidental generalisations in an unproblematic manner:
When I claim that some event causes another event, say that my turning the key causes
my car to start, I do not believe this simply because I have routinely observed that turning
the key is followed by the engine starting. I believe this because I believe that there is
a mechanism that connects key-turning to engine-starting. I believe that the key closes a
switch which causes the battery to turn the starter motor and so forth. Furthermore, this is
not a “secret connexion”. I can look under the hood and see how the mechanism works.
(Glennan, 1996, 50)
That is, a causal relationship should be characterised by both behavioural regularity and the exis-
tence of an observable mechanism capable of linking cause with effect. So a causal explanation of a
correlation between C and E will require the demonstration of a mechanism, such as C–D1–. . . –Dn–E,
connecting C and E. He goes on to offer a suitable definition of mechanism:
(M) A mechanism underlying a behavior is a complex system which produces that be-
havior by of the interaction of a number of parts according to direct causal laws.
(Glennan, 1996, 52)
That is, the individual causal linking in the mechanism C–D1–. . . –Dn–E should be understood
as instances of direct causal laws which govern the interactions of the constituent parts. The overall
behavioural correlation seen between C and E is then explicable in terms of the bundle of individual
causal laws that govern the interactions between the components of the mechanism:
. . . a mechanism is a collection of parts, in which the behavior of the aggregate stems
from a series of local interactions between parts.
(Glennan, 1996, 56)
Glennan further suggests that, characteristically, mechanisms are behaviourly polymorphous (Glen-
nan, 1996, 52). For example, combustion engines both move drive-shafts and produce heat. Glennan
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claims that we can give legitimate mechanistic explanations of either of these behaviours by appropri-
ately decomposing the mechanism into its relevant parts, depending upon what is to be explained. This
means that, depending upon what behaviour it is that we wish to explain, we can analyse a given mecha-
nism in a number of different ways to produce a range of mechanistic models. However, such modelling
practices are negatively constrained by ontic features of the mechanism itself: in order for a mechanistic
model to provide a good description of a behaviour its components must be ‘objects’ (Glennan, 1996,
53) that are ‘really there’ (Glennan, 1996, 52). So this context-dependent decomposition is not intended
to undermine claims of realism about the parts of the mechanism. Now these two facets of Glennan’s
account - mechanism-for-behaviour and behavioural polymorphism - are very useful for understanding
the distinction between mechanisms and mechanistic models, and I therefore take them up in section
5.2.6.
Glennan suggests that the manner of interactions between parts of a mechanism are governed by
causal laws, and that these causal laws should be understood as generalisations or universal propositions
which support counterfactuals (Glennan, 1996, 54). While this is clearly non-reductivist, it is rather
different from the non-reductivist approach to causality suggested by MDC. While MDC were non-
reductivist in the sense that they did not specify a particular prior notion of causality at all, Glennan
instead uses one type of causality (that of direct causal laws) to support his mechanical view. However,
like MDC, this makes his account to a degree circular: we can explain the lawlike characters of me-
chanically explicable laws by reference to the mechanisms that underlie the laws themselves (Glennan,
1996, 63). Again, like MDC, this circularity regarding causality is not vicious; even though we can
only really explicate causes in terms of other causes we can still provide useful explanations of complex
causal situations by reference to simple causal components that are easy to understand and control. It
might be argued that this position tends towards regress, in that we may well have a problem explaining
the lawlikeness of fundamental causal laws. This means that his theory offers no attempt to explain
causality in fundamental physics (Glennan, 1996, 50). However, he suggests that the best solution to this
dilemma is a dichotomous understanding of causation in fundamental physics vs understanding causa-
tion everywhere else. In other words, the truth-makers of the majority of causal claims (which happen
at non-fundamental levels) under Glennan’s theory are unproblematic and intuitively appealing, but in-
coherent at a fundamental level. This dichotomous understanding is permissible, according to Glennan,
because we need not worry too much about reducing all causal claims to the operations of physical sys-
tems. He supports this argument with two pieces of empirical evidence from scientific practice. The first
is that the vast preponderance of causal talk solely concerns higher-level causal claims:
Causal statements are typically statements about events regulated by mechanisms, and
mechanisms are complex, higher level entities. Only when we talk about interactions gov-
erned by fundamental laws does causal talk become problematic.
(Glennan, 1996, 68)
The second, based upon a reading of quantum entanglement, suggests that there may very well be
no causality governing fundamental interactions anyway (Glennan, 1996, 66-7). So the results of these
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two pieces of evidence is to suggest that causal claims about fundamental phenomena are generally
irrelevant to scientific practice, and that discussions of their nature may, in any case, be incoherent.
Given this proviso about their scope, how does Glennan suggest that these apparently non-fundamental
causal laws are constituted? First, Glennan requires that part-part interactions of a mechanism must be
governed by ‘direct causal laws’ (Glennan, 1996, 55). By this, he means to suggest that the causal laws
themselves must give an account of just how two phenomena are causally connected. This excludes
lawful generalisations that explain two phenomena as the actions of a common cause. As he suggests:
. . . it is a lawful generalization that night follows day, but certainly day does not cause
night. Rather, the onset of day and of night are events which are both caused by the earth’s
rotation. Relations between parts must be governed by causal laws because otherwise the
parts could not be said truly to interact.
(Glennan, 1996, 55)
5.2.3 Woodward
Woodward first set out his position on causality in Woodward, 2000 and Woodward, 2002, and later
substantially developed it in Woodward, 2003. This mechanistic theory of causality essentially aims to
overcome a number of difficulties that arise from relating causal explanations to the operation of laws.
His essential idea is this: that causal explanations are (and should) be done by relating phenomena to the
operations of invariant generalisations, rather than laws. This has a number of technical advantages. For
example, as Woodward suggests, the exact degree of invariance - across a particular range of background
conditions, for instance - can meaningfully vary. This grants invariant relationships a rather different
status to those relationships that are governed by laws, which are generally suggested to take the form of
exceptionless regularities of universal scope. These law-governed generalisations are generally assumed
to be capable of being simply dichotomously true or false. In contrast, using invariance gives us the
ability to speak to the truth-value of relationships in a more granular manner. For example, we can
suggest that a particular causal relationship is likely to obtain over a particular range of conditions. This
localisation is something that is not, in general, associated with truth-makers of relationships governed
by laws. So what is this property of invariance? Woodward claims that generalisations are invariant if
they are both change relating and stable. Change relating means that these generalisations speak of the
relationship between two event-types, such that the instantiation of one event-type brings about some
sort of difference in the second event-type. Stability here also has a specific meaning. As Woodward
suggests, stable generalisations are those that are robust under interventions. This relation of causes to
interventions is the main characteristic of Woodward’s account. He begins by defining an intervention:
An intervention is an exogenous causal process that changes some variable of interest X
in such a way that any change in some second variable Y occurs entirely as the result of the
change in X.
(Woodward, 2000, 199)









Figure 5.1: Woodward’s intervention condition M1. Here, X is changed by intervention I. G stands for
the causal relationship, if any, between X and Y. M1 excludes any other causes (V, W, I2 and I3) from
changing X.
He imposes certain conditions on these interventions. Take an intervention I on the variable X
(Woodward, 2000, 201). First, I should change X in some way, and this change should be entirely due
to I (M1). Second, according to postulated relationship between X and its effect, Y, the change brought
about by I on X should change Y. That is, the value of Y under intervention I on X should differ from
the value of Y when no such I had taken place (M2). Third, I should change Y only via X. That is, there
should be no effect of I that has an effect on Y via any route a) that is not an effect of X, and b) that are
not intermediate between I and X that have no effect on Y in the absence of X - that is, effects of I of this
type may not be sufficient causes of Y (M3). Finally, (M4) suggests that I should not correlate with any
other cause of Y except X, and those cases mentioned in (M3).
I find these adequacy conditions rather confusing. I have therefore attempted to represent them
diagrammatically below in figures 5.1-5.4.7
Thus, for Woodward, any causal process that meets conditions M1-4 counts as an intervention.
This means that, for example, natural experiments count as interventions (Woodward, 2000, 201).8 Thus
7Here, I am trying to take one of the aspects of the normativity so frequently encountered in the mechanisms literature seri-
ously (c.f., for instance, Bechtel and Abrahamsen, 2005, 426ff). I think that graphical representations of mechanisms provide a
substantial benefit, over textual representations of the same phenomena, when it comes to understanding the operation of complex
systems. With that intuitive claim in mind, I have lately been working on a range of tools for building mechanistic representations
in a way that is operationally convenient. That aside, Woodward gives some adequacy criteria for mechanistic representations,
which I will mention at the end of this section.
8‘[this] characterization makes no essential reference to human activities or to what human beings can or can’t do. A causal
process that does not involve human beings at any point will qualify as an intervention as long as it meets conditions M1-4. Indeed,
it is precisely this sort of possibility one has in mind when one talks about a “natural experiment” (Woodward, 2000, 201)





Figure 5.2: Woodward’s intervention condition M2. This assumes that the relationship condition, G, is







Figure 5.3: Woodward’s intervention condition M3. I3 is allowable because it is an effect of X (M3a).
I2 is likewise allowable, because it is an intermediate between I and X (M3b). However, neither the
direct effect of I on Y, nor I4 are allowable, because they are neither intermediate between I and X, nor








Figure 5.4: Woodward’s intervention condition M4. There should be no causes of Y (in this example, A,
B, C and D) that correlate with I except X.
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it is the sort of causal structure, and not the question of agency, that makes a process an intervention.
Interventions on X, and their effects on Y, can therefore tell us that there is a causal relationship between
X and Y. His account is, in common with the other theories of mechanisms, non-reductive, as causal talk
features in the definition of interventions, which in turn are used in Woodward’s definition of causation.
Anyway, interventions provide grounds for causal relationships in the following way. Given a
particular causal system, a range of interventions can be performed on it. This range of interventions
allows the establishment of a number of counterfactual dependencies that tell us just how the causal
system behaves:
. . . exhibition of patterns of counterfactual dependence of a special sort, involving active
counterfactuals - counterfactuals the antecedents of which are made true by interventions.
Only invariant generalizations will support active counterfactuals. . .
(Woodward, 2000, 199)
This has the important result that Woodward’s theory is therefore one that speaks only to the generic
case. We cannot, quite clearly, perform a range of interventions on a causal system and determine a
pattern of counterfactual dependence if that system only comes about once. However, assuming that we
have a system which is a suitable one for this sort of repetitious approach, Woodward tells us how we
can create mechanistic representations that allow us to put all these elements together to form something
that can operationally be employed to understand complex causes:
(MECH) a necessary condition for a representation to be an acceptable model of a
mechanism is that the representation (i) describe an organized or structured set of parts or
components, where (ii) the behaviour of each component is described by a generalization
that is invariant under intervention, and where (iii) the generalizations governing each com-
ponent are also independently changeable, and where (iv) the representation allows us to
see how, in virtue of (i), (ii) and (iii), the overall output of the mechanism will vary under
manipulation of the input to each component and changes in the components themselves.
(Woodward, 2002, S375)
Now I have some historically motivated concerns about this definition. Taking point iii) in partic-
ular, it is very often not the case that a claim for interventional independence of each component of a
causal mechanism is even plausible. For example, a reading of the viral oncogenesis cases from chapters
2 and 3 suggests that many variables will not be amenable to such modification. In specific terms, what
happens when our participating causal variable is something like a virus species? What does it mean to
change this under intervention? In general terms, it may well be that some variables, such as X, cannot
take different values. It cannot therefore be changed by I such that it alters Y. Now this sort of concern
does not, for me, licence totally discarding Woodward’s theory. What it does suggest, though, is that this
sort of interventionist approach does not tell us the whole story about causality. I therefore will take up
several of Woodward’s suggestions about how we can determine the structure of complex causes later.
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5.2.4 Glennan II
Glennan’s second mechanistic scheme really differs in just one respect from his first account. Instead of
explicating the causal connections between mechanistic components in terms of causal laws, this revised
account employs Woodward’s notion of change-relating invariant generalisations (CRIGs):
(M) A mechanism for a behaviour is a complex system that produces that behaviour by
the interaction of a number of parts, where the interactions between parts can be character-
ized by direct, invariant, change-relating generalization.
(Glennan, 2002, S344)
Again, Glennan carefully characterises the relationship between behaviours and mechanisms. First,
mechanisms have an external behaviour (Glennan, 2002, S347) which can be described. This external
behaviour is underwritten by a mechanism that is capable of accounting for its features. Thus mechanistic
models need to describe both the external behaviour of a mechanism, and the manner in which the
underlying mechanism in the world is supposed to account for that behaviour:
(MM) A mechanical model is a description of a mechanism, including (i) a description
of the mechanisms behavior; and (ii) a description of the mechanism which accounts for
that behavior.
(Glennan, 2002, S347; see also Glennan, 2005, 446 for a slightly revised version)
This suggests that there are two differing aspects of providing an adequate mechanistic model that
we might seek when looking for historical support for this account of mechanisms. First comes the
description of the behaviour of the mechanism. Glennan outlines just what this involves:
. . . the concept of a mechanism’s behavior generally presupposes a concept of normal
functioning. When one describes the behavior of a mechanism, one describes how it will
behave if it is not broken.
(Glennan, 2005, 448)
I think this is a critical property of adequate mechanistic description of causal relationships in
medicine. In general, a pathological process is defined by a contrastive relation with the relevant phys-
iology. In other words, our concept of a pathological mechanism for a particular set of symptoms or
behaviours presupposes a difference between that mechanism and what would (counterfactually) happen
in a healthy state. I will return to this when I discuss functional specification of medical mechanisms (in
section 5.5) and again when I introduce the concept of branching (section 5.6). For now, though, I will
simply assert that, because of the behavioural polymorphism of mechanisms, we will need to specify
carefully just which behaviours we are attempting to explain by our mechanistic models. This is critical
for a second reason, which Glennan also raises:
. . . there is a one-many relationship between behavioural and mechanical descriptions.
This is because the same behavior can be produced by different mechanisms.
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(Glennan, 2005, 449)
So not only is it the case that a given mechanism will tend to have more than one (mechanistically
explicable) behaviour, but also that a given behaviour may well have associated with it a number of possi-
ble causal mechanisms. Dealing with this unclear correspondence between behaviours and mechanisms
is a key task for my account of causality, so I will return to this issue in chapter 7.
5.2.5 Bechtel
Bechtel9 (Bechtel and Richardson, 1993) set out a theory of mechanisms that is based on a study of the
life sciences.10 In brief, Bechtel uses an interlevel concept of mechanisms in order to give meaningful
non-nomic explanations. As such, his account shares much with those that came later. However, it
is distinctive in respect of the type of things that participate in a mechanism. Rather than activities
and entities, interactions or CRIGs, he characterises mechanisms as composed of component parts that
operate on one another:
A mechanism is a structure performing a function in virtue of its component parts, com-
ponent operations, and their organization. The orchestrated functioning of the mechanism
is responsible for one or more phenomena.
(Bechtel and Abrahamsen, 2005, 423)
Bechtel uses this particular terminology because he wishes to prioritise the conceptual primacy of
the parts that participate in the mechanism. Physical parts, Bechtel claims, are the essential constituents
of mechanisms, and the operations of these parts depend fully upon them:
We use the term operation rather than activity because we want to draw attention to the
involvement of parts; for example, enzymes operate on substrates so as to catalyze changes
in the substrates.
(Bechtel and Abrahamsen, 2005, 423)
So unlike MDC, Bechtel wishes to place mechanisms on a more substantivalist footing. Thus the
causal interactions that together constitute the mechanism are properties of the physical parts of that
mechanism. Groups of these inter-part interactions constitute the component operations that can then be
used to describe the mechanism:
Each component operation involves at least one component part. Typically there is an
active part that initiates or maintains the operation (and may be changed by it) and at least
one passive part that is changed by the operation. The change may be to the location or
other propert(ies) of a part, or it may transform it into another kind of part.
9In the interests of terminological simplicity, I will refer to this position as that of Bechtel, and I will neglect the specific
contributions of his collaborators.
10‘In this paper we are targeting explanations in the life sciences. We are not claiming all scientific explanations involve appeals
to mechanisms or even that in biology all explanations take the form of identifying the responsible mechanism. The claim is far
more modest – that in many cases in the life sciences, and potentially in other sciences, the quest for explanation is the quest for a
specification of the appropriate mechanism.’ (Bechtel and Abrahamsen, 2005, 422)
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(Bechtel and Abrahamsen, 2005, 424)
And it is the orchestrated and organised character of these component operations that makes mech-
anisms work. As with the other NMP accounts, this organisation is characteristically complex.11 Like-
wise, Bechtel aims to differentiate the mechanism in the world from the kinds of epistemic activities
that can be performed with knowledge of that mechanism. In particular, mechanistic explanations can
easily be incorrect, or even absent, without challenging the actual causal operations of the ontological
mechanism:12
. . . mechanisms are real systems in nature. . . but it is crucial to note that offering an
explanation is still an epistemic activity and that the mechanism in nature does not directly
perform the explanatory work. . . This is particularly obvious when one considers incorrect
mechanistic explanations - in such a case one has still appealed to a mechanism, but not one
operative in nature. Another way to appreciate the point is to note that in many instances
the mechanism in question was operative long before scientists discovered the mechanism
and invoked it to explain the phenomenon. Thus, since explanation is itself an epistemic
activity, what figures in it are not the mechanisms in the world, but representations of them.
Bechtel has also provided a number of detailed accounts of how these epistemic models
are constructed from ontological mechanisms account of the kinds of decomposition and
complexity (Bechtel, 2001, 2008).
(Bechtel and Abrahamsen, 2005, 424-5)
Now these mechanistic models are therefore representations of the operation of a mechanism in the
world, and must therefore describe a number of features of it if they are to be explanatorily adequate.
These include the parts and operations of these parts, the manner in which these parts and operations
work together, and the overall organisation of the mechanistic system that is responsible for producing
the phenomena of interest:
A model of a mechanism describes or portrays what are taken to be its relevant compo-
nent parts and operations, the organization of the parts and operations into a system, and the
means by which operations are orchestrated so as to produce the phenomenon.
(Bechtel and Abrahamsen, 2005, 425)
They also make an interesting suggestion about levels. While it is the case that Bechtel’s mech-
anisms are interlevel, it is generally the case that the interactions in a mechanism are usually between
parts that are of a similar magnitude. This means that Bechtel seems partially to define the concept of
levels by reference to the typical operation of mechanisms:
11‘Operations can be organized simply by temporal sequence, but biological mechanisms tend to exhibit more complex forms
of organization. . . mechanisms may involve multiple levels of organization.’ (Bechtel and Abrahamsen, 2005, 424)
12I interpret this as a claim about mechanisms versus mechanistic reasoning. This means that criticisms of their position that
rely on demonstrating faulty mechanistic reasoning do not undermine their assertion that it is mechanisms that are responsible for
effects. I defend a similar position in what follows.
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Models posit parts of a particular sort within a system and operations performed by these
parts. The task in developing a model is to identify these parts and ascertain what they do
and how they interact to produce the phenomenon of interest. Typically, a part found within
a system will interact with other parts of roughly the same magnitude, and this cluster of
interacting parts will constitute a level.
(Bechtel, 1994, 15)
5.2.6 Consensus features of the NMP
While there are a number of vital differences between these accounts, I would like to extract some
consensus features of mechanisms.13 First, all five accounts claim that mechanisms are composed of
real entities that causally interact. Whether this is described in terms of entities and activities (MDC),
components and laws (Glennan I), components and CRIGs (Woodward; Glennan II) or components and
functions (Bechtel), none of these accounts can tell a wholly non-circular story about causality. That
is, they are non-reductive accounts of causality. Next, these causal interactions between elements are
organised in some way. Mechanisms are not simply aggregates of parts. Instead, the components of
the mechanism have an internal structure that contributes to their eventual function. This suggests that
giving a description of something other than the individual physical parts and their associated behaviours
is a necessary part of describing a mechanism. Part of this claim is the suggestion that upstream causal
effects of the mechanism have an effect in the later parts of the same mechanism. But to claim that this
organisation is simply a linear causal sequence is mistaken. Instead, mechanisms may internally interact
in complicated ways. So, for example, a downstream effect of a mechanism may act causally upstream in
a way that is vital for the proper function of the mechanism in subsequent instantiations. So an account of
organisation will take account, not only of the sequential choreography of elements and their activities,
but will also have to tell a story about how the mechanism is chronologically located in context. It is not
simply the case that a described mechanism runs once through, from start to termination, in isolation.
Instead, causal mechanisms are necessarily embedded in their environments. This means that we
might also have to give an account of how our mechanism is spatially, chronologically and contextually
situated in order to give a usefully full account of it as a mechanistic model.
These accounts also feature some variant of regularity or stability. Mechanisms are mechanisms
just because they are stable, to some degree and in certain contexts. This stability arises from the causal
relationships between elements. In other words, mechanisms arise because of organised causal depen-
dencies. Each element, with the possible exception of those at the extreme ‘left’ are brought about by
the effects of their causal parents. This does not mean that a given mechanism must always turn out the
same group of effects. In what follows, I try to unpick the nature of this stability. Can we give an account
of what makes mechanisms behave regularly, and what prevents them from doing so? This appears a
key issue in an operational theory of causality for medicine. After all, if we can’t suggest why a person
becomes unwell, as a mechanistic consequence of the disruption of their usual (mechanistic) physiology,
13There have been a number of previous attempts to synthesise various mechanistic accounts of causality. See, e.g. Tabery,
2004.
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then this project is in trouble. I try and pick out the manner in which regularity becomes irregular in
section 5.6.
This aspect of (ir)regularity raises a further consensus item regarding a distinction between mecha-
nisms and mechanistic models. Mechanistic models need to be functionally specified if they are to give
a meaningful mechanistic description of a phenomena. The heart is (part of) the mechanism for pumping
blood around the vascular tree. But it is also (part of) the mechanism for producing the heartbeat, for
filling the middle part of the mediastinum, for occupying the pericardium, for supporting the coronary
arteries, for regulating blood pressure, for secreting atrial natriuretic peptide, and for contributing to the
development of a great many disease states. When we want to employ the heart as part of a mechanis-
tic model, we must first specify what purpose our construction of the model is to serve. This functional
specification will control exactly the nature of the entities and activities contained within the mechanism,
what organisational concepts we employ, the nature of theories governing interactions between elements,
and the types of chronological and spatial contextualisation we employ. The heart mechanistic model
that we might use to understand why the anterior and posterior parts of the mediastinum do not collapse
into one another will be very different from that heart model that we might use to understand the manner
in which a particular form of cardiomyopathy has affected serial generations of a family. In turn, this
will be a very different mechanistic model from that we might use to explaining why an individual has
high blood pressure, should refrain from smoking or has pericarditis.
As can be seen from this outline of functional specification, I detect a further consensus regarding
the interlevel nature of mechanisms. Mechanisms are inherently interlevel. There appears to be no sin-
gle (ontically, epistemically, methodologically determined) privileged level of organisation at which the
mechanism can be said to exist, to be understood or should be investigated. In other words, mechanisms
give a non-reductionistic account of causality. Take the above sketch. The heart, as a mechanism, can
be understood at a variety of levels of organisation. We can give an account of the heart as a anatomical
tissue,14 or by the behaviour of its component cells, or by the mechanistic properties of these cells, or
by some much more detailed story of its biochemical, molecular biological, genomic, chemical, physi-
cal aspects, and so on. Yet a properly, functionally specified mechanistic model of a particular heart-y
behaviour, such as “produces heart sounds” will require elements of causal description at many of these
levels without specially privileging any of them. While a biochemical explanation of, say, myosin-actin
interactions will be required to understand why the heart beats, the appropriate level of organisation for
understanding the way that the chambers of the heart actually contract will require telling a tissue-level
story about their spatial arrangement. So giving a mechanistic account of something requires relating
together the manner at which it functions at a number of different levels simultaneously. I will discuss
this at greater length in 5.4.
These accounts of mechanism are also metascientific. That is, in general they base themselves
firmly on the study of scientific practices, rather than beginning from a metaphysical stance on causality.
Usefully for my account, this scientific starting-point has generally been a biomedical one. Most com-
14A structured organisation of cell-types. Incidentally, I think that terms such as this require at least a partial mechanistic
understanding in order to play a useful semantic role. But this digression is for another time.
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monly, the specific disciplines employed have been neuroscience (Glennan, MDC, Craver) and molecular
biology (Bechtel and Darden).15 Perhaps as a consequence (or cause?), these theories have some degree
of normative aspiration. They do not simply aim to describe causes.16 Instead, they aim to provide a
cognitive tool for determining what are good, and what are not so good, causes in the world. I will pick
up some of these normative aspirations in chapter 7.
Finally, and closely related to the normative component of these theories, all of them in some way
distinguish the mechanism in the world from our models of these mechanisms. They also distinguish
these models from our representations of them. Entities, activities, various types of temporal and spatial
organisation and their resulting causal dependencies found in mechanisms are real, ontological features
of the world. However, this does not mean that the new mechanistic philosophy makes claims solely
about the ontology of causal mechanisms; quite the opposite. Instead, there are a number of consensus
features - notably about the interlevel nature of mechanistic models, and the various discussions about
how to specify these models - that are claims about how mechanisms should be modelled. That is,
these are epistemic claims. Finally, there are also a group of metaphysical claims about mechanisms and
their models, most prominently those claims that deal with the metascientific nature of the mechanisms
project, and various normative claims. However, in what follows, I will primarily engage epistemically.
While I claim that entities, activities, causal dependencies and so on are real, mind-independent features
of the world, I think that the overarching problem of dealing with causes in practice concerns issues
related to giving accurate models of these phenomena. So in what comes after I will neglect the ontic
aspect of mechanisms. Instead, the question will be: what do we think is the cause of a phenomena? Why
do we think this is so? How should we model the causes of a phenomena? It is this sort of reasoning
about mechanistic models that I wish to use as part of my account of causality in medicine. To give
an historically adequate account of such mechanistic modelling, I will need to give a more particular
account of what I think constitutes an adequate model of a mechanism. So I will now break away
from this consensus position on mechanisms in order to achieve this. I have a clear preference for one
particular mechanistic theory of causality for the job in hand, and I will adopt a more partisan stance
below.
5.3 Mechanisms in medicine
These competing accounts of mechanisms have major differences when it comes to making mechanistic
models of medical phenomena. While each of them have something to add, MDC’s account of mech-
anistic causality appears to be the most suitable account upon which to build the expanded RWT. Why
MDC?
Following MDC’s account, I argue that we need to consider both activities and entities when we
model causal relationships in medicine. There are sound methodological and epistemic reasons for
making this claim: both types of thing are, I suggest, necessary components of making good mechanistic
15Woodward is an obvious exception to this aspect of these accounts.
16Really causal explanations, in all cases. I have rather neglected the explanatory capacities of causal mechanisms in my account
in favour of using them as tools for dealing with causality.
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models. I will defend this claim below by showing that mechanistic models that neglect the role of either
entities or activities are inadequate.
I also suggest that neither activities nor entities are prior. That is, I do not think that it is possible
to reduce all talk about entities to being about activities, and nor is it possible to reduce all activity-talk
to entity-talk. This is part of the more general sense in which this account is non-reductivistic, and
non-reductionistic. Again, I will support this claim by reference to an historically-grounded argument
in section 5.3.2. One important consequence of this argument, though, is that I do not agree with MDC
about the type of dualism that obtains. While MDC make similar arguments from epistemology to
support their ontic activity-entity dualism (Machamer, 2004), I will not extend my argument in such a
way. In fact, the argument presented in section 5.3.2 seems to undermine MDC’s attempt to make an
epistemically supported ontological argument about dualism.
5.3.1 Activities without entities; entities without activities
First, a conceptual claim about medicine - and perhaps science - in general. We are very often aware
of causal activities without knowledge of the relevant entities that produce them. Take the example
of Lucke´’s clinical descriptions of renal adenocarcinoma in the northern Leopard frog (Lucke´, 1934,
1938a,b, 1939; Schlumberger and Lucke´, 1949; Lucke´, 1952. See also section 1.1). Here, we have
an example where an activity was clearly discernible, could be very clearly described, and appeared to
play a central causal role in a plethora of mechanisms. Yet Lucke´ could not describe the entity(ies) that
produced these activities in such a clear way. In a similar way, he also did not know just what entities this
unknown entity had its causal activities on. In both cases, he could tell a partial story about the likelihood
of these features arising from an infectious agent, and perhaps give some kind of general mechanism of
oncogenesis. But what he could not provide was a detailed mechanistic model relating the clinical
findings to a particular entity. Thus, the mechanistic model for this condition would be inadequate. We
can have a degree of causal knowledge (as Lucke´ did), without having a good mechanistic model.
The converse position, where we have knowledge of an entity without knowledge of a corresponding
activity, might be illustrated as follows. Imagine the example of a discovery of a viral protein of unknown
function. This constitutes an entity that lacks a clear activity. Yet it may well be the case that this entity
appears to participate in a causal mechanism. For example, we might know about its structure, we might
give an account of how it comes about or we might also be able to say that it causally participates in
some manner downstream. For instance, we might conduct an experiment where a mutant virus, which
does not express the particular protein, was used to infect cells in culture. We might then be able to
give an account of what happens, and relate it in a contrastive way to the operation of the wild type
virus on similar cells. But all of this does not mean that we know about the activities of this protein in
detail. Activities show how entities act as causal agents; they are the way that they ‘express themselves’
(Machamer, 2004, 29). But this does not mean that entities without known activities do not ‘express
themselves’. In fact, as experiments such as this mutant virus show, we may very well know that a
particular entity expresses itself in a mechanism, and may be able to give a clear account of what form
this expression takes. What we do not know is how this expression happens. In RWT terms, we can
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show that infecting culture cells with a mutant virus makes a difference compared to the effects of using
wild-type virus. This tells us about the existence and likely shape of the underlying causal mechanism,
but does not grant us detailed mechanistic knowledge about how the two situations differ. I will return
to this distinction between types of causal knowledge later in this chapter.
In summary, such unilateral knowledge of either activities or entities does not allow us to adequately
understand the relevant causal mechanism. Thus, knowledge about both entities and activities is required
to construct a sound mechanistic model. This requirement is highly significant for the use of mechanisms
within the RWT, because if we do not understand how a mechanism operates - to some extent - then it
cannot become integrated with other forms of evidence, and thus it cannot meaningfully participate in
supporting a causal claim. Knowledge about both activities and entities is necessary to formulate an
adequate causal mechanism.
5.3.2 Some entities are really activities; some activities are really entities
A different historical argument supports the position that neither entities nor activities are prior. This
argument depends on demonstrating that, dependent on the context, some activities may be treated as if
they were entities, and some entities may be treated as activities.
I will begin by illustrating just how this interconversion thesis might manifest itself. For example,
some (medical) entities are defined in terms of activities. The term extracellular space is defined as
the area surrounding a cell which is the venue for local cell-cell interactions. But when we employ
this entity in a mechanistic model by, say, speaking of interactions that occur in it, this entity is not
characterised in terms that we generally associate with entities. We do not give a definition in terms of
spatial characteristics, morphological features, biochemical characteristics and so on. Instead, this area
is defined by a group of local interactive activities which can be (partially) described in componential
terms. Similarly, some activities are defined in terms of entities and their downstream activities. So the
activity T-cell activation is defined in terms of the entities that undergo activation. We cannot, in this
case, tell a fuller story about what the activity T-cell activation entails in terms of componential activities
and entities.
I take these kinds of cases to suggest that, in certain contexts, we may - methodologically and
epistemically - treat one kind of thing as if it were the other. However, we still require both kinds
of thing if we are to make sound causal claims - as discussed above, claims that lack either activities or
entities tend to be unsound. However, the context-dependent nature of activities and entities suggested by
the interconversion thesis means that we should not expect the (epistemic and methodological) dualism
that is required to formulate sound causal claims to be necessarily underwritten by a corresponding
ontological dualism.
5.3.3 A rebuttal of arguments against activity-entity dualism
Now there are a number of possible objections to this group of arguments in favour of dualism. First,
perhaps the Lucke´ case represents simple historical contingency. We happen to have discovered the
clinical syndrome well in advance of its related causal entity. But this chronological consideration does
not licence any argument about the relative statuses of entities and activities. I suggest that this sort
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of argument is no licence at all to discard dualism. Imagine the counterfactual case, where the clinical
syndrome and its associated viral entity were discovered simultaneously. In this case, many (functionally
specified) causal mechanisms would be unchanged. We would still have a similar understanding of the
sorts of downstream causal interactions of the tumour syndrome that we do now. So our mechanisms
dealing with frog survival and so on would be - in almost all contexts - unchanged. What would change
would be the upstream causes of the syndrome. Detailed knowledge of the relevant virus would (as with
the HBV case) allow us to intervene, make better predictions and so on, and it is this kind of difference
that makes the mechanistic model an adequate one for medical purposes.
A second, related, counterargument: perhaps activities are simply the capacities, propensities or
properties of an entity? Perhaps, in this case, the knowledge that kidney tumours and RaHV-1 are related
in certain law-like ways is sufficient. As a further example, aspirin can relieve headache. But it can also
prevent arterial thrombosis and cause peptic ulcers. We can now give a (molecular) account of all three
of these activities, and relate them to a single property of aspirin. Aspirin inhibits cyclooxygenase. Thus,
it blocks pain pathways - relieving headache. It prevents platelet aggregation - preventing thrombosis.
And it also causes gastric erosions, leading to gastrointestinal bleeding. In this case, the property of
aspirin to relieve headache (and pain more generally) was described well in advance of the other two
properties. In no small part, this was due to the simplicity, the obvious Humean constant conjunction,
of cause and effect. The other properties are rather more difficult to understand, because their effects
are temporally extended, may require various technological developments to detect, act in a stochastic
fashion, interact with manifold other causal variables and so on. But arguments of this sort un-nerve me.
Consider the effects of opium. Opium was described as having a dormative virtue that was the root of its
narcoleptic powers.17 But this is simply begging the question: users of opium sleep, because opium has
the capacity to evoke sleep. In general, like the RaHV-1 case, I think we need to tell a fuller story of the
relationship between activities and entities, rather than one that is so tightly circular. This means that we
must give a full account of both entities and activities to adequately describe causes mechanistically.
5.3.4 Against other mechanistic theories of causality
So even though we disagree about the ontological implications, dualism is the main positive reason that
I prefer MDC’s account. There are also important arguments that count against the other mechanistic
theories of causality. Very briefly, Glennan I (Glennan, 1996) seems untenable because of its require-
ment for causal laws. In biomedicine, even the use of the term appears lacking. Take the cases discussed
in chapters 2 and 3. I can find no pertinent reference to the suspicion of, search for, discovery or eval-
uation of any form of causal laws governing any actual or theorised causal interactions anywhere in the
(extensive) literatures on these cases. This lack of support for even the possibility of detecting causal
laws seems to me sufficient to discard Glennan’s first account, on the grounds that the metascientific
case lends no support to the metaphysical heart of the theory. That is not to say that everything Glennan
discusses is incorrect. In fact, I modify and employ several aspects of his account - most notably his dis-
17‘Opium facit dormire. . . Quiat est in eo / Vertus dormitiva, / Cujus eat natura / Sensus assoupire.’ [Opium brings sleep because
in it there is a dormative virtue that causes drowsing of the senses] (de Moliaure, 1673)
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tinction between mechanisms and models of mechanisms, and his account of mechanistic polymorphism
- later.
In a similar fashion, Woodward’s interventionist account lacks historical support in the historical
cases. In fact, many pieces of evidence that actually played a crucial role in suggesting, supporting and
disproving causal relationships appear very difficult to reconcile with this manipulationist account. For
example, the prospective study that played such an important role in the BL story seems to violate many
of Woodward’s conditions on interventions.18 Likewise, Burkitt’s initial clinical work that formed the
foundation for the BL research programme seems vital, but cannot be intelligible under a theory that
speaks only to interventions. But this is not to say that interventions played no significant role in causal
discovery and assessment in the case histories. In fact, the opposite; they played a critical role. It is just
that thinking in terms of interventions alone does not capture the actual richness and plurality of evidence
in play in building and assessing causal claims in practice. Thus Woodwardian interventions appear a
necessary, but insufficient, component of constructing mechanisms. It therefore seems improper to base
my account on them, instead preferring a more general account of mechanism that can accommodate a
greater range of types of evidence.
There is a second way in which Woodward’s account fails to account for the historical case. This
is in Woodward’s treatments of modularity. Modularity is a property of representations of causal sys-
tems,19 which he defines as:
Modularity. A system of equations is modular if (i) each equation is level-invariant
under some range of interventions and (ii) for each equation there is a possible intervention
on the dependent variable that changes only that equation while the other equations in the
system remain unchanged and level-invariant.
(Woodward, 2003, 329)
The important consequence of modularity is that, if a system is modular, then we can perform cer-
tain interventions on single components of it that we can subsequently expect to affect only that single
component. That is, assuming modularity means that we will be capable of performing specific, ‘sur-
gical’ interventions within a given causal system. Woodward illustrates this property with the familiar
example of the causal relationships between atmospheric pressure, a barometer and the occurrence - or
otherwise - of a storm (Woodward, 2003, 48ff).
Let us model the relationships between the reading on a barometer (B), the probability of a storm
occurring (S), and atmospheric pressure (A) by the following pair of equations:
(1) B=aA; and
18Although the divorce of interventions from human agency seems a valuable feature of Woodward’s account. For instance, the
geographical distribution of BL and its relationship to climatic factors is, essentially, a natural experiment.
19Woodward claims that it modularity is a necessary feature of an adequate representation of a causal systems as either a system
of equations or as a directed graph: ‘I assume that when causal relationships are correctly and fully represented by systems of
equations, each equation will correspond to a distinct causal mechanism and that the equation system will be modular.’ (Woodward,
2003, 49)
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(2) S=bA
If we assume that our representation is modular,20 then we expect to be able to intervene on (1)
by replacing B=aA with B=I - by, say, forcing the needle of the barometer to a particular position and
nailing it into place. In a correctly modular representation, such as this one, an intervention within one
equation will not affect any of the others. Here, intervening on the barometer will not alter the chances
of a storm taking place. Likewise, if we were to make S=I, by performing some intervention to alter the
probability of a storm occurring, then assuming that this intervention did not rely on altering A, B would
similarly remain unchanged.
Here is the difficulty with assuming that modularity must hold in order to provide an adequate
representation of a causal system: as modularity is an empirically determined property of representations
of causal systems,21 it may be that we have a causal model that is quite adequate for describing particular
aspects of the system of interest, and yet in which modularity does not generally hold.
As an example, take the role of statins in preventing coronary heart disease. While the intended
effect of these agents was to inhibit cholesterol synthesis, and thus prevent heart disease by decreasing
circulating levels of lipoproteins, it transpires that they have additional effects that are independent of
their cholesterol-lowering role.22 In fact, statins also appear to prevent heart disease by ‘improving
endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and
inflammation, and inhibiting the thrombogenic response’ (Liao and Laufs, 2005, 89). Further, these
pleiotropic effects have been seen to contribute to survival in a number of recent clinical trials (Wang
et al., 2008).
Now these pleiotropic effects potentially compromise modularity in any system that attempts to
model the causal relationship that obtains between cardiovascular outcomes cholesterol by intervention
with lipid-lowering statins. For not only will the statins alter lipid levels, but they will also affect other
contributors to coronary heart disease, such as inflammation, plaque stability, and so on. More impor-
tantly, this kind of pleiotropic behaviour is not unusual in causal systems of medical interest. In fact, it
has been found in a great many systems, including with anti-hypertensive drugs (Koh et al., 2003), in
the effect of genetic factors (Flanagan et al., 2000), in the action of immune cytokines (Veldhuis et al.,
1991) and so on.
So if we are to take seriously Woodward’s requirement that adequate causal representations be
modular, we must regard our model of the action of statins - and possibly a great many other mechanisms
- as extremely suspect, even if we lack a better alternative.23
20It need not necessarily be so,‘Modularity is thus a feature that a set of representations of causal relationships. . . may (or may
not) possess.’ (Woodward, 2003, 47).
21Woodward has previously suggested that modularity is empirically determined: ‘We are not claiming that one can determine
whether a system of equations is modular simply from its syntactic form. . . it is nature and in particular facts about what happens
or would happen under interventions that determine whether a given system of equations is modular.’ (Hausman and Woodward,
1999, 543-4).
22i.e. statins are pleiotropic.
23‘If we make the. . . plausible assumption that a necessary condition for two mechanisms to be distinct is that it be possible (in
principle) to interfere with the operation of one without interfering with the operation of the other and vice versa, we have a justi-
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This difficulties with Woodward’s account also propagates to Glennan II (Glennan, 2002; Glennan,
2005). Despite this difficulty, many features of these accounts are useful to me, and I pick them up
in subsequent sections. In particular, I will return to a more Woodwardian/Glennanian view in chapter
6, when I deal with the relationship of evidence to causality, and again in section 7.1, when I discuss
effective strategies for finding therapeutic interventions.
Bechtel claims that the parts of a mechanism are primary, just because the operations that these parts
have on one another cannot happen in the absence of their parent parts. In this case, the arguments made
in support of MDC’s activity-entity dualism serve as effective arguments against this account. Despite
this, Bechtel’s account is of great interest when it comes to the business of mechanism construction, and
in the relationship between mechanisms and mechanistic models.
So that is why I prefer MDC. As will become apparent, I think that MDC’s account needs some
modification to cope with the historical cases. Now, though, I will turn to why, in general, I prefer these
interlevel accounts of mechanisms to those that rely on either reducing causal- to non-causal processes,
or those that relate causation to the nature of physical processes.
5.3.5 In support of a non-reductivist account of causality
Does accepting the slogan ‘no causes in, no causes out’ (Cartwright, 1994) mean that this analysis of
causality is, ultimately, pointless? I suggest that it does not. While theories of causality that do not reduce
causal- to non-causal talk are circular, they are not necessarily viciously so. A well-construed, non-
reductivist, circular theory of causality can be enormously helpful in understanding causality in practice.
All of these advantages result from the leverage that such a theory allows us to exert on complicated
causal situations. In other words, our theory is useful because it allows us to cognitively digest large,
complex causes into smaller, more simple ones that are more intuitively understandable. Therefore, I feel
no sense of queasiness in simply treating causation as primitive when doing so allows us to understand
causes of practical importance.
In particular, I hope this theory is useful in the following ways: First, as a conceptual tool for under-
standing complex causal structures. Second, to allow us to develop effective strategies for modelling and
representing these complex causal structures. Third, to allow these models and representations to reflex-
ively assist in causal understanding by analogy and dissimilarity. That is to seek the ways that apparently
disparate causal situations can be unified, or to distinguish causal situations that appear deceptively sim-
ilar. Fourth, these models and representations may allow us to see how we can improve our knowledge
of these causes by showing us effective strategies for mechanistic construction and evaluation - possibly
by interventions. Fifth, perhaps related, they can grant us a greater understanding of the nature of the
relationship between our evidence for our cause and our cause itself. Especially importantly in this case,
they help us plan and operate effective therapeutic interventions. Finally, they provide an important tool
for understanding the way that understanding of causes develop. As Machamer puts it:
Just as one cannot have, or does not need, a theory of organism per se and tout court,
fication for requiring that systems of equations that fully and correctly represent causal structure should be modular.’ (Woodward,
2003, 48).
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equally one does not need a theory of cause. The problem of causes is not to find a general
and adequate ontological or stipulative definition, but a problem of finding out, in any given
case, what are the possible, plausible and actual causes at work in any given mechanism.
(Machamer, 2004, 27-8)
Just as biologists do not have a theory of organism to understand organisms, philosophers do not
need a theory of causality to understand causes.
5.4 Levels and gaps
Useful models of medical causes are generally interlevel. That is, their explicatory power relies on re-
lating phenomena at different levels of organisation together. For example, a given model might connect
the molecular causes of a disease with a range of clinical symptoms and signs that occur at the level of
the organism. In turn, antecedents of the molecular causes of the disease might consist of a range of
factors at differing levels of organisation, and these might operate via intermediates at different levels.
In this section, I will begin by introducing two reductionistic accounts of causality. I will then
attack these theories on largely historical grounds. This attack is intended to demonstrate that, contra
these accounts, there appears to be no privileged level at which causal relata must operate. I will then
make a number of positive suggestions in defence of an interlevel account of causality, before outlining
two areas of interlevel accounts of causality that are in need of some development.
5.4.1 Process theories of causality
Salmon’s theory of MT attempts to give a reductivist definition of causality that makes causality an
objective feature of the world. For Salmon, to explain something is to show how it is situated within
the causal nexus of the world. His account begins with Reichenbach’s account of the Mark Principle
(Reichenbach, 1956, 197ff), in which Reichenbach suggested that the transmission of marks could be
used to determine causal relevance relations between events.
Salmon’s development of this theory, in Salmon, 1980 and Salmon, 1984, was as follows. He
first claimed that processes, rather than events, were the basic entities of causality (Salmon, 1980, 50).
The connection between cause and effect could then be interpreted in terms of the workings of physical
processes (Salmon, 1998, 16). However, because only some physical processes are truly causal ones, this
development required Salmon to suggest a means of differentiating causal processes from non-causal
pseudo-processes. Salmon suggested that we can make this differentiation by determining the capability
of a process to transmit a mark (Salmon, 1980, 52). Causal intersections are those that transmit persistent
marks when they interact in Minkowski spacetime:
We can distinguish two types of intersections: causal interactions and noncausal inter-
sections. When there is an intersection between two processes in which both are modified,
and the modifications persist beyond the place of intersection, this intersection qualifies as
a causal interaction. One uses a causal interaction to produce a mark in a process.
(Salmon, 1998, 17)
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So causal processes are those that transmit marks, and marks are transmitted by causal interac-
tions (see also a more technical definition in Salmon, 1984, 139ff). Salmon therefore claimed that MT
could give an adequate, objective, characterisation of causal interactions in non-causal terms. However,
Kitcher (1989) suggested that these claims were mistaken. His first line of attack was to suggest that MT
could not give an adequate analysis of causality. Kitcher identified three general lines of criticism against
the adequancy of the MT theory (reviewed Kitcher, 1989, 469). First, Kitcher claims, the practical dif-
ferentiation between causal processes and non-causal pseudo-processes is very much more complicated
than simply determining whether or not they transmit marks. In fact, many apparently mark transmitting
processes do not, when examined carefully, actually transmit a mark at all. Instead, a range of situations
exist where: ‘. . . the existence of unwanted (spurious?) characteristics - pseudomarks, pseudomodifica-
tions, and the like’ confounds this distinction (Kitcher, 1989, 469). So Salmon’s - supposedly simple
- differentiation between types of processes by MT is practically very complicated. Second, and like-
wise suggesting that this practical differentiation is unworkable, the inertial properties of some (causal)
processes may mean that we can apparently mark them with pseudoprocesses. Third, this account relies
upon reducing causality to the operations of idealised, elementary processes. This means that we have to
account for the behaviour of the macroworld in terms of series of these elementary, idealised processes.
However, this presents us with a methodological difficulty, in that it makes our ordinary causal knowl-
edge parasitic upon more fundamental knowledge of these idealised processes. Kitcher argued that this
was simply not the case.
In addition to these criticisms on the grounds of adequacy, Kitcher also suggested that the MT
theory was simply a species of counterfactual theory of causality.
I shall try to show first that the counterfactual commitments of Salmon’s theory are far
more extensive than he has noted (indeed, I shall claim that the theory naturally evolves into
a counterfactual theory of causation), and second that the epistemology for counterfactuals
that Salmon outlines encounters grave difficulties.
(Kitcher, 1989, 470)
It is the case that counterfactual conditions are really required for this account to give an adequate
characterisation of causal processes. Defining causal processes in terms of transmitting persistent marks
actually requires a characterisation in terms of the capacity of these processes to transmit marks (Salmon,
1998, 19). In other words, assessing whether or not a process transmits a mark or not requires the
interpretation of a counterfactual statement regarding what would have otherwise happened.
Another, even more penetrating, critique of the MT theory came from Dowe (Dowe, 1992; devel-
oped further in Dowe, 2000). Dowe suggested that Salmon’s MT theory was flawed in four respects.
First, it was circular, in that the definition of causal interactions in terms of mark-production begged the
question (Dowe, 1992, 200-1). Next, that Salmon’s definitions of MT were vague (Dowe, 1992, 201-4),
and therefore could not really be used to differentiate causal from non-causal processes. Dowe then
suggested, on statistical grounds, that two important types of causal interactions, Y- and λ-type interac-
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tions, could not be deemed causal by MT (Dowe, 1992, 204-7). Finally, in common with Kitcher, he
demonstrated the substantially counterfactual nature of the the theory (Dowe, 1992, 207ff).
However, unlike Kitcher, Dowe then suggested a possible modification to Salmon’s theory that
could save it from this range of objections. Instead of characterising causal process in terms of MT, Dowe
suggested a definition of both causal interactions and causal processes in terms of the manifestation of
conserved quantities, which he defined as:
. . . any quantity universally conserved according to current scientific theories. Some
conserved quantities are mass-energy, linear momentum, angular momentum, and charge.
(Dowe, 1992, 210)
So, according to Dowe, intersections are causal interactions if there is a CQ-exchange between the
participating processes, while causal processes are characterised by the manifestation of CQ:
DEFINITION 1. A causal interaction is an intersection of world lines which involves
exchange of a conserved quantity.
DEFINITION 2. A causal process is a world line of an object which manifests a conserved
quantity.
(Dowe, 1992, 210)
As with Salmon’s MT interactions, these world lines are collections of points in Minkowski space-
time (Dowe, 1992, 210). Dowe claimed that this characterisation solved all four of his objections against
MT. First, defining causal processes in terms of conserved quantities was non-circular, as it did not rely
on the inherently causal notion of marking. Second, this formulation was much simpler that Salmon’s
(rather complicated) later formulations of the MT theory, and was thus not vague (Dowe, 1992, 213).
Again, unlike MT, the CQ account could correctly interpret a wider range of types of intersection, no-
tably including Y- and λ-type interactions (Dowe, 1992, 214). Finally, this modification also freed this
version of the process theory from a reliance on counterfactuals, and made it capable of giving a fully
objective account of causality.
Salmon was to admit that Kitcher and Dowe’s criticisms were correct, and that they meant that MT
could not give a fully objective account of causality (Salmon, 1984, 171ff).24 He therefore adopted a
modified version of Dowe’s CQ theory, such that it is the transmission (rather than manifestation) of CQ
that is the signifier of causal processes:
the crucial question regarding causal processes is what they do on their own without
outside intervention. My answer is that they transmit something-e.g., conserved quantities,
information, or causal influence-and it is by virtue of such transmission that events at A and
B . . . are causally related. Dowe gives a different answer.
(Salmon, 1997, 466)
24This debate led to a fascinating exchange of opinion in the philosophical literature (Hitchcock, 1995; Dowe, 1995; (Salmon,
1997); also see Salmon’s overview in the postscript to the revised version of Salmon, 1994 contained in Salmon, 1998, 260)
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5.4.2 Against reductionist accounts of causality
First, there are a number of well-known objections against process theories (reviewed in e.g. Williamson,
2010). Broadly, these fall into two camps. First are a range of objections that arise from quantum me-
chanics (violations of the common cause principle, retrocausation and action at a distance). The second
objection is a much broader one: reducing most phenomena to microphysical processes is practically
problematic.
Now this second objection receives much support from the historical cases. First, the medical
literature reveals no clear level of organisation which is assumed, or even argued, to be ontologically
privileged when it comes to demonstrating causal relationships. It is not the case that debates around
these causal claims were framed in terms of their microphysical characteristic. Further, there seems no
support for any more limited, domain-specific reductionistic programme.25 Again, it is simply not the
case that arguments about causation are framed in terms of the knowledge of causes at one particular
level. When it comes to causal claims, no one special level of organisation is historically apparent. A
closely related argument can be used to gain further support for this claim: there is a paucity of serious
attempts at reducing biomedical processes to lower-level phenomena. In the scarce instances where
these attempts are successful, they are highly constrained to particular domains. For example, it may be
exceptionally useful to give an explanation of biofilm adhesion in terms of quantum field events. But
events at this level seem largely irrelevant when it comes to giving an explanation of common causes of
falls in the elderly. Moreover, in the first case the microphysical explanation suggests likely means of
intervening, but the second case does not.
Second, a study of clinical medicine reveals the centrality of thinking about causes in an interlevel
fashion. For instance, by far the majority of diseases have manifestations at the level of the whole
organism.26 When a diagnosis is made, these whole-organism findings may be joined by the results of
a range of investigations that examine the disease state at a wide range of organisational levels. These
might include various imaging modalities, including X-rays, ultrasonography, CT or MRI scans, blood
tests for ions (sodium, potassium), small molecules (glucose, urea), polypeptides and proteins including
complexes of antibodies or enzymes, tests of blood or other bodily fluids for microorganisms, tissue
biopsies or cytological sampling procedures to examine cells and so on. Finally, evidence may well arise
from therapeutic interventions that pertains to causation. All these findings form the evidential basis
for making and assessing causal claims. Thus claims about a privileged level, on methodological or
epistemic grounds are false. As Bechtel puts it:
Explaining a phenomenon is in part a matter of finding the correct level for understand-
ing particular interactions. Moreover, the resulting model is inherently interlevel. Explain-
ing how a system works involves not only determining how it interacts with other systems,
but what its components are, what they do, and how they are integrated so as to enable the
25This is similar to the difficulties experienced with other, intertheoretical reductions in the biological sciences (Kitcher, 1984).
26We generally know these as symptoms and signs. Symptoms are those findings that are obtained from history-taking. That is,
they are phenomena which the patient reports. Signs, on the other hand, are elicited by the examining clinician. A headache is a
symptom, a swollen optic disc is a sign.
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system to perform the activity of interest. It should be emphasized that in developing such
mechanistic explanations, scientists do not generate anything resembling a theory reduction.
They do not develop two theories and connect them with deductions, but rather models that
cross levels or interlevel theories
(Bechtel, 1994, 16)
A range of more specific, empirical, objections might also be levelled against the MT and CQ
theories. Many common biomedical phenomena actually do not appear to involve the exchange of a
conserved quantity or the transmission of a mark. Take an extremely common type of cellular interaction
- that of a ligand binding with a receptor. As the ligand (a hormone, for example) binds to the receptor it
induces a conformation change in the receptor. In turn, this activates a range of various cellular machines.
However, as far as I can see (and others too, such as Craver (2007, 75-7)) there is no interaction that is
explicable in terms of CQ or MT that occur between the ligand and the receptor.
But these arguments seem less convincing than those originally raised against the MT theory by
Kitcher. We simply do not, in medicine, make, appraise or defend causal claims by discussing the
operations of physical processes. Our causal knowledge of the macro-physical world is not, in this case,
dependent upon arguments about fundamental processes. This argument seems sufficient to licence the
rejection of all three of the process theories (MT, and both variants of CQ) as unsuited for understanding
causality in medicine.
5.4.3 In support of interlevel models of causality
So if an historical reading fails to support the claim that the only real causes are those that operate
at a fundamental level, what is the alternative? I suggest that mechanistic models provide the means
by which non-fundamental phenomena can participate in useful causal models. In fact, I suggest that
most mechanistic models will only provide useful causal models if they deal with the relationships
between non-fundamental phenomena. This is not a controversial claim, at least for the new mechanistic
philosophers (see, e.g. Craver, 2005; Craver, 2007, 11-18). In fact, there may be grounds for arguing
even more strongly than this. Some have suggested that this sort of interlevel aspect of mechanisms is
what grants them any explanatory power at all:
It is the integration of different levels into productive relations that renders the phe-
nomenon intelligible. . .
(Machamer et al., 2000, 23)
I think this suggestion is correct. However, I will need to introduce a few more concepts before I
can clearly say why. I will therefore resume, by justifying this claim, in section 7.2. For now, I will deal
with an important aspect of conceptualising different levels in practical mechanistic models.
So, unlike those accounts that attempt to reduce causality to fundamental physical processes, the
causal models encountered in practice tend to bottom-out in domain-relative fundamental causal inter-
actions. Essentially, within a domain of practice, these interactions are assumed to be causally primitive.
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We can assume this because these kinds of interactions are likely to be the most striking, simple and
immediate kinds of causal interaction experienced in the domain.
This bottoming-out level will be specified in terms of action-oriented and cognitive goals. For
medicine, this bottom is generally at a macromolecular level. Below this, we find interventions and
understanding hard to do. For instance, when we talk about action potentials, we can give a rather
specific causal story about the behaviour of proteins and other large molecules (ion channels, receptors)
but only a rather limited, general one about the micromolecules (ATP, ions). We aren’t really interested
in the details of their individual activities, just their broad trends. We, similarly, tend not to intervene on
these small molecules, instead giving, say, depolarizing agents that act on cell-surface receptors, and so
on. But this neglect of fundamental phenomena is not, to me, a major concern. Even in the case that
there is no necessity or necessary connexion between these low-level events, their obscure operations
still provide the means by which we can reason causally at higher levels. If the mechanism, and hence
our models of it, behaves as if there were fundamental, necessary connexion, even if there is not, then we
do not need to worry about the origins of the apparent connexions that we uncover. For the purposes for
which the causal mechanism is employed, the existence or otherwise of causation at a fundamental level
is irrelevant. That is, even if we do not find a necessary connexion at the fundamental level, mechanistic
models may still provide a vital means of mapping the causal territory. And it is this mapping capability
that forms the backbone of my remaining account of the role of mechanistic models in understanding
causality in medicine.
5.4.4 Levels are context-dependent
The choice of phenomena that should be included in a mechanistic model is highly context-dependent.
This means that there is no objectively necessary or correct level, or range of levels, at which to describe
causal relata. I suggest that this subjective choice of phenomena will be guided, as Russo and Williamson
suggest about causes in general, by both cognitive and action-oriented reasons.
As an example, let us compare the differences between mechanistic model of cervical cancer that
might be found in different contexts. A general gynaecologist needs to know lots of clinical details about
cervical cancer: she needs to be capable of using the model to underwrite diagnosis, treatment, decisions
about prognosis, and so on. But she does not need to know a great deal about HPV itself. Apart from
knowing, for example, some details about which types of the virus confer a high chance of developing
cervical cancer, the manner in which the virus is transmitted, and how cervical cancer is prevented by
HPV vaccination, she does not need to know anything about the mechanism by which the virus acts.
Instead, her mechanistic model should allow her to understand what is happening (and what is likely to
happen) to a particular patient with cervical cancer, and to attempt to either prevent, cure or ameliorate
the disease.
On the other hand, a research virologist will need to causally understand the precise manner in
which the virus acts on cervical cells if he is to understand the viral life-cycle, or to develop new kinds
of specific interventions directed against it. Now this isn’t simply a question of the virologist having
a mechanistic model that is simply more detailed about molecular-level events than the gynaecologist.
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For instance, he would be able to quite safely ignore lots of the clinical details about cervical cancer
that form such an important part of the gynaecologist’s model of the disease. The two models differ in
respect of the degree of detail with which they describe all manner of phenomena, and they do so for
cognitive and action-oriented reasons.
This means that the gynaecologist or the virologist will use their specific causal model of the disease
quite differently from one another. As an illustration, attempting to account for clinical phenomena, such
as a particular visual appearance of cervical dysplasia at colposcopy, in terms of the patterns of protein
expression of HPV is not only a poor strategy for the clinician; it is conceptually incoherent. For one,
the reductionist component of the causal model is temporally removed from the phenomena. Second, the
same essential causal story may result in a wide variety of different clinical problems depending upon
the set-up conditions. Knowledge of how HPV proteins are expressed will not lead the diagnostician to
the correct conclusion about the phenomenological features of the cervical anomaly. Nor does it provide
an exploitable feature suitable for intervention. Instead, a story about the lesion in terms of types of
higher-level causal processes (such as the different appearances of types of cervical tumours) would be
appropriate, because it would lead to cognitive and action-oriented benefits. This suggests that there will
be a degree of incommensurability between the two mechanistic models, even in such closely related
forms of practice. Dealing with this sort of contextualised story about mechanistic models will be key to
my account of causality, and I will address it further below. For now, though, my slogan might be that
accounts of how causes operate at a fundamental level may be not only redundant, but might miss the
point of giving the account at all. The context under which the cause operates is key.
5.4.5 Levels and gaps
As the above suggests, I think that mechanistic models will tend to be gappy. In the case of the differing
models of the gynaecologist and the virologist, these gaps may well arise because part of the causal
process might be irrelevant for their practice. Thus there may well be gaps in the causal mechanism
that are elective. Given a particular context within which these mechanistic models are useful, it is not
the case that the right strategy is to include all known details about the operation of the mechanism in
the world. Instead, salient causal way-points27 are sought that grant the user of the model cognitive or
action-oriented leverage over the kinds of causal scenarios that they encounter in their practice. These
way-points, and considerations of their relationship to practice, then guide the construction of the mech-
anistic model. This employment of elective gappiness is particularly prominent in representations of
mechanistic models that are used for teaching purposes.28 There will very probably be gaps that arise
27‘orig. U.S., a stopping-place on a journey; also, (on an air journey) the computer-checked coordinates of each stage of a long
flight’ (Anonymous, 1989)
28I think it is uncontroversial to suggest that simple mechanisms are easier to teach and to learn than more complicated ones.
However, even the sorts of simplified representations of mechanistic models found in medical teaching materials tend to be very
complicated, and a significant amount of interpolation is required to properly interpret them. This interpolation generally consists
of filling in missing steps in a way that is consistent with background knowledge. The degree of gappiness in representations
will therefore vary, depending upon the intended audience and their likely background knowledge of the causal situation that
the representation deals with. There may be cases, though, where particular causal mechanisms act in a way that is generally
inconsistent with background knowledge. In such situations, representations of mechanistic models may well have to include
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from other sources too. Given the apparent failure of attempts to reduce biomedicine to physics, it must
certainly be the case that we cannot give a full description of the operations of disease in terms of fun-
damental physical phenomena. However, this difficulty in fully explicating causal mechanistic models
may well obtain at other levels too. Simply put, unless we have complete causal knowledge about the
operation of a mechanism, it seems likely that our models of that mechanism will feature gaps that arise
from a lack of knowledge. We might term this obligate gappiness to reflect the fact that it is unavoidable,
at a given state of causal knowledge anyway. While this sort of gappiness may seem troubling, particu-
larly because it seems to threaten the idea of productive continuity, I do not think it really presents any
particular problem other than those practical ones that arise from the missing knowledge itself. After all,
the gaps affect the mechanistic model, rather than the mechanism. One way that we can prevent missing
causal knowledge from threatening the utility of mechanistic models is by carefully constraining their
scope. This we do by functional definition.
5.5 Functional definition
As I suggested earlier, I am broadly realist about ontological mechanisms. That is to say that I think
that mechanisms in the world are composed of mind-independent things that causally interact with one
another in a manner that does not necessarily require, say, human agency in order to come about. Thus I
claim some sort of objective existence of mechanisms. But this is not to say that I claim the same thing
for our models of mechanisms, or our representations of them. In fact, quite the opposite: I suggest that
models and representations of mechanisms are context-dependent. As Glennan suggests, mechanisms
are behaviourally polymorphous, meaning that a single (ontic) mechanism may display a number of
different (epistemic) behaviours that we might model. Likewise, each behaviour may have, as its cause,
a number of different mechanisms. Thus the specification of mechanistic models will have to specify
just which behaviours, and which ontic mechanisms for the behaviour, they are going to employ if they
are to be adequate.
I suggest that this issue means that we require a process of functional definition when we build
mechanistic models. The question ‘what is the mechanism for x’ is only answerable when we define
which aspects of the ontological mechanism it is that concern us. More specifically, we need to define
our mechanistic model in terms of a carefully contextualised concept of production. So our mechanistic
model for x must (and can only legitimately) be construed as the model that describes how x causally
comes about. The process of contextualising the model fairly tightly constrains the sort of range of
background (and possibly unknown causal factors) over which the mechanism is thought to act. This,
then, is the broad phenomena that accounts for the differences between causal models of the same disease
in different disciplines (section 5.4.4). That section was intended to demonstrate that mechanistic models
are context-dependent. This section is designed to show how this happens.29
In the case of models (or representations) of medical mechanisms intended for clinical use, this will
generally require a consideration, not only of the specific pathological routes that come together to form
some information about just why general background knowledge is a poor guide to understanding the missing steps.
29I think that a similar functional specification occurs when it comes to making representations of these models, too.
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a productive continuity in producing the disease state, but will also require consideration of the relevant
physiological, diagnostic and interventional pathways as encountered in practice. As an example, a
clinical mechanism for cervical cancer might feature a number of HPV-dependent mechanistic routes
that lead to cervical cancer. For instance, we might take common routes as those that ‘go’ via infection
with HPV-16, -18, -33 and -35 (in the UK, at least). But in addition to these routes, there will also
be a number that do not include these entities, but that still lead to the disease state. As none of these
HPV types is a necessary cause of cervical cancer, it will be the case that many instances of the disease
come about without infection with one of these high-risk types. This means that a model mechanism
for cervical cancer intended for clinical practice necessarily includes the consideration of other causal
routes that eventually lead to cervical cancer. Similarly, as none of these types are sufficient to cause
cervical cancer, our clinical mechanism will also need to include causal routes that do not end in cervical
cancer. In fact, as I will go on to suggest, I think that mechanistic models of a particular disease state
need to include, in order to be intelligible in clinical practice, some mechanistic consideration of the
normal physiological processes that would otherwise obtain.30
Now this inclusion of physiology might well not apply in mechanistic models employed by research
virologists. In other words, the domain of intended enquiry is likely to change the precise specification
of the mechanism. So functional specification will be highly context dependent. The functional spec-
ification of a typical therapeutic mechanism for cervical cancer will be much thinner than a research
mechanism. This process of specification will demand modelling phenomena at different levels of or-
ganisation, describing the relations between these levels differently, including or excluding measures of
uncertainty, prioritising different parts of the mechanism and so on. Functional specification, as well
as the earlier concerns about levels, suggest that it is meaningless to talk of the mechanism for cervical
cancer simpliciter. Why? Put another way, why can we not simply construct the unified mechanistic
model for a particular disease, produce a suitable representation of it, and refer to this canonical text
when we need to think mechanistically?
Leaving aside the (very important but shallow) practical questions regarding our lack of knowledge
of most disease states, there are a number of more profound issues that such a unified approach raises.
For instance, if we were to try and construct such a meta-representation, it might very well be the
case that different parts of the mechanism would be incommensurable, as I suggested in section 5.4.4.
For example, general gynaecologists may rely on a model of cervical cancer that depends upon certain
properties of HPV. Yet the properties of HPV in this general gynaecological model might well be very
different from those found in a model of cervical cancer used by virologists. HPV might be a rather
different entity31 or might have different activities32 in each of the two models. Finding out just which
way we should functionally specify our mechanistic model in a particular context will require a suitably
contextualised account of evidence of difference-making, and I will therefore give a fuller account of
30In medical education, learning physiology traditionally antecedes learning about pathology. Perhaps this is the reason that so
many disease states are conceived in terms of deviation from the normal physiology. Or perhaps this is the cause of the organisation
of medical school.
31For instance, in the discussed details of viral protein expression
32For instance, in the manner in which these viral proteins act on different cellular machinery
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this in the final chapter.
For now, though, I will move on to develop my suggestion that mechanistic models tend to display
a characteristic branched morphology. This structure is a possible means of understanding just how
difference-making evidence helps us when we come to functionally specify a mechanism.
5.6 Branching and track-switching
5.6.1 Introduction
One very important aspect of mechanisms that has been previously neglected is their ability to represent
the sorts of branching relationships that play such an important part in the cognitive and action-related
roles of causal relationships. This has critical ramifications for the use of mechanistic models as a
component of the expanded RWT. In outline, branching arises from the fact that some causal entities
have a range of possible activities, and that expression of these activities may depend upon the causal
antecedents of the entities.
Let us take the insulin-secreting β-cells of the endocrine pancreas as example entities for a study of
this branching behaviour. They have, depending on the particular situation, a range of different activities.
The first of these is to secrete insulin at a rate determined by the concentration of glucose in their afferent
blood supply. Note that the rate of insulin secretion is not a simple dichotomous variable. Instead, the
rate of insulin secretion appears to be a differential function of the momentary concentration of blood
glucose within certain bounds. Thus this continuous variable is one set of activities of the islet β-cells.
Put another way, it is not the case that these entities either act, or do not act. Rather, their activities
(in this case, the rate of change of insulin secretion) are determined in a continuous way. However,
depending on the particular functional specification of our mechanistic model, we may find it more
convenient to discretise such continuous variables. So we might - fairly arbitrarily - divide the variables
blood glucose and rate of insulin secretion into ’high’ and ’low’ classes. In this simple case, a high blood
glucose concentration would instantiate the islet β-cell’s insulin-secreting activity at a high rate, while a
low blood glucose would produce the opposite effect. Thus these activities would be the normal set of
activities produced by these entities. Thus, this is a simple example of mechanistic branching.
But these β-cells may also have other activities which they do not generally express. For instance,
the cells may - given certain antecedent conditions - violate this proportional relationship between blood
glucose concentration and rate of insulin secretion by secreting insulin at an inappropriately high or
low rate. So, for example, if these cells were caused to form an insulinoma,33 they would exhibit an
extremely high rate of basal insulin secretion, irrespective of the glucose concentration in their blood
supply. Or they might, for some reason, fail to produce sufficient insulin and thus cause diabetes. All of
these activities are those of the islet β-cells. So what is the difference between them?
33A kind of functional tumour of the islet β-cells
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Figure 5.5: Simple physiological mechanism
5.7 Two kinds of effects
I think there is a clear differentiation between these two sorts of effect. The first, which I will refer
to as a sequence effect, is achieved by the particular route taken through the mechanism. That is, this
range of effects occur as a consequence of the mechanism operating normally, and are predictable given
the normal set-up conditions that apply to it. In the example above, the range of effects on the rate
of insulin secretion seen during normal homeostatic control of blood glucose would be instances of
sequence effects. The second sort of effect, which we might call a setting effect, concerns a disruption of
the way that the mechanism normally operate. Setting effects are different from sequence effects because
setting effects alter the pattern of subsequent sequence effects. In the example above, the development
of an insulinoma or diabetes would be setting effects.
As an even simpler illustration of the difference between sequence and setting effects, a sequence
effect would be that sort of behaviour that we might find if we were to operate a toaster in the normal
manner. This sort of pattern is characterised by consistency between different instantiations, in that we
would expect a similar effect to obtain each time we insert the bread and depress the lever. We would
not expect a given sequence effect to change the operation of subsequent instances of that effect. On the
other hand, the effect of changing the settings on the toaster would be a setting effect. This would then
have the effect of changing subsequent sequence effects - by, say, increasing the degree to which our
bread becomes toasted. While both sorts of effect are intelligible under this conception of mechanism,
it is setting effects that are really significant for branching. It is branching because of setting effects that
shows us just how disease states are different from normal physiology. It is setting effects too that suggest
the means by which we might effectively intervene in disease states. Think of a simple mechanism that
might be used to represent a physiological causal process that results in the production of some sort of
normal, physiological factor D (figure 5.5).
Say we then discover an individual in whom this mechanism appears disrupted - say, by them ex-
pressing D’ instead of D. Here, we know that an individual has D’, but not how, or why, this obtains.
Figure 5.6 represents such a situation, where an anomaly (D’) is presented, alongside the normal physi-
ology of this situation.
To find out how and why an individual has D’, we might then try to discover the mechanism that
leads to D’-disease. We might find, in our single patient with D’-disease, that they also have two further
anomalous entities B’ and C’ which appear to antecede D’. We might also find out about the activities
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Figure 5.6: Mechanistic model of simple physiological mechanism with D’ anomaly
of B’ and C’. Thus we can construct a partial mechanism for D’-disease that relates it to B’ and C’
via activities β’ and γ’. We can relate this partial mechanistic model for D’ disease to the relevant
physiological mechanism for D (figure 5.7).
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Figure 5.7: Mechanistic model of simple physiological mechanism, with partial mechanistic model for
the D’ anomaly
They then discover that B’ arises from A (figure 5.8). This then gives a partial explanation of how
D’ comes about. However, in order to explain why this happens, we need to attempt to discover just why
A has this divergent set of activities, α and α’.
This divergence of A’s activities is modelled experimentally, and is noted to be affected by the
actions of three antecedent entities, X, Y and Z, and their associated activities on A, χ, υ and ζ. Certain
combinations of these factors seem to cause A to do α, while others produce α’. Let us say that χ and υ
causes A to α’, while ζ causes α. In other words, χ and υ are promotors of α’ at A, while ζ is a promotor
of α (figure 5.9).
So far so good. Entities X, Y and Z act on A via their specific activities to produce two possible
A-activities, α and α’. In turn, these activities cause either the normal physiological mechanism, or the
pathological mechanism that produces D’. We can use this branched mechanism for a range of purposes.
It is a knowledge of the setting effects on A that tell us how D’ disease comes about. This knowledge
provides us, first, with cognitive tools for understanding D’-disease. We can understand what is likely to
happen in other cases of possible D’-disease. We can also employ it to develop an intervention, I, against


























Figure 5.9: X, Y and Z as causes of divergence at A
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D’-disease. We might, for example, choose to prevent X or Y becoming instantiated, thus preventing
their χ-ing or υ-ing A (figure 5.10). This blocks the α’-ing of A and thus prevents the instantiation of the


















Figure 5.10: Preventing D’ by preventing X and Y by intervention I
But this example hints at important non-mechanistic considerations that are required to interpret
branching. How, for instance, do we know the effects of X. Y and Z on A in the two populations, D
and D’? I will therefore return to this issue in chapter 7. For now, though, I will consider the role of
branching behaviours in rather special circumstances: that of explaining causation by omission.
5.8 Preventions and omissions
The objections to negative causation of some kind are well worn (see, e.g. Aronson, 1971; Fair, 1979;
Lewis, 1986, 189ff; Dowe, 2001). The essential problem is this: how can a cause that is a negative event
instantiate an existent event? Take the following example, which is due to Beebee:
Flora normally gratuitously waters her neighbor’s orchids. But she stops watering them,
and they die. Common sense judges that Flora’s omission was a cause of the orchids’ death,
since had she watered them, as she usually does, the orchids would not have died.
(Beebee, 2004, 294)
However:
Common sense intuition identifies Flora’s failure to water the orchids as a cause of their
death, but not the failure of the other neighbors, and certainly not the failure of people on
the other side of the world who neither know nor care about the orchids - even though it is
perfectly true of each of them that had they watered the orchids, they would not have died.
(Beebee, 2004, 295)
This issue affects many theories of causality, including counterfactual theories, processes and regu-
larity. Mechanistic theories are no exception, as Craver suggests:













Figure 5.12: Negative causation example 2
. . . in cases of omissions and prevention. . . there is no hidden connection between the
cause and the effect. Such causes work by absences and gaps in connections. . .
(Craver, 2007, 64)
If we admit one absence as the cause of a particular event, then we appear forced to admit a whole
range of similar absences as causes also. This appears intuitively unappealing. Can we clarify the
situation by using a representation of the relevant mechanistic model for this situation? I do not think we
can. Let us consider a mechanism for Beebee’s example (figure 5.11).
This represents the happy default state. Helen waters the orchids, which survive to bloom another
day. So far, so good. What happens when she fails to water them is outlined in figure 5.12. Here, the
orchids die because of Helen’s failure to water them. But they also die because of the failure of any other
individuals (for instance, Alfred, Bruce, Cleopatra, Davina and so on) to water them either (figure 5.13).
But these individuals seem, somehow, to be less causally responsible for the death of the orchid
than Helen. In this example, Helen customarily watered these plants, while the other individuals did
not. Thus there is some violation of normality that seems to make Helen responsible, and not the others.
As Beebee admits, there are a number of similar contrastive relations that seem to act similarly in other
cases of, intuitively appealing, negative causation:
So it seems that common sense singles out an absence as a cause when, and only when,
it stands out in some way - either from what normally happens, or from some norm of which
the absence (generally an omission) counts as a violation. The norm might be moral, legal
or epistemic. . . but other sorts of norm may well play a similar role.
(Beebee, 2004, 296)
So far so good. Thus we may be able to save these sorts of problems by reference to some sort of
norm. But this solution raises a further problem, in that it makes the analysis of causal claims critically



























Figure 5.13: Negative causation example 3
depend upon these rather fuzzy normative conditions. This, as Beebee suggests, presents formidable
metaphysical problems. I think that it raises more immediate problems too. In the spirit of the rest of
this piece, I will therefore focus almost exclusively on the epistemological and methodological aspects
of this issue. This means that I need either give some improved account of what these norms are that
allows reliable causal assessment and inference, or I must abandon the idea of accommodating negative
causal relationships.
I think the second option is impossible. If we wish to produce a theory of causality that can be
useful for understanding medical causes (and I do), we have no option but to commit to negative causes.
Even the most cursory study of causality in medicine suggests that negative events play an important role
in causation. For example, many therapeutic strategies rely upon negative events to causally intervene.
So we might attempt to reduce the incidence of HCC in a population by initiating a programme of
population vaccination against HBV.34 Similarly, negative causes play a vital role in causal inference in
medicine. This was recently stated in a very clear fashion as ‘sublata causa, tollitur effectus’ (Vonka,
2000, 1835), which we might rather crudely translate as ‘The effect ceases when the cause is removed.’35
For example, the prevention of HCC by vaccinating against HBV tells us something very useful about
the causal structure of this case. For example, seeing any such reduction in incidence suggests that HBV
34I discuss interventions of this sort in more detail in 7.1.
35This sentiment apparently derives from the work of St. Thomas Aquinas. Yet I can find no direct instance of it in the works of
the Saint. It certainly occurs in Kant at 28.573 in the Metaphysik L2: ‘. . . when the cause has been canceled, the effect is canceled
“sublata causa tollitur effectus” (Kant, 1997 (1790, 336)
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really does cause HCC - assuming that nothing else about the vaccination could potentially account for
the effect. For instance, it might be that the vaccination campaign was carried out as part of a wider
public health campaign against HCC, with surveillance measures, public engagement, actions against
other risk factors and so on. Assuming that this relationship was not so confounded, the reduction seen
in HCC incidence following such a specific intervention would also tell us a great deal of quantitative
information about the causal relationship between HCC and HBV. For example, we might be able to
estimate the proportion of HCC that was attributable to infection with HBV. From these two sorts of
claims about negative causality, and the prominent role negative causes of one sort or another play in
the medical literature, negative causality appears at least as important as positive causality for medical
practice.
This seems to be the basis of Russo and Williamson’s distinction between aetiological and ther-
apeutic causes (Russo and Williamson, 2007, 157). Here, the process of assessing aetiological causes
is concerned with those mechanisms (or components of mechanisms) that are sufficient to produce a
particular state. Therapeutic causes, on the other hand, are concerned with necessary causation. Very
often, therapeutics attempt to intervene on a mechanism in order to prevent the (pathological) effects by
preventing a necessary, rather than sufficient, part of a mechanism.
These considerations therefore commit me to incorporating negative events as causes in my scheme.
I will therefore have to try and develop this contrastive position here. While the full description of this
issue will have to wait (for section 7.1), I can give a brief outline here. My account depends on three
things. First, adequate functional specification of a mechanism. Second, the property of branching/track-
switching that I suggest above. Third, the role of difference-making evidence. With these three things in
place, scenarios of negative causation become rather more simple to understand.
Think of a correctly functionally specified mechanism for an event. As I suggested, disease mech-
anisms generally need to be specified in terms of a system of conceptually related outcomes. Changing
a positive cause (Helen watered the orchid) to a negative (Helen did not water the orchid) should be
understood as a divergence of activities at a given entity. Thus the one entity (Helen) has two possible
activities (waters/does not water) as part of this specification.36 Thus when she fails to water the orchid
in a particular time-frame, the mechanism switches to the track with Helen’s does not water activity as
its causal parent. We then have to exclude the manifold non-waterings of other possible orchid water-
ers (Alfred, Bruce, Cleopatra, Davina. . . ). The details of this exclusion depends upon the way that we
integrate difference-making evidence with our mechanistic structure. Thus the job of the next two chap-
ters will be to introduce such an account of difference-making, and then to show how mechanisms and
difference-making can be integrated. However, briefly, I suggest that we can happily ignore the negative
actions of our other possible-waterers because as individuals they make very little difference to the ulti-
mate effect. While this means, say, that the set of possible-waterers are collectively responsible for the
death of the orchid, because overall they failed to prevent it, they are individually such weak causes of
the effect that we can, in general, ignore them. In other words, difference-making evidence tells us that
36In fact, she may well have many more than two possible activities (over-waters/waters correctly/under-waters/does not water).
But I will leave this complication aside for the moment.
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their (in)actions are not salient to the functional specified Helen-orchid mechanism. Absences do not
mean that the productive continuity of a mechanism ceases. They instead mean a change in the routes
taken through a functionally specified mechanistic structure.
5.9 A definition of mechanisms for the Russo-Williamson Thesis
By means of concluding this chapter, I would like to suggest a definition of both mechanisms and of
mechanistic models suitable for the RWT.
Mechanism: a mechanism is an actively organised set of activities and entities, productive of one
or more behaviours, amenable to investigation and description.
A few words of explication are in order here. First, as per MDC’s account, active organisation is
the key characteristic of mechanisms. Only actively organised sets of entities and activities can form a
productive continuity, and it is the possession of this productive continuity that permits mechanisms to
produce particular behaviours. Usually, mechanisms are polymorphous, or productive of a number of
different such behaviours. In other words, the mechanism for x will often do y and z also. Mechanisms
are dualistic: both activities and entities are necessary participants, and neither activities nor entities
have any kind of priority over the other. Finally, as the benefits that thinking about mechanisms arises
from our ability to describe them, unknowable-in-principle mechanisms - if such things exist at all - are
excluded from this definition.
There are a few additional characterisations that I might suggest for medical mechanisms: these
tend to be interlevel - that is, relate the operation of phenomena that are disparate in terms of scale - and
display a characteristically branched structure. This comes about because medicine is often concerned
with the manner of divergence of a diseased state from a healthy, physiological state.
Together, this definition of a mechanism suggests a further definition, that of an epistemic model of
a mechanism:
Mechanistic model: a dependable, context-sensitive representation of a mechanism, such that the
model connects both cause(s) and effect(s) of interest. This model should be capable of being integrated
with other forms of evidence, in particular those that are descriptive of the overall relationship that
obtains between cause(s) and effect(s) in particular circumstances. If this model displays a branched
structure, it should include both structural details of these branching points, and some consideration of
the antecedent events that cause the mechanism to follow one or other subsequent paths. Together, this
mechanistic model should be capable of accounting for the common behaviours of the mechanism in
defined circumstances that form the contextual descriptors, including those events that obtain via the
prevention of the normal operation of the mechanism.
These definitions will form the basis for subsequent discussions of mechanisms and mechanistic




In this chapter, I will explore the relationship between evidence and causality. I will try to clarify a
number of concepts that I have previously employed rather loosely. What sorts of evidence do we
encounter in medicine? Can we legitimately make Russo and Williamson’s distinction between evidence
of mechanism and of difference-making? What constitutes evidence of mechanism? What is evidence
of difference-making? How might we characterise them?
I will begin with McKay Illari’s recent disambiguation of evidence in the RWT. This will then
suggest a number of avenues of inquiry that I will explore using my viral oncogenesis examples. Here,
I will show that the distinction drawn between mechanistic and difference-making evidence in the RWT
is historically and theoretically tenable. I will also suggest that the sorts of evidence that are important
for causation change chronologically, and that these chronological changes can be characterised in terms
of the precise aspects of causal models that are being developed at the time. I will relate this to the
model of discovery that I outlined in section 1.3. I will then move on, in section 6.4 to attempt a general
characterisation of mechanistic evidence. While doing this, I will digress slightly in order to make a few
remarks about the two unusual forms of evidence that arise from plausibility and analogy, and which
played a central role in supporting mechanistic claims in the historical examples. I will then turn to
discussing difference-making evidence. What constitutes this, and which strategies are effective means
of generating it? What sets this form of evidence apart from evidence of mechanism? I will illustrate
with some examples from the EBV and HPV cases. I then plan to introduce the reference class problem
(RCP), and its relationship to evidence of difference-making. I will suggest a possible means of tackling
the RCP that relies on the use of mechanistic models. This, I suggest, also presents a means by which we
can seek to unify evidence of difference-making with evidence of mechanism. Briefly, I suggest that we
can satisfy the reference class rule (Salmon et al., 1971) by employing features of mechanistic models.
This claim will set the scene for chapter 7, where I will demonstrate the means by which evidence of
mechanism and of difference-making can be integrated in support of causal claims in medicine.
A note on terminology at this point. From now on, I will adopt the term causal models to represent
RWT-type epistemic devices which are supported by both mechanistic and difference-making evidence.
These are clearly different from mechanistic models, in that they are supported by relevant evidence of
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difference-making.
6.2 Two types of types of evidence
McKay Illari (McKay Illari, 2010) makes an important distinctions about mechanistic evidence.1 The
essence of her claim is that, when we think about causal evidence, we need to distinguish the type
of evidence from the object of our evidence. Put another way, there is a difference between kinds of
evidence and kinds of things we have evidence of. We might illustrate this by an example. We might
gather evidence about the structure of a virus. But we should distinguish the evidence as type of evidence
(for example, arising from X-ray crystallography on protein crystals) from that evidence as evidence of
the structure of the virus. McKay Illari argues, not only that these two things are independent, but also
that the RWT only supports one of them. What the RWT requires, argues McKay Illari, is evidence
about kinds of things. That is, to evaluate a causal claim we need to have evidence that tells us about
both mechanism and difference-making as objects of evidence. The RWT is often read as supporting
a thesis about types of evidence, but McKay Illari suggests it should be interpreted as addressing the
objects of evidence.
In fact, McKay Illari suggests that it may be impossible to make the mechanistic-probabilistic dis-
tinction upon evidence as it is gathered, because the two forms of evidence may arise simultaneously:
It is in principle possible that a single experiment could establish a causal claim. Psycho-
logical work on small children investigating simple mechanical toys shows that they come
to an accurate picture of the causal structure very quickly, particularly if they are allowed to
manipulate the mechanism themselves. . . Using the framework, we can say that they acquire
both evidence of difference-making (by seeing, say, that wiggling a lever moves a wheel)
and evidence of mechanism (say, by observing the attachment of the lever to the wheel)
almost simultaneously.
(McKay Illari, 2010, 7)
She further supports this claim by arguing that our failures of classifying evidence as gathered result
from the fact that doing this fails to pick out the features important to its use in causal inference. I think
this is quite correct, and I will support a similar claim in section 6.4. Looking to characterise mechanistic
evidence by simple methodological features does not work.2 After all, the role that a piece of evidence
plays in making a causal model of a mechanism is relative to the specification of that model. However,
once this consideration is taken into account, it is possible to characterise, to an extent, mechanistic
evidence by giving general descriptions of the kinds of causal facts that it is evidence of.3 So I here agree
1She makes a number of further clarifications too, but I will concentrate on this one here
2McKay Illari suggests a range of possible distinctions on evidence as gathered. These include distinguishing evidence on the
grounds of it being either qualitative or quantitative, relating to generic relationships or single cases, or as necessarily requiring
repeated trials versus requiring simple confirmation only.
3I later characterise mechanistic evidence in terms of the kinds of causal facts that it tells us about. These are activity-
description, entity-description, activity-of and entity-of descriptions and interactivity-description
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with McKay Illari that it is only by considering the role that various bits of mechanistic evidence play in
making mechanistic models that allow us to characterise them.
I will follow McKay Illari’s terminology, too. She suggests that we should carefully distinguish
between evidence as gathered as compared to evidence describing particular types of thing. By this
distinction, mechanistic evidence (ME) and difference-making evidence (DME) are defined by the man-
ner in which they are collected, while evidence of mechanism (EM) and evidence of difference-making
(EDM) are characterised by the sorts of relationships they describe. By means of illustration, consider
the following example. Say we are investigating the aetiological relationship that might obtain between
infection with a virus, and the development of a particular clinical syndrome. We can distinguish the
following types of evidence:
Mechanistic evidence (ME): evidence that is gathered in a way characteristic of mechanistic in-
vestigations (see, for example, Darden, 2006). In this case, we might try and form a methodological
characterisation of such evidence. This might include evidence arising from electron microscopy, from
animal experiments, or from studies on viral replication in cell culture. We might then seek to form
generalisations about mechanistic evidence: we might say that it is generally qualitative, that it generally
does not require repetition in order to be significant, that it generally concentrates on the operation of
micro-level processes, and that it generally arises from laboratory investigation, for example.
Evidence of mechanism (EM): evidence that tells us about the particular mechanism by which the
virus mechanistically acts to cause the disease. For example, we might find that the virus attacks certain
types of cell, thereby causing them to rupture, in a way that explains particular features of the clinical
syndrome (say, the presence in the blood of particular cellular components). We might then be able
to characterise this evidence in a contrastive way from that characterisation of mechanistic evidence:
evidence of mechanism tends to address the manner in which particular causal processes are organised,
for example. I will return to this characterisation later in this chapter.
Difference-making evidence (DME): as with ME, we might characterise difference-making evi-
dence in terms of the way in which it is gathered. Examples of difference-making evidence in this case
might include observational trials that attempt to find a correlation between infection with our virus of
interest and the development of the relevant disease, or an interventional trial that attempts to discover
what happens to the clinical syndrome when an effective vaccination against the virus is given to a pop-
ulation. This might lead us to suggest general qualities of such evidence: that it is often quantitative,
that it concentrates on the relationship that obtains between the cause and the effect, or that it generally
arises from population-level investigations on the phenomenon of interest.
Evidence of difference-making (EDM): finally, evidence of difference-making tells us about the
particular difference that our cause makes to our effect. Here, we might find that infection with the virus
accounts for only a proportion of our clinical syndrome (suggesting the operation of other difference-
makers), or that our clinical syndrome is just one of several different individual-level effects of infection
with our virus (suggesting the operation of other pathogenic mechanisms resulting from infection with
the virus for future investigation).
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6.3 Evidence in the cases
I propose to give a rather illustrative, chronological account of causal evidence in this section using the
EBV case. How does evidence for causality arise, and how does this evidence alter our causal model? I
will use the distinct periods of causal discovery that I first applied to the case studies to distinguish the
changing types and uses of evidence as they come about. To recap from section 1.3: while discussing the
EBV and HPV case histories, I suggested that four stages of causal inference were apparent. First, each
story began with the suspicion that some sort of stable, causal system was responsible for producing the
disease in question. Next, the causal domain of this system was sought. Understanding the structure of
this system then comprised the next step, mechanism construction. Finally, this new causal model was
applied in a way that attempted to cast cognitive and therapeutic light on the disease. In the following
section, I will attempt to give an evidential characterisation of these four periods. With the exception of
the very earliest stage, I will also relate these general features of causal discovery to the RWT.
6.3.1 Evidence and the suspicion of causes
I suggested earlier that this phase of causal discovery is essentially characterised by the suspicion that a
particular clinical phenomena might arise as the result of some kind of discoverable causal mechanism.
In large part, this entails showing that a particular set of clinical findings arises because of the operation
of some sort of stable disease mechanism.4 In the EBV case, this phase essentially consists of Burkitt’s
initial clinical description of the lymphoma syndrome, and the rather speculative claim that these clinical
findings came about as a result of some kind of (potentially interpretable) causal mechanism. This phase
is, essentially, a process of syndrome recognition. A small number of clinical features - symptoms, signs
and investigation results5 - were noted to occur in regular association, and it was this regularity of co-
association that suggested the operation of a stable causal process. This is the rudimentary outline of
what it means to suspect a cause. As such, I will not give an RWT-compatible description of what it
means to suspect a cause.
I will give a more detailed account of this process in the EBV case below. While I suspect a similar
thing happened in the cervical cancer example, the details are rather more opaque, occurring as it did
in the poorly documented prehistory of medicine. However, elements of this suspicion are to be found
in the early accounts that differentiated cervical from uterine body tumours (section 3.1.1), and in those
early publications that attempted to detail the behavioural peculiarities of those social groups at high risk
of developing the disease (section 3.2ff). Given these historical difficulties, I will focus on the EBV case
for the sake of clarity.
What is the first part of the story? Burkitt first observed one child with an unusual jaw tumour
which could not be easily explained by a known clinical syndrome. However, he did not yet appear
to regard this single case as an anomaly in need of explanation. He instead - initially - treated it as a
simple curiosity. It was not until the discovery of a second, very similar case, that these observational
4This point is rather obvious, but it can be a significant part of understanding disease causation. For example, in the McArdle
case, the vital finding that this set of apparent symptoms were real, rather than spurious, and that they occurred as the result of a
disease state took a great deal of investigative effort.
5For reasons of clarity, I will generally refer to these sorts of clinical findings as symptoms
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findings began to suggest the possibility of a causal explanation. There is some historical support for this
claim. For example, Burkitt very clearly described the psychological differences from seeing the first two
cases. While the first was ‘baffling’ (Burkitt, 1983, 1777), it was not until he saw the second case that his
‘. . . interest was rivetted immediately’ (Burkitt, 1983, 1778). This suggests to me that it was not simply
the novel and unusual features of either of these two cases that made them interesting. It therefore
seems incorrect to claim that the psychological impact of either of these anomalous individuals alone
was responsible for suggesting the operation of an interesting causal process. Yet I also do not think that
this case represents a good demonstration of the psychological power of Humean constant conjunction.
Finding a group of odd symptoms together more than once plausibly suggests the operation of a common
causal process.6 But in this case I suggest that it was not simply some kind of psychologically impressive
induction across these cases that led to the search for a (causal) explanation either. It was, instead, the
novelty of the purported syndrome, rather than that of the single cases, that did the work of surprising
Burkitt.
I can provide some further support for this claim. Induction over cases alone appears historically
insufficient to explain the way that events came about. Both Burkitt and others had previously noted the
high incidence of unusual jaw tumours at Mulago without previously coming to the conclusion that they
constituted instances of a particular syndrome in need of causal attribution (see section 2.2.3). Similarly,
many other authors reported individual cases of these odd jaw tumours that they did not subsequently
go on to investigate further. Now this seems troubling, and in need of some explanation. I propose to
account for this difference between Burkitt and his contemporaries by drawing a (causally important)
distinction between a clinical syndrome as opposed to a group of cases.
This term clearly needs some elucidation. I suggest that a syndrome is best interpreted as a dis-
tinctive, evidentially complex clinical entity that occurs in a phenomenologically regular manner. This
is a definition that does not necessarily depend upon knowledge of or about an underlying causal pro-
cess. Down syndrome, for example, was known and phenomenologically well understood for some 90
years before its causation was understood at all (Down, 1866; Lejeune et al., 1959; Einfeld and Brown,
2010). However, the regularity with which the features of a syndrome co-occur does serve as evidence
of the possibility of some common cause. But I do not think that this regularity can be used to ground
the syndrome-cases distinction. Instead, the difference between sets of symptoms and syndromes is a
methodological one which arises from the differing way in which they are clinically recognised.
Syndromes are not simply aggregates of symptoms or other clinical findings. Indeed, trying to
firmly construct definitions of syndromes by groups of symptoms is likely to be problematic. Part of
this difficulty comes from the subtlety of features of the syndrome that may play an important role in
the diagnostic process, as I go on to explain. Further aspects of this difficulty might also arise from the
lack of clear necessary or sufficient relationships that symptoms and syndromes share. I suggest that it
is usually the case that no particular symptom is a necessary component of a syndrome. Likewise, there
is generally no symptom that is sufficient evidence for a syndrome.
6Generalised Reichenbach common-cause principle
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Yet here is the paradox: syndromes are distinctive in a way that sets of symptoms are not, and it
is a relatively unproblematic business to detect a syndrome in a particular individual, even though our
understanding of what - symptomatically - constitutes a syndrome is so weak. The Diagnostic and Statis-
tical Manual (DSM) provides a good operational example of this distinction.7 A study of this diagnostic
manual for psychiatry reveals a relatively small number of atomic symptoms or clinical findings that
can be used in the diagnosis of psychiatric disease. More interestingly, most combinations of symptoms
do not fall cleanly into one particular diagnostic category. Thus the business of making a diagnosis by
making a list of symptoms and then comparing the list of symptoms to the DSM categories is likely to
bring up a list of a great many possible diagnoses. Yet typically the diagnosis of, say, depression is not
problematic in this respect in clinical practice. In fact, confirming a suspected diagnosis by referring to
the features in the DSM may show a rather good fit between observed and required symptoms. How can
this be the case?
I suggest that the best candidate for explaining this apparent difficulty is to consider more subtle
features of clinical syndromes. While, say, the manner in which an individual avoids or prolongs eye-
contact may be quite plain to the observer, recording this manner may yet prove rather challenging. That
is, syndromes may have evidentially important phenomenological characteristics that defy analysis. It
may be that these features are temporally inconvenient (say, very short duration facial movements), that
they are apparent in a sensory modality which lacks a good descriptive vocabulary (sound and smell,
for example),8 or that they are only suggestive of the syndrome when seen in collaboration with other,
similarly subtle, features and so on. Rather as you might find it hard to describe which features allow
you to recognise an old friend at a distance, in low light or over a poor quality telephone line - yet it is
easy to know who it is - the actual evidence used to recognise a syndrome may well differ dramatically
from our representation of that evidence.
So I do not mean that these bits of evidence that support the recognition of a syndrome in an
individual are in any way ineffable or unknowable. It is just that these features may well be unlikely
to survive the translation to their conventional written, pictorial or numerical representations. In other
words (perhaps like the old friend) the instances of a syndrome ‘smell’ the same, and are not simply
examples of similar clinical findings. They are instead something that is indicated by the recognition of
obscure, poorly-characterised symptoms. Thus, when only the clear and present symptoms are recorded,
the discovery or diagnosis of a syndrome appears to assume the form of a gestalt recognition.9
7The DSM (American Psychiatric Association, 1994) lists a great many psychiatric conditions, along with a list of clinical
features. Diagnosis - according to the manual - can be achieved by meeting a certain number of diagnostic features of the disease.
Its construction and use in clinical practice are currently rather controversial.
8The terminological confusions that surround the written and pictorial representations of lung sounds are an excellent example
of this fragility. It may be the case that there are other reasons that important features of syndromes are difficult to represent. For
instance, certain conditions are associated with embarrassing, yet diagnostically distinctive, symptoms. It may be the case that
clinicians are reluctant to investigate or describe these symptoms for fear of upsetting patients. For instance, sufferers of isovaleric
acidaemia have a characteristic smell, which is said to resemble sweaty feet, or old socks (Tokatli et al., 1998).
9I use the term to indicate that the recognition that something might be a syndrome, or that an individual might have a particular
syndrome, appears to occur as a whole. As I have suggested, though, I think we can consider more specifically the pieces of
evidence that contribute to this process. However, the representational constraints in play may complicate the business of speaking
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This tension between the evidence used, and the representation of the evidence used, has a possible
origin in the professional conventions of medicine. Representations of evidence, learned as part of
medical training, constrain the sorts of evidence that are discussed when it comes to discussing diagnoses.
But they do not necessarily constrain the evidence considered when the clinician is actually making a
diagnosis. In fact, there is a tension here in what is learned at different parts of medical training. While
the formal representations of clinical encounters serve to negatively constrain the types and manner of
evidence used, the way that clinical training actually occurs seems to facilitate just such tacit evidential
considerations. The many years spent, under supervision, interacting with patients, attempting to make
diagnoses and comparing physiology with pathology in manifold ways serves to familiarise the clinician
with these gestalt features of disease in a way that learning lists of disease features would not. It is
familiarity with patterns of disease that grant a clinician diagnostic skill. In turn, I think that it is highly
likely that this profound familiarity with the patterns of disease not only leads to diagnostic competence,
but also grounds the possible recognition of syndromes.
Recognising something to be an novel anomaly in need of explanation necessarily requires syn-
drome recognition. Simply meeting an individual with an odd set of symptoms remains utterly unre-
markable,10 and is unlikely to provoke the sort of response that happened in the BL case. Put another
way, symptoms do not tend to provoke research, while syndromes do. As with Kuhn’s description of
anomaly recognition (section 1.3), this recognition of a novel syndrome as a prompt to research is not an
inductive process. For example, McArdle (McArdle, 1951) was prompted to carry out extensive inves-
tigations on the basis of a single case. Why it took Burkitt twice as many cases seems unimportant. In
any case, carrying out a useful induction from two samples seems almost as risky as that from the single
case.
In conclusion, how might we rationally reconstruct this early part of the EBV story. First, Burkitt
encountered two patients with distinctive features. This led him to a complex process of syndrome
recognition, whereby the clinical features of the two cases contrasted with his education, background
knowledge and experience (sections 2.2.3 and 2.2.4), leading him to conclude that these individuals rep-
resented instances of a (possibly novel) syndrome. As syndromes are peculiarly psychologically striking,
finding something that resembled a novel syndrome in an individual was more compelling than finding
a new set of symptoms. My assertion is that this makes the process of syndrome recognition in these
two children the driver of causal suspicion. What it does not do is to say very much about the nature
of the cause(s) operating. Thus, both parts of my account of causal suspicion critically depend upon
Burkitt’s education, background knowledge and clinical experience. The tacit nature of this knowledge
specifically about what precisely these features are. I therefore think it is wiser to treat this phenomena as occurring as a whole, at
once.
10This is a feature of medicine that is rather overlooked. It remains the case that a great many clinical interactions remain
diagnostically and therapeutically unsatisfactory from any perspective. It is pretty uncommon to meet an individual (un)fortunate
enough to have developed a ‘text-book’ case of any disease. Common diseases often manifest in unusual ways, many symptoms
remain resistant to useful explanation or intervention and there are so many uncommon, unexplained medical problems that much
of what is encountered in practice cannot be either unified or causally explained. This was especially likely to be the case for
Burkitt, given the geographical separation between his training and his practice.
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and experience is therefore a possible source of the historical difficulties of elucidating the precise man-
ner in which this discovery came about. However, we can point to some differences between Burkitt
and those others who encountered jaw tumours but did not attempt to investigate them by drawing this
syndrome-cases distinction. The latter treated the individuals with these lesions as instances of jaw tu-
mours simpliciter. Burkitt, on the other hand, suspected that they were suffering from the same clinical
syndrome. So these jaw tumours were, for Burkitt, striking because they were potentially manifestations
of an unknown syndrome.
I do not want to argue that the RWT can account for this first stage of causal discovery. However,
once the operation of a cause is suspected, the RWT certainly can be used to interpret the detailed
development of a new cause. So I will relate the following stages of discovery to the RWT.
6.3.2 Evidence and causal domain-finding
This phase of EBV-BL research began with a regular, syndromic anomaly in need of causal explanation.
The next step was research that looked to demonstrate the approximate way that plausible causes of this
syndrome might operate. I suggest that this means that researchers attempted to determine the domain
of the suspected cause. At the end of this phase, therefore, researchers understood the likely, rather than
actual, nature of the causes at work producing the suspected syndrome.
Because our models of causes are contextual (see section 5.4.4ff), this stage of causal inference is
therefore largely concerned with what a mechanistic theory of causality might call functional specifi-
cation. What does the cause do? Over what sorts of entities and activities is the mechanism likely to
operate? In the EBV case, I suggest that at the end of this stage of discovery, researchers knew that BL
was a malignant disease that caused a characteristic clinical syndrome. They also suspected that it was
caused, at least in part, by the actions of an infectious agent - probably a virus. The types of evidence
employed to reach these conclusions are, thankfully, rather more amenable to retrospective analysis than
those at the earliest stage of discovery. Of particular significance are clinical descriptions of the syn-
drome, histological examination of tumour material, comparisons of this syndrome to those produced by
other, known disease mechanisms, and simple epidemiological data. In the cervical cancer case a similar
process of syndrome description was also evident. Risk factors for cervical cancer were elucidated; the
similarity of these risk factors to those of an infectious disease were noted, and possible causal agents
were suggested that appeared capable of accounting for these risk factors.
Thus, in general terms, this stage of discovery involved a process of exploring two aspects of the
purported causal relationship. First, researchers looked to develop the extreme right-hand edge of the
mechanistic model11 with its descriptions of final states of affairs. This was constituted by developing
a detailed phenomenological, conventional and canonical description of the clinical syndrome associ-
ated with the disease state.12 This sort of description included symptoms, signs, investigation results
(histopathological, blood-tests, roentgenography) and basic epidemiology. As an important component
of this description, researchers began seeking plausible ways of reconciling these features. This pro-
11This is a terminological difficulty. Like MDC, I am resistant to thinking about mechanistic inputs and outputs.
12c.f. the manner in which McArdle’s description of McArdle disease rapidly became the ‘classic’ clinical picture of that disease.
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cess of unification was both internal, between different clinical features, and external, between clinical
features and their causes. As an example of internal unification, an histological finding might plausibly
explain a symptom or a haematological finding. As an example of external unification, an histological
finding might be plausibly explained by suspected pathological features of the disease state.
This broad, plausible description of the causal framework for the disease state forms that which is
to be explained by the provision of a causal model. This entails finding, like the Amazon, the nature of
the ‘source’ of plausible causal mechanisms. I interpret this, on the grounds of the historical cases, as
the search for the significant points of branching from the normal physiological mechanism that could,
plausibly, explain either syndromic aspects of the disease state, or the causal antecedents of these clinical
descriptors.13 Importantly, this stage of enquiry also involves the comparison of the morphology and
features of this disease state with others known, to make sure that this is not, say, an odd manifestation
of a known disease.
This proto-mechanism undergoes significant development as the domain of the cause is sought.
First, further syndromic features are elucidated. This includes finding additional symptoms, signs and
abnormal investigation results associated with the syndrome. A degree of causal-mechanistic attribution
may also take place. For example, in the BL case, the common histopathological features of tumours
at different anatomical sites, or of tumours in different individuals, suggested that a similar process of
oncogenesis was occurring in each distinct instance. Thus, a range of syndromic features were causally
unified into instances of the same oncogenic process.14
Next, a number of plausible alternative causal disease models were examined. One very clear
example (in the BL case) was the comparison made between the tumour syndrome and leukaemia. But
a mechanism that could account for the clinical syndrome that developed around BL would have to be
an extremely odd one. As Burkitt noted (Burkitt, 1983, 1777), the clinical features of these patients
were aetiologically ‘baffling’. No known pathological process seemed to provide an easy, plausible
explanation. He further noted that distribution across all four jaw quadrants seemed to exclude the
usual explanations for bony swelling: neoplasia and infection.15 So no existing disease state seemed to
13See section 5.6. I will later suggest that it is branching because of setting effects that is the cardinal feature that is explained.
14I will not say very much about this. I think this business of local causal attribution proceeds in the same way as the global
one. However, each individual bit of causal inference, owing to its causal simplicity and plausibility, is both much easier to
perform, and less psychologically impressive than the eventual, overall one. This lack of drama, and chronological brief-ness,
therefore renders the internal mechanics of the manner of causal inference for these simple mechanistic links much less clear to
the historical investigator than those of the main mechanism. But this historical difficulty does not challenge my thesis that causal
inference happens in a recursive way
15As a matter of interest, I have looked up the differential diagnosis for bony swellings in the jaw (Bouchier et al., 1996, 335-
9). The differential includes infections (either of dental structures or of bone), trauma, dental and gingival pathology, genetic
syndromes (familial fibrous dysplasia), salivary gland swellings and a range of tumours. Benign tumours include jaw osteomas,
ossifying or cemenifying fibromas, giant-cell granulomas, ameloblastomas and myxomas. Malignant tumours include both primary
bone tumours and metastatic disease. Because most of these diseases are well localised and circumscribed, few of them could have
offered a potential explanation for the clinical features observed by Burkitt. There are a couple of exceptions. First, while osteomas
of the jaw are generally singletons, multiple osteomas may occur as part of Gardner’s syndrome. This, however, is very rare and
the main effect of the syndrome is to produce multiple colonic polyps with malignant potential. It was described before Burkitt’s
work (Gardner, 1951). A confusion between it and the clinical features of BL seems rather unlikely. Second, fibrous dysplasia of
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present itself as a good fit with the syndrome. When considered along with the clinical features (and
their interrelations), this provided good evidence that a new causal mechanism, capable of explaining a
process of simultaneous multifocal oncogenesis, occurring in a geographically constrained manner, in
an unusually youthful group of patients, would be required.
In RWT terms, this represents evidence of difference-making. Something made a difference to this
group of children in East Africa, in contrast to those in other parts of the world,16 with other types of
disease (leukaemia), in patients of other ages (age-incidence curves) or with normal human physiology.
The contrast class, against which these findings demonstrated the existence of a difference, also act to
constrain the types of possible mechanistic models that might account for it. For instance, tumour ho-
mology between sites and cases implied the likely existence of a common cause that was of a broadly
oncogenic type. Likewise the geographical restriction of the tumour indicated that this part of the mech-
anism was, perhaps, the result of a geographically determined factor, such as an environmental toxin, a
behaviour or a pathogen.
In summary, then, evidence of both mechanism and of difference-making were in play when the
causal domain for BL was sought. The early pieces of difference-making evidence were the charac-
teristic geographical findings and the age-incidence relationships. The mechanistic findings were the
contrastive examinations of the syndromic features of BL with those arising in other disease states (i.e.
mechanistically demonstrating that the tumour syndrome was not the result, or not a likely result, of
a known mechanism), the histological details (offering both positive and negative constraints upon the
mechanism), further details of the clinical syndrome, and their manner of interrelation, and the possible
mechanisms underlying the geographical and age-incidence findings. Thus a range of simple observa-
tional evidence, together with a complex web of background knowledge, supported the beginnings of a
causal mechanism for BL.
In the case of cervical cancer a similar process occurred, although it was tempered by (phenomeno-
logically good) knowledge of the clinical syndrome of cervical cancer that was already in place at the
time that it occured. Suspicion, in this case, consisted of finding the sexual risk factors for the disease.
Domain finding, on the other hand, was a process of determining the types of entities that causally un-
derwrote these risk factors, relating these in a plausible fashion to the clinical picture, and determining
the domain of the causal structure linking the two. Essentially, therefore, this debate was focused on
the clear discrimination of cervical from uterine corpus tumours, the determination of which risk factors
appeared to make a difference at a population level, and the analysis of these risk factors in terms of their
plausible components. Moreover, the elucidation of these risk factors suggested (fairly early on) that the
correct aetiological domain involved infection with herpes viruses. Domain finding therefore involved,
in this case, extensive analogical reasoning with other types of malignant disease caused by herpesvirus
the jaw could have accounted for some of the symptoms seen. This is a rare disease affecting children in which bone is gradually
replaced by fibrous tissue. This, while it could potentialy affect all jaw quadrants simultaneously, tends to manifest as a non-focal
enlargement rather than a tumour. The low incidence of the disease also counts against it as a good explanation for Burkitt’s first
two cases.
16Burkitt was already aware that tumours of the jaw were considerably more common in Mulago that in Europe or America
(Singh, 1955, 70). We also have various reports of unusual jaw tumours recorded before Burkitt arrived in Uganda (p. 31ff).
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infection. I discuss the role of analogy as evidence for causation in section 6.4.1. There I will defend
the assertion that this sort of reasoning leads to a mechanistic type of evidence. As I have already sug-
gested, though, other types of mechanistic evidence were lacking in this case. In this period, therefore,
the majority of domain finding research in the HSV case involved the analysis of difference-making
evidence.
6.3.3 Evidence and the making of mechanisms
In both viral oncogenesis cases, this phase of inquiry had a characteristic evidential appearance. Rather
than investigating the possibility that the tumour could be caused by a virus, researchers instead at-
tempted to discover which particular virus was causing the tumour, and the underlying mechanism of
this causal relationship. An analysis of this stage will therefore concentrate on the manner in which
appropriate models of causal structures, capable of providing suitable cognitive leverage across a range
of specific situations, were developed. The task of this section is therefore to show what part evidence
played in this process. What I will not do here is to reprise the large number of well-developed accounts
of mechanism construction that are already available (see, for example, Darden, 2006; Craver, 2007;
Bechtel, 2008) What I will do instead is to use the case histories to illustrate the distinction between
kinds of evidence along McKay Illari’s lines, as introduced in section 6.2. That is, I will show that
there is a distinction between kinds of evidence and the kinds of things we have evidence of. With this
distinctions in mind, I will use the EBV case to give a broad outline of this part of my account.
At this stage of the BL research programme, the focus of the investigation changed. From at-
tempting to discover both the phenomenal nature of BL and the types of entities responsible, researchers
began to work towards giving an account, in specifically causal terms, of the precise nature of the causal
structure connecting the two. Thus the methodologies and epistemologies at work were all based, fairly
explicitly, on the earlier plausible assumption that the tumour was caused by a virus (see section 2.4).
This working assumption was methodologically essential. It granted researchers legitimate access to
the techniques, equipment and patterns of research from virology, oncology and non-human tumour vi-
rology that would otherwise have been unavailable. Epistemologically, it also offered researchers the
opportunity to gain cognitive advantage by employing general causal mechanisms and structures, short-
hands, argots and technical talk from each of these fields. As a consequence of the novelty of the BL
research programme, these first steps, with a grounding in each existent research programme, formed the
paradigmatic basis for human tumour virology as an independent, interdisciplinary research programme.
Chronologically, the very first steps in this case were purely virological. A detailed investigation,
employing a range of sophisticated virological techniques, were conducted using tumour biopsy material
(see section 2.4.1.2ff) However, these attempts initially failed. No virus was found despite extensive,
methodologically pluralist investigations of tumour material. While this failure provided little direct
advantage to BL research, it has since become an fundamental tenet of tumour virology that tumour
viruses may be extremely difficult to find in vivo. This had significant repercussions for the investigations
surrounding both cervical cancer and HCC.
It was the accidental discovery of the culturability of BL cells, that provided the first (positive) steps
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in the BL programme. While this ability to grow in culture was an unusual property for lymphoid-line
cells, it was fairly well-described in other tumours (see section 2.4.2.1). The subsequent discovery of
the general culturability of BL cells, and the production of multiple BL cell lines, suggested that - no
matter what the nature of the causal mechanism giving rise to this behaviour - BL cells possessed this
ability robustly. No matter who the tumour arose in, or where it arose in them, the tumour cells had the
ability to grow in free culture. This piece of evidence of difference-making thus arose from a contrastive
comparison of BL cells in culture versus other tumour cells in culture. It required detailed knowledge
about how cultured malignant cells usually or typically behave. Thus this finding required knowledge of
a range of oncological techniques and general causal models in order to come about.
But this (oncological) piece of evidence of difference-making was rapidly joined by a (virological)
mechanistic one: typical tumour cells are not usually packed with viral particles at many different stages
of maturity (section 2.4.2.2). This was evidence of mechanism regarding the manner in which the virus
caused the tumour. Again, it only became so when interpreted from the virological stance: the virus was
the oncogenic driver, rather than a passenger, by analogy with the properties of other viruses, and their
manner of disease causation. Thus EBV became part of a causal mechanism capable of accounting for
the disease state.
This causal-mechanistic role gained further support from cell transformation experiments. EBV, it
seemed, could be the relevant difference-maker in malignant cell transformation in vitro. This difference-
making result, when folded into the developing EBV causal model, becomes an important piece of evi-
dence of mechanism. The difference that EBV exerted on cultured cells, as a whole, became just part of
the more complex causal structure that explains the development of BL in real, complex, populations.17
In turn, this cellular transformation became mechanistically decomposed in terms of the activities of
viral entities upon cellular mechanisms. For instance, the typical chromosomal abnormalities produced
in these cells were described, and became entitified; the lack of lytic effect - unusual for a herpes virus -
produced by this agent in the test systems (Epstein et al., 1965a, 70-1); the process of integration of the
viral genome into that of the host; and so on. This is the nature of recursion seen in causal inference:
differences become mechanistically explained, mechanisms become functionally related to difference-
makers. Meanwhile, other causal-mechanistic candidates were excluded by a related process. While
possible, plausible causal mechanisms implicating these candidates in BL oncogenesis were available,
the corresponding actual difference-makers, or mechanistic findings, were not.
In a similar way, the ubiquity problem (section 4.4.1) was discovered, and resolved. The role of
EBV in other diseases arose from serological investigation. This was methodologically and epistemi-
cally a virological approach to understanding disease.18 However, the range of control sera chosen shows
an oncological colouring of this experimental instance. For those conditions in which EBV had not pre-
viously been implicated this was difference-making evidence. EBV seroconversion appeared to make a
17Cell transformation experiments are distinctively oncovirological, and neither oncology nor virology alone can lay claim to
this experimental practice
18Although since that time the role of immunology in understanding malignant disease has become more commonplace. Perhaps
this is a further example of the wider impact that the understanding of the EBV-BL story has had on medical research.
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difference to the development of these diseases. The resolution of this problem, though, depended upon
the mechanistic distinction of the manner in which the virus was causally implicated. In other words,
EBV was a difference-maker for all these conditions. But the mechanistic aspects of the developing
causal model meant that researchers could, in detail, tell a story about the differences between the differ-
ences. Without mechanistic evidence and the construction of a range of mechanistic models, the problem
would have remained insoluble. And so on.
In summary, techniques lifted from a number of medical disciplines were employed in the con-
struction of a distinctly oncovirological causal model implicating EBV in the development of BL. Elec-
tron microscopy of biopsy material was virological, not oncological. But cell culturability was onco-
logical, not virological. Immunological techniques were (until very recently) distinctively virological;
histopathological examination of cells oncological.19
Depending on the context, each piece of causal evidence can be interpreted in different ways. For
instance, a given piece of evidence can be, plausibly, interpreted as either mechanistic, or difference-
making evidence. The precise way in which a given piece of evidence is interpreted depends upon subtle
contextual factors that influence the functional specification of the piece of the causal structure under
examination. For a given type of specification, those types of evidence that relate a causal feature to
the (level-relative) properties of the part of the causal structure under examination serve as mechanistic
evidence. Those that relate behaviours to one another in a stable manner are difference-making. But
these roles are, necessarily, relative to the precise bit of causal structure under test at that time. So
evidence that originally appears to be that of difference-making (say, the serological correlation between
EBV and non-BL disease important in the formulation of the ubiquity problem) within one context (in
this instance, that of a programme to determine the causal specificity of EBV for BL) can later play
a mechanistic role in an alternative mechanistic model. In this specific example, this occurred in the
construction of an overall causal model for the roles of EBV as a human pathogen.
6.3.4 Applying evidence
The causal structure relating EBV and BL was still incomplete by the early 1970s. While the mechanistic
model component of the structure seemed highly plausible, there were a number of significant problems
with the view that this model was actually happening in the BL population. Arguments over a range of
issues (reviewed in section 4.4.1) led to much resistance to the causal model as a whole. This phase of
inquiry therefore consisted of resolving these problems by demonstrating that the EBV-BL mechanistic
model did actually occur in BL populations. This part of causal discovery was, therefore, concerned
with evidence of difference-making, and the manner in which it related to mechanistic models. I review
this process in detail, along with the similar process that revealed that HSV was not a cause of cervical
cancer, in section 6.5.
19As an aside, perhaps this lifting and modification of techniques is a source of local incommensurability in models of causal
structure. Each bit of causal structure intimately depends upon the technology, methodology and epistemology of those construct-
ing it. Important differences exist in these areas between disciplines.
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6.4 Evidence of mechanism
What constitutes evidence of mechanism? That is, what sorts of experimental or observational findings
are likely to participate in the formulation of a good mechanistic model? Is it possible to characterise
either mechanistic evidence (ME) or evidence of mechanism (EM)? Can we do this methodologically?
Epistemically? Ontologically? How do these sorts of evidence depend upon the context under which
they are sought? What is the nature of ME and EM in the viral oncogenesis case-studies?
Mechanisms and their models are concerned with causal dependencies. A model of a mechanism
should illustrate just how a regular arrangements of causal antecedents causes a particular entity to act
in a particular way. EM, therefore, has to give us some insight into how these causes connect together.
Equally importantly, EM must tell us how - under certain conditions - the interactions of these entities
and activities gives rise to the properties of the mechanism - productive continuity, stability, robustness,
polymorphism and so on. Because of these various demands, and those distinctions between object
and type of evidence outlined by McKay Illari (McKay Illari, 2010), simple methodological definitions
of ME appear unlikely to be adequate means of providing a useful characterisation of EM. First, it is
simply not the case that EM is just causal evidence that arises from in vitro investigation. Nor, I think is
it possible to characterise EM as necessarily arising from laboratory investigations. I think that arising in
a laboratory is neither necessary nor sufficient to make a piece of evidence distinctively mechanistic, in
either sense. Similarly, but in Russo and Williamson-like terms, neither EM nor ME can be characterised
as being simply non-probabilistic causal evidence. Again, some evidence of difference-making is non-
probabilistic (as in the McArdle case), while some important evidence about mechanisms found in the
viral oncogenesis case studies is absolutely and innately probabilistic.
There are, instead, a number of characteristic features of mechanistic models that seem to arise from
certain types of evidence as gathered. This suggests that it might be possible to characterise EM in terms
of the features of the ontic mechanism it purportedly describes. First, some mechanistic evidence looks
to describe the nature of entities and activities such that they can be included into a mechanistic model.
For instance, researchers looked to demonstrate the morphology of EBV, described the condition of host-
cell genomes in EBV-transformed cells, described the structure of muscle glycogen in McArdle patients
and so on. All of these were instances of descriptions of (possible) causal entities. There were similar
descriptions of causal activities: the means by which EBV infected cells, the type of exercise under which
the characteristic symptoms of McArdle disease manifested, and the role of various early HPV proteins in
disrupting cell-cycle regulation. But this is a fairly weak definition. It seems far too strong to suggest that
any research that deals with parts of a causal mechanism in detail is distinctively mechanistic. However,
there are more telling characterisations of EM. Distinctively, EM gives descriptions of the nature of the
relationship between entities and activities. A range of experimental practices give rise to evidence that
falls into this class.
First, some experiments attempt to determine the ways in which a given entity acts. Thus re-
searchers sought to determine the range of conditions under which EBV would enter either the dormant
or lytic phases of its life-cycle (section 2.1.3). Similarly, HPV researchers sought to determine the host-
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cell tropism of different types of HPV on the grounds of their genetic sequence and other properties.
The relevant conditions under which such an entity would act in a given way were sought. I term this
sort of strategy activity-description. Second, researchers looked for the entity, or entities, that were the
producers of certain activities. A good example of this is the detailed investigations that subsequently
took place to detect the precise means by which the range of early HPV proteins caused cell-cycle dereg-
ulation. This activity was found to arise by the (different) mechanistic actions of E5, E6 and E7 upon
cellular machinery (outlined in section 3.6.3). I term this sort of strategy entity-description. Third, in
the case where entities were suspected to act on an unknown target entity, investigations were performed
to try and find out what lay downstream of them. Again, the elucidation of the specific functions of
HPV E5, E6 and E7 are good examples of this. While the cellular-level activity of the expression of
these proteins (immortalisation) was well understood when they were first causally implicated, the ac-
tual molecular-level targets of these proteins were not known. Therefore research consisted of finding
out which entities were the targets of the activities of these entities. I term this type of research activity-of
and entity-of description. Fourth, the heuristic of seeking intra-mechanistic interactions - in the sense of
sections of the mechanism that had synergistic or antagonistic effects on other parts of the mechanism
- was applied. We might think of this as interactivity-description. The production of evidence that al-
lows the telling of such a detailed causal story seems distinctively mechanistic. So this is not simply
evidence regarding the existence of entities and activities, nor is it evidence revealing of the ways that
these participate in simple causal sequences, but instead deals with entities and activities as embedded
in complex causal models. For example, how do the range of viral proteins act - in concert - to effect
cellular transformation. How does the picture change if one - or some - of them is altered? Inhibited?
Increased? Does an entity really act stochastically, or is it instead the case that it acts deterministically
under certain complex arrangements of other causal factors? Evidence that tells us about the real com-
plexity of the workings of biological mechanisms in a way that allows us to construct mechanistic models
is distinctively mechanistic.20
This suggests a third means of classifying something as evidence of mechanism. While both mecha-
nisms and mechanistic models are distinctively interlevel, and medical mechanisms are characteristically
extremely complicated, EM tends to speak to the manner in which very short causal links come about.
These tend to operate at one particular, or between very closely related, levels of organisation. This
seems paradoxical, until it is remembered that the job of EM is to describe the internal workings of the
mechanism by means of mechanistic models. What it does not do is to describe the overall behaviour of
the mechanism.
While I have suggested that very simple methodological characterisations of ME are not likely to
be operationally useful, there are some more nuanced methodological features of ME that seem likely to
prove more fruitful. The generation of ME generally takes place within fairly well defined disciplinary
borders. While the entire set of mechanistic evidence acting to support, say, causal claims about the re-
lationship between EBV and the clinical development of BL appears methodologically utterly disparate,
20This sort of causal complexity appears to result in the manifold representational complexities that appear in medical contexts.
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when it is divided by bioscientific discipline a more congruent picture emerges. For example, the use
of electron microscopic techniques employed to understand EBV morphology all relied on similar tools,
techniques, epistemologies and background knowledge as the non-specific virological procedures for
understanding the morphologies of viruses in general. This kind of disciplinary reference plays a very
important role in determining the most fundamental level at which ME is sought, and hence to the level
at which the resulting mechanistic model bottoms-out (see section 5.4.3).
I will now digress slightly to discuss a critically important type of mechanistic evidence that played
a major role in all the historical cases referred to. This is the evidential role of plausibility and analogy
in causal inference and understanding.
6.4.1 Plausibility, analogy and mechanisms
Plausibility and analogy played a vital evidential role in causal inference in both of these cases of viral
oncogenesis.21 These causal structures were seen as highly implausible at the time of their construction.
Yet there is an interesting tension here: mechanisms are very often described as merely plausible de-
scriptions of the way that things happen. This role for mechanisms is explicitly present in many medical
schemes of causation.22 For instance, Surgeon General (1964, 182; 185ff) features a requirement for
determining the ‘Coherence of the association’ when determining causation. Likewise, Hill (1965, 298)
cautions us that ‘. . . the cause-and effect interpretation of our data should not seriously conflict with the
generally known facts of the natural history and biology of the disease.’ Evans (1976, 192) suggests that
‘The whole thing should make biologic and epidemiologic sense.’ Finally, Elwood (1988) demands ‘Are
the results plausible, in terms of a biological mechanism?’
I think these suggestions, that mechanisms are simply plausible descriptions of how things happen,
are mistaken. They seem to be operationally problematic too. In fact, a nuanced reading of the rela-
tionship between plausibility and mechanisms is rather complex. By way of illustrating the relationship
between those mechanistic models that are primarily constructed using plausibility and analogy (plau-
sible mechanisms) and mechanistic models that have some more concrete and direct evidential support
(empirical mechanisms), I will give some historical examples. First, there are two quite simple cases. A
plausible mechanism linking a clinical syndrome with a common cause is formulated. The features of
this plausible mechanism are then specifically investigated. In this sort of (chronological replacement)
case, the following might happen. Either an initial plausible mechanism is formulated that later turns
out to be, roughly, correct, or that initial plausible mechanism turns out to be (mainly) mistaken. For
instance, HSV was an highly plausible cause of cervical cancer because of the strong analogy between
21There are a few accounts of the role of analogy in theory construction. One notable example is Darden (1982), which is based
on Hesse, 1963 and Oppenheimer, 1956. In short, Darden suggests four roles for analogy in theory construction: the exploitation
of neutral analogy; deconstruction of causal links in new theory in terms of connections in similar theories; the construction of
new theory from relevant pieces of old, unconnected theories and the recognition of shared abstraction between theories. This
is of interest, yet these roles do not seem clearly circumscribed in my historical case. There is some other relevant work in the
mechanisms literature too; (Darden, 2006; Craver, 2007; Bechtel, 2008). In any case, here I am trying to show that mechanisms
need plausibility and analogy, and they are used in a fairly similar way to other, empirical, forms of evidence during the stages of
mechanism construction.
22See also my short review of this area in section 1.2
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cervical cancer and other tumours caused by herpesviruses.
These two patterns are fairly straightforward. But treating plausible mechanisms as simply a stage
on the path to constructing a correct, empirically determined mechanism is to mis-read the way that
things actually happen. It will fail to capture the many ways in which plausibility is important in causal
inference and evaluation. Simply treating a plausible mechanism as an early stage of an empirical mech-
anism is to fail to notice that considerations of plausibility play a vital evidential role in making mecha-
nisms. That it, a plausible mechanism is not simply a chronotropic stepping-stone on the path to a ‘real’
mechanism.
Instead, even mature mechanistic models with plenty of empirical support will tend to have had
plausible statements used as evidence in their construction, may continue to contain sections that are
primarily plausible (rather than empirical), and may be employed to do, say, interventions in a way that
uses reasoning that is largely grounded in plausibility. This richness of interactions between mechanisms
and plausibility shows itself in five plausible types of interaction between the success (or otherwise) of a
causal claim and the helpful (or impedimential) role of either plausible or implausible mechanisms:
1. The construction or acceptance of a (correct) empirical mechanism is helped by its plausibility.
Hopefully, this is not a controversial claim.
2. A (correct) empirical mechanism is helped by notions of its implausibility. This seems highly
counter-intuitive, but it is a fairly common occurrence. For example, Burkitt’s conviction that the
BL tumour syndrome was in need of a novel causal explanation resulted from the implausibility
of possible, alternative causal mechanisms that could be suggested. Similarly, once a mechanism
was suggested that was capable of explaining the weird features of the tumour syndrome, it gained
acceptance.
3. The acceptance of a correct empirical mechanism is impeded by its implausibility. This sort of
case appears much more problematic, and sadly much more historically prominent, than 5. For
instance, the notion that infection with Helicobacter pylori caused peptic ulcers was seen as highly
implausible, yet one that was ultimately shown to be correct.
4. The acceptance of an incorrect empirical mechanism is helped by its plausibility. For example,
HSV as a cause of cervical cancer.
5. The acceptance of an incorrect empirical mechanism is impeded by its implausibility. For example,
McArdle’s suggestion that the mechanism accounting for the clinical features of McArdle disease
arose from the glucolytic pathway.
So the historical cases present a difficulty for the claim that mechanisms and plausible mechanisms
are really the same thing. Plausible mechanisms, in place of empirical ones, look likely to make for
bad causal claims. But yet plausibility still seems to play an important role in making and evaluating
good causal claims.23 In this section, I will attempt to address this tension. First, I will attempt to
23Dis-analogies and implausible phenomena are also evidentially also very useful, as I go on to discuss
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differentiate and disambiguate plausibility and analogy. I will go on to support (from a metascientific
stance) the notion that plausibility and analogy are capable of acting as extremely useful evidence for
causal mechanisms, but are not an adequate replacement for a mechanism in a (RWT compatible) causal
claim. I will do this by referring back to the earlier work on gappiness in mechanisms (in section 5.4.5),
and by trying to suggest under which circumstances plausibility or analogy tend to be ‘safe’ ways of
bridging gaps, and when they will tend to be more risky.
Anyway, the first step is to differentiate plausibility and analogy. Plausibility is general, and is
relative to background knowledge. Thus claims about the behaviour of entities is said to be plausible if
(unspecified other) entities tend to behave in similar ways. So, for example, if we are trying to build a
plausible mechanism for the pattern of metastasis of a newly diagnosed tumour, we might suggest that it
is likely that the smaller tumours found are likely to be metastases, while the largest tumour is likely to
be the primary. This plausible claim would rely on (generalised) expressions of background knowledge
about the behaviour of malignant cells. So theoretical claims about tumours in general, such as “cancer
cells spread from the primary tumour” and “the older the tumour, the larger the tumour” and “cancer
cells tend to spread either by the blood, by the lymphatic system or by direct invasion” would be (tacitly)
employed in constructing and appraising such plausible claims. You do not give a description, in the
main, of what specific bits of knowledge make a plausible mechanism really plausible.
Analogies, on the other hand, are specific. To make an analogy is, explicitly, to compare aspects
of the causal system under examination with aspects of a second one, which will generally be rather
better understood. Thus when we have a novel syndrome that resembles a second, known syndrome
in its clinical features, we might (by analogy) suggest the operation of a similar causal mechanism.
Alternatively, if we discover a new pathogen that shares many features with an existing agent with well-
understood features, we might make an analogically supported claim about the likely effects of this,
new, agent.24 Again, like plausibility, this requires implicit consideration of background knowledge (e.g.
“viruses that encode similar proteins are likely to infect similar cells”). But it also features the explicit
consideration of one or more comparison systems. In other words, one has to specify what it is that the
new situation is analogous to.25
Judgements about whether something is plausible, or whether two things are analogous, are un-
stable. Plausibility depends upon background knowledge in general. Analogy likewise depends upon
changing knowledge about specifics. As my distinction is clearly based on the historical cases, and these
cases occur over a fairly short period of time (roughly 1950-90), it seems possible that the senses of, and
hence distinction between, the terms could also change. Thus I do not offer these distinctions as univer-
sal and unqualified definitions. They are, instead, relative to the historical cases in a fairly broad sense.
With that in mind, how do plausibility and analogy enter mechanism construction? What roles do they
play? First, evidence of both types have important heuristic roles early in causal inference. It seemed
plausible that a phenomenologically consistent tumour syndrome had a (common) cause of some kind.
24This happens now with HPV. When a new type of the virus is discovered, sequence homology is used to determine which
super-family it belongs to. This then guides the manner in which research is conducted on the new organism.
25This semantic difference, with the differential use of comparison, is the metascientific grounds for this distinction
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Likewise, sexually transmitted diseases were noted to have analogous epidemiological features to cervi-
cal cancer, so perhaps they shared causal similarities too. In a related way, both plausibility and analogy
played a methodological role at this early stage, in suggesting the experimental approaches suitable for
understanding novel causal situations. I think these suggestions are fairly unproblematic, so I will not
labour the point. But note, again, the different employment of the two terms in these sketched examples.
A more controversial claim for the role of plausibility and analogy is to negatively constrain the
process of mechanism construction. For example, the apparently simultaneous, multi-focal nature of
BL tumours appeared to be dis-analogous to the other known causes of jaw tumours (see footnote 15,
page 159). This negative constraint excluded, or at least made less inviting, a range of possible causal
hypotheses that could account for the BL syndrome. Similarly, the epidemiological analogies between
venereal disease and cervical cancer ruled out a raft of ideas about chronic-degenerative cancer causation
in this case. This process of ruling out competing causal hypotheses seems a vital part of causal domain-
finding.
A third evidential role for plausibility and analogy follows from my suggestion, in section 5.4, that
models and representations of mechanisms tend to be gappy. To reprise briefly: sometimes gaps are
elective. So we might omit parts of a mechanistic model that are not relevant to our particular use of it.
For example, if we are asked to make a prognostic judgement about a particular individual with cervical
cancer, we will generally not use anything like a ‘full’ model or representation to do so. Instead, we
will use an incomplete mechanistic model in which gaps will be bridged with plausible approximations
of the behaviour of entities and activities. Of course, the degree of this ellipticism will depend on the
intended purpose of the causal mechanism. So that is one sort of gappiness where plausibility is used,
fairly safely, to make mechanisms operational.
But some sorts of gappiness are more troubling. Very often, sections of mechanisms are missing
from every - rather than from a single - model. Perhaps this is because the relevant research has not yet
been done for one reason or another. Or these sections of the mechanistic model might fall outside the
specialist domains of biomedicine. Or perhaps, more worryingly, the relevant research proves impossi-
ble to complete successfully.26 Obligate gaps like these are also bridged using plausible or analogical
evidence. However, given that these these gaps sometimes arise because of real causal difficulties, these
obligate gaps are likely to be more tricky to fill successfully than elective gaps. Just such a instance
occurred with HSV and cervical cancer. There were significant, obligate, gaps in the causal models that
related HSV infection with the development of cervical cancer. These were centred around the specific
manner in which HSV caused (at a cellular-molecular level) cervical cancer. Yet these gaps were (easily)
filled with plausible and analogical evidence. In general, herpesviruses were seen as plausible causes of
cancer. A range of specific analogies (EBV and BL; Herpes samirii, Herpes atales and so on) were
also used to fill in these details. This easy filling of a difficult gap masked the experimental difficulties
encountered while attempting to unpick this causal mechanism. This means the experimental failures
26Again, this might be a feature of local incommensurability. Two different mechanistic models could be (and I think often are)
constructed focusing on adjacent areas of the mechanism that cannot be happily linked together. This may well indicate a serious
problem with the causal model.
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failed to seriously challenge the overarching HSV-based causal model in the way that we might have
wished them to.
So this is a good example of a dangerous bit of gap-filling. What makes a safe, versus what makes
a dangerous, guess about the likely shape of a mechanism? Is there any clear way of differentiating the
two? As a starting point, can we point to why the plausibility and positive analogies of HSV were so
problematic in this case? I have one suggestion. In this instance, the manner of viral classification ap-
pears to be partly responsible. Analogies were made with other herpesviruses. However, these analogies
appertained to the oncogenic activities of herpes viruses, both generally (herpes are a plausible cause
of cervical cancer) and specifically (HSV is analogous to this specific oncogenic herpesvirus, or to that
other one). Yet the classification used for herpesviruses, which is based on the location at which the
various viruses spend their dormant phases and on genomic considerations (Cleator and Klapper, 2004b,
24) does not clearly relate to the properties of the virus that does the oncogenic causing. Now there are
examples where classification is performed on features that are responsible for interesting bits of disease
causation. For instance, enteric strains of Escherichia coli are partially classified based on their mecha-
nisms of virulence (Picard et al., 1999). Analogical reasoning, based on these classifications, might well
be ‘safe’. But the HSV case was not so. Of course, in this specific instance we can be wise after the fact.
But the general principle stands: we should think about how analogies are supposed to be similar.
So it might be as well to think carefully about what mechanisms make entities and activities similar
if we wish to rely on the plausible. This approach might suggest a means of predicting which plausible
or analogical evidence is likely to make for safe gap-filling, and which will make for risky gap-filling.
In the case where both the causal antecedents, and descendants are known, analogies will tend to make
safer guesses than plausibility. This requires that (unlike the HSV case) the behaviours or features that
make the two analogous structures similar are essentially the same as the behaviours or features that are
supposed to account for the mechanistic role of the (analogically supported) gap-filler.
In the case where the either antecedents or descendants are not well understood, though, plausible
reasoning will tend to make for safer gap-filling than analogies. This is because, if the causal model that
the analogical gap-filler fits into is not well-described, use of an inappropriate analogy may licence an
inappropriately strong inference about the soundness of the general outlines of the whole causal model.
As happened in the HSV case, this may lead to the neglect of better alternatives.
6.5 Evidence of difference-making
How does EDM participate in forming causal models? That is the simple version of the question I would
like to address in this section. Here is the slogan version of the answer: EDM, relative to the functional
specification of a mechanistically understood causal model, demonstrates that a particular aspect of a
cause may bring certain effect(s) about in a specified population. This is a rather complicated slogan,
admittedly. But actually the role of EDM is very easy to see in the historical cases. I will therefore begin
with the examples, and I will draw out the details of my position on EDM using them.
Let us consider two typical, but high-quality, pieces of EDM. One is the large, prospective, case-
control study that sought a link between EBV and BL (de-The´ et al., 1978). This work successfully
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demonstrated the causal relationship between EBV and BL, and (as I argued earlier) was a vital part of
this causal model becoming generally accepted by the medical community. The second example was
also a large, prospective, case-control study. This is the Prague cervical cancer study (Vonka et al.,
1984a,b; Krcma´r et al., 1986) that attempted to find the link between HSV and cervical cancer. It, of
course, failed to find such a correlation, and these negative results played a central role in bringing about
the rejection of the HSV-cervical cancer theory by the research community. This pair of experiments are
therefore very useful for exploring the nature of EDM, as they are capable of suggesting the conditions
under which such (methodologically very similar) trials can act as either strong evidence for or against a
particular causal model tout court.
We need EDM to tell us that mechanisms happen in a particular situation. We may, for example,
formulate a very well-supported causal mechanism linking radon gas exposure to lung cancer using in
vitro models. But it will be suitable evidence of difference-making that tells us whether this mechanism
is really an important cause of lung cancer in a given population - by, say, showing that individuals in
high radon areas really do suffer excessively from lung cancer that cannot be explained by the operation
of other causal factors. In other words, this sort of evidence shows the net effect of a cause by giving the
magnitude (in a non-critical sense) of the connection between cause and effect in a specified population.
That anyway is how things should work.27
So, that is the manner in which difference-making participates in a causal model. But what char-
acterises evidence of difference-making, in itself? That is, how do we gain knowledge about difference-
making from data? What sorts of strategies tell us about difference-making in a given context? What
makes it evidence of difference-making, rather than evidence of mechanism? First, being prospective
(rather than retrospective) does not. Instead, it just makes it good quality evidence of difference-making.
However, as an historical point, many useful bits of such evidence are methodologically similar. Prospec-
tive studies, after all, are very useful for minimising the likely effects of various systematic errors. This is
particularly important for our definition of EDM, because it tends to be rather complex. In the historical
cases, the mollification of various sources of bias were vital, because the (expected) effect sizes of the
causal models were expected to be rather small. In both instances, something like a few tens of cases of
each cancer were expected, from an enormous pool (tens of thousands) of starting subjects. Moreover,
a large number of possible factors were recorded as being either factors to be controlled or investigated
as possible causal factors. Many of these were either in themselves complicated (sexual behaviours)
or difficult to clearly recall. Finally, the delay between the start of the study and the development of
clinical disease was generally years, meaning that systematic errors like recall bias were likely to present
a real problem. If the role of EDM is to figure out the overall effect of a cause, then in such causally
complicated scenarios it has to arise from complex and subtle methodologies if it is to be useful and
valid.
Similarly, the large number of trial participants, alone, does not make this EDM; it is simply the
means by which an accurate estimation of the effect size could be conducted.28 The McArdle case
27This is closely related to the distinction drawn by Hitchcock between net and component effects (Hitchcock, 2001).
28I might make a note here about statistical power. Interestingly, tumour viruses are very weak overall causes. For example,
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is a clear counterexample to a necessary characterisation of EDM in terms of probabilities. However,
because of the trend toward complexity in EDM, most useful EDM that is encountered in causal scenarios
implicating a pathogen in the development of a clinical disease will tend to be probabilistic. Thus, as
with ME and EM, we cannot give a simple methodological definition of EDM.
The types of entities under test are significant, though. In both cases, the trials examined the de-
velopment of a clinically apparent disease syndrome (defined in terms of a mixture of symptoms, signs
and investigation results) to serological evidence of viral infection.29 Thus contrasts were sought be-
tween cases and controls over a range of features of the different causal mechanisms for development,
or non-development of the disease. This does seem significant. In fact, I would like to suggest that a
characteristic of EDM is that it looks for the relationship between entities that are of disparate types. This
can take two forms. First, EDM can look for a correlation between entities that exist at widely differing
levels of organisation. For example, it might be a correlation existing between a symptom (whole organ-
ism or organ-level) and a pathogen (cellular/macromolecular). Taking the (approximate) convention that
causal mechanisms are represented with levels of organisation on the Y-axis, and the direction of mecha-
nistic flow on the X, we might think of this as vertical separation. Alternatively, this might be horizontal
separation, where the two phenomena under examination are separated by a large amount of intervening
causal mechanism. This is a clear contrast with mechanistic evidence, which tends to concentrate on the
activities of closely (time, space, type) related entities.
A second contrast can be drawn out from the relata of the evidence. Remembering that mechanistic
evidence looks to demonstrate the manner in which entities interact via their activities, it seems possible
to distinguish EDM by noting that it is concerned solely with the existence of entities. That is, EDM
makes claims about entities only, and does not care (in detail) how they came about. It instead takes
the form of existential claims about the things of the mechanism. That is not to say that EDM is static;
quite the opposite. Instead, it tends to look for patterns of change in these entities, for contrasts between
entities in different individuals, or changes that occur under different sets of background conditions.
Thus EDM cannot arise from a simple reductionistic understanding of the types of entities causally
responsible for a particular phenomena. Nor can it, alone, show how the cause operates. What it can
do, when originated from, and granted context by, a particular mechanistic model, is to show how the
entities that this mechanistic model describes, change overall. After all, if the BL prospective study had
looked for evidence of infection with EBV simpliciter it would not have detected any causal link. Useful
difference-making evidence has to demonstrate specific, rather than general, features of a mechanistic
model.
There are things that these two studies do, evidentially, other than demonstrate the magnitude of the
effect of the mechanism via a particular route. In the EBV case, they demonstrated the chronological
a maximum of 0.1% of those of the susceptible age, living in the lymphoma belt, with EBV infection, end up developing BL.
Compare this to, say, the odds of developing clinically apparent measles given de novo infection with measles virus, which
approach unity.
29The EBV study looked at a range of EBV antigens and antibodies, as well as a range of non-EBV serological indicators, while
the HSV study looked at specific serological evidence of HSV2 infection
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development of the condition, and the other differences in EBV seroconversion that obtained in patients
versus control subjects. In the HSV case, the very careful controlling for age, age at first sexual inter-
course, number of sexual partners, smoking and DKG30 revealed no difference in HSV status between
cervical cancer patients and controls matched for these factors. Not only did this suggest that the (plau-
sible) HSV mechanism was faulty; it also suggested that, because these factors did make a profound
overall difference to the rates of cervical cancer seen, that there was another pathogen at work. They also
served to indicate the likely means of transmission (sexual) by which it would spread.
Both these more subtle outcomes and the main probability altering outcome are only intelligible
as evidence for the existence and nature of a particular causal model when understood in concert with
mechanism. They would be quite unintelligible without it. Furthermore, these (expensive and compli-
cated) experiments simply would not have been conducted as they were in the absence of a postulated
mechanism. Without such a mechanistic understanding of the disease, researchers simply would not
have known which entities to look for.
In summary, it is the descriptive complexity of EDM that makes it non-mechanistic. EDM typically
describes the relationship between participant entities which are widely separated in a given mechanism.
We therefore typically expect EDM for medical mechanisms implicating a pathogen in the development
of a disease to arise methodologically from population-level observational studies31 But remembering
that I claim that the business of causal inference is recursive, the mechanism for this causal situation
will rely on other types of EDM, derived from research on the constituent behaviours of the mechanism.
These (smaller-range and micro-level) EDMs are synthesised into the causal mechanism that describes
the overarching mechanism implicating the pathogen in disease development. This is why I suggest
that DME used in the construction of one mechanistic model can act as ME for the larger model. The
judgement of evidence of difference-making versus of mechanism therefore depends upon the precise
functional specification of the causal model in question. EDM for a causal model dealing with a small
- entities, scope, narrower domain - causal model may well become EM in a larger model. Evidence
that a particular causal route happens (smaller) becomes evidence for that causal route being capable of
happening (larger).
I suggested that most EDM is probabilistic. It seems worthwhile exploring an instance when it was
not. This comes from the McArdle case. Consider McArdle’s investigation of George W. I suggest that
the evoking of a range of disparate clinical phenomena (electrically silent cramps, lactate abnormalities,
fatigue, muscle swelling) by exercise are the important EDM in this case. After all, this evidence consists
of the description of a complex (chronological and spatial) relationship between fairly atomic entities.
This then seems to be a species of DME. Why then was this high quality, useful, EDM? Why was there no
need to perform a high-powered case-control study, say, for this to count as good evidence for causation?
Why was it that limited comparisons between the metabolic functions of George W. and a small number
of volunteer subjects sufficed? My suggestion is this. First, the appearance of the clinical features were
30Electrocautery of the transformational zone of the cervix. This was widely employed in the 1950s and 1960s as a means of
managing precancerous conditions of the cervix (Vonka, personal communication).
31There are a number of legal and ethical difficulties with performing interventional studies in the field of tumour virology.
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chronologically fairly immediate. This is most unlike the viral oncogenesis cases, in which a period
of many years generally elapsed between infection and tumour development. Similarly, the effects of
McArdle disease are rather simple and striking. This immediacy and easy observability mitigated the
likely effects of the many types of systematic error to which observational studies are prone. Second,
the cause of the clinical features (exercise) is fairly internally simple32 and easy to describe. Thus it was
not subject to the same vagaries of needing to give a clear, internal, mechanistic description as were the
viruses. Finally, the clinical features described were similarly clear and unusual. While they were still
in need of causal attribution, their phenomenological features were not.
6.6 Difference-making and the Reference Class Problem
As most EDM is probabilistic,33 there is an important issue that must be addressed at this point. Say
we wish to construct an RWT-type causal claim that deals with the manner in which infection with a
particular virus leads to a particular tumour. The construction and evaluation of this causal claim will
require that we generate or interpret appropriate EDM, such that we can accurately determine the prob-
abilities associated with the instantiation of a particular mechanism in a population. How can we, from
our probabilistic EDM determine the probability of the instantiation of this single causal-mechanistic
route?
We might suggest that the probability of this particular event occurring should be the same as the
general probability of events of the same type occurring. However, we can describe any particular event
(or thing) in as many ways as we like, and we therefore have an infinite choice of classes of similar
events to which we might assign the particular event. For example, we might classify a case of BL
as a member of the malignant diseases, or a member of the diseases caused by EBV, or as a tropical
disease, or as a common disease, or as a childhood disease and so on. But the probability of occurrence
of each of these classes of disease will be widely differing. Both in practice and in theory, classification
of an event to a single, objectively most appropriate reference class is not possible, and we can only
give probabilities for single events that relate to their desciptions, rather than on the events themselves
(Gillies, 2000, 119). Therefore, it may be impossible to give an objective probability for a single event.
Reichenbach’s formulation of this RCP is especially clear:
If we are asked to find the probability holding for an individual future event, we must
first incorporate the case in a suitable reference class. An individual thing or event may be
incorporated in many reference classes, from which different probabilities will result. This
ambiguity has been called the problem of the reference class. Assume that a case of illness
can be characterized by its inclusion in the class of tuberculosis. If additional information
is obtained from an X-ray, the same case may be incorporated into the class of serious cases
of tuberculosis. Depending on the classification, different probabilities will result for the
32Although, the later discovery of the second wind phenomena revealed that it was perhaps not quite as simple as initially
suspected
33Actually, I think a similar difficulty will also apply to non-probabilistic EDM too. For example, the EDM produced by use of
case-control studies in the McArdle case will encounter similar descriptive difficulties.
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prospective issue of the illness.
(Reichenbach, 1949, 374)
While this was originally described as a problem for frequentist theories of probability, Ha´jek
(2007) has convincingly argued that slightly different versions of it will affect all informative theories of
probability.34 As the RWT certainly is intended to be an informative theory, albeit one that does not deal
with probabilities exclusively, it too will have to provide some kind of solution to the RCP.
6.6.1 Salmon’s solution(s) to the Reference Class Problem
While there may be no good theoretical solution to the RCP, by say modifying our theories of probability,
there may be some tactics that can reduce the practical problems associated with it. In fact, Salmon
suggested a number of such solutions. These are based around a simple rule for deciding which reference
class we should assign our single event to. This is the reference class rule, and is as follows:
. . . choose the broadest homogeneous reference class to which the single event belongs.
(Salmon et al., 1971, 43)
Homogeneity requires some development. Salmon suggested two possible ways of formulating this
term. His first suggestion was that homogeneity should be interpreted objectively:35
To say that a reference class is homogeneous - objectively homogeneous for emphasis -
means that there is no way, even in principle, to effect the relevant partition.
(Salmon, 1977, 399).
This still requires elaboration. Let us consider the situation where we are attempting to formulate a
prognostic judgement about the probability that an individual with BL will survive for a particular period
of time. We might begin by including BL in the class of all malignant disease. However, this reference
class will clearly be non-homogeneous with respect to this probabilistic measure of survival. Some types
of cancers kill almost all those affected very quickly, while other malignant diseases have very little effect
on survival. Thus these more aggressive tumours (within this reference class) should have a very low
probability of survival attached, while the rather slower tumours should have a higher probability. If we
wish to make a accurate single case probabilistic prediction of survival for our patient with BL, we will
34Informative here is intended in the sense of those theories that can guide actions or inferences: ‘The reference class problem
besets those theories that are genuinely informative and that plausibly constrain our inductive reasonings and decisions’ (Ha´jek,
2007, 564).
35In fact, Salmon persisted with objectively homogeneous reference classes, despite a number of difficulties. While I will go
on to discuss Salmon’s epistemic version of homogeneity later, it is important to note that Salmon did not regard this epistemic
formulation as a suitable replacement for objective homogeneity: ‘My first attempt at a detailed explication of objective homo-
geneity was badly flawed (1977b); an improved treatment, which I hope is more successful, was not published until 1984 (chap.
3). However that may be, I am still convinced that the concept of an objectively homogeneous reference class is legitimate and
important. I maintain, for example, that the class of carbon-14 atoms is objectively homogeneous with respect to the attribute of
spontaneous radioactive decay within 5730 years. If our concept does not fit cases of that sort, our explication must be at fault.’
(Salmon, 1989, 171).
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need to effect a partition in this reference-class such that the associated generic probability of survival is
the same for all members of the class. We might try forming a partition of the class of malignant disease
that just contains malignant disease of lymphoid cells. But, again, this reference class is distinctly non-
homogeneous. A B-cell lymphoma is likely to take much longer to kill an affected individual than acute
lymphoblastic leukaemia. So, again, we would have to partition this reference-class. When this process
is repeated such that it comes to the point where there is no way, even in principle, to divide the reference
class that would result in two meaningful partitions that differ in their associated probability measures,
then we would have an homogeneous reference class.
While this sort of objective formulation of homogeneity may be useful in some contexts, it does
not seem to be practically workable in the types of situations discussed in the historical cases. In fact,
methodologies that work in this way are not a feature of these historical cases at all. This is because of a
fairly simple difficulty that relates to the great number of possible causal factors which could, potentially,
make a difference.
Consider a case in which a number, n, of binary variables are suspected to be possibly and plausibly
causally relevant to the development of a disease. If we wish to do any single-case work with this
situation, and if we also wish to follow an objective version of the reference class rule, then our difficulty
will be as follows: for each n variables, we must form 2n possible reference classes. Given that there
are so many possible, plausible causal factors at play in any disease, this will almost certainly make our
reference classes impossibly narrow. So following an objective formulation of the reference class rule
seems an unworkable strategy here. However, Salmon also offers an alternative, epistemic formulation
of the reference class rule, which might be more suitable in this case:
When we know or suspect that a reference class is not homogeneous, but we do not
know how to make any statistically relevant partition, we may say that the reference class is
epistemically homogeneous.
(Salmon et al., 1971, 44)
Now this, at the price of sacrificing the objective type of description of causality that interested
Salmon, seems more promising. However, an exhaustive approach to partitioning here is, as with the
objective formulation, not really workable either. Suppose we have about a dozen (dichotomous, binary)
likely factors that might be causally significant. We might, for instance, take the range of risk factors
that were identified during the early phases of research on cervical cancer.36
We will, in order to make sure that any reference class we assign a probability to is epistemically
homogeneous, here have still to formulate more than 8000 partitions. Given the weak effects of most
tumour viruses, this would require the creation of an enormous trial. In this example, the problem
would be further exacerbated by the fact that most of these variables have a wide range of values that
might, plausibly, lead to different effects. Further, some of these variables are even more complicated.
For instance, both youth and age are, broadly, risk factors for this disease. So actually creating an
36To recap from section 3.2, these were sex, marriage, parity, faith, youth, syphilis, social class, race, age, male partner circum-
cision, smoking and use of oral contraceptives









Figure 6.1: Cervical cancer example. Here, for the sake of clarity, a number of features have been
omitted. Most importantly, at each stage along the health–HPV–cervical atypia–cervical cancer track,
side-branches that express either i: the non-progression of the relevant state or ii: a regression to a prior
state have been left out. Thus only the important, pathogenic tracks of this branched mechanism are
shown.
exhaustive set of data partitions does not seem like an operationally effective strategy for understanding
the causation of cervical cancer. Is there a more effective methodology that we might use to fulfill the
epistemic version?
6.6.2 Mechanistic models and the reference-class problem
Mechanistic models might provide a principled means of fulfilling the epistemic formulation of the
reference class rule. There also seems some historical support for this claim. For instance, the Prague
cervical cancer study (Vonka et al., 1984a; Vonka et al., 1984b; Krcma´r et al., 1986) neither attempted
to match controls over a totally exhaustive set of causal factors (as we might if we were following the
objective formulation of the reference class rule), or even an exhaustive set of all identified possible
causal factors (c.f. an exhaustive epistemic interpretation of it). Instead, researchers performed case-
matching on the basis of just five factors. These five factors - age, age at first sexual intercourse, number
of sexual partners, smoking and history of DKG - were seen, at the time, as being useful indicators of all
those possible factors likely to make some sort of causal difference (Vonka, personal communication).
Now thinking about just five factors has major advantages. Not least, if we interpret them dichotamously,
we have only 32 different partitions to make, rather than many thousands. And even with this highly
restricted class of variables used to define reference classes, the study that used these factors provided an
highly effective demonstration of the falsity of the HSV theory.
I think this sort of example provides us with a principled means of selecting those features which
we might employ to satisfy the epistemic formulation of the reference class rule. Models of mechanisms
provide the means by which we can do this. In more detail, it is the point at which the pathological routes
of our mechanistic model branching off from physiology, or their direct descendants, that are ideal targets
for epistemically dealing with the RCP. These branching points will, as earlier suggested, also generally
arise from setting effects. Depending upon the ease with which we can collect data about them, any one
of a range of possible features around this type of branching point will be a good classificatory feature.
As an example, the features identified in the Prague study might be used to construct a schematic
mechanistic model of the relevant aetiological features (figure 6.1).
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Here, only those activities and entities that constitute cervical cancer pathogenesis are shown. This
pathogenic mechanisms is influenced by a number of likely causal factors. The five factors (age at first
intercourse, number of sexual partners, increasing age, smoking status and history of DKG) are related
together in a plausible manner by a mechanistic model. If we are interested in, say, the probability of a
particular individual developing cervical cancer we can use such a non-exhaustive approach to provide
a principled means of resolving the reference-class problem in practice. We can, when attempting to
partition our EDM, refer to this example mechanism as a way of deciding which partitions we need to
form. In general, when we are trying to understand the occurrence of a particular effect, we will be
interested the various parents of that effect, as well as any other effects these parents have, and the other
parents these effects have.37 In this toy example, we only have a single effect of interest. However, as
much recent research on cervical cancer has involved the identification of disease markers, there might
well develop a case such that a number of effects, and their causes, would participate in deciding just
how to partition statistical data in a way that does not require exhaustive consideration of all possible
factors.
In summary, as the RCP forces us to restrict the features that we examine when we collect EDM,
and the rational solution to this restriction is to employ a mechanistic model to permit a principled
selection of suitable features, then we can explain why the RWT is a good descriptive theory of causality
in medicine. This suggestion also lends support to the normative interpretation of the RWT that I will
explore in the next section.
37i.e. we will be interested in the Markov Blanket (Pearl, 1987, 249). However, I avoid this term because of the very significant
connection that it has to Bayesian networks. While these tools would provide an extremely useful means of dealing with this type
of problem specifically, I will not develop this account in such a way here.
Chapter 7
Conclusion: The Russo-Willamson Thesis
Redux
I have argued that the RWT is a good descriptive theory. Chapters 2 and 3 made the historical case for
it, while chapters 5 and 6 made the related methodological case. However, I think the RWT should also
be interpreted normatively. This normative aspiration gains support from both aspects of the descriptive
adequacy of the theory. But I think the RWT is capable of telling us what is, and what is not, an high-
quality causal claim in medicine.
In what follows, I therefore give some suggestions about how this might be achieved. This begins,
in section 7.1, with a clear statement of what RWT-type causal models are, why they work, and how they
are related to the generation of appropriate evidence. This, then, explains how the descriptive method-
ological case supports a normative interpretation. Then, in section 7.2, I will give a clear restatement
of the descriptive historical case, and how this also supports a normative interpretation. Finally, I’ll
conclude with some remarks on why we might want to employ a normative interpretation of the RWT.
7.1 The Russo-Williamson Thesis redux
RWT-type causal models are composed of integrated evidence of mechanism and difference making.
Evidence of mechanism is integrated into a mechanistic model, while evidence of difference-making
(generally as probabilities of the instantiation of various parts of this mechanistic model) is put together
in a way that examines particular features of this mechanistic model. Thus, RWT-causal models are
highly context-dependent, epistemic, devices for understanding causal relationships that depend upon
two interdependent types of evidence.
Both types of constitutive evidence are necessary to support a high-quality causal claim. Mecha-
nistic models will be defeated by unfaithful causal structures, and by causal irrelevance, while systems
of EDM alone will be defeated by confounding variables, while the generation of useful EDM is often
implausible in the absence of some kind of mechanistic model. Either type of evidence-synthesis alone
is inadequate.
As an illustration, consider a purely hypothetical research programme looking to discover the rela-
tionship, if any, between smoking and atherosclerosis-induced heart disease in a population. A mecha-
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nistic model may be developed that suggests that smoking directly causes atherosclerosis. However, this
mechanistic model may not accurately reflect what actually occurs in our population of interest. This
may be as a result of two different problems with solo mechanistic models. First, the structure of our (on-
tic) mechanism in the population may be unfaithful. For instance, smoking may prevent weight gain. As
excessive weight is also cause of atherosclerosis, and therefore heart disease, the weight-reducing func-
tion of smoking could outweigh the direct atherogenic effects, leading to an overall decrease in heart
disease in smokers. Second, our mechanistic model may be irrelevant to the actual (ontic) disease mech-
anisms that occur in our population. It may be the case that the evidence which we use to construct our
mechanistic model poorly reflects the situation in the relevant population. For instance, smoking may
be unknown in the actual population. For another, the mechanistic model concerning smoking might
solely concern itself with very heavy smoking, whereas our population might contain exclusively light
smokers.
To resolve these difficulties, we need evidence of what the net effect of smoking actually is on the
population. This is evidence of difference-making. Alone, this too is inadequate. First, our EDM may
be unreliable because of confounding variables. Smoking may correlate with some third variable that
also causes heart disease, such as alcoholism. If we do not know that some smokers are also alcoholics,
we may overestimate the deleterious effects of smoking. Knowledge of mechanistic models allows us to
control for such correlates and thereby to demonstrate accurately the overall direct effects of smoking.
Without a mechanistic model, the reference class problem makes it impossible to attempt to control
for all possible plausible causal factors. Second, useful EDM may be methodologically secondary to
a mechanistic model. It may well be the case that we cannot generate the kinds of EDM that could
usefully participate in finding out about the operation of our cause without understanding the relevant
mechanism of disease. In our hypothetical case, we may never think to study the effects of heavy versus
light smoking on the development of heart disease. Similar, stronger, examples of this methodological
sequence are to be found in the EBV case (c.f. de-The´ et al., 1978), and in the HCC case (c.f. vaccine
production). In the EBV case, it seems profoundly implausible to claim that the decision to look for
the very specific serological factors in the BL-EBV prospective study would have been taken without
an understanding of how EBV interacts with the immune system. Similarly, in the HCC case, I do not
think we can plausibly claim that the development of two different, highly effective, vaccines came about
without understanding, in some detail, the nature of the relevant aetiological agent, the manner in which
it infects cells, the normal way in which the immune system functions and can be modified, and so on.
Without a detailed mechanistic understanding of these situations, the decision to perform such detailed
observational or interventionist studies would be nothing short of miraculous.
Put together, these two types of evidence show us the overall effect of a given causal factor in a
given population, while also detailing the contributions of each branch of the causal mechanism linking
cause and effect. A RWT-causal model therefore presents us with a causal road-map for a particular
factor in a population. The mechanistic aspect tells us which causal routes can happen, and describes
their morphology, while the difference-making aspect tells us which causal routes are actually taken, and
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under which circumstances.
Thinking of RWT-causal models as causal road-maps allow the understanding of a number of issues
regarding causality that are generally a bit difficult to understand. First, causation by omission should be
construed as being a change in the actual causal route taken through an RWT-type causal structure. It is
not the case that a negative cause represents termination of a causal mechanism. Rather, it is analogous
to the blocking of a street that is conventionally open to traffic. This leads to a rerouting of causal
instances around this blockage via alternative routes. A description of these routes, in terms of an altered
RWT-type causal model, is how causation by omission should be understood.
Second, these RWT-type causal structures deal with generic causality. However, because of their
treatment of the reference class problem, understanding and predicting the operation of a single-case
cause simply requires the description of the possible routes that could be taken in the particular instance.1
Third, the two sorts of effects outlined in section 5.7 are similarly easy to understand. Sequence
effects can be thought of as causal routes that move through the causal landscape without changing its
arrangement. Setting effects, on the other hand, are causal routes that change the shape of the landscape,
or the probability of subsequent instances taking particular causal routes.
Finally, the very important issue of finding effective strategies2 is greatly simplified by using road-
maps. Effective points for intervention will generally be those that alter branching points that arise by
setting effects. We can either do this by altering the setting effect itself, instantiating an alternative setting
effect, or by changing other factors such that altered sequence effects bypass the deleterious effects of
the pathological setting effect.
7.2 Integration of evidence in practice and the methodologies of
bioscientific research programmes
RWT-type causal models are highly pluralistic with respect to evidence. No particular experimental
methodology generates evidence that is either necessary or sufficient to unequivocally support a causal
claim. Instead, a wide range of different types of evidence participates in sustaining and developing a
causal model.
The change in the morphology of these causal models changes as their associated research pro-
gramme changes. This close relationship between a developing causal claim, and the organisation of
research, is clearly visible in the historical cases. For instance, the initial stage of the BL-EBV research
programme consisted primarily of formulating a basic clinical and epidemiological description that ap-
peared to arise from the operation of some kind of anomalous, novel causal process. However, once
this disease was demonstrated to be a malignant one with a characteristic geographical distribution, a
change was effected in the kinds of evidence that were considered of importance in determining the
nature of causality in this case. This too was reflected by a change in the patterns of personal and institu-
tional involvement in the case, with the recruitment of various experts in both malignant and infectious
1c.f. also Russo and Williamson’s treatment of single-case and generic causation (Russo and Williamson, 2010).
2c.f. RW2
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diseases.
This initial investigation of BL as an infectious tumour underwent a further organisational change
when the theory that it might be caused by a virus became plausible. This phase, when EBV was
discovered in the tumour cells, and investigated as the causal agent for BL was again characterised by a
change in the types of individuals and institutions involved. It was also characterised by the adoption, and
in some cases development, of a novel range of experimental methodologies. Finally, research looked to
demonstrate the applicability of the EBV mechanism to disease populations. This involved constituting
seroepidemiological research in the field that relied on this newly demonstrated mechanism. This phase
also involved research into a number of (clinically and aetiologically) related disease states.
This change in the organisation of research around a developing causal model is characteristic of
successful research programmes. More specifically, research programmes that are likely to produce use-
ful causal models are those in which various research groups and experimental methodologies become
conjoined around (local) causal models. This is initially triggered by the search for a particular causal
fact (aetiology, therapy) and is shaped by the interpretive framework adopted (cf. the distinctly oncoviro-
logical research programme that grew up around EBV). Research programmes become conjoined by the
integration of laboratory and epidemiological investigation. This integration is methodologically recur-
sive. At some points, questions raised by laboratory work guides epidemiology, while at other points it
will be the case that epidemiological research guides laboratory workers. Research in different domains
become conjoined in causally successful research programmes (such as the BL-EBV, HPV-cervical can-
cer programmes), but such conjoining does not happen in unsuccessful ones (such as the HSV-cervical
cancer programme).
Such development of a conjoint research programme leads to the production of an epistemic web
of different forms of evidence, an interdependent arrangement of the diverse types of EM and EDM that
can be employed in the construction of RWT-type causal models. This web of evidence arises from the
bidirectional interplay between types of methodologies that can only come about when multidisciplinary
research programmes are so organised. However, causally interpreting such diverse evidence requires
an interlevel understanding of causality. As Machamer et al. (2000, 23) suggests, ‘It is the integration
of different levels into productive relations that renders the phenomenon intelligible. . . ’ While this sug-
gestion relates to mechanisms as a means of understanding causality, I think that this is better construed
as a claim about the interlevel and interdisciplinary advantages of RWT-type causal models. After all,
those who would reason exclusively with mechanisms cannot account for the role of different types of
evidence in supporting causal claims.
7.3 Final conclusions
Medicine, argues Russo and Williamson, seeks causes for cognitive and action-oriented reasons. A major
advantage of the normative RWT is that it is capable of discriminating between strong and weak causal
knowledge in both these contexts.
An RWT-type causal model is not an absolute prerequisite for all forms of causal knowledge. We
may discover that, say, a particular chemical produces some therapeutic effect in the absence of a mech-
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anistic model capable of explaining its effects. There are numerous examples of such discoveries: some
of the therapeutic effects of aspirin, anaesthetics and so on were discovered without an understanding
of their mechanisms of action. However, the causal knowledge that we had about these treatments was
limited. While we knew that some of their effects occurred, we could not speak to why. Nor, in several
cases, did we know of a whole range of undesirable effects that they also possessed.
For example, while the understanding that aspirin could be used as an analgesic agent dates from
the 1890s. This discovery did not depend upon a mechanistic model, nor an RWT-type causal model, of
its mechanism of action. And aspirin was used, very successfully, with this limited causal knowledge
for many years. However, the discovery of its mechanism of action, and the later understanding of its
wide range of adverse effects (discussed in section 5.3.3) did arise from such investigations. And, as
a result, it is now the case that aspirin is no longer prescribed for analgesia, as this research has, by a
combination of clinical and laboratory research, demonstrated that a wide range of alternative agents
are safer and more effective. Furthermore, other apparently valuable features of this drug that were
previously discovered are also being questioned as clinical research becomes more closely integrated
with the mechanistic understanding of the drug. For example, it has recently been suggested that the use
of aspirin as a primary preventive agent against vascular disease is much less effective than previously
thought (Baigent et al., 2009). All this means that we should not necessarily discard all causal knowledge
of this type. What it does mean is that it should be employed in a more circumspect fashion. The
RWT is suited to exactly this purpose: causal claims that are supported by appropriate evidence of both
mechanism and difference-making are very likely to be more reliable than those that are not. Use of this
demanding causal methodology is therefore an effective means by which to critically examine causal
claims in medicine, and to suggest in which circumstances a particular causal claim is likely to be an
effective guide to practice, and when it is not. This is extremely valuable, as poorly understood causal
claims may well survive, unchallenged, in medical practice and cause great harm.
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